Safe and effective method of treating lupus with anti-IL12/IL23 antibody (2024)

This application claims the benefit of priority to U.S. Provisional Application No. 62/673,426, filed May 18, 2018, which is incorporated herein by reference in its entirety.

This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “JBI5162-SEQLIST.txt”, creation date of May 17, 2018 and having a size of 192 kb. The sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.

The present invention relates to methods for treating lupus with an antibody that binds human IL-12 and/or human IL-23 proteins. In particular, the present invention relates to methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, wherein the treatment comprises administering a safe and effective amount of an anti-IL-12 and/or anti-IL-23 antibody, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab.

Interleukin (IL)-12 is a secreted heterodimeric cytokine comprised of 2 disulfide-linked glycosylated protein subunits, designated p35 and p40 for their approximate molecular weights. IL-12 is produced primarily by antigen-presenting cells and drives cell-mediated immunity by binding to a two-chain receptor complex that is expressed on the surface of T cells or natural killer (NK) cells. The IL-12 receptor beta-1 (IL-12Rβ1) chain binds to the p40 subunit of IL-12, providing the primary interaction between IL-12 and its receptor. However, it is IL-12p35 ligation of the second receptor chain, IL-12Rβ2, that confers intracellular signaling (e.g. STAT4 phosphorylation) and activation of the receptor-bearing cell (Presky et al, 1996). IL-12 signaling concurrent with antigen presentation is thought to invoke T cell differentiation towards the T helper 1 (Th1) phenotype, characterized by interferon gamma (IFNγ) production (Trinchieri, 2003). Th1 cells are believed to promote immunity to some intracellular pathogens, generate complement-fixing antibody isotypes, and contribute to tumor immunosurveillance. Thus, IL-12 is thought to be a significant component to host defense immune mechanisms.

It was discovered that the p40 protein subunit of IL-12 can also associate with a separate protein subunit, designated p19, to form a novel cytokine, IL-23 (Oppman et al, 2000). IL-23 also signals through a two-chain receptor complex. Since the p40 subunit is shared between IL-12 and IL-23, it follows that the IL-12101 chain is also shared between IL-12 and IL-23. However, it is the IL-23p19 ligation of the second component of the IL-23 receptor complex, IL-23R, that confers IL-23 specific intracellular signaling (e.g., STAT3 phosphorylation) and subsequent IL-17 production by T cells (Parham et al, 2002; Aggarwal et al. 2003). Recent studies have demonstrated that the biological functions of IL-23 are distinct from those of IL-12, despite the structural similarity between the two cytokines (Langrish et al, 2005).

Abnormal regulation of IL-12 and Th1 cell populations has been associated with many immune-mediated diseases since neutralization of IL-12 by antibodies is effective in treating animal models of psoriasis, multiple sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease, insulin-dependent (type 1) diabetes mellitus, and uveitis (Leonard et al, 1995; Hong et al, 1999; Malfait et al, 1998; Davidson et al, 1998). IL-12 has also been shown to play a critical role in the pathogenesis of SLE in two independent mouse models of systemic lupus erythematosus (Kikawada et al, 2003; Dai et al, 2007).

Systemic lupus erythematosus (SLE) is a complex, chronic, heterogeneous autoimmune disease of unknown etiology that can affect almost any organ system, and which follows a waxing and waning disease course. Systemic lupus erythematosus occurs much more often in women than in men, up to 9 times more frequently in some studies, and often appears during the child-bearing years between ages 15 and 45. This disease is more prevalent in Afro-Caribbean, Asian, and Hispanic populations. In SLE, the immune system attacks the body's cells and tissue, resulting in inflammation and tissue damage which can harm the heart, joints, skin, lungs, blood vessels, liver, kidneys and nervous system. About half of the subjects diagnosed with SLE present with organ-threatening disease, but it can take several years to diagnose subjects who do not present with organ involvement. Some of the primary complaints of newly diagnosed lupus patients are arthralgia (62%) and cutaneous symptoms (new photosensitivity; 20%), followed by persistent fever and malaise (Wallace, 2008). The estimated annual incidence of lupus varies from 1.8 to 7.6 cases per 100,000 and the worldwide prevalence ranges from 14 to 172 cases per 100,000 people (Wallace, 2008). Patients with mild disease have mostly skin rashes and joint pain and require less aggressive therapy; regimens include nonsteroidal anti-inflammatory drugs (NSAIDs), anti-malarials (e.g., hydroxychloroquine, chloroquine, or quinacrine) and/or low dose corticosteroids. With more severe disease, patients may experience a variety of serious conditions depending on the organ systems involved, including lupus nephritis with potential renal failure, endocarditis or myocarditis, pneumonitis, pregnancy complications, stroke, neurological complications, vasculitis and cytopenias with associated risks of bleeding or infection. Common treatments for more severe disease include immunomodulatory agents, such as methotrexate (MTX), azathioprine, cyclophosphamide, cyclosporine, high dose corticosteroids, biologic B cell cytotoxic agents or B cell modulators, and other immunomodulators. Patients with serious SLE have a shortening of life expectancy by 10 to 30 years, largely due to the complications of the disease, of standard of care therapy, and/or accelerated atherosclerosis. In addition, SLE has a substantial impact on quality of life, work productivity, and healthcare expenditures. Existing therapies for SLE are generally either cytotoxic or immunomodulatory, and may have notable safety risks. Newer treatments for SLE have provided only modest benefits over standard of care therapy. Thus, there is a large unmet need for new alternative treatments that can provide significant benefit in this disease without incurring a high safety risk.

The general and preferred embodiments are defined, respectively, by the independent and dependent claims appended hereto, which for the sake of brevity are incorporated by reference herein. Other preferred embodiments, features, and advantages of the various aspects of the invention will become apparent from the detailed description below taken in conjunction with the appended drawing figures.

In certain embodiments, the invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a safe and effective treatment of an anti-IL-12 and/or anti-IL-23 antibody. In a preferred embodiment, such treatment comprises administering intravenously (IV) and/or subcutaneously (SC) to the patient an anti-IL-12 and/or anti-IL-23 antibody, wherein the anti-IL-12 and/or anti-IL-23 antibody is an anti-IL-12/23p40 antibody, such as ustekinumab.

In certain embodiments, the invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a safe and effective treatment comprising intravenously (IV) and/or subcutaneously (SC) administering to the patient an anti-IL-12 and/or anti-IL-23 antibody. The anti-IL-12 and/or anti-IL-23 antibody may be an anti-IL-12/23p40 antibody comprising: (1) (i) the heavy chain CDR amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and (ii) the light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; (2) (i) the heavy chain variable domain amino acid sequence of SEQ ID NO:7; and (ii) the light chain variable domain amino acid sequence of SEQ ID NO:8; and/or (3) the anti-IL-12/23p40 antibody ustekinumab (STELARA®), comprising: (i) the heavy chain amino acid sequence of SEQ ID NO:10; and (ii) the light chain amino acid sequence of SEQ ID NO:11.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a safe and effective treatment comprising intravenously (IV) administering to the patient a pharmaceutical composition comprising an anti-IL-12/IL-23p40 antibody comprising: (1) (i) the heavy chain CDR amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and (ii) the light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; (2) (i) the heavy chain variable domain amino acid sequence of SEQ ID NO:7; and (ii) the light chain variable domain amino acid sequence of SEQ ID NO:8; and/or (3) the anti-IL-12/23p40 antibody ustekinumab (STELARA®), comprising: (i) the heavy chain amino acid sequence of SEQ ID NO:10; and (ii) the light chain amino acid sequence of SEQ ID NO:11 in a solution comprising 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mLL methionine, and 20 μg/mL EDTA disodium salt, dehydrate, at pH 6.0 or in a solution comprising 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0.

In certain embodiments, the antibody is administered with an initial intravenous (IV) dose at week 0, followed by administrations of a subcutaneous (SC) dose every 8 weeks (q8w) or wherein the antibody is administered as an initial subcutaneous (SC) dose, followed by administrations of a SC dose every 8 weeks (q8w), and wherein the initial IV dose is 6.0 mg/kg±1.5 mg/kg.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining levels of one or more cytotoxic cell markers in biological samples from the patients, wherein the one or more cytotoxic cell markers is selected from the group consisting of: expression level of one or more cytotoxic cell-associated transcriptional genes and percentage of natural killer cells; b.) determining levels of one or more Interferon I (IFN-I) markers in biological samples from the patients, wherein the one or more IFN-I markers is selected from the group consisting of: expression level of one or more Interferon I (IFN-I) inducible genes and expression level of Interferon alpha; c.) calculating mean levels of the one or more cytotoxic cell markers and the one or more IFN-I markers in the biological samples from the patients; d.) comparing the calculated mean levels to the levels in individual patients for the one or more cytotoxic cell markers and the one or more IFN-I markers; e.) determining if individual patients have higher levels or lower levels compared to the calculated mean levels of the one or more cytotoxic cell markers and the one or more IFN-I markers; f.) selecting the individual patients from the group consisting of: individual patients with higher levels of the one or more cytotoxic cell markers and higher levels of the one or more IFN-I markers, individual patients with higher levels of the one or more cytotoxic cell markers and lower levels of the one or more IFN-I markers, and individual patients with lower levels of the one or more cytotoxic cell markers and lower levels of the one or more IFN-I markers, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/IL-23p40 antibody; and, g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the anti-IL-12/IL-23p40 antibody comprises a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; a CDRH2 amino acid sequence of SEQ ID NO:2; and a CDRH3 amino acid sequence of SEQ ID NO:3; and said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; a CDRL2 amino acid sequence of SEQ ID NO:5; and a CDRL3 amino acid sequence of SEQ ID NO:6.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the anti-IL-12/IL-23p40 antibody comprises (1) a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; a CDRH2 amino acid sequence of SEQ ID NO:2; and a CDRH3 amino acid sequence of SEQ ID NO:3; and said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; a CDRL2 amino acid sequence of SEQ ID NO:5; and a CDRL3 amino acid sequence of SEQ ID NO:6; (2) (i) the heavy chain variable domain amino acid sequence of SEQ ID NO:7; and (ii) the light chain variable domain amino acid sequence of SEQ ID NO:8; and/or (3) the anti-IL-12/23p40 antibody ustekinumab (STELARA®), comprising: (i) the heavy chain amino acid sequence of SEQ ID NO:10; and (ii) the light chain amino acid sequence of SEQ ID NO:11.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GPR56, GZMH, GZMK, XRRA1, GSTM4, KLRC3, KLRD1, KLRG1, LOC387895, MYBL1, NKG7, PRF1, TARP, TRGC2, CXCR3, GZMA, and TRGV2; and wherein the one or more IFN-I inducible genes is selected from the group consisting of: BST2, CARD17, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, FBXO39, HERC5, HERC6, IFIT1, IFIT2, IFIT3, IRF7, LAP3, LOC100133669, OAS3, OASL, OTOF, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, SPATS2L, TIMM10, USP18, ISG15 IFI27, IFI44, IFI44L, and ZBP1.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GZMH, GZMK, NKG7 and PRF1; and wherein the one or more IFN-I inducible genes is selected from the group consisting of: BST2, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, HERC5, IFIT1, IFIT2, IFIT3, IRF7, ISG15, LAP3, OAS3, OASL, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, TIMM10, USP18 and ZBP1.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the one or more cytotoxic cell-associated transcriptional genes comprises FCRL6, FGFBP2, GNLY, GZMH, NKG7, and PRF1; and wherein the one or more IFN-I inducible genes comprises IFIT3 and RSAD2.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the expression level of the one or more cytotoxic cell-associated transcriptional genes and the expression level of the one or more IFN-I inducible genes are determined by quantifying RNA transcripts in the biological samples or quantifying protein expression levels in the biological samples.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the biological sample is selected from the group consisting of: skin biopsies, whole blood, serum, and urine.

In certain embodiments, the invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the percentage of natural killer cells in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean percentage of natural killer cells and the mean expression level of and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean percentage of natural killer cells and the mean expression levels of the one or more Interferon I (IFN-I) inducible genes to the percentage of natural killer cells and expression levels of the one or more Interferon I (IFN-I) inducible genes in individual patients; e.) determining if the individual patients have higher or lower percentage of natural killer cells compared to the mean percentage of natural killer cells and higher expression levels or lower expression levels compared to the mean expression levels of the one or more Interferon I (IFN-I) inducible genes; f) selecting the individual patients from the group consisting of: individual patients with higher percentage of natural killer cells and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher percentage of natural killer cells and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower percentage of natural killer cells and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/IL-23p40 antibody; and, g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the anti-IL-12/IL-23p40 antibody comprises a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; a CDRH2 amino acid sequence of SEQ ID NO:2; and a CDRH3 amino acid sequence of SEQ ID NO:3; and said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; a CDRL2 amino acid sequence of SEQ ID NO:5; and a CDRL3 amino acid sequence of SEQ ID NO:6.

In certain embodiments, the invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level of one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of Interferon alpha in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the Interferon alpha in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the Interferon alpha; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the Interferon alpha; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the Interferon alpha, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the Interferon alpha, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the Interferon alpha, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/IL-23p40 antibody; and, g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the anti-IL-12/IL-23p40 antibody comprises a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; a CDRH2 amino acid sequence of SEQ ID NO:2; and a CDRH3 amino acid sequence of SEQ ID NO:3; and said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; a CDRL2 amino acid sequence of SEQ ID NO:5; and a CDRL3 amino acid sequence of SEQ ID NO:6.

In certain embodiments, the invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the percentage of natural killer cells in biological samples from the patients; b.) determining the expression level of Interferon alpha in biological samples from the patients; c.) calculating the mean percentage of natural killer cells and the mean expression level of and the Interferon alpha in the biological samples from the patients; d.) comparing the calculated mean percentage of natural killer cells and the mean expression levels of the Interferon alpha to the percentage of natural killer cells and expression levels of the one or more Interferon I (IFN-I) inducible genes in individual patients; e.) determining if the individual patients have higher or lower percentage of natural killer cells compared to the mean percentage of natural killer cells and higher expression levels or lower expression levels compared to the mean expression levels of the Interferon alpha; f.) selecting the individual patients from the group consisting of: individual patients with higher percentage of natural killer cells and higher expression levels of the Interferon alpha, individual patients with higher percentage of natural killer cells and lower expression levels of the Interferon alpha, and individual patients with lower percentage of natural killer cells and lower expression levels of the Interferon alpha, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/IL-23p40 antibody; and, g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the anti-IL-12/IL-23p40 antibody comprises a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; a CDRH2 amino acid sequence of SEQ ID NO:2; and a CDRH3 amino acid sequence of SEQ ID NO:3; and said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; a CDRL2 amino acid sequence of SEQ ID NO:5; and a CDRL3 amino acid sequence of SEQ ID NO:6.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the antibody is administered with an initial intravenous (IV) dose at week 0, followed by administrations of a subcutaneous (SC) dose every 8 weeks (q8w) or wherein the antibody is administered as an initial subcutaneous (SC) dose, followed by administrations of a SC dose every 8 weeks (q8w) and wherein the initial IV dose is 6.0 mg/kg 1.5 mg/kg and the SC dose is 90 mg, and/or wherein the initial IV dose is 260 mg for patients with body weight ≥35 kg and ≤55 kg, 390 mg for patients with body weight >55 kg and ≤85 kg, and 520 mg for patients with body weight >85 kg.

In certain embodiments, the present invention provides methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in biological samples from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, and individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and lower expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody, wherein the predicted increased likelihood of having a positive response to the treatment comprising administering the anti-IL-12/IL-23p40 antibody is determined with a logistic regression model of the formula:

\min_{β o, β} - [\frac{1}{N} \sum_{i = 1}^{N} y_{i} (β o + β^{T} x_{i}) - \log (1 + e^{(β o + β^{T} x_{i})})] + λ [\frac{(1 - α)}{2} { β }_{2}^{2} + α { β }_{1}]

wherein N is the number of patients used to learn the model, x_iis a vector of the centered gene expression data of patient i, y_iis the response outcome for patient i (responder/non-responder), λ controls the total penalty weight, α controls the elastic-net penalty weight: form lasso (α=1) to ridge (α=0), and α, λ are optimized using grid search based on best training accuracy; and,
wherein after βo, β parameters are determined a response probability is determined by the formula:

P (x_{new}) = \frac{1}{1 + e^{- (β^{T} x_{new})}}

and response prediction is determined with a threshold of 0.5 using the formula:

$Response (x_{new}) = {\begin{matrix} responder, & if P (x) \geq threshlod \\ non - responder, & else \end{matrix} .$

In certain embodiments, the present invention provides method for selecting patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment comprising administering an anti-IL-12/IL-23p40 antibody and an IFN-I inhibitor, the method comprising: a.) determining the expression level one or more cytotoxic cell-associated transcriptional genes in a biological sample from the patients; b.) determining the expression level of one or more Interferon I (IFN-I) inducible genes in a biological sample from the patients; c.) calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes in the biological samples from the patients; d.) comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; e.) determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes and the one or more Interferon I (IFN-I) inducible genes; f.) selecting the individual patients with lower expression levels of the one or more cytotoxic cell-associated transcriptional genes and higher expression levels of the one or more Interferon I (IFN-I) inducible genes, wherein the selected individual patients are predicted to have an increased likelihood of having a positive response to the treatment comprising administering an anti-IL-12/IL-23p40 antibody and an IFN-I inhibitor; and g.) treating the selected patients by administering the anti-IL-12/IL-23p40 antibody and the IFN-I inhibitor.

\min_{β o, β} - [\frac{1}{N} \sum_{i = 1}^{N} y_{i} (β o + β^{T} x_{i}) - \log (1 + e^{(β o + β^{T} x_{i})})] + λ [\frac{(1 - α)}{2} { β }_{2}^{2} + α { β }_{1}]

wherein N is the number of patients used to learn the model, x_iis a vector of the centered gene expression data of patient i, y_iis the response outcome for patient i (responder/non-responder), λ controls the total penalty weight, α controls the elastic-net penalty weight: form lasso (α=1) to ridge (α=0), and α, λ are optimized using grid search based on best training accuracy; and, wherein after βo, β parameters are determined a response probability is determined by the formula:

P (x_{new}) = \frac{1}{1 + e^{- (β o + β^{T} x_{new})}}

and response prediction is determined with a threshold of 0.5 using the formula:

$Response (x_{new}) = {\begin{matrix} responder, & if P (x) \geq threshlod \\ non - responder, & else \end{matrix} .$

FIG. 1 shows a Schematic Overview of the Main Study (Screening through 16-Week Safety Follow-Up. Abbreviations: DBL=database lock; FU=follow-up; IV=intravenous; PE=primary endpoint; PL=placebo; q8w=every 8 weeks; SC=subcutaneous; SLE=systemic lupus erythematosus; SRI=SLEDAI-2K Responder Index; Wks=weeks.

FIG. 2 shows a Schematic Overview of the Study Including the Study Extension. Abbreviations: DBL=database lock; FU=follow-up; IV=intravenous; PE=primary endpoint; PL=placebo; q8w=every 8 weeks; SC=subcutaneous; SLE=systemic lupus erythematosus; SRI=SLEDAI-2K Responder Index; Wks=weeks.

FIGS. 3A and 3B show serum IFN-alpha protein levels and gene set variation analysis (GSVA) enrichment scores (ES) from blood before and after treatment with ustekinumab or placebo. FIG. 3A shows serum IFN-alpha protein levels before and after treatment with ustekinumab or placebo using the Quanterix SIMOA platform (Lexington, Mass.). Samples were analysed by the CRO Myriad RBM (Austin, Tex.) using their QHSP-IFN-alpha Simoa assay. Within-subject Log 2(fold/baseline) of IFN-alpha (Mean±95% CI) is indicated on the y-axis. The x-axis indicates time in weeks post-treatment, 0=baseline prior to treatment. Status for SRI-4 response at 24 weeks is indicated by a solid black line for a positive response and a grey dashed line for non-responder. FIG. 3B shows a scatter plot of gene set variation analysis (GSVA) enrichment scores (ES) using a composite 21-gene published IFN-I signature (Yao et al, 2009) in whole blood. Dots indicate subjects and connected dots indicate longitudinal assessment within same subject. A heavy solid black line shows the median for each group. The x-axis indicates time in weeks post-treatment, 0=baseline prior to treatment. Treatment groups are labelled as PBO for placebo and UST for ustekinumab. Status for SRI-4 response at 24 weeks is indicated after treatment group name by “—R” for a positive response and “—NR” for a non-responder. ES from a healthy donor cohort (Healthy) are also shown.

FIGS. 4A and 4B show ES scatter plots from GSVA of a blood plasma blast cell gene signature and a plasma cell gene signature. FIG. 4A shows scatter plots of GSVA ES using a plasma blast cell signature composed of the following genes: CD38, CD27, P63, CD43, IRF4, CAV1, BCMA, GAS6, CD126, IL15RA, DCN, PRG1, CCR2, CXCR3, CD162, CD102, ITGA6, XBP1, CD138, PRDM1, IGJ. FIG. 4B shows scatter plots of GSVA ES using a plasma cell gene signature of DC.M4.11 Plasma Cells (Banchereau et al, 2016). For both plots (FIG. 4A and FIG. 4B), dots indicate subjects and connected dots indicate longitudinal assessment within same subject. A heavy solid black line shows the median for each group. The X axis indicates time in weeks post-treatment, 0=baseline prior to treatment. Treatment groups are labelled as PBO for placebo and UST for ustekinumab. Status for SRI-4 response at 24 weeks is indicated after treatment group name by “—R” for a positive response and “—NR” for a non-responder. ES from a healthy donor cohort (Healthy) are also shown.

FIG. 5 shows serum IFN-gamma protein levels before and after ustekinumab or placebo treatment using the MSD platform (Rockville, Md.). Data was normalized by indicated population groups and treatment groups as Log 2(fold/baseline) population data. The x-axis indicates the time in weeks post-treatment. 0=baseline prior to treatment. Black symbols with a solid line indicate mean IFN-gamma serum levels from clinical responders at 24 weeks while the grey symbols with a dashed line indicate mean IFN-gamma levels in non-responders at 24 weeks. Error bars represent ±95% confidence interval (CI).

FIG. 6 shows a hierarchical clustering heat map for the expression analysis of 58 genes, including the IFN-I-inducible gene cluster and the cytotoxic cell-associated transcriptional gene cluster that are differentially expressed in baseline whole blood between SRI-4 clinical responders and non-responders at 24 weeks. The y-axis shows 2 predominant clusters comprised of 1) the IFN-I inducible genes and 2) the cytotoxic cell-associated transcriptional genes. The upper x-axis shows clinical responders and non-responders in black and light grey, respectively. As shown in the figure legend, scaled expression levels are represented as a greyscale gradient from black (2) to white (−2). Data was scaled for the purpose of better visualization in the heatmap. Scaled expression is computed by subtracting sample mean of the lupus patients and dividing by the standard deviation. The mean after this procedure is set to zero and higher expression levels are represented as a gradient from 0 to 2, and lower expression levels are represented as a gradient from <0 to −2. The IFN-I inducible gene cluster includes (in order from top to bottom): IFIT1, HERC5, RSAD2, EPSTI1, DDX60, OAS3, CMPK2, SAMD9L, EIF2AK2, DDX58, ZBP1, OASL, IFIT3, IFIT2, CARD17, PLSCR1, FBXO39, OTOF, LOC100133669, TIMM10, LAP3, IRF7, BST2, SPATS2L, RTP4, SIGLEC1, USP18, HERC6, DHX58 and ISG15. The cytotoxic cell-associated transcriptional gene cluster includes (in order from top to bottom): KLRC3, GNLY, GPR56, PRF1, GZMH, KLRD1, FGFBP2, FCRL6, NKG7, TRGC2, TRGV2, TARP, LOC387895, GZMK, MYBL1, and KLRG1. Other genes, except GSTM4 and XRRA1 (also cytotoxic cell-associated transcriptional genes), (in order from top to bottom): IGLV3-21, IGHV3-20, IGKV6-21, IGKV1-27, MIR3939, RN5S338, RN5S134, GSTM4, XRRA1, C15orf54, TRBV7-3, and LOC647859. Brackets show groupings for IFN-I inducible genes (IFN-I Inducible Genes) and cytotoxic cell-associated transcriptional genes (Cytotox Assoc. Genes).

FIG. 7 shows a scatter plot of GSVA ES for genes within the cytotoxic cell-associated transcriptional gene cluster from FIG. 6. Dots indicate subjects and connected dots indicate longitudinal assessment within same subject. A heavy solid black line shows the median for each group. The X axis indicates time in weeks post-treatment, 0=baseline prior to treatment. Treatment groups are labelled as PBO for placebo and UST for ustekinumab. Status for SRI-4 response at 24 weeks is indicated after treatment group name by “—R” for a positive response and “—NR” for a non-responder. T-test was used to calculate a p-value for the following: Healthy vs Week 0>0.05; paired t-test was used to calculate a p-value for the following: Week 0 vs Week 4≤0.05, Week 0 vs Week 24≤0.01, and Week 4 vs Week 24>0.05.

FIGS. 8A, 8B and 8C shows a hierarchical clustering heat map for the 8-gene whole blood transcriptional signature across three racially and ethnically diverse SLE cohorts. FIG. 8A consisted of ˜90% Caucasian (N=31 SLE donors), FIG. 8B consisted of ˜50% African American/˜40% Hispanic (N=52 SLE donors), and FIG. 8C consisted of Asian (N=30 SLE donors). For FIG. 8A, FIG. 8B, and FIG. 8C, the upper x-axis shows predicted clinical responders and predicted non-responders in black and light grey, respectively, for predictions based on the 8-gene signature* and the 31-gene signature**. Data was scaled for the purpose of better visualization in the heatmap. Scaled expression is computed by subtracting sample mean of the lupus patients and dividing by the standard deviation. The mean is set to zero and higher expression levels are represented as a gradient from >0 to 2, and low expression are represented as a gradient from <0 to −2. The 8-gene signature includes (in order from top to bottom): RSAD2 and IFIT3 from the IFN-I inducible gene cluster (FIG. 8A, FIG. 8B, and FIG. 8C) and GNLY, NKG7, PRF1, FCRL6, FGFBP2, GZMH from the cytotoxic cell-associated transcriptional gene cluster (FIG. 8A, FIG. 8B, and FIG. 8C).

FIG. 9 shows an illustration of the baseline (prior to treatment) whole blood transcription profile and the predicted clinical response for treatment with ustekinumab based on the expression levels of one or more cytotoxic cell-associated transcriptional genes and one or more Interferon I (IFN-I) inducible genes. An up arrow (↑) indicates higher expression levels, a down arrow (↓) indicates lower expression levels, a check mark (✓) indicates a predicted positive clinical response, and X indicates a predicted clinical non-response.

FIG. 10 shows GSVA ES indicating the distribution and median baseline blood expression levels in healthy controls (Healthy), and in responders (Y) and non-responders (N) to treatment with placebo or ustekinumab for a subset of cytotoxic cell-associated genes (PRF1, KLRD1, GZMH, NKG7, GNLY, FGFBP2, TRGC2, TARP, TRGV2). Responders and non-responders were determined after 24 weeks of treatment. P-values from a Student's T-test are indicated for the comparisons illustrated. In this plot the bar indicates median, box represents interquartile range, whiskers show 1.5 IQR, and width indicates density of distribution.

FIG. 11 shows a hierarchical clustering heat map of expression analysis for responders (Y) and non-responders (N) after placebo or ustekinumab treatment at week 24 for a subset of cytotoxic cell-associated genes (PRF1, KLRD1, GZMH, NKG7, GNLY, FGFBP2, TRGC2, TARP, TRGV2) at baseline. The upper x-axis shows clinical responders and non-responders in black and light grey, respectively. As shown in the figure legend, scaled expression levels are represented as a greyscale gradient from black (2) to white (−2). Data was scaled for the purpose of better visualization in the heatmap. Scaled expression is computed by subtracting sample mean of the lupus patients and dividing by the standard deviation. The mean after this procedure is set to zero and higher expression levels are represented as a gradient from >0 to 2, and lower expression levels are represented as a gradient from <0 to −2.

FIG. 12 shows the GSVA ES change over time in the indicated populations from 0-weeks to 24-weeks in UST responders (UST-R), UST non-responders (UST-NR), and patients treated with placebo (PBO) for a subset of cytotoxic cell-associated genes (PRF1, KLRD1, GZMH, NKG7, GNLY, FGFBP2, TRGC2, TARP, TRGV2). Lines indicate median and bars+/−median absolute deviation for populations as indicated.

FIG. 13 shows the GSVA ES for healthy donors, UST responders, and UST non-responders at baseline using the following cytotoxic cell-associated transcripts (MYBL1, FCRL6, FGFBP2, KLRD1, TRGV2, KLRG1, LOC387895, NKG7, GPR56, PRF1, GNLY, TARP, GZMH, GSTM4, KLRC3, TRGC2, GZMK, XRRA1). The density of GSVA distribution is indicated for each population. These relative distributions suggest that UST non-responders are enriched for patients with a lower GSVA ES for these cytotoxic cell-associated transcripts versus UST responders and further indicate that a cutoff could be set by using the distribution of a healthy control reference cohort. For example, cytotoxic low is defined as a patient with a cytotoxic signature score 0.4 below the median of the healthy reference cohort as indicated by the vertical line.

FIG. 14 shows the fold change gene expression results of the indicated cytotoxic cell-associated genes (PRF1, NKG7 and GNLY1) from RNA-sequencing data after 24-hour whole blood in vitro incubation with or without recombinant IL-12 or IL-23. RNA-sequencing data were normalized using edgeR library in R (Robinson et al, 2010). Log 2 fold change was calculated subtracting the median of Untreated to the median of each stimulation (IL-12, IL-23). To determine statistical significance a paired t-test was performed on the expression value. *** P<0.01, **** P<0.001

As used herein the method of treatment of lupus comprises administering isolated, recombinant and/or synthetic anti-IL-12, IL-23 and IL12/23p40 human antibodies and diagnostic and therapeutic compositions, methods and devices.

As used herein, an “anti-IL-12 antibody,” “anti-IL-23 antibody,” “anti-IL-12/23p40 antibody,” “IL-12/23p40 antibody,” “antibody portion,” or “antibody fragment” and/or “antibody variant” and the like include any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to, at least one complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework region, or any portion thereof, or at least one portion of an IL-12 and/or IL-23 receptor or binding protein, which can be incorporated into an antibody of the present invention. Such antibody optionally further affects a specific ligand, such as but not limited to, where such antibody modulates, decreases, increases, antagonizes, agonizes, mitigates, alleviates, blocks, inhibits, abrogates and/or interferes with at least one IL-12/23 activity or binding, or with IL-12/23 receptor activity or binding, in vitro, in situ and/or in vivo. As a non-limiting example, a suitable anti-IL-12/23p40 antibody, specified portion or variant of the present invention can bind at least one IL-12/23 molecule, or specified portions, variants or domains thereof. A suitable anti-IL-12/23p40 antibody, specified portion, or variant can also optionally affect at least one of IL-12/23 activity or function, such as but not limited to, RNA, DNA or protein synthesis, IL-12/23 release, IL-12/23 receptor signaling, membrane IL-12/23 cleavage, IL-12/23 activity, IL-12/23 production and/or synthesis.

The term “antibody” is further intended to encompass antibodies, digestion fragments, specified portions and variants thereof, including antibody mimetics or comprising portions of antibodies that mimic the structure and/or function of an antibody or specified fragment or portion thereof, including single chain antibodies and fragments thereof. Functional fragments include antigen-binding fragments that bind to a mammalian IL-12/23. For example, antibody fragments capable of binding to IL-12/23 or portions thereof, including, but not limited to, Fab (e.g., by papain digestion), Fab′ (e.g., by pepsin digestion and partial reduction) and F(ab′)₂(e.g., by pepsin digestion), facb (e.g., by plasmin digestion), pFc′ (e.g., by pepsin or plasmin digestion), Fd (e.g., by pepsin digestion, partial reduction and reaggregation), Fv or scFv (e.g., by molecular biology techniques) fragments, are encompassed by the invention (see, e.g., Colligan, Immunology, supra).

Such fragments can be produced by enzymatic cleavage, synthetic or recombinant techniques, as known in the art and/or as described herein. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, a combination gene encoding a F(ab′)₂heavy chain portion can be designed to include DNA sequences encoding the C_H1 domain and/or hinge region of the heavy chain. The various portions of antibodies can be joined together chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques.

As used herein, the term “human antibody” refers to an antibody in which substantially every part of the protein (e.g., CDR, framework, C_L, C_Hdomains (e.g., C_H1, C_H2, C_H3), hinge, (V_L, V_H)) is substantially non-immunogenic in humans, with only minor sequence changes or variations. A “human antibody” may also be an antibody that is derived from or closely matches human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). Often, this means that the human antibody is substantially non-immunogenic in humans. Human antibodies have been classified into groupings based on their amino acid sequence similarities. Accordingly, using a sequence similarity search, an antibody with a similar linear sequence can be chosen as a template to create a human antibody. Similarly, antibodies designated primate (monkey, baboon, chimpanzee, etc.), rodent (mouse, rat, rabbit, guinea pig, hamster, and the like) and other mammals designate such species, sub-genus, genus, sub-family, and family specific antibodies. Further, chimeric antibodies can include any combination of the above. Such changes or variations optionally and preferably retain or reduce the immunogenicity in humans or other species relative to non-modified antibodies. Thus, a human antibody is distinct from a chimeric or humanized antibody.

It is pointed out that a human antibody can be produced by a non-human animal or prokaryotic or eukaryotic cell that is capable of expressing functionally rearranged human immunoglobulin (e.g., heavy chain and/or light chain) genes. Further, when a human antibody is a single chain antibody, it can comprise a linker peptide that is not found in native human antibodies. For example, an Fv can comprise a linker peptide, such as two to about eight glycine or other amino acid residues, which connects the variable region of the heavy chain and the variable region of the light chain. Such linker peptides are considered to be of human origin.

Anti-IL-12/23p40 antibodies (also termed IL-12/23p40 antibodies) (or antibodies to IL-23) useful in the methods and compositions of the present invention can optionally be characterized by high affinity binding to IL-12/23p40 (or to IL-23) and, optionally and preferably, having low toxicity. In particular, an antibody, specified fragment or variant of the invention, where the individual components, such as the variable region, constant region and framework, individually and/or collectively, optionally and preferably possess low immunogenicity, is useful in the present invention. The antibodies that can be used in the invention are optionally characterized by their ability to treat patients for extended periods with measurable alleviation of symptoms and low and/or acceptable toxicity. Low or acceptable immunogenicity and/or high affinity, as well as other suitable properties, can contribute to the therapeutic results achieved. “Low immunogenicity” is defined herein as raising significant HAHA, HACA or HAMA responses in less than about 75%, or preferably less than about 50% of the patients treated and/or raising low titres in the patient treated (less than about 300, preferably less than about 100 measured with a double antigen enzyme immunoassay) (Elliott et al., Lancet 344:1125-1127 (1994), entirely incorporated herein by reference). “Low immunogenicity” can also be defined as the incidence of titrable levels of antibodies to the anti-IL-12 antibody in patients treated with anti-IL-12 antibody as occurring in less than 25% of patients treated, preferably, in less than 10% of patients treated with the recommended dose for the recommended course of therapy during the treatment period.

The terms “efficacy” and “effective” as used herein in the context of a dose, dosage regimen, treatment or method refer to the effectiveness of a particular dose, dosage or treatment regimen. Efficacy can be measured based on change in the course of the disease in response to an agent of the present invention. For example, an anti-IL12/23p40 or anti-IL23 antibody of the present invention (e.g., the anti-IL12/23p40 antibody ustekinumab) is administered to a patient in an amount and for a time sufficient to induce an improvement, preferably a sustained improvement, in at least one indicator that reflects the severity of the disorder that is being treated. Various indicators that reflect the extent of the subject's illness, disease or condition may be assessed for determining whether the amount and time of the treatment is sufficient. Such indicators include, for example, clinically recognized indicators of disease severity, symptoms, or manifestations of the disorder in question. The degree of improvement generally is determined by a physician, who may make this determination based on signs, symptoms, biopsies, or other test results, and who may also employ questionnaires that are administered to the subject, such as quality-of-life questionnaires developed for a given disease. For example, an anti-IL12/23p40 or anti-IL23 antibody of the present invention may be administered to achieve an improvement in a patient's condition related to Systemic Lupus Erythematosus (SLE). Improvement may be indicated by an improvement in an index of disease activity, by amelioration of clinical symptoms or by any other measure of disease activity. One such index of disease is the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score. The SLEDAI-2K is an established, validated disease activity index for Systemic Lupus Erythematosus (SLE) that is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE patients in the previous 30 days. Features are scored if present within the last 30 days with more severe features having higher scores and the scores are added to determine the total SLEDAI-2K score, which ranges from 0 to 105. Other disease activity indexes for systemic lupus erythematosus (SLE) disease activity assessment include, for example, the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the British Isles Lupus Assessment Group (BILAG) index. The CLASI index consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. The scores are calculated by simple addition based on the extent of the symptoms. Higher activity and damage scores indicate worse disease activity. The BILAG index is a measure of disease activity consisting of 97 questions in 9 organ systems, each put into 1 of 5 categories (A, B, C, D, E) depending on presence of items. Higher scores indicate more disease involvement.

The term “safe”, as it relates to a dose, dosage regimen, treatment or method with an anti-IL12/23p40 or anti-IL23 antibody of the present invention (e.g., the anti-IL12/23p40 antibody usetkinumab), refers to a favorable risk:benefit ratio with an acceptable frequency and/or acceptable severity of treatment-emergent adverse events (referred to as AEs or TEAEs) compared to the standard of care or to another comparator. An adverse event is an untoward medical occurrence in a patient administered a medicinal product. In particular, safe as it relates to a dose, dosage regimen or treatment with an anti-IL12/23p40 or anti-IL23 antibody of the present invention refers to with an acceptable frequency and/or acceptable severity of adverse events associated with administration of the antibody if attribution is considered to be possible, probable, or very likely due to the use of the anti-IL12/23p40 or anti-IL23 antibody.

As used herein, unless otherwise noted, the term “clinically proven” (used independently or to modify the terms “safe” and/or “effective”) shall mean that it has been proven by a clinical trial wherein the clinical trial has met the approval standards of U.S. Food and Drug Administration, EMEA or a corresponding national regulatory agency. For example, the clinical study may be an adequately sized, randomized, double-blinded study used to clinically prove the effects of the drug.

Utility

The isolated nucleic acids of the present invention can be used for production of at least one anti-IL-12/23p40 (or anti-IL-23) antibody or specified variant thereof, which can be used to measure or effect in an cell, tissue, organ or animal (including mammals and humans), to diagnose, monitor, modulate, treat, alleviate, help prevent the incidence of, or reduce the symptoms of, at least one IL-12/23 condition, selected from, but not limited to, at least one of an immune disorder or disease, a cardiovascular disorder or disease, an infectious, malignant, and/or neurologic disorder or disease, or other known or specified IL-12/23 related condition.

Such a method can comprise administering an effective amount of a composition or a pharmaceutical composition comprising at least one anti-IL-12/23p40 (or anti-IL-23) antibody to a cell, tissue, organ, animal or patient in need of such modulation, treatment, alleviation, prevention, or reduction in symptoms, effects or mechanisms. The effective amount can comprise an amount of about 0.001 to 500 mg/kg per single (e.g., bolus), multiple or continuous administration, or to achieve a serum concentration of 0.01-5000 μg/ml serum concentration per single, multiple, or continuous administration, or any effective range or value therein, as done and determined using known methods, as described herein or known in the relevant arts.

CITATIONS

All publications or patents cited herein, whether or not specifically designated, are entirely incorporated herein by reference as they show the state of the art at the time of the present invention and/or to provide description and enablement of the present invention. Publications refer to any scientific or patent publications, or any other information available in any media format, including all recorded, electronic or printed formats. The following references are entirely incorporated herein by reference: Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, NY (1987-2001); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, N.Y. (1989); Harlow and Lane, antibodies, a Laboratory Manual, Cold Spring Harbor, N.Y. (1989); Colligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, Inc., NY (1994-2001); Colligan et al., Current Protocols in Protein Science, John Wiley & Sons, NY, NY, (1997-2001).

Antibodies of the Present Invention—Production and Generation

At least one anti-IL-12/23p40 (or anti-IL-23) used in the method of the present invention can be optionally produced by a cell line, a mixed cell line, an immortalized cell or clonal population of immortalized cells, as well known in the art. See, e.g., Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, NY (1987-2001); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2^ndEdition, Cold Spring Harbor, N.Y. (1989); Harlow and Lane, antibodies, a Laboratory Manual, Cold Spring Harbor, N.Y. (1989); Colligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, Inc., NY (1994-2001); Colligan et al., Current Protocols in Protein Science, John Wiley & Sons, NY, NY, (1997-2001), each entirely incorporated herein by reference.

A preferred anti-IL-12/23p40 antibody is ustekinumab (STELARA®) having the heavy chain variable region amino acid sequence of SEQ ID NO:7 and the light chain variable region amino acid sequence of SEQ ID NO:8 and having the heavy chain CDR amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO: 3; and the light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. A preferred anti-IL-23 antibody is guselkumab (also referred to as CNTO1959). Other anti-IL-23 antibodies have sequences listed herein and are described in U.S. Pat. No. 7,935,344, the entire contents of which are incorporated herein by reference).

Human antibodies that are specific for human IL-12/23p40 or IL-23 proteins or fragments thereof can be raised against an appropriate immunogenic antigen, such as an isolated IL-12/23p40 protein, IL-23 protein and/or a portion thereof (including synthetic molecules, such as synthetic peptides). Other specific or general mammalian antibodies can be similarly raised. Preparation of immunogenic antigens, and monoclonal antibody production can be performed using any suitable technique.

In one approach, a hybridoma is produced by fusing a suitable immortal cell line (e.g., a myeloma cell line, such as, but not limited to, Sp2/0, Sp2/0-AG14, NSO, NS1, NS2, AE-1, L.5, L243, P3X63Ag8.653, Sp2 SA3, Sp2 MAI, Sp2 SS1, Sp2 SA5, U937, MLA 144, ACT IV, MOLT4, DA-1, JURKAT, WEHI, K-562, COS, RAJI, NIH 3T3, HL-60, MLA 144, NAMALWA, NEURO 2A, or the like, or heteromylomas, fusion products thereof, or any cell or fusion cell derived therefrom, or any other suitable cell line as known in the art) (see, e.g., www.atcc.org, www.lifetech.com., and the like), with antibody producing cells, such as, but not limited to, isolated or cloned spleen, peripheral blood, lymph, tonsil, or other immune or B cell containing cells, or any other cells expressing heavy or light chain constant or variable or framework or CDR sequences, either as endogenous or heterologous nucleic acid, as recombinant or endogenous, viral, bacterial, algal, prokaryotic, amphibian, insect, reptilian, fish, mammalian, rodent, equine, ovine, goat, sheep, primate, eukaryotic, genomic DNA, cDNA, rDNA, mitochondrial DNA or RNA, chloroplast DNA or RNA, hnRNA, mRNA, tRNA, single, double or triple stranded, hybridized, and the like or any combination thereof. See, e.g., Ausubel, supra, and Colligan, Immunology, supra, chapter 2, entirely incorporated herein by reference.

Antibody producing cells can also be obtained from the peripheral blood or, preferably, the spleen or lymph nodes, of humans or other suitable animals that have been immunized with the antigen of interest. Any other suitable host cell can also be used for expressing heterologous or endogenous nucleic acid encoding an antibody, specified fragment or variant thereof, of the present invention. The fused cells (hybridomas) or recombinant cells can be isolated using selective culture conditions or other suitable known methods, and cloned by limiting dilution or cell sorting, or other known methods. Cells which produce antibodies with the desired specificity can be selected by a suitable assay (e.g., ELISA).

Other suitable methods of producing or isolating antibodies of the requisite specificity can be used, including, but not limited to, methods that select recombinant antibody from a peptide or protein library (e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, or the like, display library; e.g., as available from Cambridge antibody Technologies, Cambridgeshire, UK; MorphoSys, Martinsreid/Planegg, DE; Biovation, Aberdeen, Scotland, UK; BioInvent, Lund, Sweden; Dyax Corp., Enzon, Affymax/Biosite; Xoma, Berkeley, Calif.; Ixsys. See, e.g., EP 368,684, PCT/GB91/01134; PCT/GB92/01755; PCT/GB92/002240; PCT/GB92/00883; PCT/GB93/00605; U.S. Ser. No. 08/350,260(5/12/94); PCT/GB94/01422; PCT/GB94/02662; PCT/GB97/01835; (CAT/MRC); WO90/14443; WO90/14424; WO90/14430; PCT/US94/1234; WO92/18619; WO96/07754; (Scripps); WO96/13583, WO97/08320 (MorphoSys); WO95/16027 (BioInvent); WO88/06630; WO90/3809 (Dyax); U.S. Pat. No. 4,704,692 (Enzon); PCT/US91/02989 (Affymax); WO89/06283; EP 371 998; EP 550 400; (Xoma); EP 229 046; PCT/US91/07149 (Ixsys); or stochastically generated peptides or proteins—U.S. Pat. Nos. 5,723,323, 5,763,192, 5,814,476, 5,817,483, 5,824,514, 5,976,862, WO 86/05803, EP 590 689 (Ixsys, predecessor of Applied Molecular Evolution (AME), each entirely incorporated herein by reference)) or that rely upon immunization of transgenic animals (e.g., SCID mice, Nguyen et al., Microbiol. Immunol. 41:901-907 (1997); Sandhu et al., Crit. Rev. Biotechnol. 16:95-118 (1996); Eren et al., Immunol. 93:154-161 (1998), each entirely incorporated by reference as well as related patents and applications) that are capable of producing a repertoire of human antibodies, as known in the art and/or as described herein. Such techniques include, but are not limited to, ribosome display (Hanes et al., Proc. Natl. Acad. Sci. USA, 94:4937-4942 (May 1997); Hanes et al., Proc. Natl. Acad. Sci. USA, 95:14130-14135 (November 1998)); single cell antibody producing technologies (e.g., selected lymphocyte antibody method (“SLAM”) (U.S. Pat. No. 5,627,052, Wen et al., J. Immunol. 17:887-892 (1987); Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-7848 (1996)); gel microdroplet and flow cytometry (Powell et al., Biotechnol. 8:333-337 (1990); One Cell Systems, Cambridge, Mass.; Gray et al., J. Imm. Meth. 182:155-163 (1995); Kenny et al., Bio/Technol. 13:787-790 (1995)); B-cell selection (Steenbakkers et al., Molec. Biol. Reports 19:125-134 (1994); Jonak et al., Progress Biotech, Vol. 5, In Vitro Immunization in Hybridoma Technology, Borrebaeck, ed., Elsevier Science Publishers B.V., Amsterdam, Netherlands (1988)).

Methods for engineering or humanizing non-human or human antibodies can also be used and are well known in the art. Generally, a humanized or engineered antibody has one or more amino acid residues from a source that is non-human, e.g., but not limited to, mouse, rat, rabbit, non-human primate or other mammal. These non-human amino acid residues are replaced by residues often referred to as “import” residues, which are typically taken from an “import” variable, constant or other domain of a known human sequence.

Known human Ig sequences are disclosed, e.g.,
www.ncbi.nlm.nih.gov/entrez/query.fcgi;
www.ncbi.nih.gov/igblast;
www.atcc.org/phage/hdb.html;
www.mrc-cpe.cam.ac.uk/ALIGNMENTS.php;
www.kabatdatabase.com/top.html;
ftp.ncbi.nih.gov/repository/kabat;
www.sciquest.com;
www.abcam.com;
www.antibodyresource.com/onlinecomp.html;
www.public.iastate.edu/˜pedro/research_tools.html;
www.whfreeman.com/immunology/CH05/kuby05.htm;
www.hhmi.org/grants/lectures/1996/vlab;
www.path.cam.ac.uk/˜mrc7/mikeimages.html;
mcb.harvard.edu/BioLinks/Immunology.html;
www.immunologylink.com;
pathbox.wustl.edu/˜hcenter/index.html;
www.appliedbiosystems.com;
www.nal.usda.gov/awic/pubs/antibody;
www.m.ehime-u.ac.jp/˜yasuhito/Elisa.html;
www.biodesign.com;
www.cancerresearchuk.org;
www.biotech.ufl.edu;
www.isac-net.org;
baserv.uci kun.nl/˜jraats/links1.html;
www.recab.uni-hd.de/immuno.bme.nwu.edu;
www.mrc-cpe.cam.ac.uk;
www.ibt.unam.mx/vir/V_mice.html;
www.bioinf.org.uk/abs;
antibody.bath.ac.uk;
www.unizh.ch;
www.cryst.bbk.ac.uk/˜ubcg07s;
www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.html;
www.path.cam.ac.uk/˜mrc7/humanisation/TAHHP.html;
www.ibt.unam.mx/vir/structure/stat_aim.html;
www.biosci.missouri.edu/smithgp/index.html;
www.jerini.de;
and Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Dept. Health (1983), each entirely incorporated herein by reference.

Such imported sequences can be used to reduce immunogenicity or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic, as known in the art. In general, the CDR residues are directly and most substantially involved in influencing antigen binding. Accordingly, part or all of the non-human or human CDR sequences are maintained while the non-human sequences of the variable and constant regions may be replaced with human or other amino acids.

Antibodies can also optionally be humanized or human antibodies engineered with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, humanized (or human) antibodies can be optionally prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, framework (FR) residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.

In addition, the human anti-IL-12/23p40 (or anti-IL-23) specific antibody used in the method of the present invention may comprise a human germline light chain framework. In particular embodiments, the light chain germline sequence is selected from human VK sequences including, but not limited to, A1, A10, A11, A14, A17, A18, A19, A2, A20, A23, A26, A27, A3, A30, A5, A7, B2, B3, L1, L10, L11, L12, L14, L15, L16, L18, L19, L2, L20, L22, L23, L24, L25, L4/18a, L5, L6, L8, L9, O1, O11, O12, O14, O18, O2, O4, and O8. In certain embodiments, this light chain human germline framework is selected from V1-11, V1-13, V1-16, V1-17, V1-18, V1-19, V1-2, V1-20, V1-22, V1-3, V1-4, V1-5, V1-7, V1-9, V2-1, V2-11, V2-13, V2-14, V2-15, V2-17, V2-19, V2-6, V2-7, V2-8, V3-2, V3-3, V3-4, V4-1, V4-2, V4-3, V4-4, V4-6, V5-1, V5-2, V5-4, and V5-6.

In other embodiments, the human anti-IL-12/23p40 (or anti-IL-23) specific antibody used in the method of the present invention may comprise a human germline heavy chain framework. In particular embodiments, this heavy chain human germline framework is selected from VH1-18, VH1-2, VH1-24, VH1-3, VH1-45, VH1-46, VH1-58, VH1-69, VH1-8, VH2-26, VH2-5, VH2-70, VH3-11, VH3-13, VH3-15, VH3-16, VH3-20, VH3-21, VH3-23, VH3-30, VH3-33, VH3-35, VH3-38, VH3-43, VH3-48, VH3-49, VH3-53, VH3-64, VH3-66, VH3-7, VH3-72, VH3-73, VH3-74, VH3-9, VH4-28, VH4-31, VH4-34, VH4-39, VH4-4, VH4-59, VH4-61, VH5-51, VH6-1, and VH7-81.

In particular embodiments, the light chain variable region and/or heavy chain variable region comprises a framework region or at least a portion of a framework region (e.g., containing 2 or 3 subregions, such as FR2 and FR3). In certain embodiments, at least FRL1, FRL2, FRL3, or FRL4 is fully human. In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 is fully human. In some embodiments, at least FRL1, FRL2, FRL3, or FRL4 is a germline sequence (e.g., human germline) or comprises human consensus sequences for the particular framework (readily available at the sources of known human Ig sequences described above). In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 is a germline sequence (e.g., human germline) or comprises human consensus sequences for the particular framework. In preferred embodiments, the framework region is a fully human framework region.

Humanization or engineering of antibodies of the present invention can be performed using any known method, such as but not limited to those described in, Winter (Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol. 151: 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993), U.S. Pat. Nos. 5,723,323, 5,976,862, 5,824,514, 5,817,483, 5,814,476, 5,763,192, 5,723,323, 5,766886, 5714352, 6204023, 6180370, 5693762, 5530101, 5585089, 5225539; 4816567, PCT/: US98/16280, US96/18978, US91/09630, US91/05939, US94/01234, GB89/01334, GB91/01134, GB92/01755; WO90/14443, WO90/14424, WO90/14430, EP 229246, each entirely incorporated herein by reference, included references cited therein.

In certain embodiments, the antibody comprises an altered (e.g., mutated) Fc region. For example, in some embodiments, the Fc region has been altered to reduce or enhance the effector functions of the antibody. In some embodiments, the Fc region is an isotype selected from IgM, IgA, IgG, IgE, or other isotype. Alternatively, or additionally, it may be useful to combine amino acid modifications with one or more further amino acid modifications that alter C1q binding and/or the complement dependent cytotoxicity function of the Fc region of an IL-23 binding molecule. The starting polypeptide of particular interest may be one that binds to C1q and displays complement dependent cytotoxicity (CDC). Polypeptides with pre-existing C1q binding activity, optionally further having the ability to mediate CDC may be modified such that one or both of these activities are enhanced. Amino acid modifications that alter C1q and/or modify its complement dependent cytotoxicity function are described, for example, in WO0042072, which is hereby incorporated by reference.

As disclosed above, one can design an Fc region of the human anti-IL-12/23p40 (or anti-IL-23) specific antibody of the present invention with altered effector function, e.g., by modifying C1q binding and/or FcγR binding and thereby changing complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC) activity. “Effector functions” are responsible for activating or diminishing a biological activity (e.g., in a subject). Examples of effector functions include, but are not limited to: C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions may require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays (e.g., Fc binding assays, ADCC assays, CDC assays, etc.).

For example, one can generate a variant Fc region of the human anti-IL-12/23p40 (or anti-IL-23) antibody with improved C1q binding and improved FcγRIIIbinding (e.g., having both improved ADCC activity and improved CDC activity). Alternatively, if it is desired that effector function be reduced or ablated, a variant Fc region can be engineered with reduced CDC activity and/or reduced ADCC activity. In other embodiments, only one of these activities may be increased, and, optionally, also the other activity reduced (e.g., to generate an Fc region variant with improved ADCC activity, but reduced CDC activity and vice versa).

Fc mutations can also be introduced in engineer to alter their interaction with the neonatal Fc receptor (FcRn) and improve their pharmaco*kinetic properties. A collection of human Fc variants with improved binding to the FcRn have been described (Shields et al., (2001). High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR, J. Biol. Chem. 276:6591-6604).

Another type of amino acid substitution serves to alter the glycosylation pattern of the Fc region of the human anti-IL-12/23p40 (or anti-IL-23) specific antibody. Glycosylation of an Fc region is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. The recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain peptide sequences are asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline. Thus, the presence of either of these peptide sequences in a polypeptide creates a potential glycosylation site.

The glycosylation pattern may be altered, for example, by deleting one or more glycosylation site(s) found in the polypeptide, and/or adding one or more glycosylation sites that are not present in the polypeptide. Addition of glycosylation sites to the Fc region of a human IL-23 specific antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). An exemplary glycosylation variant has an amino acid substitution of residue Asn 297 of the heavy chain. The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original polypeptide (for O-linked glycosylation sites). Additionally, a change of Asn 297 to Ala can remove one of the glycosylation sites.

In certain embodiments, the human anti-IL-12/23p40 (or anti-IL-23) specific antibody of the present invention is expressed in cells that express beta (1,4)-N-acetylglucosaminyltransferase III (GnT III), such that GnT III adds GlcNAc to the human anti-IL-12/23p40 (or anti-IL-23) antibody. Methods for producing antibodies in such a fashion are provided in WO/9954342, WO/03011878, patent publication 20030003097A1, and Umana et al., Nature Biotechnology, 17:176-180, February 1999; all of which are herein specifically incorporated by reference in their entireties.

The human anti-IL-12/23p40 (or anti-IL-23) antibody can also be optionally generated by immunization of a transgenic animal (e.g., mouse, rat, hamster, non-human primate, and the like) capable of producing a repertoire of human antibodies, as described herein and/or as known in the art. Cells that produce a human anti-IL-12/23p40 (or anti-IL-23) antibody can be isolated from such animals and immortalized using suitable methods, such as the methods described herein.

Transgenic mice that can produce a repertoire of human antibodies that bind to human antigens can be produced by known methods (e.g., but not limited to, U.S. Pat. Nos. 5,770,428, 5,569,825, 5,545,806, 5,625,126, 5,625,825, 5,633,425, 5,661,016 and 5,789,650 issued to Lonberg et al.; Jakobovits et al. WO 98/50433, Jakobovits et al. WO 98/24893, Lonberg et al. WO 98/24884, Lonberg et al. WO 97/13852, Lonberg et al. WO 94/25585, Kucherlapate et al. WO 96/34096, Kucherlapate et al. EP 0463 151 B1, Kucherlapate et al. EP 0710 719 A1, Surani et al. U.S. Pat. No. 5,545,807, Bruggemann et al. WO 90/04036, Bruggemann et al. EP 0438 474 B1, Lonberg et al. EP 0814 259 A2, Lonberg et al. GB 2 272 440 A, Lonberg et al. Nature 368:856-859 (1994), Taylor et al., Int. Immunol. 6(4)579-591 (1994), Green et al, Nature Genetics 7:13-21 (1994), Mendez et al., Nature Genetics 15:146-156 (1997), Taylor et al., Nucleic Acids Research 20(23):6287-6295 (1992), Tuaillon et al., Proc Natl Acad Sci USA 90(8)3720-3724 (1993), Lonberg et al., Int Rev Immunol 13(1):65-93 (1995) and Fishwald et al., Nat Biotechnol 14(7):845-851 (1996), which are each entirely incorporated herein by reference). Generally, these mice comprise at least one transgene comprising DNA from at least one human immunoglobulin locus that is functionally rearranged, or which can undergo functional rearrangement. The endogenous immunoglobulin loci in such mice can be disrupted or deleted to eliminate the capacity of the animal to produce antibodies encoded by endogenous genes.

Screening antibodies for specific binding to similar proteins or fragments can be conveniently achieved using peptide display libraries. This method involves the screening of large collections of peptides for individual members having the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be from 3 to 5000 or more amino acids in length, frequently from 5-100 amino acids long, and often from about 8 to 25 amino acids long. In addition to direct chemical synthetic methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves the display of a peptide sequence on the surface of a bacteriophage or cell. Each bacteriophage or cell contains the nucleotide sequence encoding the particular displayed peptide sequence. Such methods are described in PCT Patent Publication Nos. 91/17271, 91/18980, 91/19818, and 93/08278.

Other systems for generating libraries of peptides have aspects of both in vitro chemical synthesis and recombinant methods. See, PCT Patent Publication Nos. 92/05258, 92/14843, and 96/19256. See also, U.S. Pat. Nos. 5,658,754; and 5,643,768. Peptide display libraries, vector, and screening kits are commercially available from such suppliers as Invitrogen (Carlsbad, Calif.), and Cambridge antibody Technologies (Cambridgeshire, UK). See, e.g., U.S. Pat. Nos. 4,704,692, 4,939,666, 4,946,778, 5,260,203, 5,455,030, 5,518,889, 5,534,621, 5,656,730, 5,763,733, 5,767,260, 5,856,456, assigned to Enzon; U.S. Pat. Nos. 5,223,409, 5,403,484, 5,571,698, 5,837,500, assigned to Dyax, 5427908, 5580717, assigned to Affymax; 5885793, assigned to Cambridge antibody Technologies; 5750373, assigned to Genentech, 5618920, 5595898, 5576195, 5698435, 5693493, 5698417, assigned to Xoma, Colligan, supra; Ausubel, supra; or Sambrook, supra, each of the above patents and publications entirely incorporated herein by reference.

Antibodies used in the method of the present invention can also be prepared using at least one anti-IL-12/23p40 (or anti-IL-23) antibody encoding nucleic acid to provide transgenic animals or mammals, such as goats, cows, horses, sheep, rabbits, and the like, that produce such antibodies in their milk. Such animals can be provided using known methods. See, e.g., but not limited to, U.S. Pat. Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362; 5,304,489, and the like, each of which is entirely incorporated herein by reference.

Antibodies used in the method of the present invention can additionally be prepared using at least one anti-IL-12/23p40 (or anti-IL-23) antibody encoding nucleic acid to provide transgenic plants and cultured plant cells (e.g., but not limited to, tobacco and maize) that produce such antibodies, specified portions or variants in the plant parts or in cells cultured therefrom. As a non-limiting example, transgenic tobacco leaves expressing recombinant proteins have been successfully used to provide large amounts of recombinant proteins, e.g., using an inducible promoter. See, e.g., Cramer et al., Curr. Top. Microbol. Immunol. 240:95-118 (1999) and references cited therein. Also, transgenic maize have been used to express mammalian proteins at commercial production levels, with biological activities equivalent to those produced in other recombinant systems or purified from natural sources. See, e.g., Hood et al., Adv. Exp. Med. Biol. 464:127-147 (1999) and references cited therein. Antibodies have also been produced in large amounts from transgenic plant seeds including antibody fragments, such as single chain antibodies (scFv's), including tobacco seeds and potato tubers. See, e.g., Conrad et al., Plant Mol. Biol. 38:101-109 (1998) and references cited therein. Thus, antibodies of the present invention can also be produced using transgenic plants, according to known methods. See also, e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99-108 (October, 1999), Ma et al., Trends Biotechnol. 13:522-7 (1995); Ma et al., Plant Physiol. 109:341-6 (1995); Whitelam et al., Biochem. Soc. Trans. 22:940-944 (1994); and references cited therein. Each of the above references is entirely incorporated herein by reference.

The antibodies used in the method of the invention can bind human IL-12/IL-23p40 or IL-23 with a wide range of affinities (K_D). In a preferred embodiment, a human mAb can optionally bind human IL-12/IL-23p40 or IL-23 with high affinity. For example, a human mAb can bind human IL-12/IL-23p40 or IL-23 with a K_Dequal to or less than about 10⁻⁷M, such as but not limited to, 0.1-9.9 (or any range or value therein)×10′, 10⁻⁸, 10⁻⁹, 10⁻¹⁰, 10⁻¹¹, 10⁻¹², 10⁻¹³or any range or value therein.

The affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method. (See, for example, Berzofsky, et al., “Antibody-Antigen Interactions,” In Fundamental Immunology, Paul, W. E., Ed., Raven Press: New York, N Y (1984); Kuby, Janis Immunology, W. H. Freeman and Company: New York, N.Y. (1992); and methods described herein). The measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions (e.g., salt concentration, pH). Thus, measurements of affinity and other antigen-binding parameters (e.g., K_D, K_a, K_d) are preferably made with standardized solutions of antibody and antigen, and a standardized buffer, such as the buffer described herein.

Nucleic Acid Molecules

Using the information provided herein, for example, the nucleotide sequences encoding at least 70-100% of the contiguous amino acids of at least one of the light or heavy chain variable or CDR regions described herein, among other sequences disclosed herein, specified fragments, variants or consensus sequences thereof, or a deposited vector comprising at least one of these sequences, a nucleic acid molecule of the present invention encoding at least one IL-12/IL-23p40 or IL-23 antibody can be obtained using methods described herein or as known in the art.

Nucleic acid molecules of the present invention can be in the form of RNA, such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA, including, but not limited to, cDNA and genomic DNA obtained by cloning or produced synthetically, or any combinations thereof. The DNA can be triple-stranded, double-stranded or single-stranded, or any combination thereof. Any portion of at least one strand of the DNA or RNA can be the coding strand, also known as the sense strand, or it can be the non-coding strand, also referred to as the anti-sense strand.

Isolated nucleic acid molecules used in the method of the present invention can include nucleic acid molecules comprising an open reading frame (ORF), optionally, with one or more introns, e.g., but not limited to, at least one specified portion of at least one CDR, such as CDR1, CDR2 and/or CDR3 of at least one heavy chain or light chain; nucleic acid molecules comprising the coding sequence for an anti-IL-12/IL-23p40 or IL-23 antibody or variable region; and nucleic acid molecules which comprise a nucleotide sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode at least one anti-IL-12/IL-23p40 or IL-23 antibody as described herein and/or as known in the art. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate nucleic acid variants that code for specific anti-IL-12/IL-23p40 or IL-23 antibodies used in the method of the present invention. See, e.g., Ausubel, et al., supra, and such nucleic acid variants are included in the present invention. Non-limiting examples of isolated nucleic acid molecules include nucleic acids encoding HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3, respectively.

As indicated herein, nucleic acid molecules which comprise a nucleic acid encoding an anti-IL-12/IL-23p40 or IL-23 antibody can include, but are not limited to, those encoding the amino acid sequence of an antibody fragment, by itself; the coding sequence for the entire antibody or a portion thereof; the coding sequence for an antibody, fragment or portion, as well as additional sequences, such as the coding sequence of at least one signal leader or fusion peptide, with or without the aforementioned additional coding sequences, such as at least one intron, together with additional, non-coding sequences, including but not limited to, non-coding 5′ and 3′ sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals (for example, ribosome binding and stability of mRNA); an additional coding sequence that codes for additional amino acids, such as those that provide additional functionalities. Thus, the sequence encoding an antibody can be fused to a marker sequence, such as a sequence encoding a peptide that facilitates purification of the fused antibody comprising an antibody fragment or portion.

Polynucleotides Selectively Hybridizing to a Polynucleotide as Described Herein

The method of the present invention uses isolated nucleic acids that hybridize under selective hybridization conditions to a polynucleotide disclosed herein. Thus, the polynucleotides of this embodiment can be used for isolating, detecting, and/or quantifying nucleic acids comprising such polynucleotides. For example, polynucleotides of the present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library. In some embodiments, the polynucleotides are genomic or cDNA sequences isolated, or otherwise complementary to, a cDNA from a human or mammalian nucleic acid library.

Preferably, the cDNA library comprises at least 80% full-length sequences, preferably, at least 85% or 90% full-length sequences, and, more preferably, at least 95% full-length sequences. The cDNA libraries can be normalized to increase the representation of rare sequences. Low or moderate stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary sequences. Moderate and high stringency conditions can optionally be employed for sequences of greater identity. Low stringency conditions allow selective hybridization of sequences having about 70% sequence identity and can be employed to identify orthologous or paralogous sequences.

Optionally, polynucleotides will encode at least a portion of an antibody. The polynucleotides embrace nucleic acid sequences that can be employed for selective hybridization to a polynucleotide encoding an antibody of the present invention. See, e.g., Ausubel, supra; Colligan, supra, each entirely incorporated herein by reference.

Construction of Nucleic Acids

The isolated nucleic acids can be made using (a) recombinant methods, (b) synthetic techniques, (c) purification techniques, and/or (d) combinations thereof, as well-known in the art.

The nucleic acids can conveniently comprise sequences in addition to a polynucleotide of the present invention. For example, a multi-cloning site comprising one or more endonuclease restriction sites can be inserted into the nucleic acid to aid in isolation of the polynucleotide. Also, translatable sequences can be inserted to aid in the isolation of the translated polynucleotide of the present invention. For example, a hexa-histidine marker sequence provides a convenient means to purify the proteins of the present invention. The nucleic acid of the present invention, excluding the coding sequence, is optionally a vector, adapter, or linker for cloning and/or expression of a polynucleotide of the present invention.

Additional sequences can be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation of the polynucleotide, or to improve the introduction of the polynucleotide into a cell. Use of cloning vectors, expression vectors, adapters, and linkers is well known in the art. (See, e.g., Ausubel, supra; or Sambrook, supra)

Recombinant Methods for Constructing Nucleic Acids

The isolated nucleic acid compositions, such as RNA, cDNA, genomic DNA, or any combination thereof, can be obtained from biological sources using any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes that selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library. The isolation of RNA, and construction of cDNA and genomic libraries, are well known to those of ordinary skill in the art. (See, e.g., Ausubel, supra; or Sambrook, supra)

Nucleic Acid Screening and Isolation Methods

A cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide used in the method of the present invention, such as those disclosed herein. Probes can be used to hybridize with genomic DNA or cDNA sequences to isolate hom*ologous genes in the same or different organisms. Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by one or more of temperature, ionic strength, pH and the presence of a partially denaturing solvent, such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through, for example, manipulation of the concentration of formamide within the range of 0% to 50%. The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100%, or 70-100%, or any range or value therein. However, it should be understood that minor sequence variations in the probes and primers can be compensated for by reducing the stringency of the hybridization and/or wash medium.

Methods of amplification of RNA or DNA are well known in the art and can be used according to the present invention without undue experimentation, based on the teaching and guidance presented herein.

Known methods of DNA or RNA amplification include, but are not limited to, polymerase chain reaction (PCR) and related amplification processes (see, e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188, to Mullis, et al.; 4,795,699 and 4,921,794 to Tabor, et al; U.S. Pat. No. 5,142,033 to Innis; U.S. Pat. No. 5,122,464 to Wilson, et al.; U.S. Pat. No. 5,091,310 to Innis; U.S. Pat. No. 5,066,584 to Gyllensten, et al; U.S. Pat. No. 4,889,818 to Gelfand, et al; U.S. Pat. No. 4,994,370 to Silver, et al; U.S. Pat. No. 4,766,067 to Biswas; U.S. Pat. No. 4,656,134 to Ringold) and RNA mediated amplification that uses anti-sense RNA to the target sequence as a template for double-stranded DNA synthesis (U.S. Pat. No. 5,130,238 to Malek, et al, with the tradename NASBA), the entire contents of which references are incorporated herein by reference. (See, e.g., Ausubel, supra; or Sambrook, supra.)

For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides used in the method of the present invention and related genes directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods can also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to direct persons of skill through in vitro amplification methods are found in Berger, supra, Sambrook, supra, and Ausubel, supra, as well as Mullis, et al., U.S. Pat. No. 4,683,202 (1987); and Innis, et al., PCR Protocols A Guide to Methods and Applications, Eds., Academic Press Inc., San Diego, Calif. (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech). Additionally, e.g., the T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.

Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids used in the method of the present invention can also be prepared by direct chemical synthesis by known methods (see, e.g., Ausubel, et al., supra). Chemical synthesis generally produces a single-stranded oligonucleotide, which can be converted into double-stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill in the art will recognize that while chemical synthesis of DNA can be limited to sequences of about 100 or more bases, longer sequences can be obtained by the ligation of shorter sequences.

Recombinant Expression Cassettes

The present invention uses recombinant expression cassettes comprising a nucleic acid. A nucleic acid sequence, for example, a cDNA or a genomic sequence encoding an antibody used in the method of the present invention, can be used to construct a recombinant expression cassette that can be introduced into at least one desired host cell. A recombinant expression cassette will typically comprise a polynucleotide operably linked to transcriptional initiation regulatory sequences that will direct the transcription of the polynucleotide in the intended host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids.

In some embodiments, isolated nucleic acids that serve as promoter, enhancer, or other elements can be introduced in the appropriate position (upstream, downstream or in the intron) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide. For example, endogenous promoters can be altered in vivo or in vitro by mutation, deletion and/or substitution.

Vectors and Host Cells

The present invention also relates to vectors that include isolated nucleic acid molecules, host cells that are genetically engineered with the recombinant vectors, and the production of at least one anti-IL-23 antibody by recombinant techniques, as is well known in the art. See, e.g., Sambrook, et al., supra; Ausubel, et al., supra, each entirely incorporated herein by reference.

The polynucleotides can optionally be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it can be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (e.g., UAA, UGA or UAG) appropriately positioned at the end of the mRNA to be translated, with UAA and UAG preferred for mammalian or eukaryotic cell expression.

Expression vectors will preferably but optionally include at least one selectable marker. Such markers include, e.g., but are not limited to, methotrexate (MTX), dihydrofolate reductase (DHFR, U.S. Pat. Nos. 4,399,216; 4,634,665; 4,656,134; 4,956,288; 5,149,636; 5,179,017, ampicillin, neomycin (G418), mycophenolic acid, or glutamine synthetase (GS, U.S. Pat. Nos. 5,122,464; 5,770,359; 5,827,739) resistance for eukaryotic cell culture, and tetracycline or ampicillin resistance genes for culturing in E. coli and other bacteria or prokaryotics (the above patents are entirely incorporated hereby by reference). Appropriate culture mediums and conditions for the above-described host cells are known in the art. Suitable vectors will be readily apparent to the skilled artisan. Introduction of a vector construct into a host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other known methods. Such methods are described in the art, such as Sambrook, supra, Chapters 1-4 and 16-18; Ausubel, supra, Chapters 1, 9, 13, 15, 16.

At least one antibody used in the method of the present invention can be expressed in a modified form, such as a fusion protein, and can include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, can be added to the N-terminus of an antibody to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to an antibody of the present invention to facilitate purification. Such regions can be removed prior to final preparation of an antibody or at least one fragment thereof. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Chapters 17.29-17.42 and 18.1-18.74; Ausubel, supra, Chapters 16, 17 and 18.

Those of ordinary skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein used in the method of the present invention. Alternatively, nucleic acids can be expressed in a host cell by turning on (by manipulation) in a host cell that contains endogenous DNA encoding an antibody. Such methods are well known in the art, e.g., as described in U.S. Pat. Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761, entirely incorporated herein by reference.

Illustrative of cell cultures useful for the production of the antibodies, specified portions or variants thereof, are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions or bioreactors can also be used. A number of suitable host cell lines capable of expressing intact glycosylated proteins have been developed in the art, and include the COS-1 (e.g., ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC CRL-10), CHO (e.g., ATCC CRL 1610) and BSC-1 (e.g., ATCC CRL-26) cell lines, Cos-7 cells, CHO cells, hep G2 cells, P3X63Ag8.653, SP2/0-Ag14, 293 cells, HeLa cells and the like, which are readily available from, for example, American Type Culture Collection, Manassas, Va. (www. atcc.org). Preferred host cells include cells of lymphoid origin, such as myeloma and lymphoma cells. Particularly preferred host cells are P3X63Ag8.653 cells (ATCC Accession Number CRL-1580) and SP2/0-Ag14 cells (ATCC Accession Number CRL-1851). In a particularly preferred embodiment, the recombinant cell is a P3X63Ab8.653 or a SP2/0-Ag14 cell.

Expression vectors for these cells can include one or more of the following expression control sequences, such as, but not limited to, an origin of replication; a promoter (e.g., late or early SV40 promoters, the CMV promoter (U.S. Pat. Nos. 5,168,062; 5,385,839), an HSV tk promoter, a pgk (phosphoglycerate kinase) promoter, an EF-1 alpha promoter (U.S. Pat. No. 5,266,491), at least one human immunoglobulin promoter; an enhancer, and/or processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. See, e.g., Ausubel et al., supra; Sambrook, et al., supra. Other cells useful for production of nucleic acids or proteins of the present invention are known and/or available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (www.atcc.org) or other known or commercial sources.

When eukaryotic host cells are employed, polyadenlyation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenlyation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript can also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, et al., J. Virol. 45:773-781 (1983)). Additionally, gene sequences to control replication in the host cell can be incorporated into the vector, as known in the art.

Purification of an Antibody

An anti-IL-12/IL-23p40 or IL-23 antibody can be recovered and purified from recombinant cell cultures by well-known methods including, but not limited to, protein A purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography (“HPLC”) can also be employed for purification. See, e.g., Colligan, Current Protocols in Immunology, or Current Protocols in Protein Science, John Wiley & Sons, NY, NY, (1997-2001), e.g., Chapters 1, 4, 6, 8, 9, 10, each entirely incorporated herein by reference.

Antibodies used in the method of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a eukaryotic host, including, for example, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the antibody can be glycosylated or can be non-glycosylated, with glycosylated preferred. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Sections 17.37-17.42; Ausubel, supra, Chapters 10, 12, 13, 16, 18 and 20, Colligan, Protein Science, supra, Chapters 12-14, all entirely incorporated herein by reference.

Anti-IL-12/IL-23p40 or IL-23 Antibodies

An anti-IL-12/IL-23p40 or IL-23 antibody according to the present invention includes any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to, at least one ligand binding portion (LBP), such as but not limited to, a complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a framework region (e.g., FR1, FR2, FR3, FR4 or fragment thereof, further optionally comprising at least one substitution, insertion or deletion), a heavy chain or light chain constant region, (e.g., comprising at least one C_H1, hinge1, hinge2, hinge3, hinge4, C_H2, or C_H3 or fragment thereof, further optionally comprising at least one substitution, insertion or deletion), or any portion thereof, that can be incorporated into an antibody. An antibody can include or be derived from any mammal, such as but not limited to, a human, a mouse, a rabbit, a rat, a rodent, a primate, or any combination thereof, and the like.

The isolated antibodies used in the method of the present invention comprise the antibody amino acid sequences disclosed herein encoded by any suitable polynucleotide, or any isolated or prepared antibody. Preferably, the human antibody or antigen-binding fragment binds human IL-12/IL-23p40 or IL-23 and, thereby, partially or substantially neutralizes at least one biological activity of the protein. An antibody, or specified portion or variant thereof, that partially or preferably substantially neutralizes at least one biological activity of at least one IL-12/IL-23p40 or IL-23 protein or fragment can bind the protein or fragment and thereby inhibit activities mediated through the binding of IL-12/IL-23p40 or IL-23 to the IL-12 and/or IL-23 receptor or through other IL-12/IL-23p40 or IL-23-dependent or mediated mechanisms. As used herein, the term “neutralizing antibody” refers to an antibody that can inhibit an IL-12/IL-23p40 or IL-23-dependent activity by about 20-120%, preferably by at least about 10, 20, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or more depending on the assay. The capacity of an anti-IL-12/IL-23p40 or IL-23 antibody to inhibit an IL-12/IL-23p40 or IL-23-dependent activity is preferably assessed by at least one suitable IL-12/IL-23p40 or IL-23 protein or receptor assay, as described herein and/or as known in the art. A human antibody can be of any class (IgG, IgA, IgM, IgE, IgD, etc.) or isotype and can comprise a kappa or lambda light chain. In one embodiment, the human antibody comprises an IgG heavy chain or defined fragment, for example, at least one of isotypes, IgG1, IgG2, IgG3 or IgG4 (e.g., γ1, γ2, γ3, γ4). Antibodies of this type can be prepared by employing a transgenic mouse or other trangenic non-human mammal comprising at least one human light chain (e.g., IgG, IgA, and IgM) transgenes as described herein and/or as known in the art. In another embodiment, the anti-IL-23 human antibody comprises an IgG1 heavy chain and an IgG1 light chain.

An antibody binds at least one specified epitope specific to at least one IL-12/IL-23p40 or IL-23 protein, subunit, fragment, portion or any combination thereof. The at least one epitope can comprise at least one antibody binding region that comprises at least one portion of the protein, which epitope is preferably comprised of at least one extracellular, soluble, hydrophillic, external or cytoplasmic portion of the protein.

Generally, the human antibody or antigen-binding fragment will comprise an antigen-binding region that comprises at least one human complementarity determining region (CDR1, CDR2 and CDR3) or variant of at least one heavy chain variable region and at least one human complementarity determining region (CDR1, CDR2 and CDR3) or variant of at least one light chain variable region. The CDR sequences may be derived from human germline sequences or closely match the germline sequences. For example, the CDRs from a synthetic library derived from the original non-human CDRs can be used. These CDRs may be formed by incorporation of conservative substitutions from the original non-human sequence. In another particular embodiment, the antibody or antigen-binding portion or variant can have an antigen-binding region that comprises at least a portion of at least one light chain CDR (i.e., CDR1, CDR2 and/or CDR3) having the amino acid sequence of the corresponding CDRs 1, 2 and/or 3.

Such antibodies can be prepared by chemically joining together the various portions (e.g., CDRs, framework) of the antibody using conventional techniques, by preparing and expressing a (i.e., one or more) nucleic acid molecule that encodes the antibody using conventional techniques of recombinant DNA technology or by using any other suitable method.

The anti-IL-12/IL-23p40 or IL-23 specific antibody can comprise at least one of a heavy or light chain variable region having a defined amino acid sequence. For example, in a preferred embodiment, the anti-IL-12/IL-23p40 or IL-23 antibody comprises an anti-IL-12/IL-23p40 antibody with a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8. The anti-IL-12/IL-23p40 or IL-23 specific antibody can also comprise at least one of a heavy or light chain having a defined amino acid sequence. In another preferred embodiment, the anti-IL-12/IL-23p40 or IL-23 antibody comprises an anti-IL-12/IL-23p40 antibody with a heavy chain comprising the amino acid sequence of SEQ ID NO:10 and a light chain comprising the amino acid sequence of SEQ ID NO:11. Antibodies that bind to human IL-12/IL-23p40 or IL-23 and that comprise a defined heavy or light chain variable region can be prepared using suitable methods, such as phage display (Katsube, Y., et al., Int J Mol. Med, 1(5):863-868 (1998)) or methods that employ transgenic animals, as known in the art and/or as described herein. For example, a transgenic mouse, comprising a functionally rearranged human immunoglobulin heavy chain transgene and a transgene comprising DNA from a human immunoglobulin light chain locus that can undergo functional rearrangement, can be immunized with human IL-12/IL-23p40 or IL-23 or a fragment thereof to elicit the production of antibodies. If desired, the antibody producing cells can be isolated and hybridomas or other immortalized antibody-producing cells can be prepared as described herein and/or as known in the art. Alternatively, the antibody, specified portion or variant can be expressed using the encoding nucleic acid or portion thereof in a suitable host cell.

The invention also relates to antibodies, antigen-binding fragments, immunoglobulin chains and CDRs comprising amino acids in a sequence that is substantially the same as an amino acid sequence described herein. Preferably, such antibodies or antigen-binding fragments and antibodies comprising such chains or CDRs can bind human IL-12/IL-23p40 or IL-23 with high affinity (e.g., K_Dless than or equal to about 10⁻⁹M). Amino acid sequences that are substantially the same as the sequences described herein include sequences comprising conservative amino acid substitutions, as well as amino acid deletions and/or insertions. A conservative amino acid substitution refers to the replacement of a first amino acid by a second amino acid that has chemical and/or physical properties (e.g., charge, structure, polarity, hydrophobicity/hydrophilicity) that are similar to those of the first amino acid. Conservative substitutions include, without limitation, replacement of one amino acid by another within the following groups: lysine (K), arginine (R) and histidine (H); aspartate (D) and glutamate (E); asparagine (N), glutamine (Q), serine (S), threonine (T), tyrosine (Y), K, R, H, D and E; alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), tryptophan (W), methionine (M), cysteine (C) and glycine (G); F, W and Y; C, S and T.

Amino Acid Codes

The amino acids that make up anti-IL-12/IL-23p40 or IL-23 antibodies of the present invention are often abbreviated. The amino acid designations can be indicated by designating the amino acid by its single letter code, its three letter code, name, or three nucleotide codon(s) as is well understood in the art (see Alberts, B., et al., Molecular Biology of The Cell, Third Ed., Garland Publishing, Inc., New York, 1994):


SINGLE	THREE		THREE
LETTER	LETTER		NUCLEOTIDE
CODE	CODE	NAME	CODON(S)

A	Ala	Alanine	GCA, GCC, GCG,
			GCU
C	Cys	Cysteine	UGC, UGU
D	Asp	Aspartic acid	GAC, GAU
E	Glu	Glutamic acid	GAA, GAG
F	Phe	Phenylanine	UUC, UUU
G	Gly	Glycine	GGA, GGC, GGG,
			GGU
H	His	Histidine	CAC, CAU
I	Ile	Isoleucine	AUA, AUC, AUU
K	Lys	Lysine	AAA, AAG
L	Leu	Leucine	UUA, UUG, CUA,
			CUC, CUG, CUU
M	Met	Methionine	AUG
N	Asn	Asparagine	AAC, AAU
P	Pro	Proline	CCA, CCC, CCG,
			CCU
Q	Gln	Glutamine	CAA, CAG
R	Arg	Arginine	AGA, AGG, CGA,
			CGC, CGG, CGU
S	Ser	Serine	AGC, AGU, UCA,
			UCC, UCG, UCU
T	Thr	Threonine	ACA, ACC, ACG,
			ACU
V	Val	Valine	GUA, GUC, GUG,
			GUU
W	Trp	Tryptophan	UGG
Y	Tyr	Tyrosine	UAC, UAU

Sequences
Example anti-IL-12/IL-23p40 antibody sequences—STELARA® (ustekinumab)

Amino acid sequence of anti-IL-12/IL-23p40 antibody complementarity determining region heavy chain 1 (CDRH1): (SEQ ID NO:1)

TYWLG

Amino acid sequence of anti-IL-12/IL-23p40 antibody complementarity determining region heavy chain 2 (CDRH2): (SEQ ID NO:2)

IMSPVDSDIRYSPSFQG

Amino acid sequence of anti-IL-12/IL-23p40 antibody complementarity determining region heavy chain 3 (CDRH3): (SEQ ID NO:3)

RRPGQGYFDF

Amino acid sequence of anti-IL-12/IL-23p40 antibody complementarity determining region light chain 1 (CDRL1): (SEQ ID NO:4)

RASQGISSWLA

Amino acid sequence of anti-IL-12/IL-23p40 antibody complementarity determining region light chain 2 (CDRL2): (SEQ ID NO:5)

AASSLQS

Amino acid sequence of anti-IL-12/IL-23p40 antibody complementarity determining region light chain 3 (CDRL3): (SEQ ID NO:6)

QQYNIYPYT

Amino acid sequence of anti-IL-12/IL-23p40 antibody variable heavy chain region (CDRs underlined): (SEQ ID NO:7)

1	EVQLVQSGAE VKKPGESLKI SCKGSGYSFT TYWLGWVRQM PGKGLDWIGI MSPVDSDIRY

61	SPSFQGQVTM SVDKSITTAY LQWNSLKASD TAMYYCARRR PGQGYFDFWG QGTLVTVSS

Amino acid sequence of anti-IL-12/IL-23p40 antibody variable light chain region (CDRs underlined): (SEQ ID NO:8)

1	DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA ASSLQSGVPS

61	RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNIYPYTFGQ GTKLEIKR

Amino acid sequence of anti-IL-12/IL-23p40 antibody heavy chain (CDRs underlined): (SEQ ID NO:10)

1	EVQLVQSGAE VKKPGESLKI SCKGSGYSFT TYWLGWVRQM PGKGLDWIGI MSPVDSDIRY

61	SPSFQGQVTM SVDKSITTAY LQWNSLKASD TAMYYCARRR PGQGYFDFWG QGTLVTVSSS

121	STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG

181	LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP

241	SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS

301	TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL

361	TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ

421	QGNVFSCSVM HEALHNHYTQ KSLSLSPGK

Amino acid sequence of anti-IL-12/IL-23p40 antibody light chain (CDRs underlined): (SEQ ID NO:11)

1	DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA ASSLQSGVPS

61	RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNIYPYTFGQ GTKLEIKRTV AAPSVFIFPP

121	SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT

181	LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC

Amino Acid Sequence IL-12

Amino acid sequence of human interleukin (IL)-12 with alpha and beta subunits: (SEQ ID NO:9)

1	RNLPVATPDP GMFPCLHHSQ NLLRAVSNML QKARQTLEFY PCTSEEIDHE DITKDKTSTV

61	EACLPLELTK NESCLNSRET SFITNGSCLA SRKTSFMMAL CLSSIYEDLK MYQVEFKTMN

121	AKLLMDPKRQ IFLDQNMLAV IDELMQALNF NSETVPQKSS LEEPDFYKTK IKLCILLHAF

181	RIRAVTIDRV MSYLNASIWE LKKDVYVVEL DWYPDAPGEM VVLTCDTPEE DGITWTLDQS

241	SEVLGSGKTL TIQVKEFGDA GQYTCHKGGE VLSHSLLLLH KKEDGIWSTD ILKDQKEPKN

301	KTFLRCEAKN YSGRFTCWWL TTISTDLTFS VKSSRGSSDP QGVTCGAATL SAERVRGDNK

361	EYEYSVECQE DSACPAAEES LPIEVMVDAV HKLKYENYTS SFFIRDIIKP DPPKNLQLKP

421	LKNSRQVEVS WEYPDTWSTP HSYFSLTFCV QVQGKSKREK KDRVFTDKTS ATVICRKNAS

481	ISVRAQDRYY SSSWSEWASV PCS

An anti-IL-12/IL-23p40 or IL-23 antibody used in the method of the present invention can include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation, as specified herein.

The number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of amino acid substitutions, insertions or deletions for any given anti-IL-12/IL-23p40 or IL-23 antibody, fragment or variant will not be more than 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, such as 1-30 or any range or value therein, as specified herein.

Amino acids in an anti-IL-12/IL-23p40 or IL-23 specific antibody that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (e.g., Ausubel, supra, Chapters 8, 15; Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity, such as, but not limited to, at least one IL-12/IL-23p40 or IL-23 neutralizing activity. Sites that are critical for antibody binding can also be identified by structural analysis, such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith, et al., J. Mol. Biol. 224:899-904 (1992) and de Vos, et al., Science 255:306-312 (1992)).

Anti-IL-12/IL-23p40 or IL-23 antibodies can include, but are not limited to, at least one portion, sequence or combination selected from 5 to all of the contiguous amino acids of at least one of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 10, or 11.

IL-12/IL-23p40 or IL-23 antibodies or specified portions or variants can include, but are not limited to, at least one portion, sequence or combination selected from at least 3-5 contiguous amino acids of the SEQ ID NOs above; 5-17 contiguous amino acids of the SEQ ID NOs above, 5-10 contiguous amino acids of the SEQ ID NOs above, 5-11 contiguous amino acids of the SEQ ID NOs above, 5-7 contiguous amino acids of the SEQ ID NOs above; 5-9 contiguous amino acids of the SEQ ID NOs above.

An anti-IL-12/IL-23p40 or IL-23 antibody can further optionally comprise a polypeptide of at least one of 70-100% of 5, 17, 10, 11, 7, 9, 119, 108, 449, or 214 contiguous amino acids of the SEQ ID NOs above. In one embodiment, the amino acid sequence of an immunoglobulin chain, or portion thereof (e.g., variable region, CDR) has about 70-100% identity (e.g., 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or any range or value therein) to the amino acid sequence of the corresponding chain of at least one of the SEQ ID NOs above. For example, the amino acid sequence of a light chain variable region can be compared with the sequence of the SEQ ID NOs above, or the amino acid sequence of a heavy chain CDR3 can be compared with the SEQ ID NOs above. Preferably, 70-100% amino acid identity (i.e., 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or any range or value therein) is determined using a suitable computer algorithm, as known in the art.

“Identity,” as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as determined by the match between strings of such sequences. “Identity” and “similarity” can be readily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., Siam J. Applied Math., 48:1073 (1988). In addition, values for percentage identity can be obtained from amino acid and nucleotide sequence alignments generated using the default settings for the AlignX component of Vector NTI Suite 8.0 (Informax, Frederick, Md.).

Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., J. Molec. Biol. 215:403-410 (1990)). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBINLM NIH Bethesda, Md. 20894: Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

(1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48:443-453 (1970) Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci, USA. 89:10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

A program useful with these parameters is publicly available as the “gap” program from Genetics Computer Group, Madison Wis. The aforementioned parameters are the default parameters for peptide sequence comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

(1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48:443-453 (1970)

Comparison matrix: matches=+10, mismatch=0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The “gap” program from Genetics Computer Group, Madison Wis. These are the default parameters for nucleic acid sequence comparisons.

By way of example, a polynucleotide sequence may be identical to another sequence, that is 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein the alterations may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in the sequence by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from the total number of nucleotides in the sequence, or: n.sub.n.ltorsim.x.sub.n-(x.sub.n.y),

wherein n.sub.n is the number of nucleotide alterations, x.sub.n is the total number of nucleotides in sequence, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of x.sub.n and y is rounded down to the nearest integer prior to subtracting from x.sub.n.

Alterations of a polynucleotide sequence encoding the the SEQ ID NOs above may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations. Similarly, a polypeptide sequence may be identical to the reference sequence of the SEQ ID NOs above, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percentage identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein the alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in the SEQ ID NOs above by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from the total number of amino acids in the SEQ ID NOs above, or: n.sub.a.ltorsim.x.sub.a-(x.sub.a.y), wherein n.sub.a is the number of amino acid alterations, x.sub.a is the total number of amino acids in the SEQ ID NOs above, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer produce of x.sub.a and y is rounded down to the nearest integer prior to subtracting it from x.sub.a.

Exemplary heavy chain and light chain variable regions sequences and portions thereof are provided in the SEQ ID NOs above. The antibodies of the present invention, or specified variants thereof, can comprise any number of contiguous amino acid residues from an antibody of the present invention, wherein that number is selected from the group of integers consisting of from 10-100% of the number of contiguous residues in an anti-IL-12/IL-23p40 or IL-23 antibody. Optionally, this subsequence of contiguous amino acids is at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250 or more amino acids in length, or any range or value therein. Further, the number of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as at least 2, 3, 4, or 5.

As those of skill will appreciate, the present invention includes at least one biologically active antibody of the present invention. Biologically active antibodies have a specific activity at least 20%, 30%, or 40%, and, preferably, at least 50%, 60%, or 70%, and, most preferably, at least 80%, 90%, or 95%-100% or more (including, without limitation, up to 10 times the specific activity) of that of the native (non-synthetic), endogenous or related and known antibody. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity are well known to those of skill in the art.

In another aspect, the invention relates to human antibodies and antigen-binding fragments, as described herein, which are modified by the covalent attachment of an organic moiety. Such modification can produce an antibody or antigen-binding fragment with improved pharmaco*kinetic properties (e.g., increased in vivo serum half-life). The organic moiety can be a linear or branched hydrophilic polymeric group, fatty acid group, or fatty acid ester group. In particular embodiments, the hydrophilic polymeric group can have a molecular weight of about 800 to about 120,000 Daltons and can be a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone, and the fatty acid or fatty acid ester group can comprise from about eight to about forty carbon atoms.

The modified antibodies and antigen-binding fragments can comprise one or more organic moieties that are covalently bonded, directly or indirectly, to the antibody. Each organic moiety that is bonded to an antibody or antigen-binding fragment of the invention can independently be a hydrophilic polymeric group, a fatty acid group or a fatty acid ester group. As used herein, the term “fatty acid” encompasses mono-carboxylic acids and dicarboxylic acids. A “hydrophilic polymeric group,” as the term is used herein, refers to an organic polymer that is more soluble in water than in octane. For example, polylysine is more soluble in water than in octane. Thus, an antibody modified by the covalent attachment of polylysine is encompassed by the invention. Hydrophilic polymers suitable for modifying antibodies of the invention can be linear or branched and include, for example, polyalkane glycols (e.g., PEG, monomethoxy-polyethylene glycol (mPEG), PPG and the like), carbohydrates (e.g., dextran, cellulose, oligosaccharides, polysaccharides and the like), polymers of hydrophilic amino acids (e.g., polylysine, polyarginine, polyaspartate and the like), polyalkane oxides (e.g., polyethylene oxide, polypropylene oxide and the like) and polyvinyl pyrolidone. Preferably, the hydrophilic polymer that modifies the antibody of the invention has a molecular weight of about 800 to about 150,000 Daltons as a separate molecular entity. For example, PEG₅₀₀₀and PEG_20,000, wherein the subscript is the average molecular weight of the polymer in Daltons, can be used. The hydrophilic polymeric group can be substituted with one to about six alkyl, fatty acid or fatty acid ester groups. Hydrophilic polymers that are substituted with a fatty acid or fatty acid ester group can be prepared by employing suitable methods. For example, a polymer comprising an amine group can be coupled to a carboxylate of the fatty acid or fatty acid ester, and an activated carboxylate (e.g., activated with N, N-carbonyl diimidazole) on a fatty acid or fatty acid ester can be coupled to a hydroxyl group on a polymer.

Fatty acids and fatty acid esters suitable for modifying antibodies of the invention can be saturated or can contain one or more units of unsaturation. Fatty acids that are suitable for modifying antibodies of the invention include, for example, n-dodecanoate (Cu, laurate), n-tetradecanoate (C₁₄, myristate), n-octadecanoate (C₁₈, stearate), n-eicosanoate (C₂₀, arachidate), n-docosanoate (C₂₂, behenate), n-triacontanoate (C₃₀), n-tetracontanoate (C₄₀), cis-Δ9-octadecanoate (C₁₈, oleate), all cis-Δ5,8,11,14-eicosatetraenoate (Cao, arachidonate), octanedioic acid, tetradecanedioic acid, octadecanedioic acid, docosanedioic acid, and the like. Suitable fatty acid esters include mono-esters of dicarboxylic acids that comprise a linear or branched lower alkyl group. The lower alkyl group can comprise from one to about twelve, preferably, one to about six, carbon atoms.

The modified human antibodies and antigen-binding fragments can be prepared using suitable methods, such as by reaction with one or more modifying agents. A “modifying agent” as the term is used herein, refers to a suitable organic group (e.g., hydrophilic polymer, a fatty acid, a fatty acid ester) that comprises an activating group. An “activating group” is a chemical moiety or functional group that can, under appropriate conditions, react with a second chemical group thereby forming a covalent bond between the modifying agent and the second chemical group. For example, amine-reactive activating groups include electrophilic groups, such as tosylate, mesylate, halo (chloro, bromo, fluoro, iodo), N-hydroxysuccinimidyl esters (NETS), and the like. Activating groups that can react with thiols include, for example, maleimide, iodoacetyl, acrylolyl, pyridyl disulfides, 5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. An aldehyde functional group can be coupled to amine- or hydrazide-containing molecules, and an azide group can react with a trivalent phosphorous group to form phosphoramidate or phosphorimide linkages. Suitable methods to introduce activating groups into molecules are known in the art (see for example, Hermanson, G. T., Bioconjugate Techniques, Academic Press: San Diego, Calif. (1996)). An activating group can be bonded directly to the organic group (e.g., hydrophilic polymer, fatty acid, fatty acid ester), or through a linker moiety, for example, a divalent C₁-C₁₂group wherein one or more carbon atoms can be replaced by a heteroatom, such as oxygen, nitrogen or sulfur. Suitable linker moieties include, for example, tetraethylene glycol, —(CH₂)₃—, —NH—(CH₂)₆—NH—, —(CH₂)₂—NH— and —CH₂—O—CH₂—CH₂—O—CH₂—CH₂—O—CH—NH—. Modifying agents that comprise a linker moiety can be produced, for example, by reacting a mono-Boc-alkyldiamine (e.g., mono-Boc-ethylenediamine, mono-Boc-diaminohexane) with a fatty acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) to form an amide bond between the free amine and the fatty acid carboxylate. The Boc protecting group can be removed from the product by treatment with trifluoroacetic acid (TFA) to expose a primary amine that can be coupled to another carboxylate, as described, or can be reacted with maleic anhydride and the resulting product cyclized to produce an activated maleimido derivative of the fatty acid. (See, for example, Thompson, et al., WO 92/16221, the entire teachings of which are incorporated herein by reference.)

The modified antibodies can be produced by reacting a human antibody or antigen-binding fragment with a modifying agent. For example, the organic moieties can be bonded to the antibody in a non-site specific manner by employing an amine-reactive modifying agent, for example, an NHS ester of PEG. Modified human antibodies or antigen-binding fragments can also be prepared by reducing disulfide bonds (e.g., intra-chain disulfide bonds) of an antibody or antigen-binding fragment. The reduced antibody or antigen-binding fragment can then be reacted with a thiol-reactive modifying agent to produce the modified antibody of the invention. Modified human antibodies and antigen-binding fragments comprising an organic moiety that is bonded to specific sites of an antibody of the present invention can be prepared using suitable methods, such as reverse proteolysis (Fisch et al., Bioconjugate Chem., 3:147-153 (1992); Werlen et al., Bioconjugate Chem., 5:411-417 (1994); Kumaran et al., Protein Sci. 6(10):2233-2241 (1997); Itoh et al., Bioorg. Chem., 24(1): 59-68 (1996); Capellas et al., Biotechnol. Bioeng., 56(4):456-463 (1997)), and the methods described in Hermanson, G. T., Bioconjugate Techniques, Academic Press: San Diego, Calif. (1996).

The method of the present invention also uses an anti-IL-12/IL-23p40 or IL-23 antibody composition comprising at least one, at least two, at least three, at least four, at least five, at least six or more anti-IL-12/IL-23p40 or IL-23 antibodies thereof, as described herein and/or as known in the art that are provided in a non-naturally occurring composition, mixture or form. Such compositions comprise non-naturally occurring compositions comprising at least one or two full length, C- and/or N-terminally deleted variants, domains, fragments, or specified variants, of the anti-IL-12/IL-23p40 or IL-23 antibody amino acid sequence selected from the group consisting of 70-100% of the contiguous amino acids of the SEQ ID NOs above, or specified fragments, domains or variants thereof. Preferred anti-IL-12/IL-23p40 or IL-23 antibody compositions include at least one or two full length, fragments, domains or variants as at least one CDR or LBP containing portions of the anti-IL-12/IL-23p40 or IL-23 antibody sequence described herein, for example, 70-100% of the SEQ ID NOs above, or specified fragments, domains or variants thereof. Further preferred compositions comprise, for example, 40-99% of at least one of 70-100% of the SEQ ID NOs above, etc., or specified fragments, domains or variants thereof. Such composition percentages are by weight, volume, concentration, molarity, or molality as liquid or dry solutions, mixtures, suspension, emulsions, particles, powder, or colloids, as known in the art or as described herein.

Antibody Compositions Comprising Further Therapeutically Active Ingredients

The antibody compositions used in the method of the invention can optionally further comprise an effective amount of at least one compound or protein selected from at least one of an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug or the like. Such drugs are well known in the art, including formulations, indications, dosing and administration for each presented herein (see, e.g., Nursing 2001 Handbook of Drugs, 21^stedition, Springhouse Corp., Springhouse, P A, 2001; Health Professional's Drug Guide 2001, ed., Shannon, Wilson, Stang, Prentice-Hall, Inc, Upper Saddle River, N.J.; Pharmcotherapy Handbook, Wells et al., ed., Appleton & Lange, Stamford, Conn., each entirely incorporated herein by reference).

By way of example of the drugs that can be combined with the antibodies for the method of the present invention, the anti-infective drug can be at least one selected from amebicides or at least one antiprotozoals, anthelmintics, antifungals, antimalarials, antituberculotics or at least one antileprotics, aminoglycosides, penicillins, cephalosporins, tetracyclines, sulfonamides, fluoroquinolones, antivirals, macrolide anti-infectives, and miscellaneous anti-infectives. The hormonal drug can be at least one selected from corticosteroids, androgens or at least one anabolic steroid, estrogen or at least one progestin, gonadotropin, antidiabetic drug or at least one glucagon, thyroid hormone, thyroid hormone antagonist, pituitary hormone, and parathyroid-like drug. The at least one cephalosporin can be at least one selected from cefaclor, cefadroxil, cefazolin sodium, cefdinir, cefepime hydrochloride, cefixime, cefmetazole sodium, cefonicid sodium, cefoperazone sodium, cefotaxime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime proxetil, cefprozil, ceftazidime, ceftibuten, ceftizoxime sodium, ceftriaxone sodium, cefuroxime axetil, cefuroxime sodium, cephalexin hydrochloride, cephalexin monohydrate, cephradine, and loracarbef.

The at least one coricosteroid can be at least one selected from betamethasone, betamethasone acetate or betamethasone sodium phosphate, betamethasone sodium phosphate, cortisone acetate, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, fludrocortisone acetate, hydrocortisone, hydrocortisone acetate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate, prednisone, triamcinolone, triamcinolone acetonide, and triamcinolone diacetate. The at least one androgen or anabolic steroid can be at least one selected from danazol, fluoxymesterone, methyltestosterone, nandrolone decanoate, nandrolone phenpropionate, testosterone, testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone transdermal system.

The at least one immunosuppressant can be at least one selected from azathioprine, basiliximab, cyclosporine, daclizumab, lymphocyte immune globulin, muromonab-CD3, mycophenolate mofetil, mycophenolate mofetil hydrochloride, sirolimus, 6-mercaptopurine, methotrexate, mizoribine, and tacrolimus.

The at least one local anti-infective can be at least one selected from acyclovir, amphotericin B, azelaic acid cream, bacitracin, butoconazole nitrate, clindamycin phosphate, clotrimazole, econazole nitrate, erythromycin, gentamicin sulfate, ketoconazole, mafenide acetate, metronidazole (topical), miconazole nitrate, mupirocin, naftifine hydrochloride, neomycin sulfate, nitrofurazone, nystatin, silver sulfadiazine, terbinafine hydrochloride, terconazole, tetracycline hydrochloride, tioconazole, and tolnaftate. The at least one scabicide or pediculicide can be at least one selected from crotamiton, lindane, permethrin, and pyrethrins. The at least one topical corticosteroid can be at least one selected from betamethasone dipropionate, betamethasone valerate, clobetasol propionate, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate, fluocinolone acetonide, fluocinonide, flurandrenolide, fluticasone propionate, halcionide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocorisone valerate, mometasone furoate, and triamcinolone acetonide. (See, e.g., pp. 1098-1136 of Nursing 2001 Drug Handbook.)

Anti-IL-12/IL-23p40 or IL-23 antibody compositions can further comprise at least one of any suitable and effective amount of a composition or pharmaceutical composition comprising at least one anti-IL-12/IL-23p40 or IL-23 antibody contacted or administered to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy, optionally further comprising at least one selected from at least one TNF antagonist (e.g., but not limited to a TNF chemical or protein antagonist, TNF monoclonal or polyclonal antibody or fragment, a soluble TNF receptor (e.g., p55, p70 or p85) or fragment, fusion polypeptides thereof, or a small molecule TNF antagonist, e.g., TNF binding protein I or II (TBP-1 or TBP-II), nerelimonmab, infliximab, eternacept, CDP-571, CDP-870, afelimomab, lenercept, and the like), an antirheumatic (e.g., methotrexate, auranofin, aurothioglucose, azathioprine, etanercept, gold sodium thiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalzine), an immunization, an immunoglobulin, an immunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), a cytokine or a cytokine antagonist. Non-limiting examples of such cytokines include, but are not limited to, any of IL-1 to IL-23 et al. (e.g., IL-1, IL-2, etc.). Suitable dosages are well known in the art. See, e.g., Wells et al., eds., Pharmacotherapy Handbook, 2^ndEdition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000), each of which references are entirely incorporated herein by reference.

Anti-IL-12/IL-23p40 or IL-23 antibody compounds, compositions or combinations used in the method of the present invention can further comprise at least one of any suitable auxiliary, such as, but not limited to, diluent, binder, stabilizer, buffers, salts, lipophilic solvents, preservative, adjuvant or the like. Pharmaceutically acceptable auxiliaries are preferred. Non-limiting examples of, and methods of preparing such sterile solutions are well known in the art, such as, but limited to, Gennaro, Ed., Remington's Pharmaceutical Sciences, 18^thEdition, Mack Publishing Co. (Easton, Pa.) 1990. Pharmaceutically acceptable carriers can be routinely selected that are suitable for the mode of administration, solubility and/or stability of the anti-IL-23 antibody, fragment or variant composition as well known in the art or as described herein.

Pharmaceutical excipients and additives useful in the present composition include, but are not limited to, proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, di-, tri-, tetra-, and oligosaccharides; derivatized sugars, such as alditols, aldonic acids, esterified sugars and the like; and polysaccharides or sugar polymers), which can be present singly or in combination, comprising alone or in combination 1-99.99% by weight or volume. Exemplary protein excipients include serum albumin, such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, and the like. Representative amino acid/antibody components, which can also function in a buffering capacity, include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, and the like. One preferred amino acid is glycine.

Carbohydrate excipients suitable for use in the invention include, for example, monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), myoinositol and the like. Preferred carbohydrate excipients for use in the present invention are mannitol, trehalose, and raffinose.

Anti-IL-12/IL-23p40 or IL-23 antibody compositions can also include a buffer or a pH adjusting agent; typically, the buffer is a salt prepared from an organic acid or base. Representative buffers include organic acid salts, such as salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris, tromethamine hydrochloride, or phosphate buffers. Preferred buffers for use in the present compositions are organic acid salts, such as citrate.

Additionally, anti-IL-12/IL-23p40 or IL-23 antibody compositions can include polymeric excipients/additives, such as polyvinylpyrrolidones, ficolls (a polymeric sugar), dextrates (e.g., cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin), polyethylene glycols, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, surfactants (e.g., polysorbates, such as “TWEEN®20” and “TWEEN®80”), lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol), and chelating agents (e.g., EDTA).

These and additional known pharmaceutical excipients and/or additives suitable for use in the anti-IL-12/IL-23p40 or IL-23 antibody, portion or variant compositions according to the invention are known in the art, e.g., as listed in “Remington: The Science & Practice of Pharmacy,” 19^thed., Williams & Williams, (1995), and in the “Physician's Desk Reference,” 52^nded., Medical Economics, Montvale, N.J. (1998), the disclosures of which are entirely incorporated herein by reference. Preferred carrier or excipient materials are carbohydrates (e.g., saccharides and alditols) and buffers (e.g., citrate) or polymeric agents. An exemplary carrier molecule is the mucopolysaccharide, hyaluronic acid, which may be useful for intraarticular delivery.

Formulations

As noted above, the invention provides for stable formulations, which preferably comprise a phosphate buffer with saline or a chosen salt, as well as preserved solutions and formulations containing a preservative as well as multi-use preserved formulations suitable for pharmaceutical or veterinary use, comprising at least one anti-IL-12/IL-23p40 or IL-23 antibody in a pharmaceutically acceptable formulation. Preserved formulations contain at least one known preservative or optionally selected from the group consisting of at least one phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate), alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an aqueous diluent. Any suitable concentration or mixture can be used as known in the art, such as 0.001-5%, or any range or value therein, such as, but not limited to 0.001, 0.003, 0.005, 0.009, 0.01, 0.02, 0.03, 0.05, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9, or any range or value therein. Non-limiting examples include, no preservative, 0.1-2% m-cresol (e.g., 0.2, 0.3, 0.4, 0.5, 0.9, 1.0%), 0.1-3% benzyl alcohol (e.g., 0.5, 0.9, 1.1, 1.5, 1.9, 2.0, 2.5%), 0.001-0.5% thimerosal (e.g., 0.005, 0.01), 0.001-2.0% phenol (e.g., 0.05, 0.25, 0.28, 0.5, 0.9, 1.0%), 0.0005-1.0% alkylparaben(s) (e.g., 0.00075, 0.0009, 0.001, 0.002, 0.005, 0.0075, 0.009, 0.01, 0.02, 0.05, 0.075, 0.09, 0.1, 0.2, 0.3, 0.5, 0.75, 0.9, 1.0%), and the like.

As noted above, the method of the invention uses an article of manufacture, comprising packaging material and at least one vial comprising a solution of at least one anti-IL-12/IL-23p40 or IL-23 antibody with the prescribed buffers and/or preservatives, optionally in an aqueous diluent, wherein said packaging material comprises a label that indicates that such solution can be held over a period of 1, 2, 3, 4, 5, 6, 9, 12, 18, 20, 24, 30, 36, 40, 48, 54, 60, 66, 72 hours or greater. The invention further uses an article of manufacture, comprising packaging material, a first vial comprising lyophilized anti-IL-12/IL-23p40 or IL-23 antibody, and a second vial comprising an aqueous diluent of prescribed buffer or preservative, wherein said packaging material comprises a label that instructs a patient to reconstitute the anti-IL-12/IL-23p40 or IL-23 antibody in the aqueous diluent to form a solution that can be held over a period of twenty-four hours or greater.

The anti-IL-12/IL-23p40 or IL-23 antibody used in accordance with the present invention can be produced by recombinant means, including from mammalian cell or transgenic preparations, or can be purified from other biological sources, as described herein or as known in the art.

The range of the anti-IL-12/IL-23p40 or IL-23 antibody includes amounts yielding upon reconstitution, if in a wet/dry system, concentrations from about 1.0 μg/ml to about 1000 mg/ml, although lower and higher concentrations are operable and are dependent on the intended delivery vehicle, e.g., solution formulations will differ from transdermal patch, pulmonary, transmucosal, or osmotic or micro pump methods.

Preferably, the aqueous diluent optionally further comprises a pharmaceutically acceptable preservative. Preferred preservatives include those selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof. The concentration of preservative used in the formulation is a concentration sufficient to yield an anti-microbial effect. Such concentrations are dependent on the preservative selected and are readily determined by the skilled artisan.

Other excipients, e.g., isotonicity agents, buffers, antioxidants, and preservative enhancers, can be optionally and preferably added to the diluent. An isotonicity agent, such as glycerin, is commonly used at known concentrations. A physiologically tolerated buffer is preferably added to provide improved pH control. The formulations can cover a wide range of pHs, such as from about pH 4 to about pH 10, and preferred ranges from about pH 5 to about pH 9, and a most preferred range of about 6.0 to about 8.0. Preferably, the formulations of the present invention have a pH between about 6.8 and about 7.8. Preferred buffers include phosphate buffers, most preferably, sodium phosphate, particularly, phosphate buffered saline (PBS).

Other additives, such as a pharmaceutically acceptable solubilizers like TWEEN®20 (polyoxyethylene (20) sorbitan monolaurate), TWEEN®40 (polyoxyethylene (20) sorbitan monopalmitate), TWEEN®80 (polyoxyethylene (20) sorbitan monooleate), PLURONIC® (polyls)F68 (polyoxyethylene polyoxypropylene block copolymers), and PEG (polyethylene glycol) or non-ionic surfactants, such as polysorbate 20 or 80 or poloxamer 184 or 188, PLURONIC® (polyls), other block co-polymers, and chelators, such as EDTA and EGTA, can optionally be added to the formulations or compositions to reduce aggregation. These additives are particularly useful if a pump or plastic container is used to administer the formulation. The presence of pharmaceutically acceptable surfactant mitigates the propensity for the protein to aggregate.

The formulations can be prepared by a process which comprises mixing at least one anti-IL-12/IL-23p40 or IL-23 antibody and a preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal or mixtures thereof in an aqueous diluent. Mixing the at least one anti-IL-12/IL-23p40 or IL-23 specific antibody and preservative in an aqueous diluent is carried out using conventional dissolution and mixing procedures. To prepare a suitable formulation, for example, a measured amount of at least one anti-IL-12/IL-23p40 or IL-23 antibody in buffered solution is combined with the desired preservative in a buffered solution in quantities sufficient to provide the protein and preservative at the desired concentrations. Variations of this process would be recognized by one of ordinary skill in the art. For example, the order the components are added, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that can be optimized for the concentration and means of administration used.

The formulations can be provided to patients as clear solutions or as dual vials comprising a vial of lyophilized anti-IL-12/IL-23p40 or IL-23 specific antibody that is reconstituted with a second vial containing water, a preservative and/or excipients, preferably, a phosphate buffer and/or saline and a chosen salt, in an aqueous diluent. Either a single solution vial or dual vial requiring reconstitution can be reused multiple times and can suffice for a single or multiple cycles of patient treatment and thus can provide a more convenient treatment regimen than currently available.

The present articles of manufacture are useful for administration over a period ranging from immediate to twenty-four hours or greater. Accordingly, the presently claimed articles of manufacture offer significant advantages to the patient. Formulations of the invention can optionally be safely stored at temperatures of from about 2° C. to about 40° C. and retain the biologically activity of the protein for extended periods of time, thus allowing a package label indicating that the solution can be held and/or used over a period of 6, 12, 18, 24, 36, 48, 72, or 96 hours or greater. If preserved diluent is used, such label can include use up to 1-12 months, one-half, one and a half, and/or two years.

The solutions of anti-IL-12/IL-23p40 or IL-23 specific antibody can be prepared by a process that comprises mixing at least one antibody in an aqueous diluent. Mixing is carried out using conventional dissolution and mixing procedures. To prepare a suitable diluent, for example, a measured amount of at least one antibody in water or buffer is combined in quantities sufficient to provide the protein and, optionally, a preservative or buffer at the desired concentrations. Variations of this process would be recognized by one of ordinary skill in the art. For example, the order the components are added, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that can be optimized for the concentration and means of administration used.

The claimed products can be provided to patients as clear solutions or as dual vials comprising a vial of lyophilized at least one anti-IL-12/IL-23p40 or IL-23 specific antibody that is reconstituted with a second vial containing the aqueous diluent. Either a single solution vial or dual vial requiring reconstitution can be reused multiple times and can suffice for a single or multiple cycles of patient treatment and thus provides a more convenient treatment regimen than currently available.

The claimed products can be provided indirectly to patients by providing to pharmacies, clinics, or other such institutions and facilities, clear solutions or dual vials comprising a vial of lyophilized at least one anti-IL-12/IL-23p40 or IL-23 specific antibody that is reconstituted with a second vial containing the aqueous diluent. The clear solution in this case can be up to one liter or even larger in size, providing a large reservoir from which smaller portions of the at least one antibody solution can be retrieved one or multiple times for transfer into smaller vials and provided by the pharmacy or clinic to their customers and/or patients.

Recognized devices comprising single vial systems include pen-injector devices for delivery of a solution, such as B-D® (pen injector device), Humaject NOVOPEN® (pen injector device), AUTOPEN® (pen injector device), OPTIPEN® (pen injector device), GENOTROPIN PEN® (pen injector device), HUMATROPEN® (pen injector device), Reco-Pen, BIOJECTOR® (pen injector device), J-tip Needle-Free Injector, Intraject, Medi-Ject, and SMARTJECT® (autoinjector device) e.g., as made or developed by Becton Dickensen (Franklin Lakes, N.J., www. bectondickenson.com), Disetronic (Burgdorf, Switzerland, www.disetronic.com; Bioject, Portland, Oreg. (www.bioject.com); National Medical Products, Weston Medical (Peterborough, UK, www.weston-medical.com), Medi-Ject Corp (Minneapolis, Minn., www. mediject.com), and similarly suitable devices. Recognized devices comprising a dual vial system include those pen-injector systems for reconstituting a lyophilized drug in a cartridge for delivery of the reconstituted solution, such as the HUMATROPEN® (pen injector device). Examples of other devices suitable include pre-filled syringes, auto-injectors, needle free injectors, SELFDOSE™ (injector device) (West Pharmaceuticals, Inc. of Exton, Pa.) and needle free IV infusion sets.

The products may include packaging material. The packaging material provides, in addition to the information required by the regulatory agencies, the conditions under which the product can be used. The packaging material of the present invention provides instructions to the patient, as applicable, to reconstitute the at least one anti-IL-12/IL-23p40 or IL-23 antibody in the aqueous diluent to form a solution and to use the solution over a period of 2-24 hours or greater for the two vial, wet/dry, product. For the single vial, solution product, pre-filled syringe or auto-injector, the label indicates that such solution can be used over a period of 2-24 hours or greater. The products are useful for human pharmaceutical product use.

The formulations used in the method of the present invention can be prepared by a process that comprises mixing an anti-IL-12/IL-23p40 or IL-23 antibody and a selected buffer, preferably, a phosphate buffer containing saline or a chosen salt. Mixing the anti-IL-23 antibody and buffer in an aqueous diluent is carried out using conventional dissolution and mixing procedures. To prepare a suitable formulation, for example, a measured amount of at least one antibody in water or buffer is combined with the desired buffering agent in water in quantities sufficient to provide the protein and buffer at the desired concentrations. Variations of this process would be recognized by one of ordinary skill in the art. For example, the order the components are added, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that can be optimized for the concentration and means of administration used.

The method of the invention provides pharmaceutical compositions comprising various formulations useful and acceptable for administration to a human or animal patient. Such pharmaceutical compositions are prepared using water at “standard state” as the diluent and routine methods well known to those of ordinary skill in the art. For example, buffering components such as histidine and histidine monohydrochloride hydrate, may be provided first followed by the addition of an appropriate, non-final volume of water diluent, sucrose and polysorbate 80 at “standard state.” Isolated antibody may then be added. Last, the volume of the pharmaceutical composition is adjusted to the desired final volume under “standard state” conditions using water as the diluent. Those skilled in the art will recognize a number of other methods suitable for the preparation of the pharmaceutical compositions.

The pharmaceutical compositions may be aqueous solutions or suspensions comprising the indicated mass of each constituent per unit of water volume or having an indicated pH at “standard state.” As used herein, the term “standard state” means a temperature of 25° C.+/−2° C. and a pressure of 1 atmosphere. The term “standard state” is not used in the art to refer to a single art recognized set of temperatures or pressure, but is instead a reference state that specifies temperatures and pressure to be used to describe a solution or suspension with a particular composition under the reference “standard state” conditions. This is because the volume of a solution is, in part, a function of temperature and pressure. Those skilled in the art will recognize that pharmaceutical compositions equivalent to those disclosed here can be produced at other temperatures and pressures. Whether such pharmaceutical compositions are equivalent to those disclosed here should be determined under the “standard state” conditions defined above (e.g. 25° C.+/−2° C. and a pressure of 1 atmosphere).

Importantly, such pharmaceutical compositions may contain component masses “about” a certain value (e.g. “about 0.53 mg L-histidine”) per unit volume of the pharmaceutical composition or have pH values about a certain value. A component mass present in a pharmaceutical composition or pH value is “about” a given numerical value if the isolated antibody present in the pharmaceutical composition is able to bind a peptide chain while the isolated antibody is present in the pharmaceutical composition or after the isolated antibody has been removed from the pharmaceutical composition (e.g., by dilution). Stated differently, a value, such as a component mass value or pH value, is “about” a given numerical value when the binding activity of the isolated antibody is maintained and detectable after placing the isolated antibody in the pharmaceutical composition.

Competition binding analysis is performed to determine if the IL-12/IL-23p40 or IL-23 specific mAbs bind to similar or different epitopes and/or compete with each other. Abs are individually coated on ELISA plates. Competing mAbs are added, followed by the addition of biotinylated hrIL-12 or IL-23. For positive control, the same mAb for coating may be used as the competing mAb (“self-competition”). IL-12/IL-23p40 or IL-23 binding is detected using streptavidin. These results demonstrate whether the mAbs recognize similar or partially overlapping epitopes on IL-12/IL-23p40 or IL-23.

One aspect of the method of the invention administers to a patient a pharmaceutical composition comprising

In one embodiment of the pharmaceutical compositions, the isolated antibody concentration is from about 77 to about 104 mg per ml of the pharmaceutical composition. In another embodiment of the pharmaceutical compositions the pH is from about 5.5 to about 6.5.

The stable or preserved formulations can be provided to patients as clear solutions or as dual vials comprising a vial of lyophilized at least one anti-IL-23 antibody that is reconstituted with a second vial containing a preservative or buffer and excipients in an aqueous diluent. Either a single solution vial or dual vial requiring reconstitution can be reused multiple times and can suffice for a single or multiple cycles of patient treatment and thus provides a more convenient treatment regimen than currently available.

Other formulations or methods of stabilizing the anti-IL-23 antibody may result in other than a clear solution of lyophilized powder comprising the antibody. Among non-clear solutions are formulations comprising particulate suspensions, said particulates being a composition containing the anti-IL-23 antibody in a structure of variable dimension and known variously as a microsphere, microparticle, nanoparticle, nanosphere, or liposome. Such relatively hom*ogenous, essentially spherical, particulate formulations containing an active agent can be formed by contacting an aqueous phase containing the active agent and a polymer and a nonaqueous phase followed by evaporation of the nonaqueous phase to cause the coalescence of particles from the aqueous phase as taught in U.S. Pat. No. 4,589,330. Porous microparticles can be prepared using a first phase containing active agent and a polymer dispersed in a continuous solvent and removing said solvent from the suspension by freeze-drying or dilution-extraction-precipitation as taught in U.S. Pat. No. 4,818,542. Preferred polymers for such preparations are natural or synthetic copolymers or polymers selected from the group consisting of gleatin agar, starch, arabinogalactan, albumin, collagen, polyglycolic acid, polylactic aced, glycolide-L(−) lactide poly(episilon-caprolactone, poly(epsilon-caprolactone-CO-lactic acid), poly(epsilon-caprolactone-CO-glycolic acid), poly(ß-hydroxy butyric acid), polyethylene oxide, polyethylene, poly(alkyl-2-cyanoacrylate), poly(hydroxyethyl methacrylate), polyamides, poly(amino acids), poly(2-hydroxyethyl DL-aspartamide), poly(ester urea), poly(L-phenylalanine/ethylene glycol/1,6-diisocyanatohexane) and poly(methyl methacrylate). Particularly preferred polymers are polyesters, such as polyglycolic acid, polylactic aced, glycolide-L(−) lactide poly(episilon-caprolactone, poly(epsilon-caprolactone-CO-lactic acid), and poly(epsilon-caprolactone-CO-glycolic acid. Solvents useful for dissolving the polymer and/or the active include: water, hexafluoroisopropanol, methylenechloride, tetrahydrofuran, hexane, benzene, or hexafluoroacetone sesquihydrate. The process of dispersing the active containing phase with a second phase may include pressure forcing said first phase through an orifice in a nozzle to affect droplet formation.

Dry powder formulations may result from processes other than lyophilization, such as by spray drying or solvent extraction by evaporation or by precipitation of a crystalline composition followed by one or more steps to remove aqueous or nonaqueous solvent. Preparation of a spray-dried antibody preparation is taught in U.S. Pat. No. 6,019,968. The antibody-based dry powder compositions may be produced by spray drying solutions or slurries of the antibody and, optionally, excipients, in a solvent under conditions to provide a respirable dry powder. Solvents may include polar compounds, such as water and ethanol, which may be readily dried. Antibody stability may be enhanced by performing the spray drying procedures in the absence of oxygen, such as under a nitrogen blanket or by using nitrogen as the drying gas. Another relatively dry formulation is a dispersion of a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant as taught in WO 9916419. The stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler. Equipment useful in the commercial manufacture of spray dried medicaments are manufactured by Buchi Ltd. or Niro Corp.

An anti-IL-23 antibody in either the stable or preserved formulations or solutions described herein, can be administered to a patient in accordance with the present invention via a variety of delivery methods including SC or IM injection; transdermal, pulmonary, transmucosal, implant, osmotic pump, cartridge, micro pump, or other means appreciated by the skilled artisan, as well-known in the art.

Therapeutic Applications

The present invention also provides a method for modulating or treating lupus, in a cell, tissue, organ, animal, or patient, as known in the art or as described herein, using at least one IL-23 antibody of the present invention, e.g., administering or contacting the cell, tissue, organ, animal, or patient with a therapeutic effective amount of IL-12/1L-23p40 or IL-23 specific antibody.

Any method of the present invention can comprise administering an effective amount of a composition or pharmaceutical composition comprising an anti-IL-23 antibody to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy. Such a method can optionally further comprise co-administration or combination therapy for treating such diseases or disorders, wherein the administering of said at least one anti-IL-23 antibody, specified portion or variant thereof, further comprises administering, before concurrently, and/or after, at least one selected from at least one TNF antagonist (e.g., but not limited to, a TNF chemical or protein antagonist, TNF monoclonal or polyclonal antibody or fragment, a soluble TNF receptor (e.g., p55, p70 or p85) or fragment, fusion polypeptides thereof, or a small molecule TNF antagonist, e.g., TNF binding protein I or II (TBP-1 or TBP-II), nerelimonmab, infliximab, eternacept (Enbrel™), adalimulab (Humira™), CDP-571, CDP-870, afelimomab, lenercept, and the like), an antirheumatic (e.g., methotrexate, auranofin, aurothioglucose, azathioprine, gold sodium thiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalzine), a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial (e.g., aminoglycoside, an antifungal, an antiparasitic, an antiviral, a carbapenem, cephalosporin, a flurorquinolone, a macrolide, a penicillin, a sulfonamide, a tetracycline, another antimicrobial), an antipsoriatic, a corticosteriod, an anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropoietin (e.g., epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim (GM-CSF, Leukine), an immunization, an immunoglobulin, an immunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha (Pulmozyme), a cytokine or a cytokine antagonist. Suitable dosages are well known in the art. See, e.g., Wells et al., eds., Pharmacotherapy Handbook, 2^ndEdition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000); Nursing 2001 Handbook of Drugs, 21^stedition, Springhouse Corp., Springhouse, P A, 2001; Health Professional's Drug Guide 2001, ed., Shannon, Wilson, Stang, Prentice-Hall, Inc, Upper Saddle River, N.J., each of which references are entirely incorporated herein by reference.

Therapeutic Treatments

Typically, treatment of lupus is affected by administering an effective amount or dosage of an anti-IL-12/23p40 or anti-IL-23 antibody composition that total, on average, a range from at least about 0.01 to 500 milligrams of an anti-IL-12/23p40 or anti-IL-23 antibody per kilogram of patient per dose, and, preferably, from at least about 0.1 to 100 milligrams antibody/kilogram of patient per single or multiple administration, depending upon the specific activity of the active agent contained in the composition. Alternatively, the effective serum concentration can comprise 0.1-5000 μg/ml serum concentration per single or multiple administrations. Suitable dosages are known to medical practitioners and will, of course, depend upon the particular disease state, specific activity of the composition being administered, and the particular patient undergoing treatment. In some instances, to achieve the desired therapeutic amount, it can be necessary to provide for repeated administration, i.e., repeated individual administrations of a particular monitored or metered dose, where the individual administrations are repeated until the desired daily dose or effect is achieved.

Preferred doses can optionally include 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and/or 100-500 mg/kg/administration, or any range, value or fraction thereof, or to achieve a serum concentration of 0.1, 0.5, 0.9, 1.0, 1.1, 1.2, 1.5, 1.9, 2.0, 2.5, 2.9, 3.0, 3.5, 3.9, 4.0, 4.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 20, 12.5, 12.9, 13.0, 13.5, 13.9, 14.0, 14.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 12, 12.5, 12.9, 13.0, 13.5, 13.9, 14, 14.5, 15, 15.5, 15.9, 16, 16.5, 16.9, 17, 17.5, 17.9, 18, 18.5, 18.9, 19, 19.5, 19.9, 20, 20.5, 20.9, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 96, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, and/or 5000 μg/ml serum concentration per single or multiple administration, or any range, value or fraction thereof.

Alternatively, the dosage administered can vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. Usually a dosage of active ingredient can be about 0.1 to 100 milligrams per kilogram of body weight. Ordinarily 0.1 to 50, and, preferably, 0.1 to 10 milligrams per kilogram per administration or in sustained release form is effective to obtain desired results.

As a non-limiting example, treatment of humans or animals can be provided as a one-time or periodic dosage of at least one antibody of the present invention 0.1 to 100 mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or, alternatively or additionally, at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, or, alternatively or additionally, at least one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years, or any combination thereof, using single, infusion or repeated doses.

Dosage forms (composition) suitable for internal administration generally contain from about 0.001 milligram to about 500 milligrams of active ingredient per unit or container. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5-99.999% by weight based on the total weight of the composition.

For parenteral administration, the antibody can be formulated as a solution, suspension, emulsion, particle, powder, or lyophilized powder in association, or separately provided, with a pharmaceutically acceptable parenteral vehicle. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 1-10% human serum albumin.

Liposomes and nonaqueous vehicles, such as fixed oils, can also be used. The vehicle or lyophilized powder can contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation is sterilized by known or suitable techniques.

Suitable pharmaceutical carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.

Alternative Administration

Many known and developed modes can be used according to the present invention for administering pharmaceutically effective amounts of an anti-IL-23 antibody. While pulmonary administration is used in the following description, other modes of administration can be used according to the present invention with suitable results. IL-12/IL-23p40 or IL-23 antibodies of the present invention can be delivered in a carrier, as a solution, emulsion, colloid, or suspension, or as a dry powder, using any of a variety of devices and methods suitable for administration by inhalation or other modes described here within or known in the art.

Parenteral Formulations and Administration

Formulations for parenteral administration can contain as common excipients sterile water or saline, polyalkylene glycols, such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. Aqueous or oily suspensions for injection can be prepared by using an appropriate emulsifier or humidifier and a suspending agent, according to known methods. Agents for injection can be a non-toxic, non-orally administrable diluting agent, such as aqueous solution, a sterile injectable solution or suspension in a solvent. As the usable vehicle or solvent, water, Ringer's solution, isotonic saline, etc. are allowed; as an ordinary solvent or suspending solvent, sterile involatile oil can be used. For these purposes, any kind of involatile oil and fatty acid can be used, including natural or synthetic or semisynthetic fatty oils or fatty acids; natural or synthetic or semisynthetic mono- or di- or tri-glycerides. Parental administration is known in the art and includes, but is not limited to, conventional means of injections, a gas pressured needle-less injection device as described in U.S. Pat. No. 5,851,198, and a laser perforator device as described in U.S. Pat. No. 5,839,446 entirely incorporated herein by reference.

Alternative Delivery

The invention further relates to the administration of an anti-IL-12/IL-23p40 or IL-23 antibody by parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vagin*l, rectal, buccal, sublingual, intranasal, or transdermal means. An anti-IL-12/IL-23p40 or IL-23 antibody composition can be prepared for use for parenteral (subcutaneous, intramuscular or intravenous) or any other administration particularly in the form of liquid solutions or suspensions; for use in vagin*l or rectal administration particularly in semisolid forms, such as, but not limited to, creams and suppositories; for buccal, or sublingual administration, such as, but not limited to, in the form of tablets or capsules; or intranasally, such as, but not limited to, the form of powders, nasal drops or aerosols or certain agents; or transdermally, such as not limited to a gel, ointment, lotion, suspension or patch delivery system with chemical enhancers such as dimethyl sulfoxide to either modify the skin structure or to increase the drug concentration in the transdermal patch (Junginger, et al. In “Drug Permeation Enhancement;” Hsieh, D. S., Eds., pp. 59-90 (Marcel Dekker, Inc. New York 1994, entirely incorporated herein by reference), or with oxidizing agents that enable the application of formulations containing proteins and peptides onto the skin (WO 98/53847), or applications of electric fields to create transient transport pathways, such as electroporation, or to increase the mobility of charged drugs through the skin, such as iontophoresis, or application of ultrasound, such as sonophoresis (U.S. Pat. Nos. 4,309,989 and 4,767,402) (the above publications and patents being entirely incorporated herein by reference).

Having generally described the invention, the same will be more readily understood by reference to the following Examples, which are provided by way of illustration and are not intended as limiting. Further details of the invention are illustrated by the following non-limiting Examples. The disclosures of all citations in the specification are expressly incorporated herein by reference.

Synopsis

STELARA® (ustekinumab) is a fully human G1 kappa monoclonal antibody that binds with high affinity and specificity to the shared p40 subunit of human interleukin (IL)-12 and IL-23 cytokines. The binding of ustekinumab to the IL-12/23p40 subunit blocks the binding of IL-12 or IL-23 to the IL-12Rβ1 receptor on the surface of natural killer and CD4⁺ T cells, inhibiting IL-12- and IL-23-specific intracellular signaling and subsequent activation and cytokine production. Abnormal regulation of IL-12 and IL-23 has been associated with multiple immune-mediated diseases including Systemic Lupus Erythematosus (SLE). Therefore, inhibition of IL-12 and IL-23 has the potential to be effective in the treatment of SLE.

Objective and Hypothesis

Primary Objective

The primary objective is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active SLE.

Secondary Objectives

The secondary objectives are to evaluate:

- The safety and tolerability of ustekinumab in subjects with SLE.
- The effect of ustekinumab administration on health-related quality of life in subjects with SLE.
- The effects of ustekinumab on cutaneous manifestations of SLE.
- Pharmaco*kinetics and immunogenicity of ustekinumab in subjects with SLE.
  Exploratory Objective

The exploratory objectives are to evaluate:

- Safety and efficacy during long-term administration of ustekinumab.
- Reduction in corticosteroid dosing during long-term administration of ustekinumab.
- Additional composite clinical endpoints or methods of calculation of clinical response with potential for greater sensitivity to improvement and/or worsening of SLE.
- Biomarkers related to lupus disease (genetic, systemic, and skin-related).
  Hypothesis

The hypothesis is that dosing with ustekinumab is significantly superior to placebo as measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index (SRI-4) composite measure at Week 24.

Overview of Study Design

CNTO1275SLE2001 is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of ustekinumab added to standard of care background in subjects with active SLE. Subjects to be enrolled must have SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score≥6, despite conventional treatment (e.g., immunomodulators, antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, anti-hypertensive drugs, and/or topical medications). In addition, subjects must have at least 1 positive autoantibody test (antinuclear antibodies [ANA], anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies, and/or anti-Smith antibodies) observed during screening, as well as a well-documented positive autoantibody test in medical history. Subjects must also demonstrate at least 1 British Isles Lupus Assessment Group (BILAG) A and/or 2 BILAG B domain scores observed during screening. In addition, subjects must have a clinical SLEDAI-2K score ≥4 (excluding laboratory results) at week 0, prior to randomization.

Approximately 100 subjects will be randomly assigned in a 3:2 ratio to receive either ustekinumab or placebo through Week 24. Following randomization at Week 0, subjects will receive an initial body weight-range based IV dose approximating 6 mg/kg of ustekinumab (ustekinumab 260 mg [weight ≥35 kg to ≤55 kg]; ustekinumab 390 mg [weight >55 kg and ≤85 kg]; ustekinumab 520 mg [weight >85 kg]) followed by 90 mg SC administered every 8 weeks (q8w).

At Week 24, subjects receiving placebo will cross-over and all subjects will receive ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up through Week 56 in a blinded fashion for 16 weeks (i.e., approximately 5 half-lives) after last study agent SC administration.

A placebo comparator (added to standard of care background therapy) will be used through Week 24 for the evaluation of the efficacy and safety of ustekinumab in subjects with SLE. From Week 24 through Week 40, the placebo group will cross-over to receive ustekinumab 90 mg SC q8w. This cross-over design will permit placebo subjects to receive study agent and provide experience with ustekinumab 90 mg SC without the IV loading dose in subjects with SLE. The 40-Week dosing period will be useful to understand the longer-term safety and time course of potential clinical response of ustekinumab in the SLE population.

Every reasonable effort should be made to keep concomitant medications stable as defined in the protocol. All concomitant therapies must be recorded throughout the study beginning at entry into screening and any changes must be recorded throughout the study.

All subjects with cutaneous disease will be evaluated using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scoring. Additionally, subjects with cutaneous disease who consent to participate in the cutaneous lupus substudy will have other assessments including collection of skin biopsies (optional consent) and/or photographs of a cutaneous lesion or area of active disease (optional consent). There will not be any restrictions on the number of subjects with cutaneous disease who can enroll into either the main study or the cutaneous lupus substudy.

Interim analyses (IA) will be conducted when approximately ⅓ and ⅔ of subjects reach Week 24. In the first IA, only an assessment of notable efficacy will be performed. In the second IA, evidence for notable efficacy as well as treatment futility will be analyzed. Database locks (DBLs) will occur at Weeks 24 and following the last subject's Week 56 visit, or the final subject's Week 16 safety follow-up visit from the main study. In addition, an independent data monitoring committee (DMC) will review interim safety data periodically including a formal review when approximately ⅓ and ⅔ of subjects reach Week 24, as well as at the Week 24 DBL. The DMC will make a recommendation to the Sponsor committee whether the study should be stopped for futility or for safety concerns or if data meet prespecified criteria demonstrating notable efficacy. The content of the summaries, the DMC role and responsibilities, and the general procedures (including communications) will be defined in the DMC charter.

The amended study design will continue to provide open-label ustekinumab 90 mg q8w SC administration through Week 104. Subjects will be eligible to continue study treatment through Week 104 if they meet the study inclusion criteria (Section 4.1.3) including:

- must not have permanently discontinued study treatment on or before their Week 40 visit, and
- are able to continue q8 week study treatment at approximately 8 weeks (±2 weeks) after their Week 40 visit or
- are able to resume study treatment with no more than 16 weeks (±2 weeks) since their Week 40 visit.

In addition to the DBL planned after the final subject's Week 56 visit, or after the last subject's Week 16 safety follow-up visit from the main study, there will be an additional DBL at the end of the study extension (following Study Extension 16-week safety follow-up visit).

Subject Population

Screening for eligible subjects must be performed no more than 6 weeks prior to the randomization visit (Week 0). The target study population is subjects with SLE according to SLICC criteria and SLEDAI-2K score ≥6, despite conventional treatment (e.g., immunomodulators, antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, anti-hypertensive drugs, and/or topical medications). In addition, subjects must have at least 1 positive autoantibody test (ANA, anti-dsDNA antibodies, and/or anti-Smith antibodies) observed during screening, as well as a well-documented positive autoantibody test in medical history. Subjects must also have at least 1 BILAG A and/or 2 BILAG B domain scores observed during screening prior to first administration of study agent.

In addition, to be eligible for study participation, subjects must have a clinical SLEDAI-2K score ≥4 (excluding laboratory results) for clinical features at Week 0 (prior to randomization) and have received approval for study randomization following review and adjudication of screening lupus assessments by the Sponsor and/or Sponsor-selected independent reviewer(s).

SLE subjects enrolling into the main study with active cutaneous lupus (including subjects with discoid lupus erythematosus, subacute cutaneous lupus erythematosus, alopecia or SLE malar rash or other SLE skin lesions characterized by erythema and or scale) will be evaluated using CLASI scoring. In addition, subjects who provide consent will be enrolled in the cutaneous lupus substudy evaluating the histology of cutaneous biopsies and/or skin photographs. Subjects participating in the cutaneous lupus substudy are not required to undergo biopsies, and may allow only photographs to document changes in an identified lesion or area of active disease.

Dosage and Administration

All subjects will receive a body weight range-based IV administration of study agent (placebo or ustekinumab) at Week 0 and then SC administration of placebo or ustekinumab at Weeks 8 and 16, followed by all subjects receiving ustekinumab dosing at Weeks 24, 32, and 40. Every reasonable effort should be made to keep concomitant medications stable at least through Week 28, with some adjustments allowed beyond Week 28 through the 8-Week Safety Follow-Up or study extension as defined in the protocol. A concomitant medication may be reduced or medication temporarily discontinued because of abnormal laboratory values, side effects, concurrent illness, or the performance of a surgical procedure, but the change and reason for the medication change should be clearly documented in the subject's medical record. If concomitant medications have been adjusted after randomization as allowed per protocol, every effort should be made to return subject back to the baseline (Week 0) dose level by the Week 12 visit; or increased medication use may render a subject to be considered a treatment failure.

Subjects who are enrolled in the study extension will continue to receive ustekinumab 90 mg SC administration every 8 weeks through Week 104. With the exception of corticosteroids, concomitant medications should be maintained at stable doses through the study extension.

Week 0 Up to Week 24 (Blinded Study Agent Administration Phase)

Group 1: Subjects will receive weight-range based IV dosing of approximately 6 mg/kg of ustekinumab at Week 0 followed by ustekinumab 90 mg SC administrations at Weeks 8 and 16.

Group 2: Subjects will receive weight-range based IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8 and 16.

Week 24 to Week 40 (Cross-over Administration Phase)

Group 1: Subjects will receive an ustekinumab 90 mg SC administration at Week 24 followed by q8w administrations through Week 40.

Group 2: Subjects in the placebo dosing group will cross-over to ustekinumab 90 mg SC administrations at Week 24 followed by q8w administrations through Week 40.

After Week 40 to 16-Week Safety Follow-Up (Safety Follow-Up Phase)

Groups 1 and 2: Subjects who do not participate in the study extension are expected to return for safety follow-up visits at Week 44 and for 8- and 16-weeks safety follow up.

Study Extension (Week 48/Week 56 Through Week 120)

Subjects who meet the study extension inclusion criteria (Section 4.1.3) will receive an additional 1 year of open label ustekinumab administration for the purpose of expanding the safety experience and maintenance of efficacy in lupus patients exposed to ustekinumab 90 mg q8w. Subjects who continue dosing in the extended study starting at Week 48 or at Week 56 will receive open-label ustekinumab SC dosing through Week 104. If the development of ustekinumab in SLE is terminated, then the study extension will also be discontinued.

Efficacy Evaluations

The primary efficacy endpoint of this study is to compare the proportion of subjects with a composite SRI-4 response at Week 24 for subjects receiving ustekinumab as compared to placebo treatment.

Efficacy evaluations and patient reported quality of life measures include:

- SLEDAI-2K
- S2K RI-50
- BILAG
- CLASI
- Physician's Global Assessment of Disease Activity
- Patient's Global Assessment of Disease Activity
- Short-form 36 questionnaire
- Fatigue Severity Scale
- Patient's Assessment of Pain
  Pharmaco*kinetic and Immunogenicity Evaluations

Serum samples will be used to evaluate the pharmaco*kinetics of ustekinumab, as well as the immunogenicity of ustekinumab (antibodies to ustekinumab).

Biomarker Evaluations and Serologic Markers

The collection, preparation, storage and shipment of skin biopsies, blood, serum and urine are detailed in the Laboratory Manual. Biomarkers may include, but are not limited to, inflammatory markers, ribonucleic acid (RNA), cell surface markers, autoantibodies, T cell and B cell repertoire, target specific markers, and other categories of biomarkers potentially involved in the development and the progression of lupus.

Serum Analyses

Serum will be analyzed for levels of specific proteins including but not limited to soluble CD40 ligand (sCD154), interleukin (IL)-6, IL-12p40, IL-17, IL-21, IL-22, IL-23p19, C—X—C motif chemokine 10 (CXCL10), B cell activating factor (BAFF), interferons, autoantibodies and other inflammation-related molecules.

Skin Biopsy Analyses

Skin biopsies will be utilized for cellular, molecular, and gene expression analyses.

Whole Blood Gene Expression Analyses

Whole blood will be collected from all subjects for RNA, flow cytometry, T cell and B cell repertoire and epigenetics analysis (e.g., deoxyribonucleic acid [DNA] methylation).

Serologic Markers

Autoantibodies (e.g., ANA, anti-dsDNA, etc.), complement C3 and C4 will be collected as described in the Table of Events (Table 1).

Pharmacogenomic (DNA) Evaluations

DNA samples will be used for research related to this study (CNTO1275SLE2001). Specific genomic testing will be undertaken for consenting subjects (subjects participating in this portion of the study must sign a separate informed consent form. The procedure will involve taking a blood sample that may be analyzed for specific target genes that may play a role in lupus. Any genomic assessments will be performed in strict adherence to current subject confidentiality standards for genetic testing. Refusal to participate in genomics testing will not result in ineligibility for participation in the rest of the clinical study.

Cutaneous Lupus Substudy

All subjects with cutaneous disease will be evaluated using CLASI scoring. Additionally, subjects with cutaneous disease who consent to participate in the cutaneous lupus sub study will have other assessments including collection of skin biopsies (optional consent) and/or photographs of an identified cutaneous lesion or area of active disease (optional consent). There will not be any restrictions on the number of subjects with cutaneous disease who can enroll into either the main study or the cutaneous lupus substudy.

Subjects who provide consent will be enrolled in the cutaneous lupus substudy evaluating the histology of cutaneous biopsies and/or skin photographs. Biopsy samples (2 samples, 4 mm size) from consenting subjects will be collected prior to dosing at Week 0 and at Week 24 from a single lesion or area of active cutaneous disease. Photographs and skin biopsies can target a different area of active disease, but the follow-up photographs or biopsies should re-evaluate the same area of active disease as originally assessed at week 0. Subjects participating in the cutaneous lupus substudy are not required to undergo biopsies, and may allow only photographs to document changes in an identified lesion or area of active disease. Subjects with cutaneous lupus deemed unsuitable for biopsy (e.g., malar rash or alopecia) can also be enrolled in the substudy, and may be evaluated by photography.

Independent of cutaneous biopsy collection, subjects who participate in the cutaneous lupus substudy will be requested to provide consent for photographs to be collected from an identified lesion or area of active disease. The photographs are for exploratory purposes only. The photographs will be used to assist in a qualitative evaluation of clinical response. Confidentiality of the subjects involved in this study will be maintained; specifically photographs of subjects in this study will not be published or otherwise made public without blocking adequate portions of the subject's face or body so that the individual cannot be identified.

Safety Evaluations

Safety assessments include vital signs, general physical exam and skin evaluations, adverse events (AE), serious AEs, concomitant medication review, pregnancy testing, infusion reactions, chemistry and hematology laboratory tests, and antibodies to ustekinumab. Chest x-ray and tuberculosis, human immunodeficiency virus, hepatitis B, and hepatitis C testing will be required at time of screening. Any clinically significant abnormalities persisting at the end of the study will be followed by the investigator until resolution or until a clinically stable endpoint is reached. Subject diary cards will be used to capture medication changes that occur in between study visits during the main portion of this study. Safety data collected up to 16 weeks after the final administration of study agent will be evaluated.

Statistical Methods

Sample Size Determination

Approximately 100 subjects will be randomly assigned in a 3:2 ratio to receive either ustekinumab or placebo through Week 24. Approximately sixty subjects treated with ustekinumab and approximately 40 subjects with placebo is projected to give approximately 80% power to detect a significant difference in response rate compared with placebo (assume 35% and 60% response rates in placebo and ustekinumab respectively, which translates to 25% absolute increase over placebo or an odds ratio of 2.79) with an alpha level of 0.1.

Efficacy Analyses

The primary endpoint of this study is the proportion of subjects with a composite measure of SLE disease activity (SLE Responder Index [SRI]-4 response) at Week 24. The primary analysis will be based upon the primary endpoint and will be conducted on the modified intent-to-treat (mITT) population, which includes all randomized subjects who receive at least 1 dose of study agent, have at least 1 measurement prior to the administration, and have at least 1 post-baseline SRI-4 measurement.

Last observation carried forward (LOCF) procedure will be used to impute the missing SRI-4 component if the subjects have data for at least 1 SRI-4 component at Week 24. If the subjects do not have data for any SRI components at Week 24, the subjects will be considered not to have achieved the SRI-4 response.

In addition, subjects who meet any of a variety of treatment failure criteria, such as receiving a dose of immunomodulator that is higher at Week 24 than at baseline, or initiated prohibited treatment (dose or timing) with corticosteroids, or discontinued study agent due to a lack of efficacy will be considered to have not achieved the primary endpoint, SRI-4 response at Week 24.

Logistic regression, adjusting for baseline stratifications and baseline SLEDAI, will be used to analyze the primary endpoint. The baseline SLEDAI value is defined as the closest non-missing measurement taken prior to the Week 0 infusion. If significant non-normality is observed, appropriate nonparametric tests will be used to evaluate the differences between treatments.

The study will be considered positive if the primary analysis achieves statistical significance at a significance level of 0.1 (2-sided) and ustekinumab shows a positive treatment effect relative to placebo treatment.

Safety Analyses

Safety will be assessed by analyses of the incidence and type of AEs, SAES, reasonably related AEs, infections, and infusion reactions. Safety assessments will also include analyses of laboratory parameters and change from baseline in laboratory parameters (hematology and chemistry) and incidence of abnormal laboratory parameters (hematology and chemistry).

TABLE 1

Time and Events Schedule for Main Study (Screening through 8-Week/16-Week Safety Follow-up)

	Cross-over
Blinded Study Agent	Administration
Administration Phase	Phase	Safety Follow-up

Week

16-Week

8-Week

Safety

Follow-up/

Follow-

Final

Study

Screening/Administrative

Informed consent

Inclusion/exclusion criteria

X^a

Medical history sod demographics

SLE classification by SLICC criteria

Study Drug Administration

Randomization

Study agent administration

Diary card

Train on diary card and distribute

Collect, review and distribute diary cards

Safety Assessments

Physical examination

HIV, HBV, and HCV

QuantiFERON ®-TB Gold test

Tuberculin skin test^e

Serum pregnancy

Urine pregnancy

Vital signs

Height

Weight

Chest x-

Concomitant therapy

Adverse Events

Study

Urinalysis (dipstick, all study

Urine sample for biomarkers (all subjects)

Protein/Creatinine ratio^s

Microscopy of urine

Pharmaco*kinetics/Immunogenicity

Serum ustekinumab

2X^r

Antibodies to study

Pharmacogenomics (DNA)^u

Whole blood DNA

Biomarkers

Serum sample

Whole blood for RNA gene expression

T cell and B cell repertoire

Epigenetics

Flow

Study

^aScreening visit must be performed no more than 6 weeks prior to the randomization visit (Week 0). To be eligible for stady participation, subjects must have SLEDAI score ≥4 (excluding laboratory results) for clinical features at Week 0 and have received approval for study randomization following review and adjudication of screening lupus assessments by the Sponsor and/or Sponsor-selected independent reviewer(s).

^bSubjects, who discontinue study agent administrations on or before the Week 40 visit, must return, approximately 8 and 16 weeks after last study agent administration for safety follow-up visits. The 8-week and/or 16-week safety follow-up visits are not required for subjects who continue treatment in the study extension within 8 (±2 weeks) or 16 (±2 weeks) weeks, respectively, of their Week 40 visit (refer to Table 2).

^cAll assessments (except for injection-site evaluation) are to be completed prior to study agent administration, unless otherwise specified.

^dIntravenous administration of study agent st Week 0, all other doses will be SC.

^eOnly required if QuantiFERON ®-TB is not registered/approved locally or the tuberculin skin test (TST) is mandated by local health authorities.

^fIf TB is suspected at any time during the study, a chest x-ray (local), and QuantiFERON ®-TB Gold test should be performed. A TST is additionally required if the QuantiFERON ®-TB Gold test is not registered/approved locally or the TST is mandated by local health authorities.

^gIn addition to the screening evaluation, the pregnancy test may be repeated at any time at tbe discretion of investigator or subject.

^hMay conduct urine pregnancy test more frequently monthly basis) if required by local regulations.

ⁱPosterior/anterior and lateral views must be taken within 3 months prior to the first administration of study agent for TB detection.

^jSubjects should be monitored for the occurrence of infusion or injection-site reactions for 30 minutes after the infusion (TV administration) or injection.

^kOnly for subjects who consented to participate in the cutaneous lupus for biopsy and/or photograph collection.

^lAll visit-specific patient reported outcome assessments should be conducted before any tests, procedures, or other consultations for that visit to prevent influencing subjects' perceptions.

^mComplete SLEDAI-2K (Baseline) will be evaluated during screening and at Week 0, although at Week 0 only the clinical (non-laboratory) features will be considered to confirm eligibility for study enrollment. The photographs and skin biopsies can target a different location of active disease, but the follow-up photographs or biopsies should re-evaluate the same area of active disease as originally assessed at week 0.

ⁿCLASI scoring will be obtained for all enrolled subjects with cutaneous lupus regardless of enrollment in the cutaneous lupus substudy.

^o perform B cell analyses at screening for subjects previously exposed to B cell depleting therapies.

^pIf abnormal test result is not obtained at screening or at Week 0, no additional follow-up testing is required. However, additional testing may be performed if needed.

^qThese tests will be performed on-site or at local lab(s).

^rAnti-dsDNA should be analyzed at every specified visit. If the other autoantibody tests are negative at both the screening and Week 0 visits, then those autoantibody test need only be analyzed again at Weeks 24 and 48. However, if the other autoantibodies tests are positive at either screening or Week 0, then they should be analyzed at all visits.

^sThe same blood draw will be used for the measurement of concentration and detection of antibodies to . For visits with study agent administration, all blood samples fpr assessing pre-dose concentration and antibodies to MUST be collected BEFORE the administration of the study agent.

^tAt Week 0 visit, 2 separate samples for serum concentrations (indicated by “2X” in the Schedule above) will be collected (1 sample will be collected prior to IV infusion and the other collected 1 hour after the end of the infusion) for all subjects.

^uOnly for subjects who consent to allow genomic analyses.

^vFlow cytometry samples will be analyzed from subjects at selected sites.

^wBiopsies occur 1-2 days prior to randomization and at the Week 24 visit.

^xPhotographs do not need to be taken at the same area of active disease as the biopsy; however, follow-up photographs or biopsies should re-evaluate the same area of active disease as originally assessed at week 0.

TABLE 2

Time and Events Schedule in Study Extension (Week 48/56 through Extension Safety Follow-up)

Study Extension

Extension Safety Follow-

Week

										Extension 16-
									Extension 8-	Week Safety
									Week Safety	Follow-
	48	56	64	72	80	88	96	104	Follow-up	up/Final Visit

Study
Screening/Administrative
Informed	X	X
Study Drug Administration
Study agent administration			X	X	X	X	X	X
Safety Assessments
Physical examination	X		X		X			X	X	X
TB	X	X	X	X	X	X	X	X	X	X
Urine pregnancy test^e	X	X	X	X	X	X	X	X	X	X
Vital signs	X	X	X	X	X	X	X	X	X	X
Concomitant therapy	X	X	X	X	X	X	X	X	X	X
Adverse Events	X	X	X	X	X	X	X	X	X	X
Injection-site reaction	X	X	X	X	X	X	X	X
Efficacy
S2K RI-50	X			X		X		X	X
	X			X		X		X	X
BILAG	X			X		X		X	X
Physician's Global Assessment of	X			X		X		X	X
Disease Activity
Patient's Global Assessments	X			X		X		X	X
(Pain andDisease Activity)
SF-36	X			X				X	X
Fatigue Severity Scale	X			X				X	X
Clinical Laboratory Assessments
	X	X	X	X	X	X	X	X	X	X
C3, C4	X	X	X	X	X	X	X	X	X	X
Coombs direct (as needed)	X				X			X	X	X
Coagulation Labs (as needed)^i,j	X				X			X	X	X
	X	X	X	X	X	X	X	X	X	X
Anti-dsDNA	X	X	X	X	X	X	X	X	X	X
Other	X				X^l			X
Study
Anti-phospholipid	X				X			X
Ig isotype profile	X							X
Urine Analyses (spot urine)ⁱ
Urinalysis (dipstick, all study	X	X	X	X	X	X	X	X	X	X
Urine sample for biomarkers (all	X				X			X	X	X
subjects)
Protein/Creatinine	X	X	X	X	X	X	X	X	X	X
Microscopy of urine	X	X	X	X	X	X	X	X	X	X
Pharmaco*kinetics/Immunogenicity
Serum ustekinumab	X				X			X	X	X
Antibodies to study	X				X			X	X	X
Biomarkers
Serum sample	X				X			X	X	X
Whole blood for RNA gene expression	X				X			X	X	X
Study

^aSubjects, who complete all scheduled doses or discontinue study agent administration befofe the end of the study extension, must return at approximately 8 and 16 weeks after last study agent administration for safety follow-up visits.
^bAll assessments (except for injection-site evaluation) are to be completed prior to study agent administration.
^cPrior to dosing in the study extension, subjects must sign a revised ICF indicating agreement to participate in the extended study.
^dTB evaluation includes an assessment of recent exposure or risk of TB including new or chronic cough, fever, night sweats, unintentional weight loss or recent contact with someone with active TB. If TB is suspected at any time during the study, a chest x-ray (local), and TB Gold test should be performed. A TST is additionally required if the TB Gold test is not registered/approved locally or the TST is mandated by local health authorities.
^eIn addition to scheduled urine dipstick testing, a serum or urine pregnancy test may be conducted at any time at the discretion of investigator or subject, or if required by local regulations.
^fSubjects should be monitored fer the occurrence of injection-site reactions for 30 minutes after the injection.
^gAll visit-specific patient reported outcome assessments should be conducted before any tests, procedures, or other consultations for that visit to prevent influencing subjects' perceptions.
^hCLASI scoring will be obtained for all enrolled subjects who have cutaneous lupus.
ⁱIf clinical concerns or abnormal results from prior visit observed in these assessments, then strong consideration should be given to more frequent testing (at least q4 week assesments) until normalized
^jIf history of abnormal test result was observed in main study, then follow scheduled assessments. Additional testing may be performed if needed.
^kThese tests will be performed on-site or at local lab(s).
^lIf the “other autoantibody” tests were routinely negative prior to Week 48, then those, autoantibody tests need only be analyzed annually. However, if the other autoantibodies tests were positive at either screening or Week 0, then they should be analyzed every 6 months as shown.
^mUrine sediment analyses to be performed at study site or local lab if possible. If necessary with agreement from study sponsor, urine sediment analyses can be conducted at the Cental Lab for specific sites that cannot arrange local analyses.
ⁿThe same blood draw will be used for the measurement of concentration and detection of antibodies to . All blood samples collected for assessing pre-dose concentration and antibodies to MUST be collected BEFORE the administration of the study agent.

ACE angiotensin-converting enzyme
AE adverse event
ANA antinuclear antibodies
ANCOVA analysis of covariance
anti-dsDNA anti-double stranded deoxyribonucleic acid
anti-HBc total HBV core antibody total
anti HBs HBV surface antibody
ARB angiotensin II receptor blocker
AZA/6 MP azathioprine/6 mercaptopurine
BAFF B cell activating factor, also known as B lymphocyte stimulator (BLyS)
BCG Bacille Calmette-Guérin
β-hCG β human chorionic gonadotropin
BICLA BILAG-based Combined Lupus Assessment
BILAG British Isles Lupus Assessment Group
BLyS B lymphocyte stimulator, also known as B cell activating factor (BAFF)
CLASI Cutaneous Lupus Erythematosus Disease Area and Severity Index
CLE cutaneous lupus erythematosus
CNS central nervous system
COX-2 cyclooxygenase-2
CD Crohn's disease
CTCAE Common Terminology Criteria for Adverse Events
CXCL10 C—X—C motif chemokine 10
DMC data monitoring committee
DNA deoxyribonucleic acid
eDC Electronic Data Capture
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
FSS Fatigue Severity Scale
FVP Final Vialed Product
GCP Good Clinical Practice
HBsAg HBV surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
IA interim analyses
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
Ig Immunoglobulin
IL Interleukin
IM Intramuscular
IP Investigative Product
IRB Institutional Review Board
IV Intravenous
IWRS interactive web response system
JAK j anus kinase
mITT modified intent to-treat
MMF mycophenolate mofetil
MPA mycophenolic acid
MTX Methotrexate
NAbs neutralizing antibodies
NSAIDs nonsteroidal anti inflammatory drugs
PFS prefilled syringe
PGA Physician's Global Assessment of Disease Activity
PK Pharmaco*kinetic
PQC product quality complaint
PROs patient reported outcomes
PsA psoriatic arthritis
PtGA Patient's Global Assessment of Disease Activity
q8w every 8 weeks
RA rheumatoid arthritis
RNA ribonucleic acid
RNP Ribonucleoprotein
S2K RI-50 SLEDAI-2K Responder Index
SAE serious AE
SAP statistical analysis plan
SC Subcutaneous
SF Short-form
SLE Systemic Lupus Erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000
SLICC Systemic Lupus International Collaborating Clinics
SRI-4 SLE Responder Index
SSA anti-Sjögren's-syndrome-related antigen A
SSB anti-Sjögren's-syndrome-related antigen B
TB Tuberculosis
Th T helper
TNFα tumor necrosis factor alpha
ULN upper limit of normal
VAS visual analogue scale
WBC white blood cells

STELARA® (ustekinumab) is a fully human G1 kappa monoclonal antibody that binds with high affinity and specificity to the shared p40 subunit of human interleukin (IL)-12 and IL-23 cytokines. The binding of ustekinumab to the IL-12/23p40 subunit blocks the binding of IL-12 or IL-23 to the IL-12Rβ1 receptor on the surface of natural killer and CD4⁺ T cells, inhibiting IL-12- and IL-23-specific intracellular signaling and subsequent activation and cytokine production. Abnormal regulation of IL-12 and IL-23 has been associated with multiple immune-mediated diseases including systemic lupus erythematosus (SLE). Therefore, inhibition of IL-12 and IL-23 has the potential to be effective in the treatment of SLE.

Systemic lupus erythematosus is a complex, chronic heterogeneous autoimmune disease of unknown etiology that can affect almost any organ system, and which follows a waxing and waning disease course. Systemic lupus erythematosus occurs much more often in women than in men, up to 9 times more frequently in some studies, and often appears during the child-bearing years between ages 15 and 45. This disease is more prevalent in Afro-Caribbean, Asian, and Hispanic populations. In SLE, the immune system attacks the body's cells and tissue, resulting in inflammation and tissue damage which can harm the heart, joints, skin, lungs, blood vessels, liver, kidneys and nervous system. About half of the subjects diagnosed with SLE present with organ-threatening disease, but it can take several years to diagnose subjects who do not present with organ involvement. Some of the primary complaints of newly diagnosed lupus patients are arthralgia (62%) and cutaneous symptoms (new photosensitivity; 20%), followed by persistent fever and malaise (Wallace, 2008). The estimated annual incidence of lupus varies from 1.8 to 7.6 cases per 100,000 and the worldwide prevalence ranges from 14 to 172 cases per 100,000 people (Wallace, 2008). Patients with mild disease have mostly skin rashes and joint pain and require less aggressive therapy; regimens include nonsteroidal anti-inflammatory drugs (NSAIDs), anti-malarials (e.g., hydroxychloroquine, chloroquine, or quinacrine) and/or low dose corticosteroids. With more severe disease patients may experience a variety of serious conditions depending on the organ systems involved, including lupus nephritis with potential renal failure, endocarditis or myocarditis, pneumonitis, pregnancy complications, stroke, neurological complications, vasculitis and cytopenias with associated risks of bleeding or infection. Common treatments for more severe disease include immunomodulatory agents, such as methotrexate (MTX), azathioprine, cyclophosphamide, cyclosporine, high dose corticosteroids, biologic B cell cytotoxic agents or B cell modulators, and other immunomodulators. Patients with serious SLE have a shortening of life expectancy by 10 to 30 years, largely due to the complications of the disease, of standard of care therapy, and/or accelerated atherosclerosis. In addition, SLE has a substantial impact on quality of life, work productivity, and healthcare expenditures. Existing therapies for SLE are generally either cytotoxic or immunomodulatory, and may have notable safety risks. Newer treatments for SLE have provided only modest benefits over standard of care therapy. Thus, there is a large unmet need for new alternative treatments that can provide significant benefit in this disease without incurring a high safety risk.

The long-term outcome for patients with lupus depends on a variety of factors including whether they have organ involvement, the presence of certain laboratory measures (such as anti-phospholipid antibodies), race, gender, age of consent, access to health care, adherence to treatment, education and other comorbidities. Only about 5% of patients who are diagnosed with SLE will demonstrate a spontaneous remission without treatment. A variety of new therapeutic agents are being evaluated for the treatment of subjects with refractory lupus, however to date very few have demonstrated notable clinical efficacy beyond those medications currently considered standard of care for patients with this disease.

In this study, the target population is subjects with SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥6 (Gladman et al, 2002), despite conventional treatment (e.g., immunomodulators, antimalarial drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topical medications). In addition, subjects must have at least 1 positive autoantibody test (antinuclear antibodies [ANA], anti-double stranded deoxyribonucleic acid [anti-dsDNA] antibodies, and/or anti-Smith antibodies) observed during screening, as well as a well-documented positive autoantibody test in medical history. Subjects must also demonstrate at least 1 British Isles Lupus Assessment Group (BILAG) (Wallace et al, 2011) A and/or 2 BILAG B domain scores during screening. In addition, subjects must have a SLEDAI score ≥4 at Week 0 (prior to randomization) for clinical features (excluding laboratory results). This level of disease activity is consistent with prior studies that have investigated an experimental therapy for systemic lupus (Van Vollenhoven et al, 2012).

1.1. Background

To date, ustekinumab has received marketing approval globally, including countries in North America, Europe, South America, and the Asia-Pacific region, for the treatment of adult patients including those with chronic moderate to severe plaque psoriasis and/or active psoriatic arthritis. Ustekinumab is also being evaluated in a Phase 3 studies for Crohn's disease (CD).

1.2. Overall Rationale for the Study

1.2.1. Scientific Rationale for Use of Anti-IL-12/23p40 Therapy in Systemic Lupus Erythematosus

Systemic lupus erythematosus is a complex, immune-mediated inflammatory disorder exhibiting dysregulated B lymphocytes that produce destructive autoantibodies. B cell targeted therapies (e.g., belimumab) for SLE, however, have shown only modest clinical results beyond a limited standard of care control (Navarra et al, 2011), suggesting that additional immune pathways play an important role in SLE pathogenesis. Chronic immune activation in SLE leads to the increased production of inflammatory cytokines that contribute actively to local inflammation and to processes that mediate tissue damage. Many SLE patients, for example, have a characteristic type I interferon signature observed in their blood cells (Bennett e al, 2003). Interferon signatures have also been observed to occur more frequently in lupus families and may be a risk factor for development of SLE (Niewold et al, 2007). Several studies have also reported an elevation of IL-12, IL-6, and IL-23 in both serum and tissues of patients (Crispin et al, 2008; Linker-Israeli et al, 1991; Oh et al, 2011; Qiu et al, 2013; Shah et al, 2010; Wong et al, 2008) suggesting that the inflammatory environment in SLE is prone to induce T helper (Th)1 and Th17 cells. Increased levels of IL-17 in the serum have been observed in SLE patients (Chen et al, 2010; Tanasescu et al, 2010; Van Vollenhoven et al, 2012; Wong et al, 2008; Yang et al, 2013; Zhao et al, 2010), but the correlation of IL-17 levels to disease activity is not strong (Vincent et al, 2013; Zhao et al, 2010). No direct genetic links have been established in SLE to the IL-12/IL-23/Th17 pathway (Kim et al, 2009; Sánchez et al, 2007; Sestak et al, 2011), although genome-wide association studies in SLE have identified STAT4, which mediates IL-12 signaling, as a susceptibility gene in both the Caucasian and Asian populations (Han et al, 2009; Harley et al, 2008). In patients with active SLE, messenger RNA levels of p19, p40, and p35 were significantly higher compared with those in the inactive SLE patients (Huang et al, 2007). Targeting IL-12/23p40 with ustekinumab has been shown in 3 separate case reports to be associated with a marked improvement of cutaneous lupus (Dahl et al, 2013; De Souza et al, 2011; Winchester et al, 2012). Taken together, there is accumulating evidence to demonstrate the importance of the IL-12 and IL-23 cytokine pathways in SLE pathogenesis, warranting further clinical investigation of ustekinumab as an interventional therapy in this disease.

In addition, 2 disease-related groups, the Alliance for Lupus Research and Lupus Research Institute, independently commissioned a scientific review of a large set of commercially available lupus drug candidates, from which ustekinumab was recommended to be evaluated in SLE based on its molecular mechanism, which further supports the scientific rationale for a placebo-controlled clinical study to evaluate the efficacy and safety of ustekinumab in subjects with active SLE.

1.1.2.1. Subgroup of Subjects with Active Cutaneous Manifestations of Systemic Lupus Erythematosus

The above-mentioned case reports of patients with refractory cutaneous lupus responding to ustekinumab treatment prompts an evaluation of the effects of ustekinumab on cutaneous lesions. Given the relatively common occurrence of cutaneous manifestations in SLE, the feasibility of repeated punch biopsy and/or photographs of an identified lesion or area of active disease, and the availability of cutaneous lupus erythematosus (CLE)-specific disease assessment tools, this patient population may provide useful data regarding the effects of ustekinumab on SLE and the symptoms of cutaneous disease. All subjects with cutaneous disease will be evaluated using CLASI scoring. Additionally, subjects with cutaneous disease who consent to participate in the cutaneous lupus substudy will be requested to provide potential collection of skin biopsies (optional consent) and/or photographs of an identified lesion or area of active disease (optional consent). There are no pre-specified numbers of subjects to be enrolled with cutaneous disease for either the main study or the cutaneous lupus substudy.

1.3. Justification for Dosing Regimen

The dosing regimen for this study was selected based on experience with the use of ustekinumab in the treatment of subjects with moderately to severely active CD (C0743T26, CNTO1275CRD3001, and CNTO1275CRD3002). Both CD and SLE are immune-mediated inflammatory diseases, which are commonly treated with immunomodulators, such as methotrexate (MTX), azathioprine and corticosteroids, and thus this indication serves as a useful model for risk assessment of ustekinumab in lupus. Although the dosing rationale has not changed, additional safety and efficacy information has become available from the ustekinumab Phase 3 CD (UNITI) studies which supports amending the protocol to further extend treatment with ustekinumab 90 mg SC q8w for an additional year. These results from the UNITI CD studies are summarized later in this section.

Although the dosing rationale has not changed, some additional safety and efficacy information has become available from the ustekinumab Phase 3 CD (UNITI) studies which supports the treatment extension planned for this study. These results from the UNITI CD studies are summarized later in this section (Section 1.3).

In the Phase 2b dose ranging study C0743T26, a single IV ustekinumab dose of 6 mg/kg was the highest loading dose tested in subjects with CD. In this study, the 6 mg/kg IV dose was shown to be effective in inducing clinical response through Week 8 and was well tolerated with a safety profile generally comparable to the other treatment groups. Results from ustekinumab CD studies also suggest that an IV loading dose may provide a rapid onset of clinical response following IL-12 and IL-23 inhibition. In the Phase 3 studies CNTO1275CRD3001 and CNTO1275CRD3002, body weight-range dosing approach (ustekinumab 260 mg [weight ≤55 kg]; ustekinumab 390 mg [weight >55 kg and ≤85 kg]; ustekinumab 520 mg [weight >85 kg]) was used to approximate the IV loading dose of 6 mg/kg. The body weight-range based dosing allows administration of complete vials to patients to simplify dose calculation and reduce the potential for errors in dosing. This weight range dosing is intended to achieve drug exposure similar to that observed with 6 mg/kg weight-adjusted dosing. Thus, in this study, a strategy of IV loading dose based on body weight range at Week 0 will be evaluated to assess the ability of the drug to rapidly reduce the disease activity of SLE without causing significant concern for increased safety risk based on data obtained from previous studies.

The ustekinumab maintenance dosing regimen of 90 mg SC every 8 weeks (q8w) was studied in subjects with CD (C0743T26). The results from C0743T26 study suggest that ustekinumab 90 mg SC q8w was safe and effective in maintaining subjects in clinical remission. The q8w dosing frequency is selected to maintain sufficient ustekinumab exposure to determine if treatment with ustekinumab can provide sustained clinical response. In addition, SC administration is considered more convenient compared with IV administration. A 16-week follow-up period following last ustekinumab study dose was selected to allow more than 5 half-lives for drug elimination and adequate safety follow-up.

In addition, there were also 3 Phase 3 studies in subjects with CD initiated in 2011 that have recently provided additional safety and efficacy data; UNITI-1, UNITI 2, and IM-UNITI. UNITI-1 and UNITI-2 were 8-week induction studies and were identical in design but studied distinct patient populations. UNITI-1 studied subjects who had failed or were intolerant to anti-TNF agents while UNITI-2 studied subjects who had not failed a TNF antagonist but who had failed conventional immunomodulator or steroid therapies. The IM-UNITI study evaluated maintenance treatment for patients enrolled from both UNITI-1 and UNITI-2 studies. The UNITI studies randomized 1,367 subjects to either placebo, 130 mg IV or approximately 6 mg/kg IV. After Week 8 of therapy, subjects in both UNITI-1 and UNITI-2 studies could enter into IM-UNITI, which primarily evaluated two maintenance regimens of 90 mg every 8 or 12 weeks compared to placebo in induction responders. While the IM-UNITI study is still ongoing in long-term extension phase, the primary results of all 3 studies have been published (Feagan et al, 2016), and the results supported the approval of ustekinumab in patients with active moderate to severe CD. The approved dose in induction is a single IV weight-based dose approximating 6 mg/kg and the approved maintenance dose is 90 mg either every 8 or 12 weeks depending on the approval region. The results of these studies are particularly relevant to the CNTO1275SLE2001 SLE study in that a similar dose is being evaluated. In addition, similar to the SLE population, about ⅓ of the CD patients enrolled into the UNITI studies were using concomitant immunomodulators (e.g MTX, AZA, 6-MP) and approximately 46% were on concomitant glucocorticoids. The results of these studies are reviewed in detail. in the primary publication (Feagan et al, 2016), and the highlights are presented below:

- In the 2 UNITI induction studies, the primary endpoint and all major secondary endpoints were met for both doses studied including the 6 mg/kg dose.
- In the IM-UNITI maintenance study, both the 90 mg every 8 or every 12 week regimens were superior to placebo in maintaining response or achieving remission compared to placebo at Week 44.
- Importantly, the safety profiles of both maintenance doses were comparable to placebo over 44 weeks and no new safety signals were identified. The safety profile was similar to that seen in the psoriatic indications.

In summary, these CD studies support the dosing regimen planned for this proof-of concept SLE study including body weight-range based IV loading dose approximating 6 mg/kg followed by 90 mg SC q8w to ensure a high level of systemic exposure of ustekinumab to inhibit the actions of IL-12/23.

Open label 90 mg SC q8w ustekinumab dosing will be provided to subjects starting at Week 24 though Week 40. Per the amended study design, subjects who are able to continue q8w study treatment at approximately 8 weeks (±2 weeks) after their Week 40 visit, or are able to resume study treatment with no more than 16 weeks (±2 weeks) since their Week 40 visit will be eligible for continued 90 mg SC q8w ustekinumab treatment through Week 104, followed by an additional 16-week safety follow-up period.

2.1. Objectives

Primary Objective

The primary objective is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active SLE.

Secondary Objectives

The secondary objectives are to evaluate:

- The safety and tolerability of ustekinumab in subjects with SLE.
  The effect of ustekinumab administration on health-related quality of life in subjects with SLE.
  The effects of ustekinumab on cutaneous manifestations of SLE.
  Pharmaco*kinetics and immunogenicity of ustekinumab in subjects with SLE.
  Exploratory Objectives
  The exploratory objectives are to evaluate:
  Safety and efficacy during long-term administration of ustekinumab.
  Reduction in corticosteroid dosing during long-term administration of ustekinumab.
  Additional composite clinical endpoints or methods for calculation of response with potential for greater sensitivity to improvement and/or worsening of SLE.
  Biomarkers related to lupus disease (genetic, systemic, and skin-related).
  2.2. Hypothesis

The hypothesis is that ustekinumab is significantly superior to placebo as measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index (SRI-4) composite measure at Week 24.

A complete list describing all efficacy evaluations and endpoints, and which evaluations are included in the composite endpoints is provided in Appendix 1. The main study is defined from the original protocol as screening through the Main Study 8-week and 16-week safety follow-up visits. Note that the Main Study 8-week and 16-week safety follow-up visits were previously described in the original protocol as the Week 48 and Week 56 visits. However, with this amendment, the Week 48 and Week 56 visits will only be used to describe treatment visits for those subjects who are participating in the study extension. The study extension (applicable to subjects meeting the inclusion criteria) is defined as the Week 48 or Week 56 visits through the Study Extension 16-week safety follow-up visit.

3.1. Overview of Study Design

CNTO1275SLE2001 is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of ustekinumab added to standard of care background therapy in subjects with active SLE. Subjects between 18 and 75 years of age must have SLE according to SLICC criteria and SLEDAI-2K score ≥6, despite conventional treatment (e.g., immunomodulators, antimalarial drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topical medications). In addition, subjects must have at least 1 positive autoantibody test (ANA, anti-dsDNA antibodies, and/or anti-Smith antibodies) observed during screening, as well as a well-documented positive autoantibody test in their medical history. Subjects must also demonstrate at least 1 BILAG A and/or 2 BILAG B domain scores observed during screening. In addition, subjects must have a clinical SLEDAI-2K score ≥4 (excluding laboratory results) at week 0, prior to randomization.

Subject randomization will be stratified according to consent for skin biopsy collection (y/n), and other features (e.g., presence of lupus nephritis [y/n], baseline SLE medications and SLEDAI score), site/region, and race, or concomitant medications as described in Section 8.

Approximately 100 subjects will be randomly assigned by 3:2 ratio to receive either ustekinumab or placebo through Week 24. Following randomization at Week 0, subjects will receive an initial body weight-range based IV dose approximating 6 mg/kg of ustekinumab (ustekinumab 260 mg [weight ≥35 kg to ≤55 kg]; ustekinumab 390 mg [weight >55 kg and ≤85 kg]; ustekinumab 520 mg [weight >85 kg]) followed by 90 mg SC administered q8w (Section 6). At Week 24, subjects receiving placebo will cross-over and all subjects will receive ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up through Week 56 in a blinded fashion for 16 weeks (i.e., approximately 5 half-lives) after last study agent SC administration.

A placebo comparator (added to standard of care background therapy) will be used through Week 24 for the evaluation of the efficacy and safety of ustekinumab in subjects with SLE. From Week 24 through Week 40, the placebo group will cross-over to ustekinumab 90 mg SC q8w. This cross-over design will permit placebo subjects to receive study agent and provide experience with ustekinumab 90 mg SC without the IV loading dose in subjects with SLE. The 40-Week dosing period will be useful to understand the longer-term safety and time course of potential clinical response of ustekinumab in the SLE population.

Interim analyses (IA) will be conducted when approximately ⅓ and ⅔ of subjects reach Week 24. In the first IA, only evidence for notable efficacy will be assessed. In the second IA, evidence for notable efficacy as well as treatment futility will be analyzed. Variations in placebo effect across regions will be incorporated into the interim analyses. Database locks (DBLs) will occur at Weeks 24 and after the final subject's Week 56 visit or following the last subject's 16-week safety follow-up visit from the main study. In addition, an independent data monitoring committee (DMC) will review interim safety data periodically including a formal review when approximately ⅓ and ⅔ of subjects reach Week 24, as well as at the Week 24 DBL. The DMC will make a recommendation to the Sponsor committee whether the study should be stopped for futility or for safety concerns or if data meet prespecified criteria demonstrating notable efficacy. The content of the summaries, the DMC role and responsibilities, and the general procedures (including communications) will be defined in the DMC charter.

The amended study design will continue to provide open-label ustekinumab 90 mg q8w SC administration through Week 104 (study extension). Subjects will be eligible to continue study treatment through Week 104 if they meet the study inclusion criteria (Section 4.13):

must not have permanently discontinued study treatment on or before their Week 40 visit, and

are able to continue q8 week study treatment at approximately 8 weeks (±2 weeks) after their Week 40 visit

are able to resume study treatment with no more than 16 weeks (±2 weeks) since their Week 40 visit

In addition to the DBL planned following the last subject's Week 56 visit or the final 16-week safety follow-up visit from the main study, there will be an additional DBL following the Extension 16-Week Safety Follow-up period.

A diagram of the main study design is provided in FIG. 1, and a diagram of the extended study is provided in FIG. 2.

3.2. Study Design Rationale

Blinding, Control, Study Phase/Periods, Treatment Groups

A placebo control will be used to establish the frequency and magnitude of changes in clinical endpoints that may occur in the absence of active treatment. Randomization will be used to minimize bias in the assignment of subjects to treatment groups, to increase the likelihood that known and unknown subject attributes (e.g., demographic and baseline characteristics) are evenly balanced across treatment groups, and to enhance the validity of statistical comparisons across treatment groups. Blinded treatment will be used to reduce potential bias during data collection and evaluation of clinical endpoints.

DNA and Biomarker Collection

It is recognized that genetic variation can be an important contributory factor to interindividual differences in drug distribution and response and can also serve as a marker for disease susceptibility and prognosis. Pharmacogenomic research may help to explain interindividual variability in clinical outcomes and may help to identify population subgroups that respond differently to a drug. The goal of the pharmacogenomic component is to collect deoxyribonucleic acid (DNA) to allow the identification of genetic factors that may influence the pharmaco*kinetics, pharmacodynamics, efficacy, safety, or tolerability of ustekinumab and to identify genetic factors associated with SLE.

Biomarker samples will be collected to evaluate the mechanism of action of ustekinumab or help to explain inter-individual variability in clinical outcomes or may help to identify population subgroups that respond differently to a drug. The goal of the biomarker analyses is to evaluate the pharmacodynamics of ustekinumab and aid in evaluating the drug-clinical response relationship.

DNA and Biomarker samples may be used to help address emerging issues and to enable the development of safer, more effective, and ultimately individualized therapies.

The target study population is subjects with SLE according to SLICC criteria and SLEDAI-2K score ≥6, despite conventional treatment (e.g., immunomodulators, antimalarial drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topical medications). Subjects must have at least 1 BILAG A and/or 2 BILAG B domain scores observed during screening. In addition, subjects must have at least 1 positive autoantibody test (ANA, anti-dsDNA antibodies, and/or anti-Smith antibodies) observed during screening, as well as a well-documented positive autoantibody test in their medical history, and they must also have a clinical SLEDAI-2K score ≥4 (excluding laboratory results) prior to randomization at week 0.

The inclusion and exclusion criteria for enrolling subjects in this study are described in the following 2 subsections. If there is a question about the inclusion or exclusion criteria, the investigator should consult with the appropriate Sponsor representative before enrolling a subject in the study.

Subjects with SLE enrolling into the main study with active cutaneous lupus (including subjects with discoid lupus erythematosus, subacute cutaneous lupus erythematosus, or SLE malar rash or other SLE skin lesions characterized by erythema and/or scale) will be evaluated using CLASI scoring. In addition, subjects who provide consent will be enrolled in the cutaneous lupus substudy evaluating the histology of cutaneous biopsies and/or skin photographs. Biopsy samples (2 samples, 4 mm size) from consenting subjects will be collected prior to dosing at Week 0 and at Week 24 from a lesion demonstrating active cutaneous disease. Subjects participating in the cutaneous lupus substudy are not required to undergo biopsies, and may allow only photographs to document changes in an identified cutaneous lesion or area of active disease. Subjects with cutaneous lupus deemed unsuitable for biopsy (e.g., malar rash or alopecia) can also be enrolled in the substudy, and may be evaluated by photography.

The study extension population will be comprised of those subjects who have not permanently discontinued study treatment before or at the Week 40 dose and for whom the investigators judge that there is a potential benefit that outweighs the potential risks to continued ustekinumab treatment.

For a discussion of the statistical considerations of subject selection, refer to Section 11.2, Sample Size Determination.

4.1. Inclusion Criteria

4.1.1. Inclusion Criteria Applicable to all Subjects

Each potential subject must satisfy all of the following criteria to be enrolled in the study.

1. Subject must be between 18 (or older as per local requirements) and 75 years of age, inclusive, and weigh at least 35 kg.

2. Subjects must have documented medical history to meet SLICC classification criteria for SLE for a minimum of 3 months prior to first dose (Table 3).

Subjects eligible for enrollment in this study must qualify as having SLE by meeting the SLICC classification criteria for SLE25 based upon 1 or both of the following:

- Meeting 4 criteria with at least 1 clinical criterion and at least 1 immunologic criterion, or
- A diagnosis of lupus nephritis with presence of at least 1 of the immunological variables

TABLE 3

Clinical and Immunological Criteria Used in the SLICC
Classification Criteria* (Petri et al, 2012)

Clinical Criteria	Specific Criteria

1.	Acute Cutaneous Lupus	Bullous lupus
	including lupus malar rash (do	Toxic epidermal necrolysis variant of
	not count if malar discoid)	SLE
		Maculopapular lupus rash
		Photosensitive lupus rash (in absence of
		dermatomyositis)
		Subacute cutaneous lupus (nonindurated
		psoriaform and/or annular polycyclic
		lesions that resolve without scarring,
		although occasionally with
		postinflammatory dyspigmentation or
		telangiectasias)
2.	Chronic cutaneous lupus	Localized (above the neck)
	including classical discoid rash	Generalized (above and below the neck)
		Hypertrophic (verrucous) lupus
		Lupus panniculitis (profundus)
		Mucosal lupus
		Lupus erythematosus tumidus
		Chilblains lupus
		Discoid lupus/lichen planus overlap
3.	Oral ulcers: palate	Buccal
		Tongue
		Nasal
		In the absence of other causes such as
		vasculitis, Behcets, infection (herpes),
		inflammatory bowel disease, reactive
		arthritis, and acidic foods
4.	Non-scarring alopecia (diffuse	In the absence of other causes such as
	thinning or hair fragility with	alopecia areata, drugs, iron deficiency and
	visible broken hairs)	androgenic alopecia
5.	Synovitis involving two or	Characterized by swelling or effusion OR
	more joints	tenderness in 2 or more joints and thirty
		minutes or more of morning stiffness
6.	Serositis	Typical pleurisy for more than 1 day
		Or pleural effusions
		Or pleural rub
		Typical pericardial pain (pain with
		recumbency improved by sitting forward)
		for more than 1 day
		Or pericardial effusion
		Or pericardial rub
		Or pericarditis by EKG
		In the absence of other causes such as
		infection, uremia and Dressier's pericarditis
7.	Renal	Urine protein/creatinine (or 24-hour urine
		protein) representing 500 mg of
		protein/24 hour, or
		Red blood cell casts
8.	Neurologic	Seizures
		Psychosis
		Mononeuritis multiplex (in the absence
		of other known causes such as primary
		vasculitis)
		Myelitis
		Peripheral or cranial neuropathy (in the
		absence of other known causes such as
		primary vasculitis, infection and diabetes
		mellitus)
		Acute confusional state (in the absence of
		other causes including toxic-metabolic,
		uremia, drugs)
9.	Hemolytic anemia	Presence
	10a. Leukopenia (<4000/mm³	In the absence of other known causes such as
	at least once), or	Felty's, drugs, and portal hypertension
	10b. Lymphopenia	In the absence of other known causes such as
	(<1000/mm3 at least once)	corticosteroids, drugs, and infection
	11. Thrombocytopenia	In the absence of other known causes such as
	(<100,000/mm³at least once)	drugs, portal hypertension, and TTP

	Immunological Criteria	Specific Criteria

1.	ANA	above laboratory reference range
2.	Anti-dsDNA	above laboratory reference range, except
		ELISA; twice above laboratory reference
		range
3.	Anti-Smith	Presence
4.	Anti-phospholipid antibody	Lupus anticoagulant
	(any shown to right)	False-positive RPR
		Medium or high titer anticardiolipin
		(IgA, IgG or IgM)
		Anit-β₂glycoprotein 1 (IgA, IgG or IgM)
5.	Low Complement	Low C3
		Low C4
		Low CH50
6.	Direct Coombs test	In the absence of hemolytic anemia

*Criteria are cumulative and do not need to be present concurrently

3. To be eligible for study enrollment, subjects must have:

- At least 1 well-documented (subject file, referring physician letter, or laboratory result) unequivocally positive, documented test for autoantibodies in medical history including either of the following: ANA, and/or anti dsDNA antibodies, and/or anti Smith antibodies (Section 9.1.2).
- At least 1 unequivocally positive autoantibody test including ANA and/or anti dsDNA antibodies and/or anti Smith antibodies (Section 9.1.2) detected during screening.
- At least 1 BILAG A and/or 2 BILAG B domain scores observed during screening prior to first administration of study agent.
  4. Demonstrate active disease based on SLEDAI-2K score ≥6 observed during screening and assessed approximately 2 to 6 weeks prior to randomization. Must also have SLEDAI-2K≥4 for clinical features (i.e., SLEDAI excluding laboratory results) at Week 0 prior to the first administration of study agent.
  5. Data from the SLICC, SLEDAI and BILAG evaluations will be reviewed and adjudicated by the Sponsor and/or the Sponsor-selected independent reviewer(s). For subjects to receive their first administration of study agent, approval must be received by the Sponsor and/or Sponsor-selected independent reviewers.
  6. If using oral corticosteroids, subjects must be receiving this medication for at least 6 weeks and on a stable dose equivalent to an average dose of ≥20 mg/day of prednisone for at least 4 weeks prior to the first administration of study agent. If currently not using corticosteroids, must have not received oral corticosteroids for at least 6 weeks prior to the first administration of study agent.
  7. If using antimalarials (e.g., chloroquine, hydroxychloroquine, or quinacrine), subjects must have used the medication for ≥8 weeks and be on a stable dose for at least 6 weeks prior to the first administration of study agent.
  8. If using immunomodulatory drugs (mycophenolate mofetil [MMF]/mycophenolic acid [MPA]≤2 g/day, azathioprine/6 mercaptopurine (AZA/6 MP)≤2 mg/kg/day and/or MTX≤25 mg/wk with concomitant folic acid [recommend ≥5 mg/wk]), subjects must be receiving a stable dose for at least 6 weeks prior to the first administration of study agent.
  9. If receiving regular treatment with NSAIDs or other analgesics, subjects must be receiving stable dosing for at least 2 weeks prior to first administration of study agent.
  10. Before randomization, a woman must be either:
- Not of childbearing potential: premenarchal; postmenopausal (>45 years of age with amenorrhea for at least 12 months); permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy.
- Of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: e.g., established use of oral, injected or implanted hormonal methods of contraception associated with inhibition of ovulation; placement of an intrauterine device or intrauterine system; male partner sterilization (the vasectomized partner should be the sole partner for that subject); true abstinence (when this is in line with the preferred and usual lifestyle of the subject).
- Note: If the childbearing potential changes after start of the study (e.g., woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) a woman must begin a highly effective method of birth control, as described above.
  11. A woman of childbearing potential must have a negative serum pregnancy test β-human chorionic gonadotropin [β-hCG]) at screening, and a negative urine pregnancy test at Week 0 before the first administration of study agent.
  12. Women of childbearing potential must be willing to remain on a highly effective method of birth control during the study and for 4 months after receiving the last study agent. Also, women of childbearing potential must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 4 months after receiving the last dose of study agent.
  13. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 4 months after receiving the last dose of study agent.
  14. Are considered eligible according to the following tuberculosis (TB) screening criteria:
- a. Have no history of latent or active TB prior to screening. An exception is made for subjects who have a history of latent TB and are currently receiving treatment for latent TB, will initiate treatment for latent TB prior to first administration of study agent, or have documentation of having completed appropriate treatment for latent TB within 3 years prior to the first administration of study agent. It is the responsibility of the investigator to verify the adequacy of previous anti-tuberculous treatment and provide appropriate documentation.
- b. Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- c. Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to the first administration of study agent.
- d. Within 6 weeks prior to the first administration of study agent, have a negative QUANTIFERON®-TB Gold (blood test for tuberculosis) test result, or have a newly identified positive QUANTIFERON®-TB Gold (blood test for tuberculosis) test result in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated prior to the first administration of study agent. Within 6 weeks prior to the first administration of study agent, a negative tuberculin skin test, or a newly identified positive tuberculin skin test in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated prior to the first administration of study agent, is additionally required if the QUANTIFERON®-TB Gold (blood test for tuberculosis) test is not approved/registered in that country or the tuberculin skin test is mandated by local health authorities.
  - i. Subjects with persistently indeterminate QUANTIFERON®-TB Gold (blood test for tuberculosis) test results may be enrolled without treatment for latent TB, if active TB is ruled out, their chest radiograph shows no abnormality suggestive of TB (active or old, inactive TB), and the subject has no additional risk factors for TB as determined by the investigator. This determination must be promptly reported to the Sponsor's medical monitor and recorded in the subject's source documents and initialed by the investigator.
  - ii. The QUANTIFERON®-TB Gold (blood test for tuberculosis) test and the tuberculin skin test are not required at screening for subjects with a history of latent TB and ongoing treatment for latent TB or documentation of having completed adequate treatment as described above; Subjects with documentation of having completed adequate treatment as described above are not required to initiate additional treatment for latent TB.
- e. Subjects who test positive for TB by a TB test other than QUANTIFERON®-TB Gold (blood test for tuberculosis) and TB skin test and who have no evidence of TB on chest radiograph will in the context of this protocol be considered latent TB positive and be required to undergo evaluation by a TB specialist and receive treatment for TB to be eligible for this study.
- f. Have a chest radiograph (both posterior-anterior and lateral views) taken within 3 months prior to the first administration of study agent and read by a qualified radiologist or pulmonologist, with no evidence of current, active TB or old, inactive TB.
  15. Have laboratory test results within the following parameters at screening:


Hemoglobin	≥8.5 g/dL	(SI: ≥85 g/L)
Lymphocytes	≥0.5 × 103/μL	(SI: ≥0.5 GI/L)
Neutrophils	≥1.0 × 103/μL	(SI: ≥1.0 GI/L)
Platelets	≥75 × 103/μL	(SI: ≥75 GI/L)
Serum creatinine	≤1.8 mg/dL	(SI: ≤159 μmol/L)
White blood cells	≥2.0 × 103/μL	(SI: ≥2.0 GI/L)

The aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels must be within 2×upper limit of normal (ULN) range for the laboratory conducting the test. For subjects within the range of 1.5 to 2×ULN for transaminases, the subject may be included only if the investigator judges the abnormalities or deviations from normal to not be clinically significant or to be appropriate and reasonable for the population under study. This determination must be promptly reported to the Sponsor's medical monitor and recorded in the subject's source documents and initialed by the investigator.

Subjects with other marked disease-associated laboratory abnormalities may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be promptly reported to the Sponsor's medical monitor and recorded in the subject's source documents and initialed by the investigator.

16. Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.

17. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.

18. Each subject must sign a separate informed consent form if he or she agrees to provide an optional DNA sample for research (where local regulations permit). Refusal to give consent for the optional DNA research sample does not exclude a subject from participation in the study.
4.1.2. Additional Inclusion Criteria for the Cutaneous Lupus Substudy

To be enrolled in the cutaneous lupus substudy, an SLE subject must satisfy all previously listed inclusion criteria (Section 4.1.1) in addition to the criteria listed below:

- 1. Have diagnosis of active CLE at screening as well as documented cutaneous disease prior to study enrollment, including subjects with discoid lupus erythematosus, subacute cutaneous lupus erythematosus, or SLE malar rash or other SLE skin lesions including those characterized by erythema and/or scale.
- 2. Subjects taking systemic, topical, or intra-lesional medications for CLE must be on a stable dose or treatment regimen for 4 weeks prior to first study agent administration.
- 3. Subjects who consent to participate in the cutaneous lupus substudy will be asked to provide biopsies of an active CLE target lesion prior to dosing at Weeks 0 and 24. An active CLE lesion is characterized by scale and/or erythema, excluding previously scarred tissue. In addition, separate consent will be obtained to collect photographs of a cutaneous lesion or area of active disease according to the schedule defined in Table 1.
- 4. Subjects with cutaneous lupus deemed unsuitable for biopsy (e.g., malar rash or alopecia) can also be enrolled in the substudy, and may be evaluated by photography.
  4.1.3. Inclusion Criteria Applicable to all Subjects Entering into the Study Extension (Week 48 or Week 56 Visits)

Any subjects who do not meet the inclusion criteria for the study extension must follow the Time and Events schedule for the main study design (Table 1), and have safety follow-up visits conducted at 8 and 16 weeks following their Week 40 or final study dose.

- 1. Subjects must not have permanently discontinued study treatment on or before their Week 40 visit, and are able to either continue q8w SC dosing at approximately 8 weeks (±2 weeks) after their Week 40 visit, or are able to resume dosing at Week 56 with no more than 16 weeks (±2 weeks) since their Week 40 visit.
- 2. In the judgment of the study investigator, the potential benefit of continuing ustekinumab long-term treatment outweighs the potential risks for the subject.
- 3. Each subject must sign a revised informed consent indicating agreement to participate in the extended study.
  4.2. Exclusion Criteria

Any potential subject who meets any of the following criteria will be excluded from participating in the study.

1. Have other inflammatory diseases that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), RA/lupus overlap, psoriasis, or active Lyme disease.

2. Are pregnant, nursing, or planning a pregnancy or fathering a child while enrolled in the study or within 4 months after receiving the last administration of study agent.

3. Have received systemic or topical cream/ointment preparations of cyclosporine A or other systemic immunomodulatory agents other than those described in inclusion criteria within the past 3 months prior to first administration of study agent (Section 4.1). Corticosteroids are not included in this criterion; see Sections 4.3 and 8.3 regarding corticosteroids.
4. Have received a single B cell targeting agent within 3 months prior to first study agent administration; or received more than 1 previous B cell targeting therapy including belimumab or epratuzamab within 6 months prior to first administration of the study agent; or received B cell depleting therapy (e.g., rituximab) within 12 months prior to first administration of the study agent or have evidence of continued B cell depletion following such therapy.
5. Have ever received ustekinumab.
6. Have received prior immunomodulatory biologic therapy for lupus not described in Exclusion Criterion #4 including, but not limited to, tocilizumab, alefacept, efalizumab, natalizumab, abatacept, anakinra, brodalumab, secukinumab, ixekizumab, or inhibitors of TNF, IL-1, IL-6, IL-17, or interferon pathways, less than 5 half-lives or 3 months, whichever is longer, prior to first administration of the study agent.
7. Have a known hypersensitivity to human immunoglobulin (Ig) proteins (e.g., intravenous Ig).
8. Have used oral cyclophosphamide within 90 days or IV cyclophosphamide within 180 days of starting screening.
9. Have a history of active granulomatous infection, including histoplasmosis, or coccidioidomycosis, prior to screening. Refer to inclusion criteria for information regarding eligibility with a history of latent TB.
10. Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.
11. Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including TB.
12. Have had a nontuberculous mycobacterial infection or opportunistic infection (e.g., cytomegalovirus, pneumocystosis, aspergillosis) within 6 months prior to screening.
13. Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of study agent, during the study, or within 3 months after the last administration of study agent. For BCG vaccination criterion, see Exclusion Criterion 10 and Prohibition/Restriction Criterion 8.
14. Have had a serious infection (including but not limited to, hepatitis, pneumonia, sepsis, or pyelonephritis), or have been hospitalized for an infection, or have been treated with intravenous antibiotics for an infection within 2 months prior to first administration of study agent. Less serious infections (e.g., acute upper respiratory tract infection, simple urinary tract infection) need not be considered exclusionary at the discretion of the investigator.
15. Have a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (e.g., bronchiectasis), sinusitis, recurrent urinary tract infection (e.g., recurrent pyelonephritis), an open, draining, or infected skin wound, or an ulcer.
16. Subject has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening.
17. Has a hepatitis B infection. Subjects must undergo screening for hepatitis B virus (HBV). At a minimum, this includes testing for HBsAg (HBV surface antigen), anti HBs (HBV surface antibody), and anti-HBc total (HBV core antibody total).
18. Subjects who are seropositive for antibodies to hepatitis C virus (HCV), unless they have 2 negative HCV RNA test results 6 months apart prior to screening and have a third negative HCV RNA test result at screening.
19. Subjects having experienced a recent single dermatomal herpes zoster eruption within the past 4 months are excluded. Those with multi-dermatomal herpes zoster or central nervous system (CNS) zoster within the past 5 years are excluded.
20. Subjects with a history or suspected occurrence of drug-induced lupus.
21. Have urinary protein >4 g/day or protein/creatinine ratio >4.
22. Have inherited complement deficiency or combined variable immunodeficiency.
23. Have end-stage renal disease, or severe or rapidly progressive glomerulonephritis, including severe, active lupus nephritis reported in recent biopsy and/or other assessments such as active urinary sediment, rapidly increasing creatinine, or other factors that suggest severe or rapidly progressing nephritis (see also limits on serum creatinine in Inclusion Criterion #15).
24. Have severe CNS lupus including but not limited to seizures, psychosis, transverse myelitis, CNS vasculitis and optic neuritis.
25. Have severe, progressive, or uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic/cerebral, or psychiatric disease, or current signs and symptoms thereof.
26. Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location, clinically significant splenomegaly, or history of monoclonal gammopathy of undetermined significance.
27. Subject has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin that has been treated with no evidence of recurrence for at least 3 months before the first study agent administration and carcinoma in situ of the cervix that has been surgically cured).
28. Has known allergies, hypersensitivity, or intolerance to ustekinumab, its excipients or latex (contained in the syringe needle cover, see Section 14.1).
29. Are currently receiving venom immunotherapy (honeybee, wasp, yellow jacket, hornet, or fire ant).
30. Has received an investigational drug that is not previously defined in other exclusion criteria (including investigational vaccines or other medications specified in section 4.3, Prohibition/Restriction No. 3) within 5 half lives or 3 months, whichever is longer, or used an invasive investigational medical device within 3 months before the planned first dose of study drug, or is currently enrolled in an interventional study.
31. Has any condition for which, in the opinion of the investigator and/or Sponsor, participation would not be in the best interest of the subject (e.g., compromise the well being) or that could prevent, limit, or confound the protocol-specified assessments including a previous pattern of non-compliance with medical follow-up or being deemed unlikely to be compliant with a study visit schedule.
32. Has had major surgery, (e.g., requiring general anesthesia) within 1 month before screening, or will not have fully recovered from surgery, or has major surgery (e.g., requiring general anesthesia) planned during the time the subject is expected to participate in the study or within 1 month after the last dose of study drug administration.

Note: Subjects with planned minor surgical procedures to be conducted under local anesthesia may participate.

33. Have a transplanted organ (with the exception of a corneal transplant performed ≥3 months prior to first administration of study agent).

34. Have or have had a substance abuse (drug or alcohol) problem within the previous 3 years.

35. Are unwilling or unable to undergo multiple venipunctures because of poor tolerability or lack of easy venous access.

36. Subject is an employee of the investigator or study site (i.e. personnel to whom the investigator has delegated a role or responsibility for conducting the study), with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.
37. Lives in an institution on court or authority order, unless permitted by local regulations.

- NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. If a subject's status changes (including laboratory results or receipt of additional medical records) after screening but before the first dose of study drug is given such that he or she no longer meets all eligibility criteria, then the subject should be excluded from participation in the study. Sponsor reserves the right to discontinue the subject for any operational or safety reasons.
  4.3. Prohibitions and Restrictions

Potential subjects must be willing and able to adhere to the following prohibitions and restrictions during the course of the study (including the study extension) to be eligible for continued dosing in the study:

1. If a woman is capable of pregnancy, she must remain on a highly effective method of birth control during the study and for 4 months after receiving the last study agent. The exception to this restriction is if the subject or her male partner is sterilized; this situation does not require birth control. A woman must not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 4 months after receiving the last dose of study agent.
2. If a man, he is to use an effective method of birth control and not donate sperm during the study and for 4 months after receiving the last dose of study agent. The exception to this is if the subject or his female partner is sterilized; this situation does not require birth control.
3. Use of additional immunosuppressants or immunomodulators, other than those explicitly allowed in the inclusion/exclusion criteria, are prohibited including but not limited to the following:
Biologic agents targeted at reducing TNF□ (including but not limited to infliximab, golimumab, certolizumab pegol, etanercept, yisaipu, CT-P13 [Remsima®] and adalimumab)
B cell depleting agents (anti-CD20 [e.g., rituximab], anti-B cell activating factor [BAFF], also known as B lymphocyte stimulator [BLyS], [e.g., belimumab], or anti CD22 [e.g., epratuzumab])
Interleukin-1 inhibitors (e.g., canakinumab)
Interferon inhibitors
IL-1ra (e.g., anakinra)
Tocilizumab or any other biologic targeting IL-6 or IL-6 receptor
Tofacitinib or any other j anus kinase (JAK) inhibitor
Abatacept
Anti-IL-17 agents (e.g., brodalumab, secukinumab, and ixekizumab)
Leflunomide
Cyclosporine A (oral or topical ointment/cream preparations)
Tacrolimus or picrolimus, oral or topical preparations
Toll-like receptor inhibitors
Thalidomide or lenalidomide
Dapsone
Adrenocorticotropic hormone (ACTH) by injection
4. Use of cytotoxic drugs is prohibited including, but not limited to, cyclophosphamide, chlorambucil, nitrogen mustard, or other alkylating agents.
5. Multiple administrations of high doses of corticosteroids, and initiation of medium or high potency topical corticosteroids, are prohibited during the study as defined in Section 8.3.
6. The initiation of a new permitted immunomodulatory agent (MTX, azathioprine, 6-mercaptopurine, mycophenolate mofetil/mycophenolic acid) in addition to an ongoing immunomodulatory therapy is prohibited.
7. Initiation of new angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme (ACE) inhibitor therapy after first dose of study agent is not permitted for the treatment of lupus-related disease through Week 28.
8. Must agree not to receive a live virus or live bacterial vaccination during the study. Subjects must also agree not to receive BCG vaccination for 12 months after last dose of study agent, or any other live vaccine for 3 months after receiving the last administration of study agent.
9. Must agree not to receive an investigational medical device or an investigational drug other than study agent for the duration of this study.
10. The use of complementary therapies that may trigger activation of lupus or mitigate the symptoms of SLE, including but not limited to, traditional medicine (e.g., herbal/alternative preparations [e.g., Echinacea], Chinese, acupuncture, ayurvedic) is prohibited through Week 40.
11. Study subjects should avoid excessive sun exposure and may not participate in commercial ultraviolet tanning or ultraviolet phototherapy during the study.
12. Skin concealers or topical tan preparations should be avoided due to their potential to obscure skin disease activity.
13. Sulfa-based antibiotics, where reasonable, should generally be avoided.

5.1. Procedures for Randomization

Dynamic central randomization will be implemented in conducting this study. Subjects will be assigned to 1 of 2 treatment groups based on a minimization randomization algorithm implemented in the interactive web response system (IWRS) before the study. Dynamic central randomization targets to balance the distribution of subjects to achieve the randomization ratio (3:2) at the study level and within the levels of each individual stratification factor: skin biopsy (y/n, when n<16 for y), presence of lupus nephritis (y/n), baseline SLE medications and SLEDAI-2K score (combined factor)*, site, region (approximately 4 categories), and race (3 categories). Based on the algorithm, each subject will be assigned to the treatment group which will produce minimum total imbalance score with a high probability, where the total imbalance score is a weighted average of the imbalance scores for each stratification factor and for the whole study. The IWRS will the assign a unique treatment code, which will dictate the treatment assignment for the subject.

*The baseline SLE medications and SLEDAI-2K score will be calculated as a combined factor, including:

- SLEDAI-2K score (<10 or ≥10) combined with
- Baseline medications:
  - High medications defined as ≥15 mg/wk MTX, or ≥1.5 mg/kg/day AZA/6-MP, or ≥1.5 g/day MMF/MPA, and/or ≥15 mg/day prednisone.
- Low medications defined as <15 mg/wk MTX, or <1.5 mg/kg/day AZA/6-MP, or <1.5 g/day MMF/MPA, and/or <15 mg/day prednisone.
  5.2. Blinding

The investigator will not be provided with randomization codes. The codes will be maintained within the IWRS, which has the functionality to allow the investigator to break the blind for an individual subject.

Under normal circ*mstances, the blind should not be broken until all subjects have completed the study at Week 56 or terminated study participation, and the database is finalized. Otherwise, the blind should be broken only if specific emergency treatment/course of action would be dictated by knowing the treatment status of the subject. In such cases, the investigator may in an emergency determine the identity of the treatment by contacting IWRS. It is recommended that the investigator contact the Sponsor or its designee if possible to discuss the particular situation, before breaking the blind. Telephone contact with the Sponsor or its designee will be available 24 hours per day, 7 days per week. In the event the blind is broken, the Sponsor must be informed as soon as possible. The date and reason for the unblinding must be documented by the IWRS. The documentation received from the IWRS indicating the code break must be retained with the subject's source documents in a secure manner.

Subjects who have had their treatment assignment unblinded may be discontinued from further administration of study agent and should return for safety follow-up.

In general, randomization codes will be disclosed fully only if the study is completed and the clinical database is closed. The Sponsor will be blinded through the Week 24 evaluation and until the database is cleaned and finalized for planned analyses. The clinical site, subjects, investigators, and site personnel will remain blinded through the end of the study until Week 56 data are finalized. Data that may potentially unblind the treatment assignment will be handled with special care.

6.1. IV Administration

For IV administration, the study agent will be administered to each subject over a period of not less than 1 hour.

Ustekinumab 5 mg/mL Final Vialed Product (FVP) (IV) is supplied as a single-use, sterile solution in 30 mL vials with 1 dose strength (i.e., 130 mg in 26 mL nominal volume). In addition to ustekinumab, the solution contains 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate at pH 6.0. No preservatives are present.

Placebo for FVP (IV) is supplied as single-use, sterile solution in 30 mL vials with a 26 mL nominal volume. The composition of the placebo is 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt dihydrate at pH 6.0. No preservatives are present.

Body weight-range based dosing will allow administration of complete vials to patients to simplify dose calculation and reduce the potential for errors in dosing. This body weight-range based IV dosing is intended to achieve drug exposure similar to that observed with weight adjusted 6 mg/kg dosing. Comparable numbers of vials will be administered to subjects receiving placebo based on their body weight-range. The body weight-range doses are based on the following:

- Body weight ≥35 kg and ≤55 kg: 260 mg ustekinumab (2 vials)
- Body weight >55 kg and ≤85 kg: 390 mg ustekinumab (3 vials)
- Body weight >85 kg: 520 mg ustekinumab (4 vials)
  6.2. SC Administration

Ustekinumab will also be supplied as a single-use latex-free prefilled syringe (PFS) in a strength of 90 mg in 1 mL nominal volume for SC administration. Each 1 mL of ustekinumab solution in the PFS contains 90 mg ustekinumab with nominal excipient concentrations of 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No preservatives are present. The needle cover on the PFS contains dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.

Placebo administrations will have the same appearance as the respective ustekinumab administrations. Liquid placebo will also be supplied in a 1 mL PFS, and have a composition 10 mM L-histidine, 8.5% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No preservatives are present. The needle cover on the PFS contains dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.

Week 0 Up to Week 24 (Blinded Study Agent Administration Phase)

Group 1: Subjects will receive weight-range based IV dosing of approximately 6 mg/kg of ustekinumab at Week 0 followed by ustekinumab 90 mg SC administrations at Weeks 8 and 16.

Group 2: Subjects will receive weight-range based IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8 and 16.

Week 24 to Week 40 (Cross-Over Administration Phase)

Group 1: Subjects will receive an ustekinumab 90 mg SC administration at Week 24 followed by q8w administrations through Week 40.

Group 2: Subjects will cross-over to ustekinumab 90 mg SC administrations at Week 24 followed by q8w administrations through Week 40.

After Week 40 to 16-Week Safety Follow-Up (Safety Follow-Up Phase)

Groups 1 and 2: Subjects who do not participate in the study extension are expected to return for safety follow-up visits at Weeks 44 and for 8- and 16-weeks safety follow-up.

Study Extension (Week 48/Week 56 Through Week 120)

Subjects who meet the study extension inclusion criteria will receive open-label ustekinumab administration for the purpose of expanding the safety experience and maintenance of efficacy in lupus patients continuously exposed to ustekinumab 90 mg q8w. Subjects who continue dosing in the extended study starting at Week 48 or at Week 56 will receive open-label ustekinumab SC dosing through Week 104. If the development of ustekinumab in SLE is terminated, then the study extension will also be discontinued.

Study personnel will maintain a log of all study agent administrations. Study agent supplies for each subject will be inventoried and accounted for. All ongoing therapies administered at the time of screening must be recorded.

Compliance with the treatment schedule is strongly encouraged. It is understood that treatment may be interrupted for health-related or safety reasons. The Weeks 0, 24, and 48 visits are essential for assessing efficacy and safety of ustekinumab as therapy for active SLE.

Therefore, if for any reason a subject cannot receive a dose of study agent at the scheduled visits, the subjects must make every effort to come for scheduled assessments. Through the Week 32 visit, the visit and study agent administration should occur within ±7 days of the scheduled visit day (relative to Week 0). Following the Week 32 visit, the study agent administrations are allowed to occur within ±2 weeks of the scheduled visit day (relative to Week 0). The study agent administrations are scheduled to occur approximately 8 weeks apart, and cannot occur <14 days apart. If there is a delay in treatment, the subject should resume the normal study schedule relative to the baseline visit (Week 0).

All subjects will be monitored by a site monitor designated by the Sponsor. During these monitoring visits, all procedures will be evaluated for compliance with the protocol. Subject charts will be reviewed and compared with earlier data entries on the to ensure accuracy. The Sponsor must be contacted for any deviation to the timeframes above.

All prestudy therapies administered up to 90 days before entry into screening must be recorded at screening. Modification of an effective preexisting therapy should not be made for the explicit purpose of entering a subject into the study. All concomitant therapies must be recorded throughout the study beginning at entry into screening and any changes must be recorded throughout the study.

Every reasonable effort should be made to keep concomitant medications stable at least through Week 28, and if possible also through the main study 8-week safety follow-up or through the study extension (if applicable). With the exception of corticosteroids (see Section 8.3 regarding corticosteroid tapering), all other concomitant medications should be maintained at stable doses throughout the study. A concomitant medication may be reduced or medication temporarily discontinued because of abnormal laboratory values, side effects, concurrent illness, or the performance of a surgical procedure, but the change and reason for the medication change should be clearly documented in the subject's medical record. If concomitant medications have been adjusted after randomization as allowed per protocol, every effort should be made to return subject back to the baseline (Week 0) dose level by the Week 12 visit; or increased medication use (relative to baseline) may render a subject to be considered a treatment failure. Corticosteroid adjustments for cause are permitted as defined in Section 8.3.

The Sponsor must be notified in advance (or as soon as possible thereafter) of any instances in which prohibited therapies are administered.

All pharmacologic therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal supplements) different from the study agent must be recorded. Subject diary cards will be used to capture changes in subject-administered medications that occur in between study visits during the main portion of this study, and these changes must also be recorded.

8.1. Immunomodulators

If receiving immunomodulators, subjects should be receiving stable dosing from screening through Week 28. Subjects can be receiving MMF/MPA (≤2 g/day), azathioprine/6-mercaptopurine (≤2 mg/kg/day) and/or MTX (≤25 mg/wk) with concomitant folic acid (recommend ≥5 mg/wk), during screening and through Week 28. A reduction in immunomodulators from Week 12 through Week 28 is allowed only if the subject develops unacceptable side effects, with the implication that this may affect interpretation of the subjects' clinical data. A higher dose of an immunomodulator (relative to the baseline dose) or the addition of a new immunomodulator to the existing treatment regimen between the Week 12 and 24 visit will cause subjects to be considered a treatment failure for the purposes of the primary endpoint analysis. Permanent discontinuation of the study treatment must be considered for subjects receiving an increase (relative to baseline) in their immunomodulator dose. Beyond Week 28, immunomodulators should remain as stable as possible through the 8-week safety follow-up or through the study extension (if applicable); however, dose adjustment is allowed for unacceptable side effects.

8.2. Antimalarial Medications

Stable treatment with hydroxychloroquine, chloroquine, or quinacrine is permitted through the 8-week safety follow-up. Beyond Week 28, it is permitted to introduce or adjust dosing of antimalarials. Antimalarials produced by a licensed compounding pharmacy (e.g., quinacrine) in the country of administration and using pharmacaceutical grade components are allowed.

8.3. Corticosteroid Therapy

Unnecessary dose changes are discouraged, and any dose adjustments should be made in increments. Changes in corticosteroids through the 8-week safety follow-up or through the study extension (if applicable) are allowed for medical necessity, but the degree and timing of the adjustment should be carefully considered as this may have an impact on the study results, especially during the period between 12 and 28 weeks.

Oral Corticosteroids*

If using oral corticosteroids, must be receiving this medication for at least 6 weeks and on a stable dose equivalent to an average dose of ≤20 mg of prednisone/day for at least 4 weeks prior to the first administration of study agent. Corticosteroid dose adjustment (increase or decrease) of no more than 5 mg prednisone (equivalent/day) to a maximum dose of 25 mg/day is permitted through Week 6. From Week 6 through Week 12, no corticosteroid dose increases are permitted, and within this window only a gradual decrease of up to 5.0 mg prednisone (equivalent/day) adjustment towards the baseline dose are allowed up to the Week 12 visit. No further adjustments in doses of corticosteroid for the treatment of SLE disease are permitted between Weeks 12 and 28. Following Week 28, changes in corticosteroid dosing through the 8-week safety follow up is allowed for medical necessity, but the degree and timing of the adjustment should be carefully considered as this may have an impact on the study. Dose increases of oral corticosteroids of 40 mg/day or more should be discussed with the medical monitor and may result in discontinuation of study agent administration.

Subjects may receive short courses (2 weeks or less) of oral corticosteroids for reasons such as prophylactic therapy before surgery (stress-dose corticosteroids) or therapy for limited infections, exacerbation of asthma, or chronic obstructive pulmonary disease.

Subjects likely to require multiple courses of steroids for reasons other than SLE should be excluded from study participation.

Gradual tapering of oral corticosteroid dosing in the study extension (recommended reductions of no more than 10 to 20% of the original dose per week) is encouraged starting after the Week 48 dose at the discretion of the study investigator. Tapering to the lowest possible maintenance dose of corticosteroids is recommended, including complete weaning off of corticosteroids if possible. It is recommended that subjects should be educated and monitored by study staff for symptoms of steroid deficiency (e.g., Addisonian symptoms) during periods of steroid tapering, as appropriate.

If subjects experience a worsening in their disease activity while tapering corticosteroids, further dose decreases may be suspended, and/or their oral corticosteroid dose may be temporarily increased if deemed necessary by the investigator. For subjects whose corticosteroid taper is interrupted, investigators are encouraged to resume tapering within 4 weeks.

In the event of increased corticosteroid dosing, it is recommended that the average dose should not be increased above the baseline dose unless medically necessary. Discretion should be used as any corticosteroid increases may render a subject to be considered a treatment or steroid tapering failure. Sustained oral corticosteroid doses of 40 mg/day or higher may result in discontinuation of study agent.

*Rectal administration of corticosteroids, if necessary, should be short-term and using topical preparations.

Epidural, Intravenous, Intramuscular, Intra-Articular, and Intra-Lesional Corticosteroids

Epidural, IV, IM, IA, or intra-lesional administration of corticosteroids is strongly discouraged within 4 weeks prior to the first administration of study agent and is not allowed for the treatment of SLE through Week 28. Drugs that induce release of endogenous steroids such as ACTH administered by injection are not allowed within 3 months prior to the first administration of study agent and throughout the study. Short-term (≤2 weeks) epidural, IV, IM, IA, or intra-lesional corticosteroid use for the treatment of indications other than SLE should be limited to situations where, in the opinion of the treating physician, there are no adequate alternatives. If clinically necessary, a total of 1 or 2 IA injections may be permitted up to the Week 16 dosing, however this would render those joints unevaluable for subsequent assessments. For conditions other than SLE, corticosteroid therapy should be limited to situations in which, in the opinion of the treating physician, there are no adequate alternatives. Intravenous corticosteroids of >625 mg prednisone equivalent/day for 2 or more days total in the 24-week period will be evaluated for treatment failure as per the statistical analysis plan (SAP).

Inhalation Corticosteroids

Corticosteroids administered by bronchial or nasal inhalation for treatment of conditions other than SLE may be given as needed.

Corticosteroid Use in Cutaneous Lupus Substudy

For subjects in the cutaneous lupus substudy, the initiation of, or an increase from baseline in, the use of potent topical corticosteroids, or intra-lesional corticosteroid injections, is not allowed and should be avoided through the 8-week safety follow-up or in the study extension.

8.4. Nonsteroidal Anti-Inflammatory Drugs

Subjects treated with NSAIDs, including aspirin and selective cyclooxygenase-2 (COX-2) inhibitors, and other analgesics should receive the usual marketed doses approved in the country in which the study is being conducted. Prescriptions of NSAIDs and other regularly administered analgesics should not be adjusted for at least 2 weeks prior to the first administration of the study drug and through Week 28, and may be changed only if the subject develops unacceptable side effects. After Week 16 and through Week 28 the addition of new NSAIDs to the treatment regimen is not permitted. Minor adjustments in NSAID therapy are allowed after Week 28 although it is recommended that the use of any NSAIDS remain as stable as possible, and any notable changes should be recorded.

8.5. Anti-Hypertensive Medications

Subjects are permitted to receive stable doses of ARB or ACE inhibitors for the treatment of hypertension and lupus. Initiation of new ARB or ACE inhibitor therapy after first dose of study agent is not permitted for the treatment of lupus-related disease through Week 28. Subjects should not initiate any new ARB or ACE inhibitor therapy between randomization and Week 28. New or adjusted ARB or ACE inhibitor therapy is allowed beyond Week 28.

8.6. Topical Medications

Topical medications are permitted; however, topical compounds cannot include a prohibited medication. Topical ointments or creams of cyclosporine A are prohibited through Week 28; however ophthalmic use is permitted. Low potency topical steroids are allowed except on day of study visit. Medium to high potency topical corticosteroids are disallowed for all subjects through the 8-week safety follow-up, and high potency topical corticosteroids are not allowed during the study extension. For subjects in the cutaneous lupus substudy, topical treatment of target lesions should remain stable during the cutaneous lupus substudy period. For 72 hours prior to study visit, topical medications should not be applied to lesions under evaluation.

9.1. Study Procedures

9.1.1. Overview

The Time and Events Schedule summarizes the frequency and timing of efficacy, pharmaco*kinetics, antibodies to ustekinumab, pharmacodynamics, pharmacogenomics, health-related quality of life, safety, and other measurements applicable to this study.

Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the subject's participation in the study.

The total blood volume to be collected from each subject over the course of the main portion of the study will be approximately 640 mL. The total blood volume to be collected in the study extension between Weeks 48 and 120 will be approximately 250 mL.

Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the collection or analysis of specific samples.

A blood sample will be collected from subjects who have consented to participate in the pharmacogenomics component of the study. In the event of DNA extraction failure, a replacement pharmacogenomics blood sample may be requested from the subject. A separate informed consent would not be required to obtain a replacement sample.

Subjects who have consented to participate in the cutaneous lupus substudy will be requested to allow collection of skin biopsy samples at Week 0 and at Week 24. In addition, photographs will be taken of a target cutaneous lesion or area of active disease as noted in the Time and Events Schedule (Table 1). For additional detail regarding the cutaneous lupus substudy, refer to Section 9.7.

9.1.2. Screening Phase

9.1.2.1. Screening Procedures

Written informed consent must be obtained and reviewed by investigator before any screening data is collected.

Screening procedures will be performed as indicated in the Time and Events Schedule (Table 1). The screening visit must be performed no more than 6 weeks prior to the randomization visit (Week 0). In addition, to be eligible for study participation, subjects must have SLEDAI score 4 for clinical features at Week 0 and have received approval for study randomization following review and adjudication of screening lupus assessments by the Sponsor and/or Sponsor-selected independent reviewer(s).

Subjects will be trained on how to complete the Diary cards. Diary cards will be distributed to subjects for completion during the screening period.

Women of childbearing potential must have a negative serum β-hCG pregnancy test at screening and a negative urine β-hCG pregnancy test before randomization. Women of childbearing potential and men must consent to use highly effective methods of contraception (see inclusion criteria, Section 4.1) and continue to use contraception for the duration of the study and for 4 months after the last study agent administration. The method(s) of contraception used by each subject must be documented.

All screening evaluations establishing subject eligibility will be performed and reviewed by investigator before subject can be randomized. Although the SLICC criteria may not have been formally assessed, to be eligible for enrollment subjects must have demonstrated symptoms (documented in subject file) of SLE sufficient to meet SLICC criteria for a minimum of 3 months prior to first dose of study agent. Subjects eligible for enrollment in this study must qualify as having SLE by meeting the SLICC classification criteria for SLE based upon 1 or both of the following (as described in Inclusion Criterion #2):

- Meeting 4 criteria with at least 1 clinical criterion and at least 1 immunologic criterion, or
- A diagnosis of lupus nephritis with presence of at least 1 of the immunological variables,

Subjects must also have 1 well-documented (subject file, referring physician letter, or laboratory result) medical historical value for unequivocally positive ANA, anti-dsDNA antibodies, and/or anti-Smith antibodies. Medical historical documentation of a positive test of ANA (e.g., ANA by HEp-2 titer, ANA by enzyme-linked immunosorbent assay) or anti-dsDNA (e.g., anti-dsDNA by Farr assay or ELISA) must include the date and type of the test, the testing laboratory name, numerical reference range, and a key that explains that the values provided are positive versus negative/equivocal or borderline. Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted.

In addition, in order to assess the stability of SLE disease activity, subjects must demonstrate SLEDAI-2K score ≥6, despite conventional treatment (e.g., immunomodulators, antimalarial drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topical medications). In addition, subjects must have at least 1 positive autoantibody test (ANA, anti-dsDNA antibodies, and/or anti-Smith antibodies) observed during screening. Subjects must also demonstrate at least 1 BILAG A and/or 2 BILAG B domain scores observed prior to first administration of study agent.

9.1.2.2. Retesting

If a subject has signed the ICF and failed to meet at least 1 entry requirement, a one-time retest of screening laboratory test(s) will be allowed in the event of suspected error in sample collection or analysis performance, or a study entry procedure may be repeated once during the screening period if needed. A request to use a local test to replace the central lab test should be discussed with the medical monitor prior to retesting. This is inclusive of only 1 additional blood draw to be completed for retesting, regardless of whether an additional laboratory value is found to be out of range. The goal of the retest procedure is to assess if the subject is eligible for randomization within the screening window or should be screen failed. Subjects that have laboratory values that do not meet entry criteria following the retest or do not meet disease activity criteria following the repeat procedure are to be deemed a screen failure. Exceptions to this are positive QUANTIFERON®-TB Gold (blood test for tuberculosis), hepatitis C or B, or HIV tests; unless there is a suspected error in sample collection or analysis performance, these tests may not be repeated to meet eligibility criteria.

9.1.2.3. Rescreening

If a subject has failed screening and investigator wishes to rescreen the subject, this should be discussed with the study Sponsor and/or their designee. Only 1 rescreening is allowed per subject. Subjects who are rescreened will be assigned a new subject number, undergo the informed consent process, and then restart a new screening phase.

9.1.3. Double-Blind Treatment Phase

9.1.3.1. Week 0/Day of Randomization

At Week 0, eligible subjects will be randomly assigned by the IWRS in a 3:2 ratio to receive either ustekinumab or placebo in a blinded manner. Assessments will be performed as indicated in the Time and Events Schedule (Table 1). Subjects participating in the cutaneous lupus substudy will have baseline, pre-treatment photographs and/or skin biopsies collected. Subject's diary card which was distributed during screening will be reviewed at Week 0, and a new card will be provided at each study visit to record medication changes during the subsequent 4 weeks through the main portion of the study.

9.1.3.2. Placebo-Controlled Treatment Period (Through Week 24)

After randomization and the first administration of study agent by IV infusion, subjects will have blinded study agent administrations SC q8w through the Week 24 visit. Assessments will be performed as indicated in the Time and Events Schedule (Table 1).

9.1.4. Cross-Over Treatment (Through Week 40)

At Week 24, subjects in the placebo group will cross-over to receive ustekinumab dosing, and all subjects will continue to receive SC administrations q8w through Week 40. All subjects will continue to remain blinded to study treatment received during the placebo-controlled treatment period as described in Section 9.1.3.2.

9.1.5. Study Extension (Week 48/Week 56 Through Week 104)

Subjects who qualify for participation in the study extension through Week 104 will continue ustekinumab 90 mg q8w SC dosing at approximately 8 weeks (±2 weeks) after their Week 40 visit, or resume ustekinumab dosing at Week 56 with no more than 16 weeks (±2 weeks) since their Week 40 visit.

9.1.6. Subjects Withdrawing from Study Participation

Subjects who withdraw from study participation will not be required to return for any follow-up assessments.

9.1.7. Post-Treatment Safety Follow-Up

Subjects who permanently discontinue study agent at or before Week 40, or permanently discontinue at or before Week 104 if they are participating in the study extension, but do not withdraw from study participation, should be followed for approximately 16 weeks (5 half-lives) after the last study agent administration according to the visit schedule and assessments indicated in the appropriate Time and Events Schedules (Table 1 and Table 2). Follow-up visits should occur approximately 8 weeks and 16 weeks after the last study agent administration. Subjects who permanently discontinue study agent before or at Week 40 will not be eligible to participate in the study extension.

Telephone contact will be made to determine reasons for study discontinuation for up to 16 weeks after the last dose of study drug, unless the subject is lost to follow-up, or has withdrawn consent. If the information on reason for discontinuation is obtained via telephone contact, written documentation of the communication must be available for review in the source documents. If the subject has died, the date and cause of death will be collected and documented.

9.2. Efficacy

All efficacy evaluations should be consistently performed by the study investigator or sub-investigator to achieve comparable measures over time. Independent adjudication by Sponsor or Sponsor-designated independent reviewer(s) will be performed for key lupus assessments (e.g., SLEDAI, BILAG, and CLASI). These data will be reviewed at every visit that these data are collected and may require reconciliation of inconsistencies across assessments.

9.2.1. Evaluations

A complete list describing all efficacy evaluations and endpoints, and which evaluations are included in the composite endpoints is provided in Appendix 1.

9.2.1.1. SLEDAI-2K and S2K RI-50

The SLE disease activity index 2000 (SLEDAI-2K/S2K RI-50 [Baseline]) is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE patients in the previous 30 days. It is weighted according to the feature. At screening, features are scored by the assessing physician if present within the last 30 days with more severe features having higher scores, and then simply added to determine the total SLEDAI-2K score, which ranges from 0 to 105 (Touma et al, 2010a). At baseline, the features assessed in the SLEDAI-2K are used for comparison to the S2K RI-50 index described below.

The SLEDAI-2K has been adapted and developed into the SLEDAI-2K Responder Index (S2K RI-50 [Follow-up]) (Touma et al, 2010b), a measure that can document partial improvement in the 24 disease features between SLEDAI-2K assessments (Touma et al, 2010c). A threshold of 50% improvement was judged to reflect clinically significant improvement and is scored as half the weight for the feature. “When a descriptor is recorded as present at the initial visit, 1 of 3 situations can follow: (1) the descriptor achieves complete remission at follow-up, in which case the score would be “0”; (2) the descriptor does not achieve a minimum of 50% improvement at follow-up, in which case the score would be identical to its corresponding SLEDAI-2K value; or (3) the descriptor improves by ≥50% (according to the S2K RI-50 definition) but has not achieved complete remission, in which case the score is evaluated as one-half the score that would be assigned for SLEDAI-2K (Touma et al, 2011). The S2K RI-50 score is the sum of the 24 scored items, which ranges from 0 to 105.

9.2.1.2. BILAG

The BILAG (Hay et al, 1993; Isenberg et al, 2005) index scores subjects based on the need for alterations or intensification of therapy. The assessing physician will evaluate 97 items divided into the following 9 organ/systems domains.

- Constitutional
- Mucocutaneous
- Neuropsychiatric
- Musculoskeletal
- Cardiorespiratory
- Gastrointestinal
- Ophthalmic
- Renal
- Hematological

The assessing physician ought to consider each item as to its presence in the past 4 weeks, and answer 0=not present, 1=improving, 2=same, 3=worse, or 4=new as compared with a specified reference visit. Each organ/system domain is classified as BILAG A, B, C, D, or E based upon organ/system specific items and criteria specific to the domain.

9.2.1.3. CLASI

Cutaneous lupus erythematosus disease activity will be measured by the CLASI. The CLASI is an instrument the assessing physician will use to assess the disease activity and damage caused to the skin for CLE patients with or without systemic involvement. The CLASI consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. Damage is scored in terms of dyspigmentation and scarring, including scarring alopecia. The scores are calculated by simple addition based on the extent of the symptoms (Albrecht et al. 2005). Higher activity and damage scores indicate worse disease activity.

9.2.1.4. Physician Global Assessment of Disease Activity

The physician must complete the Physician Global Assessment of Disease Activity (Felson et al, 1995) independent of subjects' assessment. The assessments will be recorded on a visual analogue scale (VAS; 0 to 10 cm). The scale for the assessment ranges from “no Lupus activity” (0) to ‘extremely active Lupus” (10).

The physician assessor should preferably be the same person at every study visit for a given subject.

9.2.1.5. Patient Global Assessments

The subject must complete the Patient Global Assessment of Disease Activity and Patient's Assessment of Pain independent of the Physician's Global Assessment of Disease Activity.

9.2.1.5.1 Patient Global Assessment of Disease Activity

The Global Assessment of Disease Activity will be recorded on a visual analogue scale (VAS; 0 to 10 cm). The scale for the assessment ranges from “very well” (0) to “very poor” (10).

9.2.1.5.2. Patient Assessment of Pain

The Patient's Assessment of Pain is used to assess the patient reported pain intensity. The patient's will be asked to assess their average pain during the past week on a visual analogue scale (VAS; 0 to 10 cm). The anchors of the instrument include 0 to represent ‘no pain’ and 10 to represent ‘the worst possible pain’.

9.2.1.6. Short-Form-36

The RAND short-form (SF)-36 questionnaire is a self-administered multi-domain scale with 36 items. Eight health domains cover a range of functioning:

- Limitations in physical function
- Limitations in usual role activities
- Bodily pain
- General mental health (psychological distress and well-being)
- Vitality (energy and fatigue)
- Limitations in social functioning due to physical or mental health problems
- Limitations in usual role activities due to personal or emotional problems
- General health perception

The subscales are scored from 0 to 100. The scoring yields a Physical Component Summary score and a Mental Component Summary score, a total score, and subscale scores. Higher scores represent better outcomes. It is appropriate for persons over the age of 14 and may be completed in 5 to 10 minutes. Translations are available in most languages; the instrument has undergone extensive linguistic and cultural validation. Version 2 acute will be used in the study.

The concepts measured by the SF-36 are not specific to any age, disease, or treatment group, allowing comparison of relative burden of different diseases and the benefit of different treatments (Ware & Sherbourne, 1992). A change of 3 points in any of the subscales or 5 points for the component score is associated with clinically meaningful change (Samsa et al, 1999; Ware, 2000; Ware et al, 1994). The SF-36 has been used extensively in clinical trials providing evidence of psychometric properties. Reliability estimates for physical and mental component summary scores exceeded 0.90 in early studies (McHorney et al, 1994) and have been further confirmed in later studies. Construct validation was established through comparison to several other generic health surveys.

9.2.1.7. Fatigue Severity Scale

The Fatigue Severity Scale (FSS) is a 9-item questionnaire designed to assess the severity of fatigue and its impact on daily living using 7 response options (1=Completely Disagree, 7=Completely Agree) during a recall period of the past week. It can be completed within 5 minutes by the subject. Scores above 36 of the total possible score of 63 reflect increasing severity of fatigue. The scale was developed for use in SLE (Krupp et al, 1989). The scores on the scale correlate with patient reported pain, sleep, depression, and with each subscale of the SF-36. The FSS has shown a high internal consistency, and differentiates patients from controls in studies with SLE subjects. The instrument was translated from the original English version and is available in several languages.

9.2.2. Definitions

A complete list describing all efficacy evaluations and endpoints, and which evaluations are included in the composite endpoints is provided in Appendix 1.

9.2.2.1. SRI-4

Systemic Lupus Erythematosus Disease Activity Index 2000 SRI-4 response is defined as a composite endpoint requiring at least a 4 point reduction in SLEDAI 2K score (Section 9.2.1.1), no worsening (<10 mm increase) from baseline in the Physician's Global Assessment of Disease Activity score (PGA) (Section 9.2.1.4), and no new BILAG Domain A and no more than 1 new BILAG Domain B scores (Section 9.2.1.2) (Fine et al, 2009). SRI-5 and SRI-6 are similarly defined with response requiring a ≥5 point reduction or ≥6 point reduction in SLEDAI 2K, respectively. SRI-5 and SRI-6 are similarly defined with response requiring a ≥5 point reduction or ≥6 point reduction in SLEDAI-2K, respectively.

9.2.2.2. BILAG-Based Combined Lupus Assessment

The BILAG-based Combined Lupus Assessment (BICLA) requires patients to meet response criteria across 3 assessment tools: (1) the BILAG-2004 index (2) the SLEDAI index and (3) a PGA. Patients are identified as responders or non-responders based upon the following requirements (Wallace, 2008):


Requirements for BICLA Response

BILAG	BILAG improvement classified as:
	All BILAG A scores at baseline improved to either
	BILAG B, C or D
	All BILAG B scores at baseline improved to either
	BILAG C or D
	No worsening in disease activity defined as no new
	BILAG A scores and ≤1 new BILAG B score
SLEDAI-2K	No worsening of total SLEDAI-2K from baseline
	(change ≤0)
PGA	No significant deterioration (<10 mm increase)
	in 100 mm visual analogue PGA
Treatment Failure	No treatment failure (see SAP for definition of
	treatment failure)

9.2.2.3. Flares
Flares for this study will be defined as:

- SLEDAI Flare: At least a 4+ point increase in SLEDAI-2K score (includes severe flares)
- Severe SLEDAI flare: At least a 7+ point increase in SLEDAI-2K score
- BILAG flare: At least 1 new BILAG A or 2 new BILAG B scores (from scores <B)
  9.2.2.4. S2K RI-50 Response

S2K RI-50 response is defined as a decrease of at least 6 points from baseline in the SLEDAI-2K score.

9.2.2.5. No Worsening in PGA

No worsening in PGA is defined as less than a 10 mm increase on 100 mm VAS.

9.2.3. Endpoints

Primary Endpoint

The primary endpoint of this study is the proportion of subjects with a composite SRI-4 response at Week 24.

Major Secondary Endpoints

The major secondary endpoints are listed in order of importance as specified below:

- 1. The change from baseline in SLEDAI-2K at Week 24.
- 2. The change from baseline in PGA at Week 24.
- 3. The proportion of subjects with BICLA response at Week 24.
  Other Endpoints
  Flares:
- 4. Time to first flare (SLEDAI flare, Severe SLEDAI flare, BILAG flare) from Week 12 through Week 24 and from Week 24 through Main Study 8-week Safety Follow-up Visit/Week 48 as well as from Week 48 through Week 104.
- 5. Number of flare (SLEDAI flare, Severe SLEDAI flare, BILAG flare) free visits from Week 12 through Week 24 and from Week 24 through Main Study 8-week Safety Follow-up Visit/Week 48 as well as from Week 48 through Week 104.
  SLE Disease Activity:
- 6. The proportion of subjects with responses in SRI-4, SRI-5, SRI-6, S2K RI-50 response and BICLA over time.
- 7. The proportion of subjects with no worsening in SLEDAI, BILAG, PGA, and Patient's Global Assessment of Disease Activity (PtGA) over time.
- 8. The proportion of subjects with improvement in SLEDAI (4, 5, and 6, points), BILAG, and PGA over time.
- 9. The absolute change from baseline in SLEDAI-2K, S2K RI-50, PGA over time.
- 10. The percent change in serological activity (e.g., ANA, anti-dsDNA, other autoantibodies, C3, C4) or SLEDAI feature measurements over time.
- 11. Shift table of BILAG by organ domain over time.
- 12. The percent change in CLASI scores (activity and damage) in subjects with cutaneous disease over time.
  Pro Outcomes:
- 13. The change in patient reported outcomes (PROs) (Pain VAS scale, FSS, SF-36 physical and mental component summary scores and individual domains) over time.
- 14. The proportion of subjects with clinically (the minimally clinical important difference) in PROs (i.e., FSS, improvement in SF-36) over time.
- 15. The change from baseline in PtGA at Week 24.
  Medications:
- 16. The proportion of subjects with meaningful changes in selected SLE medications from Week 12 through Main Study 8-week Safety Follow-up Visit/Week 48.
- 17. Change in corticosteroid dose from Week 48 through Week 104 for subjects who participate in the study extension.
- Development and analyses of the new endpoint(s) will be included in a separated technical report.
  9.3. Pharmaco*kinetics and Immunogenicity

Serum samples will be used to evaluate the pharmaco*kinetics (PK) of ustekinumab, as well as the immunogenicity of ustekinumab (antibodies to ustekinumab). Serum collected for PK and immunogenicity analyses may additionally be used to evaluate safety or efficacy aspects that address concerns arising during or after the study period. Genetic analyses will not be performed on these serum samples. Subject confidentiality will be maintained.

9.3.1. Serum Collection and Handling

Venous blood samples will be collected at the time points shown in the Time and Events Schedule for the determination of serum ustekinumab concentrations and antibodies to ustekinumab. Serum samples will also be collected at the final visit from subjects who terminate study participation early. At visits where PK and immunogenicity will be evaluated, 1 blood draw of sufficient volume can be used. Each sample will be split into 3 aliquots (1 aliquot for serum ustekinumab concentration, 1 aliquot for antibodies to ustekinumab, and 1 aliquot as a back-up). Samples must be collected before study drug administration at visits when study drug administration is scheduled. The exact dates and times of blood sample collection must be recorded in the laboratory requisition form.

9.3.2. Analytical Procedures

Serum samples will be analyzed to determine ustekinumab concentrations using a validated, specific, and sensitive immunoassay method by Sponsor's bioanalytical facility or under the supervision of the Sponsor. The Sponsor, or its designee, under conditions in which the subjects' identity remains blinded, will assay these samples.

9.3.3. Immunogenicity Assessments

Antibodies to ustekinumab will be detected using a validated immunoassay method in serum samples collected from all subjects. Serum samples that test positive for antibodies to ustekinumab will be further characterized to determine if antibodies to ustekinumab could neutralize the biological effects of ustekinumab in vitro (i.e., neutralizing antibodies [NAbs] to ustekinumab). All samples will be tested by the Sponsor or Sponsor's designee.

9.4. Biomarkers

The collection, preparation, storage and shipment of skin biopsies, blood, serum and urine are detailed in the Time and Events schedule (Table 1) and the Laboratory Manual. Biomarkers may include, but are not limited to, inflammatory markers, RNA, cell surface markers, auto-antibodies, T cell and B cell repertoire, target specific markers, and other categories of biomarkers potentially involved in the development and the progression of lupus.

Serum Analyses

Serum will be analyzed for levels of specific proteins including but not limited to soluble CD40 ligand (sCD154), interleukin (IL)-6, IL-12p40, IL-17, IL-21, IL-22, IL-23p19, C—X—C motif chemokine 10 (CXCL10), BAFF, interferons, auto-antibodies and other inflammation-related molecules.

Urine Samples

Urine samples will be evaluated for excreted proteins or other markers believed to have relevance in SLE.

Skin Biopsy Analyses

Skin biopsies will be utilized for cellular, molecular, and gene expression analyses.

Whole Blood Gene Expression Analyses

Whole blood will be collected from all subjects for RNA, flow cytometry (samples from selected sites will be analyzed at central laboratory or other analytical laboratory), T cell and B cell repertoire (nucleic acid analyses [RNA and DNA] for specific T and B cell receptors only) and epigenetics analysis (e.g., DNA methylation).

9.5. Pharmacogenomic Evaluations

The DNA samples will be used for research related to this study (CNTO1275SLE2001). Specific genomic testing will be undertaken for consenting subjects (subjects participating in this portion of the study must sign a separate ICF). The procedure will involve taking a blood sample that may be analyzed for specific target genes that may play a role in lupus. Any genomic assessments will be performed in strict adherence to current subject confidentiality standards for genetic testing. Refusal to participate in genomics testing will not result in ineligibility for participation in the rest of the clinical study.

9.6. Serologic Markers

Sample for autoantibodies (including ANA, anti-dsDNA, anti-Smith), complement C3, C4, and other analytes will be collected as described in the Table of Events (Table 1) and Section 9.8 Safety Evaluations (Clinical Laboratory Tests).

9.7. Cutaneous Lupus Substudy

Subjects with cutaneous disease will be evaluated using CLASI scoring. Additionally, subjects with cutaneous disease who consent to participate in the cutaneous lupus sub study will have additional assessments including collection of skin biopsies (optional consent) prior to study agent administration at Week 0 and at Week 24 and/or photographs of a cutaneous lesion or an area of active disease (optional consent) to be performed as shown in the Table of Events (Table 1). There will not be any restrictions on the number of subjects with cutaneous disease who can enroll into either the main study or the cutaneous lupus substudy.

Subjects who consent to the optional biopsy collection will have 2 skin biopsies (4 mm) excised from an active target lesion at Week 0, followed by 2 additional biopsies of the same lesion (regardless of cutaneous disease activity) at Week 24 (Cutaneous Lupus Substudy Manual). Skin biopsies will be utilized for cellular, molecular, and gene expression analyses.

Independent of cutaneous biopsy collection, subjects who participate in the cutaneous lupus substudy will be requested to provide consent for photographs to be collected from an identified cutaneous lesion or an area of active disease. Consenting subjects with cutaneous lupus unsuitable for biopsy (e.g., malar rash or alopecia) may be evaluated by photography. The photographs are for exploratory purposes only. The photographs will be used to assist in a qualitative evaluation of clinical response. The photographs and skin biopsies can target a different area of active disease, but the follow-up photographs or biopsies should re-evaluate the same area of active disease as originally assessed at week 0. Confidentiality of the subjects involved in this study will be maintained; specifically photographs of subjects in this study will not be published or otherwise made public without blocking adequate portions of the subject's face or body so that the individual cannot be identified.

9.8. Safety Evaluations

Safety assessments include vital signs, general physical examinations and skin evaluations (assessed during S2K RI-50 and CLASI evaluations), adverse events, concomitant medication review, pregnancy testing (refer to Section 12.3.3), administration reactions, chemistry and hematology laboratory tests, and antibodies to ustekinumab. Chest x-ray and TB, HIV, hepatitis B, and hepatitis C testing will be required at time of screening (Table 1). Refer to Section 4.1 for tuberculosis screening criteria. Subject diary cards will be used to capture medication changes that occur in between study visits through the main portion of the study.

Any clinically significant abnormalities persisting at the end of the study will be followed by the investigator until resolution or until a clinically stable endpoint is reached.

The study will include the following evaluations of safety and tolerability according to the time points provided in Table 1 and Table 2 for the extended study.

Adverse Events

Adverse events (AE) will be reported by the subject (or, when appropriate, by a caregiver) for the duration of the study, and will be followed by the investigator.

Infections

Subjects will be provided an alert card of signs and symptoms for infections, and will be instructed to contact the site between scheduled visits should any signs and symptoms occur. At each site visit, investigators or other site personnel are required to evaluate subjects for any signs or symptoms of infection, and ask about symptoms of infection or other AEs that may have occurred in between site visits.

Study agent should not be administered to a subject with a clinically important, active infection. Treatment with study agent should be withheld until serious and/or severe infections are completely resolved. If a subject develops a serious or severe infection, including but not limited to sepsis or pneumonia, discontinuation of study treatment must be considered. Treatment must be permanently discontinued for subjects who develop an opportunistic infection. For active varicella-zoster infection or a significant exposure to varicella zoster infection in a subject without history of chickenpox, the subject should be evaluated for symptoms of infection and if the subject has received appropriate treatment and/or recovered or no symptoms of infection, may continue study administration after discussion with the study Sponsor.

Clinical Laboratory Tests

Blood samples for serum chemistry and hematology will be collected according to the Time and Events Schedule (Table 1 and Table 2 for the extended study). The investigator must review the laboratory report immediately upon availability, document this review, and record any clinically relevant changes occurring during the study. Coomb's direct test, urine dipstick, urine sediment microscopy and urine pregnancy test will be performed by site staff or the local laboratory. With the approval of the study Sponsor, the use of local laboratories may also be allowed in cases where initiation of treatment or safety follow-up is time-critical and the central laboratory results are not expected to be available before the need to provide study agent treatment or if actions need to be taken for safety reasons.

A one-time retest of screening laboratory test(s) analyzed by the central laboratory will be allowed in the event of suspected error in sample collection or analysis performance.

- Hematology Panel
  - hemoglobin
  - hematocrit
  - white blood cell (WBC) count with differential (basophils, eosinophils, lymphocytes, monocytes, neutrophils)
  - platelet count
  - CD 19 B-cell analyses during screening only if needed for subjects previously exposed to B-cell depleting therapies (Section 4.1.3)
  - Coomb's direct test (local laboratories, if available)
- Serology Laboratory
  - Ig isotype profile (IgG, IgM, IgA levels)
  - C3 and C4 Complement
  - ANA
  - anti-dsDNA
  - anti-phospholipid antibodies including lupus anticoagulant, anti-cardiolipin, and anti-β₂-glycoprotein-I antibodies
  - other autoantibodies including anti-Smith, anti-Sjögren's-syndrome-related antigen A (SSA [anti-Ro], and B (SSB [anti-La]), anti-ribonucleoprotein (anti-RNP)
- Coagulation Labs
  - Prothrombin Time
  - Partial Thromboplastin Time
  - International Normalized Ratio


Serum Chemistry Panel

sodium	alkaline phosphatase
potassium	calcium
chloride	phosphorous
bicarbonate	albumin
blood urea nitrogen	total protein
creatinine	creatinine kinase
glucose	aspartate aminotransferase
aldolase (if creatine kinase is elevated	alanine aminotransferase
at screening then aldolase	total bilirubin, and if total bilirubin
test at Week 0 and follow-up	is abnormally elevated, then direct
as needed)	bilirubin, and indirect bilirubin

- Urine Analyses—Fresh spot urine
  - Urinalysis using urine dipstick. Urine sample will be further analyzed at Central laboratory.
  - Urinary protein/creatinine ratio (Fine et al, 2009) will be analyzed at the central laboratory using an aliquot of spot urine collected from subjects.
  - Urine Sediment Microscopy (Local Laboratory Assessment using spot urine samples)
    - Red blood cells
    - WBC, with note if urinary tract infection is present/absent
    - epithelial cells
    - crystals
    - Red blood cells, WBC, or heme-granular casts
    - bacteria
- Serum and urine pregnancy testing for women of childbearing potential only
- Viral serology (HIV antibody, HBsAg, anti-HBs, anti-HBc total, and hepatitis C virus antibody)
  Vital Signs

Weight and temperature will be assessed. Blood pressure and heart rate measurements will be assessed.

Physical Examination

A full body physical examination will be performed pre-treatment and during the study as shown in Table 1 and Table 2 for the extended study.

9.9. Sample Collection and Handling

The actual dates and times of sample collection must be recorded on the laboratory requisition form.

Refer to the Time and Events Schedule (Table 1 and Table 2 for the extended study) for the timing and frequency of all sample collections.

Instructions for the collection, handling, and shipment of samples are found in the laboratory manual that will be provided for sample collection and handling.

10.1. Completion

A subject who does not enter into the study extension will be considered to have completed the main study if he or she has completed assessments through 16-week safety follow-up of the main study. A subject who has enrolled into the study extension will be considered to have completed the main portion of this study if he or she has completed assessments through the 8-week safety follow-up visit of the main study. Subjects who prematurely discontinue study treatment for any reason before the Week 8 or Week 16 safety follow-up visits (from the main study), will not be considered to have completed the main portion of the study. A subject who has enrolled into the study extension will be considered to have completed the study extension if he or she has completed assessments through Week 120.

Discontinuation of Study Treatment

If a subject's study treatment must be discontinued before or at Week 40 (for subjects who do not participate in the study extension) or before Week 104 (for subjects who do participate in the study extension), this will not result in automatic withdrawal of the subject from the study and follow-up assessments should be obtained approximately 8 and 16 weeks following the last dose of study agent.

A subject's study treatment must be permanently discontinued if any of the following occur:

- 1. An AE temporally associated with study agent infusion or injection, resulting in bronchospasm with wheezing and/or dyspnea requiring ventilatory support, or symptomatic hypotension with a greater than 40 mm Hg decrease in systolic blood pressure.
- 2. The subject withdraws consent for administration of study agent.
- 3. Pregnancy or planning to become pregnant within the study period or within 16 weeks after the last study agent injection.
- 4. The initiation of prohibited medications or treatments (as per Section 4.3).
- 5. Malignancy, with the exception of no more than 2 localized basal cell skin cancers that are treated with no evidence of recurrence or residual disease.
- 6. An opportunistic infection.
- 7. The investigator or Sponsor's medical monitor deems it is in the subject's best interest.
- 8. The subject is deemed ineligible according to the following TB criteria:
  - A diagnosis of active TB is made.
  - A subject has symptoms suggestive of active TB based on follow-up assessment questions and/or physical examination, or has had recent close contact with a person with active TB, and cannot or will not continue to undergo additional evaluation.
  - A subject undergoing continued screening has a chest radiograph with evidence of current active TB and/or a positive QUANTIFERON®-TB Gold (blood test for tuberculosis) test and/or a positive tuberculin skin test result in countries in which the QUANTIFERON®-TB Gold (blood test for tuberculosis) is not approved/registered result and/or an indeterminate QUANTIFERON®-TB Gold (blood test for tuberculosis) test result on repeat testing, unless active TB can be ruled out and appropriate treatment for latent TB can be initiated either prior to or simultaneously with the next administration of study agent and continued to completion.
  - A subject receiving treatment for latent TB discontinues this treatment prematurely or is noncompliant with the therapy.
- 9. Significant worsening of SLE disease activity from baseline or having high disease activity for 2 or more consecutive visits starting at Week 16 based on overall clinical assessments; or if a subject requires the addition of a new immunomodulator to the existing treatment regimen after Week 16.

In addition, permanent discontinuation of study agent treatment must be considered for subjects who:

- Receive an increase (relative to baseline) in their immunomodulator dose.
- Develop any of the following adverse events that are reported as serious or severe: study agent infusion reaction, injection-site reaction, or infection.
  10.3. Withdrawal from the Study

A subject will be withdrawn from the study for any of the following reasons:

- Lost to follow-up
- Withdrawal of consent
- Death

If a subject is lost to follow-up, every reasonable effort must be made by the study site personnel to contact the subject and determine the reason for discontinuation/withdrawal. The measures taken to follow-up must be documented.

When a subject withdraws before completing the study, the reason for withdrawal is to be documented. Study drug assigned to the withdrawn subject may not be assigned to another subject. Subjects who withdraw from this study will not be replaced.

A subject who withdraws from the study will have the following options regarding the optional research samples:

- The collected samples will be retained and used in accordance with the subject's original informed consent for optional research samples.
- The subject may withdraw consent for optional research samples, in which case the samples will be destroyed and no further testing will take place. To initiate the sample destruction process, the investigator must notify the Sponsor study site contact (or appropriate designee) of withdrawal of consent for the optional research samples and to request sample destruction. The Sponsor study site contact will, in turn, contact the biomarker representative to execute sample destruction. If requested, the investigator will receive written confirmation from the Sponsor that the samples have been destroyed.
  Withdrawal from the Optional Research Samples while Remaining in the Main Study

The subject may withdraw consent for optional research samples while remaining in the study. In such a case, the optional research samples will be destroyed. The sample destruction process will proceed as described above.

Withdrawal from the Use of Samples in Future Research

The subject may withdraw consent for use of samples for research (refer to Section 16.2.5, Long-Term Retention of Samples for Additional Future Research). In such a case, samples will be destroyed after they are no longer needed for the clinical study. Details of the sample retention for research are presented in the main ICF and in the separate ICF for optional research samples.

Statistical analysis will be done by the Sponsor or under the authority of the Sponsor. A general description of the statistical methods to be used to analyze the efficacy and safety data is outlined below. Specific details will be provided in the Statistical Analysis Plan.

11.1. Subject Information

For all subjects who receive at least 1 dose of study drug descriptive statistics will be provided for demographic data and baseline characteristics, including prior and background SLE therapies. All subjects who are randomized and received at least 1 dose of study agent will be included in the efficacy analyses according to their assigned treatment group. The safety analysis population will include those subjects who received at least 1 dose of study agent, and will be analyzed according to the actual study agent received.

11.2. Sample Size Determination

The sample size calculation is based upon the primary endpoint, proportion of SRI-4 responders at Week 24. Approximately 60 subjects treated with ustekinumab and approximately 40 subjects with placebo is projected to give approximately 80% power to detect a significant difference in response rate compared with placebo (assume 35% and 60% response rates in placebo and ustekinumab respectively, which translates to 25% absolute increase over placebo or an odds ratio of 2.79) with an alpha level of 0.1. The assumption of a 35% responder rate for placebo is based upon a previous study in which a similar SLE population was treated (Van Vollenhoven et al, 2012). Recent studies have shown very high placebo rates in certain regions, thus the power for the study could be reduced (Huang et al, 2007).

The power to detect a significant treatment difference at α=0.1 (2-sided) is calculated under various assumptions (see Table 4).

TABLE 4

Power to Detect a Significant Treatment Difference in the
Proportion of Subjects with SRI-4 Response at Week 24

Proportion of		Proportion of
Placebo Group	Absolute Increase	Ustekinumab Group
with Response (%)	in Response (%)	with Response (%)	Odds Ratio	Power

20	20	40	2.67	70%
	25	45	3.27	85%
	30	50	4.00	94%
25	20	45	2.45	67%
	25	50	3.00	82%
	30	55	3.67	92%
30	20	50	2.33	64%
	25	55	2.85	80%
	30	60	3.50	91%
35	20	55	2.27	62%
	25	60	2.79	79%
	30	65	3.45	91%
40	20	60	2.25	62%
	25	65	2.79	79%
	30	70	3.50	91%

*Note:
SRI-4 response is defined as a ≥4-point reduction in SLEDAI-2K score, no new domain scores in either BILAG A or BILAG B and no worsening (<10 mm increase) from baseline in the PGA (Furie et al, 2009).

11.3. Efficacy Analyses

All efficacy analyses will be performed on the modified intent-to-treat (mITT) analysis set. The mITT analysis set will include all subjects who are randomized and received at least 1 dose of study agent. The efficacy analyses will be calculated according to their assigned treatment group.

11.3.1. Primary Endpoint Analysis

The primary endpoint of this study is the proportion of subjects with a composite measure of SLE disease activity (SRI-4 response) at Week 24 (Section 9.2.2.1). The primary analysis will be based upon the primary endpoint and will be conducted on the mITT population, which includes all randomized subjects who receive at least 1 dose of study agent, have at least 1 measurement prior to the administration, and have at least 1 post-baseline SRI-4 measurement.

Last observation carried forward procedure will be used to impute the missing SRI-4 component if the subjects have data for at least 1 SRI-4 component at Week 24. If the subjects do not have data for any SRI components at Week 24, the subjects will be considered not to have achieved the SRI-4 response. In addition, subjects who meet any 1 of the following criteria will be considered to have not achieved the primary endpoint, SRI-4 response at Week 24 (full details will be provided in the SAP):

Between the Week 12 visit and the Week 24 visit, either the dose of an immunomodulator is higher than at baseline, or a new immunomodulator has been added to the existing treatment regimen.

The addition of a new immunomodulator to the existing treatment regimen before Week 12 and subject still was receiving that immunomodulator after Week 12.

Initiate treatment with disallowed dose or disallowed use of oral, IV or IM or other type of corticosteroid administration for SLE, or increase the dose of oral corticosteroids for SLE above baseline between the Week 12 and 24 visits.

Subjects who were not receiving ARB or ACE inhibitor therapy who then initiated a new ARB or ACE inhibitor therapy between Week 12 and Week 24. Subjects who substitute an ARB or ACE inhibitor for a comparable medication would not be considered treatment failures.
Discontinue study agent due to lack of efficacy for an AE of worsening of SLE prior to Week 24.

For subjects who use systemic corticosteroids for another indication, the efficacy measurement will be carried forward from the last observation prior to the initiation of the treatment, for the period of 2 weeks after initiation of the treatment. After the 2 week period, the subject's calculated value will be as measured.

Other situations may confound the primary endpoint, such as a subject initiating NSAIDs after Week 16, or using epidural, IV, IM, IA, or intra-lesional, inhaled corticosteroids, and topical medication. Data handling rules will be specified in the Statistical Analysis Plan.

In addition to the primary analysis, sensitivity analyses will be performed to explore the effects with different data handling rules. If it is deemed necessary, the primary endpoint will be analyzed on the per protocol population. Details of the inclusion/exclusion rules for per protocol population will be provided in the SAP.

Subgroup analysis based on region will be performed. This is due to potential regional differences in evaluating efficacy, and high placebo response rates in certain regions. Subgroup analysis of the primary endpoint by other selected baseline characteristics will be presented. Details will be outlined in the SAP.

11.3.2. Major Secondary Analyses

- The change from baseline in SLEDAI-2K at Week 24.
- The change from baseline in PGA at Week 24.
- The proportion of subjects with BICLA response at Week 24.

Continuous responses will be analyzed using an analysis of covariance model with treatment group as a fixed factor and baseline stratifications (e.g., regions) as a covariate. Nonparametric methods will be adopted when the normality assumption is violated.

11.3.3. Other Planned Efficacy Analyses

For the other efficacy endpoints listed in Section 9.2.3, the following statistical methods will be applied:

Binary data will be analyzed using the same statistical method as in the primary efficacy analysis. Continuous responses will be analyzed using an analysis of covariance model with treatment group as a fixed factor and baseline stratifications (e.g., regions) as a covariate. Nonparametric methods will be adopted when the normality assumption is violated. Log-rank tests will be used to compare endpoints defined by time to an event.

11.3.4. Efficacy Analyses in the Study Extension

Long-term evaluations of efficacy including SRI-4, SLEDAI-2K, PGA, reduction in corticosteroid dosing, and evaluations of flare over time will also be performed for those subjects who participate in the study extension.

11.4. Interim Analyses

11.5. Pharmaco*kinetic Analyses

Serum ustekinumab concentrations will be summarized for each treatment group over time. Descriptive statistics, including arithmetic mean, standard deviation, median, interquartile range, minimum, and maximum will be calculated at each sampling time point.

If feasible, a population PK analysis using nonlinear mixed effects modeling may be used to characterize the disposition characteristics of ustekinumab in the current study. The influence of important variables such as body weight and antibodies to ustekinumab status on the population PK parameter estimates may be evaluated. Details will be given in a population PK analysis plan, and results of the population PK analysis will be presented in a separate technical report.

11.6. Immunogenicity Analyses

The incidence and titers of antibodies to ustekinumab will be summarized for subjects who received at least 1 administration of ustekinumab and have appropriate samples for detection of antibodies to ustekinumab (i.e., subjects with at least 1 sample obtained after their first dose of ustekinumab).

The incidence of NAbs to ustekinumab will be summarized for subjects who are positive for antibodies to ustekinumab and have samples evaluable for NAbs.

11.7. Biomarker Analyses

The following results from treated and untreated SLE subjects will be summarized:

- The concentration of individual serum and urine markers.
- Results from selected biomarkers in skin biopsy tissue by RNA-sequencing and immunohistochemistry.
- Results from whole blood gene expression profiling, flow cytometry, T cell and B cell repertoire, and epigenetics.
- Additional exploratory analyses may be performed following evaluation of the data.

The samples collected from other ongoing clinical studies may also be included in the biomarker data analyses. Results of biomarker analyses may be presented in a separate report.

11.8. Pharmacogenetics Analyses

The DNA research may consist of the analysis of 1 or more candidate genes or of the analysis of genetic markers throughout the genome (as appropriate) in relation to this study.

Results of genomic analyses will be presented in a separate report once the overall number of samples including those collected from other sources is appropriate.

11.9. Pharmaco*kinetic and Pharmacodynamic Analysis

If data permit, the relationships between serum ustekinumab concentration and efficacy or pharmacodynamic measures may be analyzed graphically.

11.10. Safety Analyses

Safety analyses will be based on the population of subjects who received at least 1 dose of either study agent; subjects will be summarized by the treatment they actually received.

Adverse Events (AEs)

The verbatim terms used to identify AEs will be coded using the Medical Dictionary for Regulatory Activities. All reported AEs with onset during the treatment phase (i.e., treatment-emergent AEs, and AEs that have worsened since baseline) will be included in the analysis. For each AE, the percentage of subjects who experience at least 1 occurrence of the given event will be summarized by treatment group. Routine safety evaluations will be performed. Adverse events, serious AEs (SAEs), reasonably related AEs, and AEs by severity will be summarized by treatment group.

The incidence and types of infections, infusion reaction, and inject site reactions will be analyzed for this study. An infusion reaction is defined as an AE that occurs during or within 1 hour following the infusion of study agent, with the exception of laboratory abnormalities.

Special attention will be given to those subjects who died, or who discontinued treatment due to an adverse event, or who experienced a severe or a serious adverse event (e.g., summaries, listings, and narrative preparation may be provided, as appropriate).

Clinical Laboratory Tests

Laboratory data will be summarized by the type of laboratory test. Reference ranges and Common Terminology Criteria for Adverse Events (CTCAE) will be used in the summary of laboratory data. Descriptive statistics will be calculated for each laboratory analyte at baseline and at each scheduled time point. Changes from baseline results will be presented in pre-versus post-treatment cross-tabulations (with classes for below, within, and above normal ranges based on laboratory reference ranges). The baseline is defined as the last measurement prior to the first dose of the randomized treatment. The number and percentage of subjects by Maximum CTCAE Grade will be summarized for each treatment group for each laboratory analyte. The laboratory parameters and change from baseline in selected laboratory parameters (hematology and chemistry), and the number of subjects with abnormal laboratory parameters (hematology and chemistry) based on CTCAE toxicity grading will be summarized treatment group. Listings of SAEs will also be provided. All safety analyses will be based on the population of subjects who received at least 1 dose of either study agent; subjects will be summarized by the treatment they actually received.

Urine protein and creatinine measurements will be used to calculate the urine protein to creatinine ratio. Descriptive statistics will be calculated for these ratios at baseline and at each scheduled time point.

Vital Signs

Vital sign measures at each scheduled time point and their changes from baseline will be summarized using descriptive statistics. The baseline is defined as the last measurement prior to the first dose of the randomized treatment.

11.11. Data Monitoring Committee

An independent DMC will be established to monitor data on an ongoing basis to ensure the continuing safety of the subjects enrolled in this study and to conduct interim efficacy analysis. The committee will meet at least twice to review interim data, including when ⅓ and ⅔ of subjects reach Week 24. After each review, the DMC will make a recommendation to the Sponsor committee whether the study should be stopped for safety concerns. In the first IA, Sponsor will also be notified for notable efficacy in order to advance to next trial. In the second IA, Sponsor will be notified for notable efficacy as well as futility. The details will be provided in a separate DMC charter and in the IA Statistical Plan.

The DMC will have 3 to 6 members who are independent of the Sponsor. The DMC will consist of at least 1 medical expert in the relevant therapeutic area and at least 1 statistician. The DMC responsibilities, authorities, and procedures will be documented in its charter.

The DMC will no longer be active after the assessment of the primary endpoint in this study.

Timely, accurate, and complete reporting and analysis of safety information from clinical studies are crucial for the protection of subjects, investigators, and the Sponsor, and are mandated by regulatory agencies worldwide. The Sponsor has established Standard Operating Procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting of safety information; all clinical studies conducted by the Sponsor or its affiliates will be conducted in accordance with those procedures.

12.1. Definitions

12.1.1. Adverse Event Definitions and Classifications

Adverse Event

An adverse event is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. (Definition per International Conference on Harmonisation [ICH])

This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities.

Note: The Sponsor collects adverse events starting with the signing of the ICF (refer to Section 12.3.1, All Adverse Events, for time of last adverse event recording).

Serious Adverse Event

A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

- Results in death
- Is life-threatening
- (The subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe.)
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Is a suspected transmission of any infectious agent via a medicinal product
- Is Medically Important*

*Medical and scientific judgment should be exercised in deciding whether expedited reporting is also appropriate in other situations, such as important medical events that may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. These should usually be considered serious.

If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal relationship between the study drug and the event (e.g., death from anaphylaxis), the event must be reported as a serious and unexpected suspected adverse reaction.

Unlisted (Unexpected) Adverse Event/Reference Safety Information

An adverse event is considered unlisted if the nature or severity is not consistent with the applicable product reference safety information.

Adverse Event Associated With the Use of the Drug

An adverse event is considered associated with the use of the drug if the attribution is possible, probable, or very likely by the definitions.

12.1.2. Attribution Definitions

Not Related

An adverse event that is not related to the use of the drug.

Doubtful

An adverse event for which an alternative explanation is more likely, e.g., concomitant drug(s), concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely.

Possible

An adverse event that might be due to the use of the drug. An alternative explanation, e.g., concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, the causal relationship cannot be excluded.

Probable

An adverse event that might be due to the use of the drug. The relationship in time is suggestive (e.g., confirmed by dechallenge). An alternative explanation is less likely, e.g., concomitant drug(s), concomitant disease(s).

Very Likely

An adverse event that is listed as a possible adverse reaction and cannot be reasonably explained by an alternative explanation, e.g., concomitant drug(s), concomitant disease(s). The relationship in time is very suggestive (e.g., it is confirmed by dechallenge and rechallenge).

12.1.3. Severity Criteria

An assessment of severity grade will be made using the following general categorical descriptors:

Mild:

Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities.

Moderate:

Sufficient discomfort is present to cause interference with normal activity.

Severe:

Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities.

The investigator should use clinical judgment in assessing the severity of events not directly experienced by the subject (e.g., laboratory abnormalities).

12.2. Special Reporting Situations

Safety events of interest on a Sponsor study drug that may require expedited reporting and/or safety evaluation include, but are not limited to:

- Overdose of a Sponsor study drug
- Suspected abuse/misuse of a Sponsor study drug
- Inadvertent or accidental exposure to a Sponsor study drug
- Medication error involving a Sponsor product (with or without subject/patient exposure to the Sponsor study drug, e.g., name confusion)
- Adverse events of special interest: any newly identified malignancy, opportunistic infection (i.e., infection by an organism that normally is not pathogenic or does not cause invasive infection in immunocompetent hosts), or case of active TB occurring after the first administration of study agent in subjects participating in this clinical trial must be reported by the investigator following procedures. Investigators are also advised that active TB is considered a reportable disease in most countries. These events are to be considered serious only if they meet the definition of an SAE.

Special reporting situations should also be recorded. Any special reporting situation that meets the criteria of a serious adverse event should be recorded.

12.3. Procedures

12.3.1. All Adverse Events

All adverse events and special reporting situations, whether serious or non-serious, will be reported from the time a signed and dated ICF is obtained until completion of the subject's last study-related procedure (which may include contact for follow-up of safety). Serious adverse events, including those spontaneously reported to the investigator within 16 weeks after the last dose of study drug, must be reported using the Serious Adverse Event Form. The Sponsor will evaluate any safety information that is spontaneously reported by an investigator beyond the time frame specified in the protocol.

All events that meet the definition of a serious adverse event will be reported as serious adverse events, regardless of whether they are protocol-specific assessments.

All adverse events, regardless of seriousness, severity, or presumed relationship to study drug, must be recorded using medical terminology in the source document. Whenever possible, diagnoses should be given when signs and symptoms are due to a common etiology (e.g., cough, runny nose, sneezing, sore throat, and head congestion should be reported as “upper respiratory infection”). Investigators must record their opinion concerning the relationship of the adverse event to study therapy. All measures required for adverse event management must be recorded in the source document and reported according to Sponsor instructions.

The Sponsor assumes responsibility for appropriate reporting of adverse events to the regulatory authorities. The Sponsor will also report to the investigator (and the head of the investigational institute where required) all serious adverse events that are unlisted (unexpected) and associated with the use of the study drug. The investigator (or Sponsor where required) must report these events to the appropriate Independent Ethics Committee/Institutional Review Board (IEC/IRB) that approved the protocol unless otherwise required and documented by the IEC/IRB.

The subject must be provided with a “wallet (study) card” and instructed to carry this card with them for the duration of the study indicating the following:

- Study number
- Statement, in the local language(s), that the subject is participating in a clinical study
- Investigator's name and 24-hour contact telephone number
- Local Sponsor's name and 24-hour contact telephone number (for medical staff only)
- Site number
- Subject number
- Any other information that is required to do an emergency breaking of the blind
  12.3.2. Serious Adverse Events

All serious adverse events occurring during the study must be reported to the appropriate Sponsor contact person by study-site personnel within 24 hours of their knowledge of the event.

Information regarding serious adverse events will be transmitted to the Sponsor using the Serious Adverse Event Form, which must be completed and signed by a physician from the study site, and transmitted to the Sponsor within 24 hours. The initial and follow-up reports of a serious adverse event should be made by facsimile (fax).

All serious adverse events that have not resolved by the end of the study, or that have not resolved upon discontinuation of the subject's participation in the study, must be followed until any of the following occurs:

- The event resolves
- The event stabilizes
- The event returns to baseline, if a baseline value/status is available
- The event can be attributed to agents other than the study drug or to factors unrelated to study conduct
- It becomes unlikely that any additional information can be obtained (subject or health care practitioner refusal to provide additional information, lost to follow-up after demonstration of due diligence with follow-up efforts)

Suspected transmission of an infectious agent by a medicinal product will be reported as a serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the course of a subject's participation in a study must be reported as a serious adverse event, except hospitalizations for the following:

- Hospitalizations not intended to treat an acute illness or adverse event (e.g., social reasons such as pending placement in long-term care facility)
- Surgery or procedure planned before entry into the study (must be documented).

The cause of death of a subject in a study within 16 weeks of the last dose of study drug, whether or not the event is expected or associated with the study drug, is considered a serious adverse event.

12.3.3. Pregnancy

All initial reports of pregnancy must be reported to the Sponsor by the study-site personnel within 24 hours of their knowledge of the event using the appropriate pregnancy notification form. This includes subject report of a positive home over-the-counter pregnancy test. Abnormal pregnancy outcomes (e.g., spontaneous abortion, stillbirth, and congenital anomaly) are considered serious adverse events and must be reported using the Serious Adverse Event Form. Any subject who becomes pregnant during the study must discontinue further study treatment, and followed for 4 months after last study dose.

Because the effect of the study drug on sperm is unknown, pregnancies in partners of male subjects included in the study will be reported by the study-site personnel within 24 hours of their knowledge of the event using the appropriate pregnancy notification form.

Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the infant will be required.

A product quality complaint (PQC) is defined as any suspicion of a product defect related to manufacturing, labeling, or packaging, i.e., any dissatisfaction relative to the identity, quality, durability, or reliability of a product, including its labeling or package integrity. A PQC may have an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and analysis of PQC information from studies are crucial for the protection of subjects, investigators, and the Sponsor, and are mandated by regulatory agencies worldwide. The Sponsor has established procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting of PQC information; all studies conducted by the Sponsor or its affiliates will be conducted in accordance with those procedures.

13.1. Procedures

All initial PQCs must be reported to the Sponsor by the study-site personnel within 24 hours after being made aware of the event.

If the defect is combined with a serious adverse event, the study-site personnel must report the PQC to the Sponsor according to the serious adverse event reporting timelines (refer to Section 12.3.2, Serious Adverse Events). A sample of the suspected product should be maintained for further investigation if requested by the Sponsor.

14.1. Physical Description of Study Drug

14.1.1. IV Administration

Ustekinumab 5 mg/mL FVP (IV) is supplied as a single-use, sterile solution in 30 mL vials with 1 dose strength (i.e., 130 mg in 26 mL nominal volume). In addition to ustekinumab, the solution contains 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt, dihydrate at pH 6.0. No preservatives are present.

Placebo for FVP (IV) is supplied as single-use, sterile solution in 30 mL vials with a 26 mL nominal volume. The composition of the placebo is 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt, dihydrate at pH 6.0. No preservatives are present.

14.1.2. SC Administration

Ustekinumab will also be supplied as a single-use latex-free PFS in a strength of 90 mg in 1 mL nominal volume for SC administration. Each 1 mL of ustekinumab solution in the PFS contains 90 mg ustekinumab with nominal excipient concentrations of 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No preservatives are present. The needle cover on the PFS contains dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.

Background/Purpose:

The IL-12/23 pathway has been implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE). The anti-IL-12/IL-23p40 antibody ustekinumab is used in the treatment of psoriasis, psoriatic arthritis, and Crohn's disease. Here, the safety and efficacy of usetkinumab was evaluated in patients with active SLE.

Methods:

A phase 2, placebo-controlled study, was conducted in 102 adults with seropositive (ANA, anti-dsDNA, and/or anti-Smith antibodies) SLE by SLICC criteria and active disease (SLEDAI-2K≥6 and ≥1 BILAG A and/or ≥2 BILAG B scores) despite conventional therapy. Patients (n=102) were randomized (3:2) to receive ustekinumab intravenous (IV) at ˜6 mg/kg or placebo at week 0, then subcutaneous (SC) injections of ustekinumab 90 mg q8w or placebo, both added to standard care; stratification factors were consent for skin biopsy (yes/no), disease features, (e.g., presence of LN, baseline concomitant SLE medications, SLEDAI score), site/region, and race. At week 24, placebo patients crossed over to ustekinumab (90 mg SC q8w). Primary endpoint was SLE response index (SRI-4) response at week 24. Major secondary endpoints at week 24 included change from baseline in SLEDAI-2K, change from baseline in Physician's Global Assessment (PGA), and proportion of patients with BICLA response. Endpoint analyses included all patients who received ≥1 dose of study agent, had ≥1 measurement prior to administration, and had ≥1 post-baseline measurement. Modified intention-to-treat (mITT) analyses across SLE disease activity measures were performed to evaluate for maintenance of response with ustekinumab between week 24 and week 48. Subjects crossing over from placebo to SC ustekinumab were also assessed for de novo clinical responses across disease activity measures. Safety was assessed through week 56. Patients with missing data and treatment failures were imputed as nonresponders.

Results:

Patient demographic and disease characteristics were well-balanced between treatment groups (female=91%; mean age=41 (18-66) years; mean SLEDAI-2K=10.9). At week 24, 61.7% of patients in the ustekinumab group had an SRI-4 response vs 33.3% in the placebo group (p=0.0057), with a treatment effect favoring ustekinumab beginning at week 12. Patients in the ustekinumab group had greater median improvements from week 0 to week 24 in SLEDAI-2K and PGA vs placebo (Table 5). Furthermore, rates of SLEDAI-2K (65% at week 24 vs 66.7% at 1 year), PGA (67.9% at week 24 vs 75% at 1 year), and active joint (86.5% at week 24 vs 86.5% at 1 year) responses were also sustained from week 24 to 1 year in the ustekinumab group (Table 6). CLASI response rate plateaued by week 28 (53.1% at week 24 vs 67.7% at week 28) and was maintained through 1 year in the ustekinumab group (68.6%) (Table 6). No difference was observed in the proportion of patients achieving a BICLA composite response at week 24, although a notable difference in the proportion of patients with no BILAG worsening among BICLA nonresponders was observed. The risk of a new BILAG flare (≥1 new BILAG A or ≥2 new BILAG B) was significantly lower in the ustekinumab group vs. placebo (HR 0.12 [95% CI 0.01-0.94]; p=0.0119). Ustekinumab also demonstrated improvement in musculoskeletal and mucocutaneous disease features vs placebo. Improvements in anti-dsDNA and C3 levels were also noted through week 24 with ustekinumab. Through week 24, 78% of ustekinumab patients and 67% of placebo patients had ≥1 adverse event (Table). Among placebo patients who crossed over to SC ustekinumab at week 24 (n=33), 54.5% achieved an SRI-4 response at 1 year. Placebo patients who crossed over to SC ustekinumab at week 24 also demonstrated greater response rates across multiple efficacy measures including proportion of patients with point improvement from baseline SLEDAI-2K (46% at 24 weeks vs 55% at 1 year), proportion of patients with ≥30% improvement from baseline PGA (56% at 24 weeks vs 77% at 1 year), proportion of patients with 50% improvement in the number of active joints at baseline (61% at week 24 vs 82% at 1 year), and proportion of patients with 50% improvement from baseline CLASI Activity Score (35% at Wk 24 vs. 47% at 1 year). Of ustekinumab-exposed patients, 81.7% had ≥1 TEAE, 15.1% had ≥1 SAE, and 7.5% had ≥1 serious infection through 1 year (Table 7). There were no deaths, malignancies, opportunistic infections, or tuberculosis cases observed in the study. The ustekinumab safety profile was consistent with earlier studies in other diseases.

Ustekinumab showed significantly better efficacy in many clinical and laboratory parameters in active SLE compared to placebo and comparable safety at 24 weeks. Ustekinumab also provided sustained clinical benefit in global and organ-specific SLE activity measures through 1 year. De novo increases in response rates across disease activity measures were observed in patients who crossed over from placebo to SC ustekinumab at week 24. The safety profile of ustekinumab was also consistent with other indications. Thus, ustekinumab is a clinically proven safe and clinically proven effective therapy with a novel mechanism of action for the treatment of SLE.

TABLE 5

Efficacy and Safety results at Week 24.

	Placebo	Ustekinumab

Patients randomized, n

Efficacy

Proportion with SRI-4 response,	14	(33.3%)	37	(61.7%)
n (%)

P value		0.0057
Median change from baseline in	−2.0	−6.0
SLEDAI-2K
P value		0.0265^a
Median change from baseline in PGA	−1.6	−2.5
P value		0.2110^a

Proportion with BICLA response

(33.3)

(35.0)

P value

0.9939

Proportion with no BILAG	11/42	(26.2)	29/60	(48)
worsening, n/N (%)

P value	0.3	0.0281
Proportion with 50% improvement	61	86
from baseline joint disease
activity^b
P value		0.0100^d
Proportion with 50% improvement	29.9	64.1
from baseline CLASI activity
score^c
P value		0.0319^d

Mean (SD) change from baseline in	−3.7	(96.8)	−226.6	(686.5)
anti-dsDNA (kIU/L)

P value

0.2482

Complement C3 (mg/dL)

3.6

(10.7)

8.3

(15.1)

P value

0.2749

Adverse events

Proportion with ≥1 TEAE, n (%)

(69.0)

(78.3)

Most Common TEAEs, n (%)

Upper respiratory tract infection	9	(21.4)	5	(8.3%)
Urinary tract infection	5	(11.9)	6	(10.0%)
Nasopharyngitis	3	(7.1)	6	(10.0%)
Headache	5	(11.9)	4	(6.7%)
Proportion with ≥1 SAE, n (%)	4	(9.5)	5	(8.3%)

^aOne-sided test for no difference between two treatment groups based upon a Wilcoxon non-parametric median test for difference of location.
^bPatient subpopulation (~70% of total population) with at least 4 joints with pain and signs of inflammation at baseline
^cPatient subpopulation (~60% of total population) with CLASI activity score of at least 4 at baseline
SRI-4, SLE Response Index; SLEDAI 2K, Systemic Lupus Erythematosus Disease Activity Index; PGA, physician's global assessment; BICLA, BILAG-based Combined Lupus Assessment; BILAG, British Isles Lupus Assessment Group; TEAE, treatment emergent adverse event
^dProportions of responders and p values based on a modified intention to treat analysis using a multiple imputation model for missing data from weeks 16 to 24

TABLE 6

Efficacy results at 24 weeks and 1 year in patients
initially randomized to ustekinumab

Ustekinumab

	Week 24	Week 48

Randomized patients (mITT)	60	60
SRI-4 response^a, n/randomized (%)	37/60 (61.7)	38/60 (63.3)
Improvement from baseline in SLEDAI-	39/60 (65.0)	40/60 (66.7)
2K score^b, n/randomized (%)
≥30% improvement from baseline in	38/56 (67.9)	39/52 (75.0)
PGA, n/evaluable^c(%)
≥50% improvement from baseline in the	32/37 (86.5)	32/37 (86.5)
number of joints with pain and signs of
inflammation, n/evaluable^c,d(%)
≥50% improvement from baseline	17/32 (53.1)	24/35 (68.6)
CLASI activity score, n/evaluable^c,e(%)

^aSRI-4 response was defined as a ≥4-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score, and no worsening (<10% increase) from baseline in the PGA of disease activity score
^bSLEDAI-2K response defined as ≥4-point improvement from baseline score
^cValues for patients meeting treatment failure criteria are set to missing from the point of treatment failure forward
^dPatient subpopulation (67% of total population) with ≥4 joints with pain and signs of inflammation at baseline
^ePatient subpopulation (60% of total population) with CLASI activity score of ≥4 at baseline
CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; mITT, modified intention-to-treat; PBO, placebo; PGA, Physician Global Assessment; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI-4, SLE Responder Index-4; UST, ustekinumab

TABLE 7

Safety results at 24 weeks and 1 year

		Exposed to ustekinumab
	Placebo-controlled	through 1 year

through Week 24

Randomized

All UST

	PBO	UST	to UST	(UST + PBO-UST)

Treated patients

Patients with ≥1	29	(69.0)	47	(78.3)	54	(90.0)	76	(81.7)
TEAE
Patients with ≥1 SAE	4	(9.5)	5	(8.3)	10	(16.7)	14	(15.1)
Patients with ≥1	21	(50.0)	29	(48.3)	40	(66.7)	56	(60.2)
infection^a
Patients with ≥1	0	(0)	2	(3.3)	6	(10.0)	7	(7.5)
serious infection^a
Patients with ≥1	4	(9.5)	4	(6.7)	5	(8.3)	6	(6.5)
DCAE

All data are presented as n (%).
^aBased on infection system organ class
DCAE, adverse event leading to discontinuation; PBO, placebo; PBO-UST, patients who crossed over from PBO to UST at week 24; SAE, serious adverse event; TEAE, treatment-emergent adverse event; UST, ustekinumab

TABLE 8

Comprehensive Summary of Efficacy Results at Week 24.

	Placebo	Ustekinumab	Difference	P value

Patients randomized, n

Primary Endpoint

SRI-4 response, n (%)

(33%)

(62%)

28.4%

(9.5 to 47.2)

0.0057^a

Major Secondary Endpoints

Change from baseline in	−3.8	(5.4)	−4.4	(2.9)	−0.63	(−2.4 to 1.17)	0.0929^a
SLEDAI-2K, mean (SD)
Change from baseline in	−1.9	(2.2)	−2.2	(1.9)	−0.24	(−1.13 to 0.64)	0.3944^a,b
PGA, mean (SD)
BICLA response, n (%)	14	(33%)	21	(35%)	1.7%	(−17.0 to 20.3)	0.9939^a,b

Additional Endpoints

SRI-5 response, n (%)	9	(21%)	26	(43%)	21.9%	(4.3 to 39.5)	0.0218^a,b
SRI-6 response, n (%)	8	(19%)	26	(43%)	24.3%	(7.0 to 41.6)	0.0122^a,b

SLEDAI-2K response^c,d

Patients, n/N (%)

15/31

(48%)

38/53

(72%)

23.3%

(4.4 to 42.2)

Mean response rate, %	49.1%	(48.2 to 50.0)	76.8%	(76.4 to 77.2)		0.0071^a,b
(95% CI)

Modified SLEDAI-2K response^c,e

Patients, n/N (%)

18/32

(56%)

40/56

(71%)

15.2%

(−3.7 to 34.0)

Mean response rate, %	51.6%	(35.4 to 67.4)	75.0%	(61.4 to 85.0)		0.0162^b
(95% CI)

PGA improvement from	18	(43%)	37	(62%)	18.8%	(−0.6 to 38.2)	0.0815^b
baseline ≥30%, n (%)
No worsening in PGA^c	29/32	(91%)	51/55	(93%)	2.1%	(−8.9 to 13.1)
Patients, n/N (%)

Mean response rate, %	88.9%	(73.4 to 95.9)	92.4%	(81.4 to 97.1)		0.3121^a,b
(95% CI)

No worsening in BILAG	11	(26%)	29	(48%)	22.1%	(3.8 to 40.5)	0.0281^a,b
score, n (%)

≥50% improvement from baseline joint disease activity^c,f, % (95% CI)

Patients, n/N (%)

14/23

(61%)

32/37

(86%)

25.6%

(8.5 to 42.7)

Mean response rate, %	65.5%	(44.6 to 81.7)	90.1%	(75.2 to 96.5)		0.0100^b
(95% CI)

≥50% improvement from baseline CLASI activity score^c,g, % (95% CI)

Patients, n/N (%)

6/17

(35%)

17/32

(53%)

17.8%

(−1.4 to 37.0)

Mean response rate, %	29.9%	(12.0 to 57.0)	64.1%	(43.0 to 80.9)	0.0319^b
(95% CI)

^aPrespecified analyses; all other analyses shown here were post-hoc.
^bNominal p value; not adjusted for multiplicity.
^cProportion of patients with response are reported as observed values at Week 24 and mean response rates using multiple imputation for missing data.
^dSLEDAI-2K response is the proportion of patients with at least 4-point improvement from baseline SLEDAI score.
^eModified SLEDAI-2K response is the proportion of patients with SLEDAI-2K response excluding serologic markers of disease activity (C3, C4, and anti-double-stranded DNA antibodies).
^fPatient subpopulation (67% of total population) with ≥4 joints with pain and signs of inflammation at baseline.
^gPatient subpopulation (58% of total population) with CLASI activity score ≥4 at baseline.
BICLA = BILAG-based Combined Lupus Assessment. BILAG = British Isles Lupus Assessment Group. CI = confidence interval. CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. PGA = physician's global assessment. SD = standard deviation. SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2000. SRI = Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index.

Example 2: Gene signatures to predict response to STELARA® (Ustekinumab, UST) for patients with lupus.
Background:

Systemic lupus erythematosus (SLE) is a heterogenous disease in presentation and course affecting virtually any organ system. This heterogeneity has posed a significant challenge to successful drug development and one strategy to overcome this problem is to utilize biomarkers to identify patients exhibiting a disease driven by the mechanism of action modulated by a given therapy. Currently, there is some clinical validation for IFN-I and B-cell targeted mechanisms in the treatment of lupus. In both cases, unique baseline biomarkers have been identified to potentially enrich for responders. For example, for sifalimumab (Khamashta et al, 2016) (an anti-IFN alpha human monoclonal antibody) and anifrolumab (Furie et al, 2017) (an anti IFN-I receptor human monoclonal antibody), whole blood monitoring of IFN-I inducible transcript expression indicated that treatment response was enriched in subjects with higher baseline levels of these transcripts and these same transcripts were downmodulated after treatment. In addition, after a failed phase 2 trial with Benlysta® (a.k.a., belimumab, a human monoclonal antibody that inhibits B-cell activating factor), belimumab was approved after successful phase 3 programs that incorporated a novel composite disease instrument based on clinical assessments and biomarker-based changes in inclusion criteria, i.e., ANA titer ≥1:80 and/or a positive anti-dsDNA test at entry (Stohl & Hilbert, 2012). In spite of these successes, the identification of biomarkers and the routine use of biomarkers to enrich for or predict patient subsets more likely to respond to a given treatment remains an unmet medical need for the treatment of SLE.

Herein are disclosed unexpected gene expression signatures associated with a clinical response to UST in patients with active SLE. Within these signatures are transcripts belonging to the interferon pathway (Interferon I inducible genes) and those associated with cytotoxic lymphocytes (cytotoxic cell-associated transcriptional genes). These transcriptional signatures are differentially expressed prior to treatment when comparing clinical responders to non-responders and they can be used to select patients for treatment based on the predicted response to treatment with UST.

Methods and Results:

Methods and results from serum and whole blood transcriptional biomarker data analysis from a phase 2a study (NCT02349061) to examine the efficacy and safety of UST in SLE are described herein.

Unless otherwise indicated, practice of the present invention employs conventional biological methods known by those skilled in the art, e.g., molecular biology methods (including recombinant methods), microbiology methods, cell biology methods, and biochemistry methods. Such biological methods include gene expression profiling by, e.g., determining cellular RNA or protein levels. Non-limiting examples of methods that measure RNA include, e.g., microarray profiling, reverse transcriptase PCR (RT-PCR), e.g., quantitative RT-PCR (RT-qPCR), and serial analysis of gene expression (SAGE). Non-limiting examples of methods of measuring protein expression levels include, e.g., mass spectrometry, two-dimensional gel electrophoresis, antibody microarrays, tissue microarrays, ELISA, immunohistochemistry, proteomics, flow cytometry, and other methods known by those skilled in the art. An advantage of using microarray profiling is that it provides for assaying large numbers of distinct sequences in parallel, including all known coding and non-coding splice variants. Microarray profiling is also compatible with a variety of clinically relevant biological sample types, e.g., skin biopsies, whole blood, and different isolated cell types from blood or tissue. Quantification can be relative or absolute quantification or a combination of both as applied to the normalization process, e.g., as discussed below in more detail. Briefly, relative quantification references expression of a target gene to a control value for expression such as, for example, expression obtained from a control sample or pretreatment sample or expression of a reference gene. Absolute quantification is based upon an internal or external calibration curve (Pfaffl, 2001; Livak & Schmittgen, 2001).

Microarray Analysis

PAXgene RNA tubes were processed for microarray by Biostorage Technologies, Inc. RNA extraction was performed using the QIAsymphony automation platform (QIAGEN GmbH). The RNA quantity and purity was assessed using the Trinean DropSense (Perkin Elmer). The RNA quality was assessed using the Caliper LabChip Gx (Perkin Elmer). RNA samples (100 ng where available) were amplified using the Affymetrix HT WT Plus Reagent kit (Thermo Fisher, cat #902414) according to manufacturer's instructions. cDNA QC was performed using the Caliper LabChipGX and cDNA is used as input in the fragmentation and labeling reaction that is performed using the Affymetrix HT WT Plus module designed specifically for fragmentation and labeling of cDNA for analysis on Affymetrix GeneChip® arrays. Microarray processing was performed using the Hu Gene 2.1 ST array+PM 96-Array Plate (Thermo Fisher, cat #902138) on the Affymetrix Gene Titan MC instrument (Thermo Fisher) that automates array processing from target hybridization to data generation.

The UST transcriptome microarrays (gene chip: Hu Gene 2.1 ST+PM 96-Array Plate) were generated in two batches. The data contained 282 and 95 CEL files respectively. 31 healthy donor samples obtained from the CROs (BioIVT [formally known as Bioreclamation], Westbury, N.Y., and Biological Specialty Corp., Colmar, Pa.) were measured in both batches to enable data bridging. The data was loaded using the “oligo 1.38.0” (Carvalho et al, 2010) and quantile normalized (bringing all samples to identical statistical properties) using the Robust Multichip Average algorithm (RMA) 1.52.0″ (Gautier et al, 2004) packages (Affymetrix, Santa Clara, Calif.). The quantile normalized data has been used as the starting dataset to perform all the analysis. The batch effects were reduced employing LOESS as local non-parametric regression model (Cleveland et al, 1993). The batch effect reduction was achieved by establishing for each gene a batch model using the bridging samples to predict the new corrected expression value. Visual inspection using PCA confirmed reduction of the batch effect.

Determination of Dynamic Genes

A random simulation was implemented to determine genes that exhibited consistent expression differences between distinct groups of lupus patients dosed with UST. That approach was chosen due to the small sample size while having tested a large number of probe sets.

For every probe set measured:

- 1. 75% of the samples were randomly selected
- 2. The samples were split into high and low expression groups
- 3. The difference between the two high and low groups was assessed using a t-test
- 4. The process was repeated 1000 times, to define the frequency of each probe
- 5. Probes that had a nominal statistical difference (P<0.05) in more than 60% of the repeats and had a nominal difference between UST responders and non-responders (P<0.05; not adjusted) were retained

The initial analysis resulted in the identification of 58 genes (Table 9) that were identified with different probe sets (Appendix 2). Those genes are referred to as dynamic genes because they consistently showed differential expression between distinct groups of lupus patients treated with UST. The group of 58 dynamic genes includes genes from the IFN-I inducible gene cluster, the cytotoxic cell-associated transcriptional gene cluster, and some genes from an assortment of other gene clusters. The expression of those 58 dynamic genes in three different lupus cohorts of distinct ethnic backgrounds for which expression data using RNA sequencing was generated, were examined. Of the 58 dynamic genes identified, 31 of the genes were expressed in all the examined datasets. The 31-gene signature only includes genes from the IFN-I inducible gene cluster and the cytotoxic cell-associated transcriptional gene cluster.

As used herein, the terms “differential expression,” “differentially expressed,” and their synonyms, which are used interchangeably, refer to a gene whose expression level is higher or lower in a patient suffering from a disease, e.g., active systemic lupus erythematosus (SLE). It is also understood that a differentially expressed gene may be expressed at either a higher or lower level at the nucleic acid level (e.g., RNA transcripts) or at the protein level.

TABLE 9

Dynamic Genes

Probe ID	Gene Symbol	Gene Name	Accession No.	Gene Cluster

16870200	BST2	bone marrow	NM_004335	IFN-I inducible
		stromal cell
		antigen 2
16743922	CARD17	caspase	NM_001007232	IFN-I inducible
		recruitment
		domain family
		member 17
16894127	CMPK2	cytidine/uridine	NM_207315	IFN-I inducible
		monophosphate
		kinase 2
17093090	DDX58	DExD/H-box	NM_014314	IFN-I inducible
		helicase 58
16981219	DDX60	DExD/H-box	NM_017631	IFN-I inducible
		helicase 60
16844999	DHX58	DExH-box	NM_024119	IFN-I inducible
		helicase 58
16896442	EIF2AK2	eukaryotic	NM_002759	IFN-I inducible
		translation
		initiation factor 2
		alpha kinase 2
16778559	EPSTI1	epithelial stromal	NM_001002264	IFN-I inducible
		interaction 1
16830214	FBXO39	F-box protein 39	NM_153230	IFN-I inducible
16968765	HERC5	HECT and RLD	NM_016323	IFN-I inducible
		domain
		containing E3
		ubiquitin protein
		ligase 5
16968735	HERC6	HECT and RLD	NM_017912	IFN-I inducible
		domain
		containing E3
		ubiquitin protein
		ligase family
		member 6
16707196	IFIT1	interferon induced	NM_001548	IFN-I inducible
		protein with
		tetratricopeptide
		repeats 1
16707180	IFIT2	interferon induced	NM_001547	IFN-I inducible
		protein with
		tetratricopeptide
		repeats 2
16707184	IFIT3	interferon induced	NM_001549	IFN-I inducible
		protein with
		tetratricopeptide
		repeats 3
16733995	IRF7	interferon	NM_001572	IFN-I inducible
		regulatory factor 7
16965313	LAP3	leucine	NM_015907	IFN-I inducible
		aminopeptidase 3
17082012	LOC100133669	LY6E divergent	NR_026913	IFN-I inducible
		transcript (LY6E-
		DT), long non-
		coding RNA
16757347	OAS3	2′-5′-	NM_006187	IFN-I inducible
		oligoadenylate
		synthetase 3
16771417	OASL	2′-5′-	NM_003733	IFN-I inducible
		oligoadenylate
		synthetase like
16895530	OTOF	otoferlin	NM_194248	IFN-I inducible
16960186	PLSCR1	phospholipid	NM_021105	IFN-I inducible
		scramblase 1
16876764	RSAD2	radical S-adenosyl	NM_080657	IFN-I inducible
		methionine
		domain
		containing 2
16949442	RTP4	receptor	NM_022147	IFN-I inducible
		transporter protein
		4
17059776	SAMD9L	sterile alpha motif	NM_152703	IFN-I inducible
		domain
		containing 9 like
16916802	SIGLEC1	sialic acid binding	NM_023068	IFN-I inducible
		Ig like lectin 1
16889218	SPATS2L	spermatogenesis	NM_015535	IFN-I inducible
		associated serine
		rich 2 like
16738536	TIMM10	translocase of	NM_012456	IFN-I inducible
		inner
		mitochondrial
		membrane 10
16926942	USP18	ubiquitin specific	NM_017414	IFN-I inducible
		peptidase 18
16920651	ZBP1	Z-DNA binding	NM_030776	IFN-I inducible
		protein 1
16672462	FCRL6	Fc receptor like 6	NM_001004310	Cytotoxic cell
16974529	FGFBP2	fibroblast growth	NM_031950	Cytotoxic cell
		factor binding
		protein 2
16882332	GNLY	granulysin	NM_001302758	Cytotoxic cell
16819539	GPR56 (ADGRG1)	adhesion G	NM_005682	Cytotoxic cell
		protein-coupled
		receptor G1
16791436	GZMH	granzyme H	NM_033423	Cytotoxic cell
16984783	GZMK	granzyme K	NM_002104	Cytotoxic cell
16657594	ISG15	ISG15 ubiquitin-	NM_005101	IFN-I inducible
		like modifier
16761350	KLRC3	killer cell lectin	NM_002261	Cytotoxic cell
		like receptor C3
16748327	KLRD1	killer cell lectin	NM_002262	Cytotoxic cell
		like receptor D1
16748095	KLRG1	killer cell lectin	NM_001329099	Cytotoxic cell
		like receptor G1
16772285	LOC387895	homo sapiens*	BC040060	Cytotoxic cell
		cDNA clone
		IMAGE: 6160413
17077826	MYBL1	MYB proto-	NM_001080416	Cytotoxic cell
		oncogene like 1
16874828	NKG7	natural killer cell	NM_005601	Cytotoxic cell
		granule protein 7
16715170	PRF1	perforin 1	NM_005041	Cytotoxic cell
17056823	TARP	TCR gamma	NM_001003799	Cytotoxic cell
		alternate reading
		frame protein
17056807	TRGC2	T cell receptor	BC039116	Cytotoxic cell
		gamma constant 2
17056853	TRGV2	T cell receptor	ENST00000426402	Cytotoxic cell
		gamma variable 2
16799289	C15orf54	chromosome 15	NR_144507	Others
		open reading
		frame 54
16668333	GSTM4	glutathione S-	NM_000850	Cytotoxic cell
		transferase mu 4
16797490	IGHV3-20	immunoglobulin	ENST00000390606	Others
		heavy variable 3-
		20
16900152	IGKV1-27	immunoglobulin	ENST00000498435	Others
		kappa variable 1-
		27
16900144	IGKV6-21	immunoglobulin	ENST00000390256	Others
		kappa variable 6-
		21 (non-
		functional)
16927801	IGLV3-21	immunoglobulin	ENST00000390308	Others
		lambda variable
		3-21
16997041	LOC647859	occludin	NR_026578	Others
		pseudogene
		(LOC647859),
		non-coding RNA
17025697	MIR3939	microRNA 3939	NR_037504	Others
16942367	RN5S134	RNA, 5S	ENST00000516492	Others
		ribosomal
		pseudogene 134
16722960	RN5S338	RNA, 5S	ENST00000410495	Others
		ribosomal
		pseudogene 338
17063828	TRBV7-3	T cell receptor	ENST00000390361	Others
		beta variable 7-3
16742150	XRRA1	X-ray radiation	NM_182969	Cytotoxic cell
		resistance
		associated 1

*Note:
The 58 genes are listed in alphabetical order for each gene cluster: the IFN-I inducible gene cluster (IFN-I inducible), the cytotoxic cell-associated transcriptional gene cluster (Cytotoxic cell), and other gene clusters (Others). For genes with multiple reference transcript variants, only the accession number for reference transcript variant 1 is included in the table.

Clustering & Enrichment Analysis

A co-expression network of the 58 genes based on Pearson correlations computed using the “cor” function of R was constructed (available online at, www.r-project.org). The network was clustered into four clusters using the Ward's algorithm implemented in “hclust” function of R (available online at, www.r-project.org). Gene ontology biological process (GOBP) and Reactome pathway enrichment analysis of the identified clusters was computed using “clusterProfiler 3.2.4” (Yu et al, 2012) package from Bioconductor (Huber et al, 2015).

Prediction Model

Due to the high correlation between the dynamic genes, different groupings of the genes were examined to determine if they could be used to predict response to UST: one that used all 58 dynamic genes (58-genes) identified during the initial analysis (Table 9); one that used a subset of the dynamic genes that included all of the genes from the IFN-I inducible gene cluster and all of the genes from the cytotoxic cell-associated transcriptional gene cluster (48-genes); one that used a subset of the dynamic genes that included the 31 genes expressed in all examined different lupus cohorts (31-genes); and one that used a smaller subset of the 31-genes (8-genes) that were identified by random forest feature selection method (random Forest 4.6-12″ package in R) (Liaw & Wiener, 2002).

The 48-gene subset of dynamic genes includes the IFN-I inducible gene cluster component comprising: BST2, CARD17, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, FBXO39, HERC5, HERC6, IFIT1, IFIT2, IFIT3, IRF7, LAP3, LOC100133669, OAS3, OASL, OTOF, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, SPATS2L, TIMM10, USP18, ZBP1, ISG15, and the cytotoxic cell-associated transcriptional component comprising: FCRL6, FGFBP2, GNLY, GPR56 (ADGRG1), GZMH, GZMK, XRAA1, GSTM4, KLRC3, KLRD1, KLRG1, LOC387895, MYBL1, NKG7, PRF1, TARP, TRGC2, TRGV2.

The 31-gene subset of dynamic genes includes the IFN-I inducible gene cluster component: BST2, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, HERC5, IFIT1, IFIT2, IFIT3, IRF7, ISG15, LAP3, OAS3, OASL, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, TIMM10, USP18 and ZBP1; and the cytotoxic cell-associated transcriptional component: FCRL6, FGFBP2, GNLY, GZMH, GZMK, NKG7 and PRF1.

The 8-gene subset of dynamic genes includes the IFN-I inducible gene cluster component: IFIT3, RSAD2 and the cytotoxic cell-associated transcriptional component: FCRL6, FGFBP2, GNLY, GZMH, NKG7, PRF1.

To avoid any overfitting, feature selection was run 1000 times. Only genes which were identified in >50% of the testing cycles were retained. Using this process, 8 genes were identified. To evaluate the predictability of response using those gene sets (58, 46, 31 and 8 genes), we assessed 1000 different generalized linear models using different sample permutations of the training set and testing sets (before any model learning, the samples were split at a 75 to 25% ratio to provide for a training and testing set). Distributions of prediction performance were reported. Finally, one model for each gene set was generated using random split of training set and testing set (75% and 25%). Machine learning, and performance evaluations were conducted using the “caret 6.0-78” package (available online at, topepo.github.io/caret/index.html).

The logistic regression model optimized the following objective function,

$\min_{β o, β} - [\frac{1}{N} \sum_{i = 1}^{N} y_{i} (β o + β^{T} x_{i}) - \log (1 + e^{(β o + β^{T} x_{i})})] + λ [\frac{(1 - α)}{2} { β }_{2}^{2} + α { β }_{1}]$

Where,

- 1. N is the number of patients used to learn the model.
- 2. The x_ia vector of the centered gene expression data (subtracted mean of lupus patients) of patient i.
- 3. The y_iis the response outcome for patient i (responder/non-responder).
- 4. The λ controls the total penalty weight.
- 5. The α controls the elastic-net penalty weight: form lasso (α=1) to ridge (α=0).
- 6. The α, λ are optimized using grid search based on best training accuracy.

Once βo, β parameters are determined, response probability is computed as,

$P (x_{new}) = \frac{1}{1 + e^{- (β o + β^{T} x_{new})}}$

and response prediction is determined as

$Response (x_{new}) = {\begin{matrix} responder, & if P (x) \geq threshlod \\ non - responder, & else \end{matrix} .$

threshold is 0.5.

Prediction Analysis

Prediction analysis using the different groups of genes showed that differential expression of the IFN-1 inducible genes and the cytotoxic cell-associated transcriptional genes could be used to predict the response to treatment with UST. The 46-gene, 31-gene and 8-gene signatures were shown to have a positive predictive value of: 0.746 95% IC [0.740,0.751], 0.726 95% IC [0.720,0.732] and 0.755 95% IC [0.749,0.761], respectively. The negative predictive values for the 46-gene, 31-gene and 8-gene signatures were: 0.67 95% IC [0.661,0.688], 0.659 95% IC [0.645,0.673] and 0.715 95% IC [0.702,0.728], respectively.

2—Gene Prediction Model

In addition, the possibility of using only two genes to predict response was also explored, e.g., one gene from the IFN-I inducible gene cluster and one gene from the cytotoxic-cell associated transcriptional gene cluster. Fifty dynamic gene pairs (one gene from each of the IFN-I inducible gene cluster and the cytotoxic cell-associated transcriptional gene cluster) were randomly selected to generate 100 prediction models for each 2-gene pair. The 2-gene models had a mean positive predictive value (PPV) of 0.735 95% IC [0.733, 0.738] and negative predictive value (NPV) of 0.678 95% IC [0.671, 0.684] and the average mean accuracy of the models was 70.71% (95% CIs [70.41, 71.01]). Thus, it was concluded that combinations of one or more genes from the IFN-I inducible gene cluster and one or more genes from the cytotoxic-cell associated transcriptional gene cluster have predictive power to predict response.

TABLE 10

Prediction testing with 2-gene combinations

	Accuracy	Sensitivity	Specificity	PPV	NPV	AUC	Source

Mean1	0.7071538	0.8352750	0.5021600	0.7359871	0.6782053	0.7007335	Testing
CI95lo1	0.7041555	0.8316300	0.4962238	0.7334166	0.6718727	0.6983119	Testing
CI95Hi1	0.7101522	0.8389200	0.5080962	0.7385575	0.6845379	0.7031551	Testing

PPV: Positive Predictive Value
NPV: Negative Predictive Value
AUC: Area Under Curve

Simplified Prediction Model

In addition to the prediction model explained above, a simplified model was also generated using scaled expression data. Scaled expression is computed by subtracting the sample mean of the gene expression level in lupus patients and dividing by the standard deviation. After this procedure, the mean expression level of each gene is set to zero and a gene is defined as having “higher expression” in a patient if its value is above 0 and “lower expression” in a patient if its value is below 0. That concept was extended to the entire cluster by calculating the mean of all the genes in the cytotoxic cell-associated transcriptional gene cluster, and the mean of all the genes in the Interferon I (IFN-I) inducible gene cluster. A cluster is defined as having “higher expression” (↑) if the mean is above zero and “lower expression” (↓) if the mean is below zero. This simplified model can be described as shown in Table 11 and FIG. 9.

TABLE 11

Simplified Prediction Model

Gene Clusters

Cytotoxic cell-associated		Predicted
transcriptional	IFN-I inducible	Outcome

mean genes > 0 (↑)	mean genes < 0 (↓)	Responder
mean genes > 0 (↑)	mean genes > 0 (↑)	Responder
mean genes < 0 (↓)	mean genes < 0 (↓)	Responder
mean genes < 0 (↓)	mean genes > 0 (↑)	Non-Responder

As used herein, the terms “predict,” “prediction,” “predicting,” or “predicted” refer to the likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs, e.g., have a positive response (responder) or be a non-responder, e.g., a positive response is a significant improvement in disease activity as determined by a decrease from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥4 (SRI-4 response) at 24 weeks of treatment with the anti-IL-12/IL-23p40 antibody (ustekinumab, UST). The predictive methods of the present invention can be used clinically to make treatment decisions by selecting patients for treatment and/or by choosing the most appropriate treatment modalities for any particular patient, e.g., treatment comprising administering an anti-IL-12/IL-23p40 antibody and/or treatment comprising administering an anti-IL-12/IL-23p40 antibody and an IFN-I inhibitor.

As used herein, a “positive response” to treatment with UST relates to a significant improvement in disease activity as determined by a decrease from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥4 (SRI-4 response) at 24 weeks of treatment. Other indications of a positive response to treatment with UST include, e.g., a statistically significant reduction in the risk of a new British Isles Lupus Assessment Group (BILAG) flare, defined as ≥1 new BILAG A domain score or ≥2 new BILAG B domain score, by week 24 of treatment with the antibody; a statistically significant increase in the proportion of patients with a 50% improvement from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score; and a statistically significant improvement in disease activity as determined by a 50% improvement from baseline joint disease activity by week 24 of treatment.

Examination of Additional Lupus Cohorts for the Presence of UST Response Signature

To determine if the UST response signature is also present in other SLE cohorts, cluster analysis was performed in three different lupus cohorts each enriched for a different racial and ethnic background. Cluster analysis was performed in R using the gene predictive signature from UST data.

Gene Set Variation Analysis

An interferon and cytotoxic signature enrichment scores (ES) were computed for each patient using Gene Set Variation Analysis (GSVA) (Hänzelmann et al, 2013) to be able to track the variation of these signatures over weeks of treatment. Kolmogorov-Smirnov statistics was applied to test if the distribution of gene ranks of the tested gene set (ranking by p-values of association with the phenotype) differed from a uniform distribution (Hänzelmann et al, 2013; Subramanian et al, 2005).

Cross Over Analysis

Expression analysis was extended to placebo patients who crossed over to SC ustekinumab (UST) at week 24. For this population of patients, the positive predictive value (PPV) for the 31-gene signature was 0.645 95% CI [0.645,0.650] and the PPV for the 8-gene signature was 0.649 [0.647, 0.651] for the response to treatment with UST at 48 weeks. The negative predictive values (NPV) were determined to be 0.607 95% CI [0.599,0.615] for the 31-gene signature and 0.626 [0.619, 0.633] for the 8-gene signature.

UST Response Prediction Models Using qPCR, Serum Protein, and Flow Cytometry

An independent analysis of baseline whole blood gene expression was performed using a 103 leukocyte-lineage qPCR array card. From this analysis, 13 genes were identified with significant (P<0.05) baseline expression level differences between responders and non-responders (SRI-4 at 24 weeks) in the UST treatment group (Table 12).

The goal for prediction of response was to identify prediction models for Wk24 SRI-4 response, with: PPV >prevalence of response for UST treatment group; PPV <prevalence of response for placebo treatment group; and at least moderately high sensitivity for UST treatment group. Prediction modeling was performed using logistic regression modeling (GLMnet package) with LOOCV (CARET package) for selection of model coefficients, selecting probability cut-points to fulfil the criteria below (Candia and Tsang, 2019).

TABLE 12

Week 24 SRI4-response associated genes from OpenArray qPCR

Group(s)

		SLE: UST,	SLE: Placebo,
	SLE, Healthy	baseline	baseline

Comparison

	Week 0 SLE	SRI4 (TF) Wk24:	SRI4 (TF) Wk24:
	vs. Healthy	Y vs. N	Y vs. N

Gene*	Fold	P-Value	Fold	P-Value	Fold	P-Value

BCL6	−1.37	0.0068	−1.29	0.0122	−1.53	0.1405
CXCR3	−1.30	0.094	1.42	0.0449	−1.69	0.1035
GZMA	−1.48	0.0093	1.55	0.0253	−1.14	0.63
HLX	−1.13	0.2797	−1.34	0.0176	−1.63	0.0681
IFIT3	6.79	<10⁻⁴	−1.95	0.03	−2.11	0.0262
IFITM3	4.04	<10⁻⁴	−1.90	0.0106	−2.00	0.0295
KLRD1	−1.09	0.6184	1.70	0.0151	−1.56	0.148
MX2	1.96	<10⁻⁴	−1.39	0.0357	−2.00	0.0035
PLSCR1	2.87	<10⁻⁴	−1.56	0.0221	−2.06	0.015
SPATS2L	5.84	<10⁻⁴	−2.09	0.0252	−2.37	0.0069
TLR5	1.41	0.0029	−1.32	0.0067	−1.75	0.0525
TNFSF10	1.58	0.0002	−1.39	0.0288	−1.73	0.0557
USP18	10.02	<10⁻⁴	−2.19	0.0483	−2.74	0.0112

*Genes with p < 0.05 for SRI4 (TF) Wk24: Y vs. N for ustekinumab treatment group.

From these 13 genes, three cytotoxic cell-associated genes (CXCR3, GZMA, KLRD1) were further analyzed due to the greater expression differential between responders versus non-responders in the UST treatment group in comparison to the placebo group indicating that they may exhibit UST response predictive capacity. Correlations between expression levels of CXCR3, GZMA, and KLRD1 ranged from 0.60-0.76 (Pearson's correlation coefficient, R). Since expression of (KLRD1, CXCR3 and GZMA) were well correlated, baseline expression of the cytotoxic cell-associated transcript (KLRD1) was selected for additional modeling strategies to test suitability for prediction of UST response.

Multivariate Prediction Models with qPCR, Serum Protein, and Flow Cytometry

Multivariate models combining KLRD1, a measure of Natural Killer cell (NK cell)/cytotoxic phenotype, and serum IFN-alpha levels were developed, using a training set of 39 patients to build the model (selected as those that had NK cell data available from flow cytometry analyses) and a small test set of 15 subjects to independently evaluate the model performance (those that did not have NK cell data available).

The KLRD1+serum IFN-alpha model exhibited a performance of AUC-ROC=83% and PPV=81% for ustekinumab treatment in the training set. The model applied to the placebo treatment group had no predictive power (AUC-ROC=0.51, PPV=31%, compared to prevalence of 30%) (Table 13). The difference in response rates for UST vs. placebo treatment groups would improve if applying the model for patient selection (81%-31%=50%) compared to no patient selection (59%-30%=29%), with 64% of patients included in the selected population. Application in the small test set of patients had lower performance, with PPV of 67% for ustekinumab group and 40% for placebo treatment group, for a treatment effect difference of 37%.

Alternative measurements representing IFN-alpha activity and NK cell lineage markers were also evaluated to obtain a prediction model. Only subjects with baseline % NK cell data values (flow cytometry) were included in the training set for model development (UST, n=39; placebo, N=27). Compared to the original serum IFN-alpha+KLRD1 (qPCR) model (AUC=0.83 for training set), the model of serum IFN-alpha+% NK cells in whole blood (flow cytometry analysis platform, replacing KLRD1 qPCR) had only slightly numerically lower AUC=0.79 (Table 13).

An additional model was executed based solely on qPCR, using KLRD1 to represent the cytotoxic cell-associated cluster and 4 IFN-inducible transcripts (IFN-4-gene score, defined as median −ddCRT for IFI27+IFI44+IFI44L+RSAD2 genes) replacing serum IFN-alpha as predictor. This KLRD1+IFN-4-gene score model had a performance characteristic of AUC-ROC=0.83 and a favorable balance of PPV (84%) and NPV (80%) (Table 13). The model applied to the placebo group did not have predictive power (AUC-ROC=0.49), with the PPV (40%) (Table 13). The test set (n=15) model statistics, after applying the ustekinumab training model, were consistent with the ustekinumab training set model, with a similar PPV of 80% but a reduced NPV of 67% (Table 13). The placebo test set had no positive predictive power, with the PPV of 25% below the prevalence of response (Table 13). Applying the training model to the full ustekinumab dataset (n=54), the PPV was 81%, compared to a PPV of 33% for the full placebo dataset (n=35) (Table 13). Therefore, the prediction model provides for a treatment effect of 48% compared to 30% without the model, with 61% of patients testing positive for the prediction model.

TABLE 13

Multivariate models from IFN and KLRD1/NK cell predictors

Endpoint:
Wk24 SRI4	Prob.	AUC	Prev.	Pass	Spec.	Sens.	PPV	NPV

Ustekinumab

serum IFNa +	50%	83.2	59%	64%	69	87	81	79
KLRD1
(qPCR),
TRAIN
serum IFNa +	50%	64.6	57%	43%	67	50	67	50
KLRD1
(qPCR),
TEST*
serum	50%	79.3	59%	56%	50	74	78	65
IFN-alpha +
% NK, TRAIN
IFN-4-gene-	50%	83.4	59%	62%	75	87	84	80
score +
KLDR1,
TRAIN
IFN-4-gene-	50%	59.3	60%	60%	67	78	80	67
score +
KLDR1,
TEST*
IFN-4-gene-	50%	76.7	59%	61%	73	84	81	76
score +
KLDR1,
TRAIN +
TEST*

Placebo (Ustekinumab model*)

serum IFNa +	50%	50.7	30%	59%	42	63	31	73
KLRD1
(qPCR),
TRAIN
serum IFNa +	50%	66.7	25%	38%	50	100	40	100
KLRD1
(qPCR),
TEST*
serum	50%	56.6	30%	74%	21	63	26	60
IFN-alpha +
% NK, TRAIN
IFN-4-gene-	50%	49.3	30%	63%	68	50	40	78
score +
KLDR1,
TRAIN
IFN-4-gene-	50%	41.7	25%	50%	50	50	25	75
score +
KLDR1,
TEST*
IFN-4-gene-	50%	50.8	29%	60%	64	50	33	75
score +
KLDR1,
TRAIN +
TEST*

*The ustekinumab training model was applied to the test set and to the placebo group, i.e., models were not built based on test set or placebo treatment group data.

Summary for Prediction Models with qPCR, Serum Protein, and Flow Cytometry

Multiple biomarker data types were assessed for discovery of predictors of response to ustekinumab, including serum proteins, whole blood gene expression, and peripheral blood flow cytometry. Simple models, built by standard logistic regression modeling with cross-validation in a training set (n=39), with confirmation in a test set (n=15) for ustekinumab treatment group were evaluated.

A model of the cytotoxic cell-associated transcript KLRD1+4 IFN-inducible genes ((IFI27, IFI44, IFI44L, RSAD2) all from qPCR evaluation of whole blood gene expression) for the ustekinumab group had: 84% PPV/80% NPV for the training set, 80% PPV/67% NPV for the test set, and 81% PPV/76% NPV for the full dataset (training+test sets).

Serum IFN-alpha levels were highly correlated with IFN-signature gene expression (Rsp=0.83) and % NK cells by flow cytometry were modestly correlated with KLRD1 gene expression levels (Rs_p=0.36). Prediction models interchanging serum IFN-alpha with 4 IFN-inducible genes (IF127, IF144, IFI44L, RSAD2) and % NK cells with KLRD1 expression performed similarly. These observations boost confidence in results from the limited numbers of subjects when alternative methods give similar results.

Cytotoxic Cell-Associated Signature

In addition to the models shown above based on combined cytotoxic cell-associated and IFN-I inducible signatures, tests were also run for models based only on the cytotoxic cell-associated signature (7 genes) or the IFN-I inducible gene signature (24 genes) selected from the 31-gene subset of dynamic genes. The positive predictive value (PPV) was 0.710 95% IC [0.706,0.715] for the cytotoxic cell-associated signature and the PPV was 0.662 95% IC [0.658,0.667] for the IFN-I inducible gene signature. The negative predictive values (NPV) were 0.591 95% IC [0.575,0.607] for the cytotoxic cell-associated signature and 0.488 95% IC [0.470,0.505] for the IFN-I inducible gene signature.

Furthermore, as shown in FIG. 10, analysis of the baseline gene expression of a subset of genes from the cytotoxic cell-associated signature (PRF1, KLRD1, NKG7, GNLY, FGFBP2, TRGC2, TARP, TRGV2) further indicated that the distribution of healthy control and UST responder populations were largely overlapping (P=0.31), while non-responders exhibited significantly lower levels than UST responders (P=0.0087) and reduced levels compared to healthy controls (P=0.056). Age-matched and sex-matched healthy control donor samples were procured from BioIVT [formally known as Bioreclamation], Westbury, N.Y., and Biological Specialty Corp., Colmar, Pa. Similar cytotoxic cell-associated signature levels were observed at baseline when comparing PBO-responders to non-responders and healthy controls indicating the specificity of these cytotoxic cell-associated transcripts for UST but not PBO response. The higher levels of cytotoxic cell-associated transcripts in the blood of UST responders versus non-responders can be further seen in the hierarchical clustering heat map (FIG. 11). Whereas the majority of UST responders are clustered together and associated with higher baseline expression of these transcripts, the responder distribution within the placebo population appears more randomly distributed in relation to cytotoxic cell-associated signature gene expression. Although the decrease was not statistically significant over the time tested, a trend of decreased cytotoxic cell-associated signature levels was observed only in the UST responders (FIG. 12).

Further analysis of cytotoxic cell-associated gene expression in UST responders, UST non-responders, and healthy donors showed that UST non-responders are enriched for patients with a lower GSVA ES for cytotoxic cell-associated transcripts versus UST responders (FIG. 13). The results also indicated that expression levels of cytotoxic cell-associated transcripts could be used to enrich for patient populations with UST responders by using a cutoff based on the distribution of expression of a healthy control reference cohort. For example, cytotoxic low could be defined as a patient with a cytotoxic signature score 0.4 below the median of the healthy reference cohort as indicated by the vertical line shown in FIG. 13.

Cytotoxic Cell-Associated Signature and IL-12

To examine the potential relationship between the cytotoxic cell-associated signature genes and targets of UST (IL-12 and IL-23), in vitro whole blood stimulation studies were performed. Under the conditions tested, the addition of recombinant IL-12 resulted in a significant increase in the expression level of the indicated cytotoxic cell-associated genes across the 6 healthy donor blood samples tested whereas IL-23 stimulation did not induce significant changes in these genes under the conditions tested (FIG. 14). Based on these results of the in vitro whole blood stimulation studies and the analysis of the baseline expression levels of the cytotoxic cell-associated signature in UST responders and non-responders, the role of IL-12 blockade is clearly implicated as a factor in UST efficacy. Furthermore, IL-12 is also known to be an important driver of IFN-γ, which was also shown to be implicated in UST response (FIG. 5), further supporting an important role of IL-12 blockade in the mechanism of action of UST in SLE.

Discussion:

Multiple trials targeting other therapeutic mechanisms distinct from IFN-I and B-cell modulation have failed to meet clinical efficacy and/or safety profiles to merit further development or approval in lupus. In the UST phase 2 lupus trial, no pharmacodynamic treatment effect was observed with IFN-alpha levels (FIG. 3A). Further, no modulation was seen at the level of the type I interferon transcriptional signature (FIG. 3B). Despite a perceptible reduction in anti-dsDNA levels little impact was observed on plasma blast or plasma cell transcriptional gene signatures in the blood indicating that UST efficacy was unlikely due to direct modulation of the B-cell compartment (FIG. 4). Down modulation of type II interferon (IFN-gamma) was observed in UST-treated subjects particularly in the SRI-4 responder group (FIG. 5). Despite the observed reduction of IFN-gamma in the UST lupus trial, direct blockade of IFN-gamma was shown to have minimal clinical efficacy in lupus despite demonstration of target engagement (Boedigheimer et al, 2017; Werth et al, 2017). This data suggests that UST modulates disease through a novel mechanism of action largely differentiated from other therapies either in clinical development or approved for the treatment of lupus.

An unbiased analysis of whole blood microarray data from the UST phase 2 trial was performed to identify transcriptional signatures that could potentially discriminate response from non-response as defined by a significant difference in the primary endpoint of SRI-4 at 24 weeks of treatment with UST. This approach led to the identification of gene expression patterns within two gene clusters that can largely distinguish UST responders from non-responders and thus select patients that are predicted to have an increased likelihood of having a positive response to the treatment. The first gene cluster comprised a collection of IFN-I-inducible transcripts and the second gene cluster was composed of transcripts associated with cytotoxic cells (e.g., NK, CD8 T cells) (FIG. 6). Independent analysis of responders versus non-responders utilizing identical methods with the placebo group resulted in no overlap with the individual genes comprising these two clusters. Thus, implying that the gene clusters that discriminated UST response from non-response was specific for this therapeutic agent and not related to general improvement in disease activity using the SRI-4 instrument. The expression levels of the individual genes comprising the IFN-I inducible gene cluster and the cytotoxic cell-associated transcriptional gene cluster are shown in FIG. 6 and collectively map to the IFN-I pathway and pathways associated with cytotoxic cells, respectively. Longitudinal analysis of gene expression for both the identified IFN-I inducible gene cluster and the cytotoxic cell-associated transcriptional gene cluster revealed a novel pharmacodynamic effect in UST responders. Transcripts within the cytotoxic cell-associated transcriptional gene cluster exhibited temporal down-modulation (lower expression levels) only in UST-treated responders (FIG. 7). No transcriptional changes occurred with transcripts comprising the IFN-I inducible gene cluster as also corroborated by analysis using a previously described IFN-I signature (Yao et al, 2009) (FIG. 3). This result is also supported by a lack of modulation of IFN-alpha protein levels (FIG. 3). UST responders in general exhibit a higher baseline level of the expression levels of the cytotoxic cell-associated transcriptional gene signature versus non-responders and exhibit a decrease of this signature over time after drug treatment. Thus, it can be speculated that higher baseline levels of the cytotoxic cell-associated transcriptional gene signature could reflect a disease mechanism largely nurtured by p40 signaling (IL-12 and/or IL-23) which is supported by the observation that blockade of p40 reduces the cytotoxic signature sequestering factors that may drive its perpetuation. Importantly, patients can respond to UST irrespective of IFN-I inducible gene signature status if the cytotoxic cell-associated transcriptional gene signature is sufficiently expressed at baseline (FIG. 6). This observation supports that UST represents a unique mechanism of action that does not modulate IFN-I and which can improve lupus disease outcomes in patients also having evidence of IFN-I dysregulation. Thus, p40 neutralization may be sufficient to improve disease even while IFN-I mediated pathogenic effects are still present. One characteristic of UST non-responders from this data is the presence of elevated IFN-I inducible gene signature (higher expression levels) and lower cytotoxic cell-associated transcriptional gene signature (lower expression levels) in the blood at baseline. In this said population, an IFN-I modulator may offer enhanced clinical benefit. Furthermore, therapy comprising administering UST and an IFN-I inhibitor may even more broadly impact this SLE patient population by targeting patients having a p40-mediated disease and a more IFN-I modulated disease profile. Examples of IFN-I inhibitors include anti-IFN alpha antibodies, anti IFN-I receptor antibodies and other agents that inhibit the IFN-I pathway. Examples of anti-IFN alpha antibodies include, e.g., sifalimumab and JNJ-55920839 (CNTO 6358). Anti IFN-I receptor antibodies include, e.g., anifrolumab. Other agents that inhibit the IFN-I pathway include, e.g., agents that inhibit Toll-Like Receptors (TLRs) 7, 8, and 9, agents that deplete or inhibit plasmacytoid dendritic cell function, and agents that inhibit Janus Kinase 1 (JAK1).

Further refinement of the signature comprising transcripts from the IFN-I inducible gene cluster and the cytotoxic cell-associated transcriptional gene cluster was undertaken using machine learning approaches to define an optimal whole blood signature to predict UST response prior to treatment. To that end, an 8-gene signature was identified which still comprised transcripts from both the IFN-I inducible gene cluster and cytotoxic cell-associated transcriptional gene cluster. This signature exhibited a positive predictive value of 0.78, and a negative predictive value of 0.75. Lupus exhibits a female to male gender bias ratio of 9:1 and can manifest differently based on racial and ethnic background adding to the complexity of developing predictive biomarkers (Manzi & Merrill, 2017). Further examination of this 8-gene signature confirmed its presence in multiple racially and ethnically diverse SLE cohorts indicating that it is universally expressed irrespective of genetic background (FIG. 8).

It was also determined that models based on only the cytotoxic cell-associated signature (7 genes from the 31-gene subset) or only the IFN-I inducible gene signature (24 genes from the 31-gene subset) could be used to predict the likelihood of having a positive response to UST. The positive predictive value (PPV) was 0.710 95% IC [0.706,0.715] for the cytotoxic cell-associated signature and the PPV was 0.662 95% IC [0.658,0.667] for the IFN-I inducible gene signature. The negative predictive values (NPV) were 0.591 95% IC [0.575,0.607] for the cytotoxic cell-associated signature and 0.488 95% IC [0.470,0.505] for the IFN-I inducible gene signature.

In addition, it was determined that baseline blood expression levels of cytotoxic cell-associated genes where similar between healthy controls and UST responders, but UST non-responders exhibited significantly lower expression levels than UST responders and reduced levels compared to healthy controls. Furthermore, results indicated that expression levels of cytotoxic cell-associated transcripts could be used to enrich for patient populations with UST responders by using a cutoff based on the distribution of expression of a healthy control reference cohort. For example, cytotoxic low could be defined as a patient with a cytotoxic signature score below the median of the healthy controls.

Multiple additional biomarker data types were also assessed with standard logistic regression modeling to determine if they could also be used as predictors of response to ustekinumab. The additional biomarker data types included serum proteins, whole blood gene expression, and peripheral blood flow cytometry. These additional biomarker data types and standard logistic regression models confirmed the relationships identified with sophisticated and extensive analysis of the microarray data.

Conclusion:

As described herein, 58-genes were identified that are differentially expressed in patients with active Systemic Lupus Erythematosus (SLE). The differentially expressed genes are referred to herein as dynamic genes. It was determined that subsets of the dynamic genes including one or more cytotoxic cell-associated transcriptional genes and one or more IFN-I inducible genes can be used to predict the likelihood of having a positive response to treatment with the anti-IL-12/IL-23p40 antibody ustekinumab (UST). A 46-gene signature, a 31-gene signature, and an 8-gene signature were shown to have a positive predictive value of: 0.746 95% IC [0.740,0.751], 0.726 95% IC [0.720,0.732] and 0.755 95% IC [0.749,0.761], respectively. The negative predictive values for the 46-gene, 31-gene and 8-gene signatures were: 0.67 95% IC [0.661,0.688], 0.659 95% IC [0.645,0.673] and 0.715 95% IC [0.702,0.728], respectively. In addition, randomly selected 2-gene prediction models including one cytotoxic cell-associated transcriptional gene and one IFN-I inducible gene were shown to have a mean positive predictive value (PPV) of 0.735 95% IC [0.733, 0.738] and negative predictive value of 0.678 95% IC [0.671, 0. 684]. The average mean accuracy of the 2-gene models was 70.71% (95% CIs [70.41, 71.01]).

Thus, it was concluded that expression levels of one or more genes from the IFN-I inducible gene cluster and one or more genes from the cytotoxic-cell associated transcriptional gene cluster can predict the likelihood of having a positive response to treatment with the anti-IL-12/IL-23p40 antibody ustekinumab (UST). It was also concluded that expression levels of one or more cytotoxic cell-associated transcriptional genes and expression levels of one or more IFN-I inducible genes could be used as a method to pre-screen biological samples (e.g., blood samples) from patients with active SLE to select patients predicted to have an increased likelihood of a positive response to treatment with UST (Table 11 and FIG. 9). Furthermore, it was determined that just a cytotoxic-cell associated signature could also be used to predict the likelihood of having a positive response to treatment with UST. It was also determined that expression levels of the cytotoxic cell-associated transcripts could be used to enrich for patient populations with UST responders by comparison to the expression in healthy controls. The data contained herein further suggests using the expression levels to select patients with active SLE predicted to have an increased likelihood of a positive response to treatment comprising UST and an IFN-I inhibitor.

APPENDIX 1

EFFICACY EVALUATIONS AND ENDPOINTS

		Composed of Other
Efficacy Evaluations	Description	Assessments

BILAG	British Isles Lupus	Measure of alterations to therapy consisting of 97 questions
	Assessment Group	in 9 organ systems, each put into 1 of 5 categories
		(A, B, C, D, E) depending on presence of items. Higher scores
		indicate more disease involvement.
BICLA	BILAG-based Combined	Composite requiring subjects to meet response criteria	BILAG
	Lupus Assessment	across the BILAG, PGA and SLEDAI-2K index.	PGA
			SLEDAI-2K
CLASI	Cutaneous Lupus	Assesses the disease activity and damage caused to the skin
	Erythematosus Disease	for CLE patients. Scored 0-70 for activity and 0-56 for
	Area and Severity Index	damage with higher scores indicating extremely active
		Lupus.
Flares	SLEDAI flare	SLEDAI flare: At least a 4+ point increase in SLEDAI-2K	BILAG
	Severe SLEDAI flare	score (includes severe flares). Severe SLEDAI flare: At	SLEDAI-2K
	BILAG flare	least a 7+ point increase in SLEDAI-2K score. BILAG
		flare: At least 1 new BILAG A or 2 new BILAG B scores
		(from scores < B)
FSS	Fatigue Severity Scale	A 9-item questionnaire designed to assess the severity of
		fatigue and its impact on daily living. Each item scored
		from 1-7 with higher score indicating more severe impact.
		Scored 9-63.
Pain VAS	Patients Numeric Rating	Measures the patient's assessment of pain on a visual
	Scale of Pain	analogue scale (VAS; 0 to 10 cm). The anchors of the
		instrument include 0 to represent ‘no pain’ and 10 to
		represent ‘the worst pain.’
PGA	Physician's Global	Measures the PGA on a VAS scale. Each scored from 0-10
	Assessment of Disease	with higher scores indicating worse activity.
	Activity
PtGA	Patient's Global Assessment	Measures the PtGA on a VAS scale. Each scored from 0-10
	of Disease Activity	with higher scores indicating worse activity.
SF-36	RAND Short-Form-36	Measures 36 items within 8 health domains. Scored 0-100
	Health Survey	for each health concept with higher scores indicating an
		improved health state. In addition, health concepts can be
		combined into either a physical or mental component, also
		scored 0-100.
SLEDAI-2K	Systemic Lupus	Measures 24 features in 9 organ domains over the previous
(Baseline)	Erythematosus Disease	30 days. Scored 0-105 with higher scores indicating more
	Activity Index 2000	disease activity.
S2K RI-50	SLEDAI-2K Responder	Measures clinically important 50% reduction in SLEDAI-	SLEDAI-2K
(Follow-up)	Index 50	2K score.
SRI-4	SLE Responder Index-4	Composite endpoint requiring at least a 4 point reduction in	SLEDAI-2K
		SLEDAI 2K, no worsening (<10 mm increase) from	PGA
		baseline in PGA and no new BILAG Domain A and no	BILAG
		more than 1 new BILAG Domain B scores (see Section
		9.2.2.1.).
SRI-5 and SRI-6	SLEDAI 2-K SLE	Same criteria as SRI-4 however the SRI-5 and SRI-6	SLEDAI-2K
	Responder Index-5 and	require at least a 5 point or 6 point reduction in SLEDAI-2K	PGA
	SLEDAI 2-K SLE	respectively.	BILAG
	Responder Index-6

APPENDIX 2

PROBE SEQUENCES

				SEQ
Probe	Probe	Gene		ID
Set ID	ID	Symbol	Probe Sequence	NO

16657594	134419	ISG15	TAAGCCTGAGGCACACACGTCAGGG	12

16657594	250152	ISG15	GCAGCACCGGCCCTATTATAAGCCT	13

16657594	819200	ISG15	AGATGAGTTCGCTGCCTCTCAGCCG	14

16657594	1043700	ISG15	TACTGGCAAAGATGAGTTCGCTGCC	15

16657594	145244	ISG15	TCCTGTACTGGCAAAGATGAGTTCG	16

16657594	295654	ISG15	TGTGGGCCACGGCACAAGCTCCTGT	17

16657594	1272230	ISG15	ACACCTGGAATTCGTTGCCCGCCAG	18

16657594	1394070	ISG15	TGACACCGACATGGAGCTGCTCAGG	19

16657594	306590	ISG15	GCGTGCACGCCGATCTTCTGGGTGA	20

16657594	316346	ISG15	TCAGAGGTTCGTCGCATTTGTCCAC	21

16657594	571659	ISG15	TGCGGCCCTTGTTATTCCTCACCAG	22

16657594	487471	ISG15	TGCGTCAGCCGTACCTCGTAGGTGC	23

16657594	37116	ISG15	CCCTCGAAGGTCAGCCAGAACAGGT	24

16657594	456718	ISG15	GCAGGCGCAGATTCATGAACACGGT	25

16657594	649732	ISG15	TCCGGCCCTTGATCCTGCTCGGATG	26

16657594	162045	ISG15	TTCCGGCCCTTGATCCTGCTCGGAT	27

16657594	250261	ISG15	TTTCCGGCCCTTGATCCTGCTCGGA	28

16657594	250713	ISG15	ATTTCCGGCCCTTGATCCTGCTCGG	29

16657594	116618	ISG15	TATTTCCGGCCCTTGATCCTGCTCG	30

16657594	286930	ISG15	TTATTTCCGGCCCTTGATCCTGCTC	31

16657594	379499	ISG15	CAGCCTTTATTTCCGGCCCTTGATC	32

16657594	1286489	ISG15	ACAGCCTTTATTTCCGGCCCTTGAT	33

16668333	447613	GSTM4	TCCGAGTGTTCAGGGAGCAAGGTCC	34

16668333	1182660	GSTM4	AAGGTCGTCACTTCCAACCAACAGG	35

16668333	1321536	GSTM4	TCTGGCCAGCTGATTGGAGACGTCC	36

16668333	1281870	GSTM4	TAGATGGGAATACAAGCCTGGCTTC	37

16668333	219883	GSTM4	GAAAGTTCCTCCTAGTGCAGTGGCA	38

16668333	450093	GSTM4	GAACTGGCTTCAGCTGGACATACCA	39

16668333	1049169	GSTM4	GCTGCATCATTGTAGGAAGTTCCTC	40

16668333	1251332	GSTM4	TGTTGGACCAGCAAAAGAAACGCCA	41

16668333	691418	GSTM4	TATGAAGATTCTACCCGGTGCTGGG	42

16668333	929065	GSTM4	CCCTTGTGTACAGAGGTTTTGGGAG	43

16668333	159093	GSTM4	CAGACAGCCACCCTTGTGTACAGAG	44

16668333	702481	GSTM4	GGTGGATGCCTCCTTCATTGCTGAA	45

16672462	900249	FCRL6	TTGTCTTCAACTTCGTTCAGCTGCA	46

16672462	467434	FCRL6	TCCTCTATCGTTCTCTTTCCAACAG	47

16672462	526066	FCRL6	GCAGCACAGCCGTCCAGAGCAGCAT	48

16672462	1186882	FCRL6	GAATATACATCACCTGCCCAGAGCA	49

16672462	1350826	FCRL6	GACCCCGATGGGAGGCAGTTTCATC	50

16672462	1211745	FCRL6	AGGGTCACCAGGCTACCCTCTCGGG	51

16672462	1199823	FCRL6	CCCTGTCCTGCAAGGTGTGGCCGTC	52

16672462	209810	FCRL6	GAGTAGTTCCCAGCATCCTGTTCTG	53

16672462	51693	FCRL6	TTGCTGGCGGGAGTGAACAAGACTT	54

16672462	882763	FCRL6	GGATCTCACATAAACCAGAAGTGCA	55

16672462	608001	FCRL6	TTGGCATATAGTGGGCACTGCTCTC	56

16672462	1058098	FCRL6	CGTTGGCATATAGTGGGCACTGCTC	57

16672462	910206	FCRL6	GAGTAGACAACACCTTCATCTTTCC	58

16672462	1347482	FCRL6	GAGGTTCTATGCACCACAGAGTAGA	59

16672462	1162501	FCRL6	TTCTCCCCACGGTGAACTCAGCAGA	60

16672462	185716	FCRL6	TTTCTCCCCACGGTGAACTCAGCAG	61

16672462	331310	FCRL6	TCTCACCTCCGCACAGATGATAGAA	62

16672462	700176	FCRL6	GGCATCTCACCTCCGCACAGATGAT	63

16672462	1342090	FCRL6	TATTTGTATATGACTAGCGGCGCTG	64

16707180	644377	IFIT2	TGTTTCCCTTCAGCTGACGTTACAA	65

16707180	1030125	IFIT2	TATATATACAAGTGGCCTCTGGTTC	66

16707180	1296645	IFIT2	GACCTATATATACAAGTGGCCTCTG	67

16707180	669883	IFIT2	GAAGAGACCTATATATACAAGTGGC	68

16707180	808811	IFIT2	GCAATTCTCAGCTGTTCGGCAGGGC	69

16707180	810497	IFIT2	TGCAATTCTCAGCTGTTCGGCAGGG	70

16707180	1200774	IFIT2	GGTTGCAGTGCAATTCTCAGCTGTT	71

16707180	122618	IFIT2	CTTTAGATAGGCCAGTAGGTTGCAC	72

16707180	372297	IFIT2	TGGAAGACTTTTGCCCTATAGCAGC	73

16707180	279980	IFIT2	TGAAAGTTGCCATACCGCAGATGGA	74

16707180	952810	IFIT2	TCCTGAAGGAATGCCAAGACATGCA	75

16707180	597370	IFIT2	CCAACTTGGTGGAGGAATTTCAGCT	76

16707180	191195	IFIT2	TCTCAAGACCCAGCAATTCAGGTGT	77

16707180	1343317	IFIT2	TAACCTCTATGGGATGCAAAATGAC	78

16707180	991341	IFIT2	CCTATTTAGACTTTGGTCCGCCAGC	79

16707180	234560	IFIT2	AACATTTTCCAACCCAGAGTGTGGC	80

16707180	495557	IFIT2	GATTATGATAGTAGACCAGTCGAGG	81

16707180	105924	IFIT2	GAAGCCCTGGACTCTTAAAGCTGAG	82

16707180	1047526	IFIT2	TGTTCACGTAGGTCAATGGTAGCAG	83

16707184	363523	IFIT3	GCATCAGCTGATGTTTTCTCCGTTT	84

16707184	714300	IFIT3	TCCTGTCTGCCTCAAGTAAATACTG	85

16707184	303532	IFIT3	TCTGCTGTTCCGAAAAGCTGGTGAC	86

16707184	814868	IFIT3	CCCAGGGTGCTGTTAGGTCTGTGCT	87

16707184	363933	IFIT3	TGAAGAGGTTTCCACCCAGGGTGCT	88

16707184	812070	IFIT3	CCAAGCAAATGCTGAAGAGGTTTCC	89

16707184	1078280	IFIT3	GTTTTTAGCTTACTGATTCCAAGCA	90

16707184	448153	IFIT3	AAATGGCATTTCAGCTGTGGAAGGA	91

16707184	651215	IFIT3	TCTAGATCCCTTGAGACACTGTCTT	92

16707184	502597	IFIT3	CCATCTAGGTGTTTTATGTAGGCCA	93

16707184	1030764	IFIT3	cCTCACAGTCAAGTTCAGAATACTC	94

16707184	1173314	IFIT3	ATTTCTTCCACACTTCAGTTGTGTC	95

16707184	616072	IFIT3	CCCAATCTGGTGATAGAGGTAGCCA	96

16707184	799743	IFIT3	GAAAATACTGCCTATGCCTGAAGGG	97

16707184	568911	IFIT3	CAGTGATTAGTTGTAAGACCTTCGG	98

16707184	1255614	IFIT3	GAACTAATCAGCATCATGTGGGCCT	99

16707184	505251	IFIT3	CAAATTTTGTTGTTAGGCAGTCACC	100

16707184	1072347	IFIT3	TACATGCCTGAAGCTATAAGTGAGA	101

16707196	502640	IFIT1	CCAAGACAGTGTTATATAAGGGAGC	102

16707196	1291276	IFIT1	GAGATCTGGCTATTCTGTCTTGTGG	103

16707196	410346	IFIT1	TGCTGTAAATTAGGCAGCCGTTCTG	104

16707196	28659	IFIT1	CAACATAAGAGGGTTAAGGCTTCAA	105

16707196	715817	IFIT1	GCCTTTCCTCAGTGGCACAGAGAGA	106

16707196	1058988	IFIT1	GAAGTCCTAGATGAAGGTGACAACC	107

16707196	181106	IFIT1	TATCCTTGACCTGATGATCATCACC	108

16707196	111824	IFIT1	TCGTCATCAATGGATAACTCCCATG	109

16707196	249058	IFIT1	TAAAGCCATCCAGGCGATAGGCAGA	110

16707196	1067392	IFIT1	TGGATTTAAGCGGACAGCCTGCCTT	111

16707196	308116	IFIT1	TTTGTAGACGAACCCAAGGAGGCTC	112

16707196	839469	IFIT1	GAAATGTGAAAGTGGCTGATATCTG	113

16707196	1205612	IFIT1	TACTACATAGCACTCATACAAATGA	114

16715170	1234870	PRF1	CAAAGAAGACAGAGCAGCTGGAGCT	115

16715170	1166385	PRF1	GCTTTGCCACACCATAGAGGGCTCA	116

16715170	1080236	PRF1	TGTGATCTGTGTAGCTGTGACTGCA	117

16715170	512217	PRF1	GATTAGCGTGTAAACCCAGCCACCT	118

16715170	308559	PRF1	TGGGAATACGAAGACAGCCCTGGCT	119

16715170	772253	PRF1	TCCAAGCATACTGGTCCTTTCCAAG	120

16715170	1274545	PRF1	CATGATAGCGGAATTTTAGGTGGCC	121

16715170	199396	PRF1	TCATGGGAACCAGACTTGGGAGCCT	122

16715170	212026	PRF1	TGTTATTGTCCCACACGGTGCTCGT	123

16715170	1189366	PRF1	GAAGAGCTTCACATAGGCATCCGTG	124

16715170	605202	PRF1	TAATGGAGGTGTGATGGCCGCCAAC	125

16715170	306915	PRF1	CAGTGAGGGCCGATATGCGGCCACC	126

16715170	306536	PRF1	GTGAGGGCCGATATGCGGCCACCCA	127

16715170	912016	PRF1	TGAGGGCCGATATGCGGCCACCCAG	128

16715170	157011	PRF1	CAGCTCCACAGCCCGGATGAAGTGG	129

16715170	474921	PRF1	GTGCCGTAGTTGGAGATAAGCCTGA	130

16715170	570022	PRF1	GAACCTTTGTGTGTCCACTGGGAAG	131

16715170	310778	PRF1	CATGCACCAGGCACGAACTTGTGGC	132

16715170	290028	PRF1	CTGGAATCCCGTATAGAGAAGCGGC	133

16715170	289880	PRF1	TGGAATCCCGTATAGAGAAGCGGCT	134

16715170	490338	PRF1	GAATCCCGTATAGAGAAGCGGCTAC	135

16715170	933640	PRF1	GAAGCGGCTACACAGATGGATATCC	136

16715170	1084814	PRF1	TCTTCACCGAGGCTCCTGGAATGGT	137

16722960	774657	RN5S338	TCAGACGAGACTGGGCATGTTCAGG	138

16722960	774788	RN5S338	ATCAGACGAGACTGGGCATGTTCAG	139

16722960	994502	RN5S338	GATCAGACGAGACTGGGCATGTTCA	140

16722960	995195	RN5S338	AGATCAGACGAGACTGGGCATGTTC	141

16722960	1102153	RN5S338	GAGATCAGACGAGACTGGGCATGTT	142

16722960	1101964	RN5S338	CGAGATCAGACGAGACTGGGCATGT	143

16733995	409092	IRF7	CTTTTTATTAGACTGGGCGGCCGCG	144

16733995	429973	IRF7	TTCTGGAGTTCTCATTAGACTGGGT	145

16733995	946056	IRF7	TCCATAAGGAAGCACTCGATGTCGT	146

16733995	509264	IRF7	TCATAGAGGCTGTTGGCGCTGGACA	147

16733995	191856	IRF7	ccCGAAGCCCAGGTAGATGGTATAG	148

16733995	43097	IRF7	GAAGCCCAGGTAGATGGTATAGCGT	149

16733995	212818	IRF7	TGTCACAGTTCCGAGGCAGCAGGCA	150

16733995	298384	IRF7	TATAGGAACGTGCAGCTCGGGTGTC	151

16733995	1223216	IRF7	GAGGGTGACAGGTACGGCTCTGCCT	152

16733995	296159	IRF7	TGACAGGTACGGCTCTGCCTGGTGC	153

16733995	1017053	IRF7	CTGCATCCGGAAGGGAATCCTGTGC	154

16733995	24829	IRF7	CATCCGGAAGGGAATCCTGTGCTGG	155

16733995	607584	IRF7	CTTCTAAAGTGTCCGTCCAGGTGCA	156

16733995	1265145	IRF7	TGACGCTGTCAGCAGATGGTCTGCC	157

16733995	625497	IRF7	AGTCCAGCATGTGTGTGTGCCAGGA	158

16733995	611948	IRF7	AAGTCAGGGTGAACGTAAGCAGCTC	159

16733995	970667	IRF7	AGTCAGGGTGAACGTAAGCAGCTCC	160

16733995	489112	IRF7	CGGCTGAGCGCGTACACCTTGTGCG	161

16733995	1166142	IRF7	TGAGCGCGTACACCTTGTGCGGGTC	162

16733995	943014	IRF7	CAGTGCGCAGCGGAAGTTGGTTTTC	163

16733995	360488	IRF7	AAGTTGGTTTTCCAGCCGGCGCGCT	164

16733995	299683	IRF7	GACAGAACACGTGTGCCGGGCCCGC	165

16733995	344611	IRF7	TCCTTGCGCGCGAAGTGCTTCCAGG	166

16733995	20562	IRF7	TAGGTGGCGGTCAGGTGTTATAACA	167

16733995	736819	IRF7	GACTGAGGGCTTGTAGCCACCGACG	168

16733995	1220439	IRF7	TGTTGAACCAGTGTCCAGGCCTGGC	169

16733995	832274	IRF7	GAAAGCGAAACCTAAACAGTGGCGC	170

16733995	869962	IRF7	GAAACCTAAACAGTGGCGCTTCGCA	171

16738536	709536	TIMM10	AGCGCTACCACTCCGGGATCTTGAA	172

16738536	1117260	TIMM10	TCTCTACAGAGAGCCTAGGCCTGGC	173

16738536	1130572	TIMM10	GATGACACCCAACAGGGAGCACGTT	174

16738536	18050	TIMM10	CACCCCAGGGTGTATACTGACAGGG	175

16738536	587840	TIMM10	AACTTTTTGCCCATCCGCTCATGGA	176

16738536	1062427	TIMM10	GGTACTTAGAGACACATCGGTCCAG	177

16738536	133813	TIMM10	TAGTGAGGAGGCACACACTTCCGGT	178

16738536	1309190	TIMM10	CTGTTGTACATATCGGCCATCATCT	179

16738536	1307702	TIMM10	TGTTGTACATATCGGCCATCATCTC	180

16738536	250889	TIMM10	AGCTGTTGGGCCCTGAGAGGATCCA	181

16738536	250483	TIMM10	GCTGTTGGGCCCTGAGAGGATCCAT	182

16738536	174896	TIMM10	CTCAGCCTAGCACCGTGGAAGGGAT	183

16738536	598942	TIMM10	CCTAGCACCGTGGAAGGGATCTCCT	184

16738536	100662	TIMM10	CTAGCACCGTGGAAGGGATCTCCTT	185

16738536	225436	TIMM10	AAGGGATCTCCTTCTGGCCTCCTAA	186

16738536	1382104	TIMM10	CTGGGAGCAGACATCACCATCAGCA	187

16738536	1381156	TIMM10	TGGGAGCAGACATCACCATCAGCAC	188

16738536	983930	TIMM10	CACTGCCTGGGACGGATCACAATGC	189

16738536	296005	TIMM10	CTGCCTGGGACGGATCACAATGCCC	190

16738536	1141349	TIMM10	CAACTTCTGACAAATACTATAACGT	191

16738536	671461	TIMM10	TGACAAATACTATAACGTTACCCGC	192

16738536	946583	TIMM10	GCTCCAGCGGAAGCACGTGGGTTAC	193

16738536	1074148	TIMM10	TCCAGCGGAAGCACGTGGGTTACTT	194

16738536	1167764	TIMM10	CCAGCGGAAGCACGTGGGTTACTTC	195

16738536	156510	TIMM10	GAAAGTCCCGCCTCTTCTTTGATTC	196

16742150	64395	XRRA1	CATGAACTCGAGGAAGTGGCCGAAC	197

16742150	254835	XRRA1	TCTAAGGGCCTTTCCTGCACTGACA	198

16742150	705895	XRRA1	TAGTGGAGCCTCTGTAATGTTCCGG	199

16742150	611410	XRRA1	TTCTGAAGAGTGTCCAGCTTGGGCT	200

16742150	1373220	XRRA1	CAGCAGTTCTTCATAGCCGTGGTAC	201

16742150	529167	XRRA1	GGACAGGGTCTCTTCACTATGCACA	202

16742150	695327	XRRA1	GAGTGAGCAGCTCTACAGCCAGGTT	203

16742150	437545	XRRA1	TAAGTGGATTCCCAGTCGCTCCTGG	204

16742150	114412	XRRA1	TCGTGTATGGGCCACCAGAGGGTTG	205

16742150	948787	XRRA1	TGAAAGACGAACTCGCAGAGAGATG	206

16742150	743989	XRRA1	TAGGCCAGGCTAAGGTATCTCAGCT	207

16742150	868330	XRRA1	TCCAGGGTAAGATGAAAACACAACC	208

16742150	1063743	XRRA1	TGATTGATGCCTAGAGCACCCAGGA	209

16742150	231585	XRRA1	GGTCAACATCCTTTTTCATGGGCAG	210

16742150	537282	XRRA1	GTTGGAGAGTCTGTTGTCATCCAGC	211

16742150	703987	XRRA1	GGATGTACCTCTTGCTTGTCAGCGA	212

16742150	104352	XRRA1	TTAGGGCTGGAAACGTGTGAAATGC	213

16742150	1325693	XRRA1	TCTTTAATGATATGCTCCTATCAAG	214

16742150	1198852	XRRA1	TCTGGAGGTGCAAGAGACAAACCAC	215

16742150	238872	XRRA1	CCAGGATATGTCCAGGAAGGTCCAC	216

16742150	344281	XRRA1	TCCGGCACGCGAAGCAGATTTCTGG	217

16742150	657775	XRRA1	GATCTTTGACTTTGGGAATGGCCCC	218

16742150	798243	XRRA1	TTAGTAACTGCGACGCGACGGCAGA	219

16743922	1039363	CARD17	TACTGGGAAGAGATAGAAACGTCTT	220

16743922	711361	CARD17	CGAAGTAACTCTTTCAGTGCTGGGC	221

16743922	1026980	CARD17	GGAAGGAAGTACTATTTGAGAATCT	222

16743922	675758	CARD17	GGAAGTACTATTTGAGAATCTTGTG	223

16743922	1289587	CARD17	GAAGTACTATTTGAGAATCTTGTGT	224

16743922	40508	CARD17	GTAGTAAGGTGATTTCCAGATGTTG	225

16743922	373360	CARD17	GAGCCCCTTTCCGAATAACAGAGTC	226

16743922	1073423	CARD17	AACAGAGTCAAGCAAAGCTCGGGCC	227

16743922	882591	CARD17	TGTCTCCAATAATTCACCCAGTAAG	228

16743922	176202	CARD17	TTATTGTACCTTCGCCCACTGAACG	229

16743922	972120	CARD17	TCGCCCACTGAACGGATAAACTGCT	230

16743922	888234	CARD17	GCCCACTGAACGGATAAACTGCTTT	231

16748095	322140	KLRG1	AGTCGAGACTCGAAGCTTCCACGCG	232

16748095	1032773	KLRG1	TGTCGTTAAGAAAGCCAGGACGCAC	233

16748095	452740	KLRG1	CCAAAGCTTTCATTGTGGGAAAACT	234

16748095	1127603	KLRG1	TCTGGGCCCAAAGCTTTCATTGTGG	235

16748095	1169308	KLRG1	TGTAAGTACACTCTCCCAATTTGGT	236

16748095	895305	KLRG1	AAAGAAAACTTCGTGCTCAGGTGAC	237

16748095	1326320	KLRG1	CTTCAGCTAAGATCTTTCACATGCA	238

16748095	1190235	KLRG1	GCCGTAGGCAACTCTAACATGGAAT	239

16748095	83998	KLRG1	CATAGTCATTCTGGGCTTGGGTTGC	240

16748095	696857	KLRG1	TCTCAGGGCTCTATGTAAAAATGGC	241

16748095	901717	KLRG1	TAGTGGGAACTGAGATCCAGGCCAT	242

16748095	31823	KLRG1	GAAAGTCAGGGAAGGATATCGCATC	243

16748095	1266182	KLRG1	GAAGAACTGCAGTCAGAAGCCCCAA	244

16748095	775430	KLRG1	CACAGGATCCACTGGTATAGCAGCA	245

16748095	1145312	KLRG1	GACAGCTGGCACAAGTGGAGTAGTT	246

16748095	1049607	KLRG1	TCTGGGCAGCTAGGACAGCTGGCAC	247

16748095	745155	KLRG1	TGAGTCTCTGGCTAGGCAGAATTCC	248

16748095	466685	KLRG1	GATTGTCCGTTATCACAAGGAGGTG	249

16748095	829858	KLRG1	TCACTGAGGAAAACTTGGAGCAGGC	250

16748095	502494	KLRG1	CAGCCAGAATTGTTCCTCAGACCAA	251

16748095	144478	KLRG1	TTTGTTGATGGCACCGCATGTCTGC	252

16748095	898161	KLRG1	TAAAGGAACTTCACAGCTTGAGGCT	253

16748095	248393	KLRG1	CAAAGAGAATCCATCAGTTAGGCAT	254

16748095	59951	KLRG1	TACCATCAGGGATCAGTAATGTACA	255

16748095	584511	KLRG1	AATAAAGCTTGATCTGCAAAGGGAC	256

16748095	740847	KLRG1	GAATAAAGCTTGATCTGCAAAGGGA	257

16748095	648195	KLRG1	GAAAATGCCTTATCGAATTGACTGC	258

16748095	842406	KLRG1	TGTATGTCCAAACTCTACTGAGGAG	259

16748327	857438	KLRD1	GAAGTGCCAAATCCAATCCAGCCTG	260

16748327	969702	KLRD1	GAGTCTCTTGAACTTGATGAGCTGA	261

16748327	974856	KLRD1	CACAAGCCTCTGAAGTGTTCCAGGA	262

16748327	575299	KLRD1	GAATCATCTATTGGTGAGACATGTA	263

16748327	513675	KLRD1	GGCACGATGTGTACTTTTTCAGAAA	264

16748327	510571	KLRD1	GAAATTATGTTCCAAGAGCGAAGTA	265

16748327	902011	KLRD1	GGTAACAACTTTGAGGCCTGGCTTC	266

16748327	615724	KLRD1	CAGAAACTAGTGACGGAGAATCCAC	267

16748327	887482	KLRD1	CAGAAATTAACCTCCACAGAGTGGT	268

16748327	659077	KLRD1	TTATGGAGACTTGCTTAGAAAAACT	269

16748327	412402	KLRD1	TATTACACATTAGCAAGATGAAGCC	270

16748327	1089574	KLRD1	GGTCCTGGAGTAAATGCTGGCTCAA	271

16748327	474900	KLRD1	CTTTCTGGAGTTCTATGTTGGGTCC	272

16748327	1224593	KLRD1	GAAGTAACAGTTGCACCGGTACCCA	273

16748327	656895	KLRD1	CAGAGATGCCGACTTTCGTTCCAAG	274

16748327	247282	KLRD1	GAGTCCAATCCAGTAAAATTGTTGA	275

16748327	531680	KLRD1	TGTAAGAGAGTCCAATCCAGTAAAA	276

16748327	1097424	KLRD1	TACTGGGAGAGTGCAGAGCCATTCT	277

16748327	1099245	KLRD1	GATACTGGGAGAGTGCAGAGCCATT	278

16748327	1311956	KLRD1	TCCATTTGGATTATACGCTATGCAG	279

16748327	632568	KLRD1	CATAGTGACATGGTGCCTGCAGTCC	280

16757347	255130	OAS3	TCTGGCGCGGCCTTCGGATTTCTGG	281

16757347	359923	OAS3	CTTGACAGTTTTCAGCACCCGCGGG	282

16757347	60760	OAS3	CAAGATCTACGGATGTCAGGCGGAA	283

16757347	527423	OAS3	CCTGGAATGGTCTAGGAACCCCTCA	284

16757347	141317	OAS3	TCCAGGCAGTGGCTGAGGGAAACTC	285

16757347	832091	OAS3	TGTCTGGAGAAACCCTTCCAAGTGG	286

16757347	1055726	OAS3	CCTGGCAGGATAGGGAAAGACTTCT	287

16757347	962396	OAS3	TGACAGTCCAGAAAACACACAGGTG	288

16757347	123820	OAS3	GACTCTTGAGGCCTTGTGAACACAG	289

16757347	1245424	OAS3	AAGAACAGCTCAGATCAGGGACCCT	290

16757347	1327922	OAS3	TCTCATCAAGGATCTCTGCGCGGCG	291

16757347	1253800	OAS3	CAGGTTCTTCAGCTTGACAGGGCGA	292

16757347	1147136	OAS3	TGTTGAAACAATCCTGCCTGCAGCC	293

16757347	254610	OAS3	TATCAACGGCCTTGTTCACCTGGGC	294

16757347	765105	OAS3	TGTTGCCCTGCTCAGTGAACTGGCT	295

16757347	582051	OAS3	TTCAAACTTGACCTCGAACTGCCGC	296

16757347	290200	OAS3	GAAGTCCCGTTGTAGCTCTGTGAAG	297

16757347	163861	OAS3	TGCGGAAGCCCTCAGCCATGTTGAA	298

16757347	1171829	OAS3	GCTCCTATACACTACAGGGCAGGTA	299

16757347	375500	OAS3	CAGTCAAGTCTTTCCATCCGAGGGT	300

16761350	1138120	KLRC3	TATTTTCCAATCATAACGGTCTGCA	301

16761350	1294744	KLRC3	TCAAACTATATAGAGAGGGAAAAGT	302

16761350	472797	KLRC3	AACATCATCTAGTTAAAAATAGGGA	303

16761350	1334607	KLRC3	CACAAGCTAAATGGTACATGAGCAC	304

16761350	485025	KLRC3	GCTAAATGGTACATGAGCACTCAGG	305

16761350	761465	KLRC3	TGATGCACTGCAAGCTCAAGCGCTT	306

16761350	761138	KLRC3	GATGCACTGCAAGCTCAAGCGCTTT	307

16761350	1156635	KLRC3	TGCACTGCAAGCTCAAGCGCTTTAA	308

16761350	1153599	KLRC3	GCACTGCAAGCTCAAGCGCTTTAAT	309

16761350	1320459	KLRC3	CACACTGGTCTGATATAAGTCCACG	310

16761350	880292	KLRC3	GGTCTGATATAAGTCCACGTACATG	311

16761350	1364809	KLRC3	TCCACGTACATGTAGCATTGCACAG	312

16761350	1063513	KLRC3	AAAGCAGACTAGAAGAGTTCTTTGA	313

16761350	960254	KLRC3	AAGCAGACTAGAAGAGTTCTTTGAA	314

16771417	767946	OASL	CACGTCTGGCCTGGGATAACTCATT	315

16771417	773191	OASL	TGTAAAACTGGTGAAGACCTGGGAC	316

16771417	1234405	OASL	CAGAAATGTACAGAGAAGTCTCCCA	317

16771417	76037	OASL	TCTTCGAGAGGATGAGAGTGTCACT	318

16771417	872009	OASL	TATTTGGCTAAGGAGCACCTGCTGC	319

16771417	109865	OASL	ACTGTCAAGTGGATGTCTCGTGCCC	320

16771417	236353	OASL	GAATTTGTCCAAGTTCACGGAGCCC	321

16771417	642139	OASL	TGCAGCTGGCCCTTAAACGGTGACT	322

16771417	1229876	OASL	CTTGACAGCCCAGAGAGGAGCCATT	323

16771417	163043	OASL	TGGGAGGCCCTCTGAGCAACGATGT	324

16771417	644977	OASL	TCTGTACCCTTCTGCCACGTTGAGG	325

16771417	649352	OASL	GGTGAAGCCTTCGTCCAACATGAAA	326

16771417	137213	OASL	GCTTAGTTGGCCGATGTTTCACGAA	327

16771417	1272089	OASL	TGGGCAGAAATTTCCAGGACCACCG	328

16771417	135172	OASL	TCTGTAGGCAGGCACAATGGTGACC	329

16771417	785591	OASL	CCCCTGGTCTGGATGGTGAAGACGA	330

16771417	1112485	OASL	TGGTGCTCCTGAGAACCGTGCCATT	331

16771417	949899	OASL	ACTGAGCCACGAAGGAGTCCAGCCT	332

16771417	1295565	OASL	GCTGGTGTGCTATACAGTTCCTGCA	333

16771417	1297212	OASL	TGGGCAGATATATAGCCAGGCTCCT	334

16771417	603816	OASL	AAACCAGGTGTGACGGGCTGACTCC	335

16771417	174376	OASL	CTTGGAGACACCCTTGCTGCAGTAG	336

16772285	1126337	LOC387895	CATTCTGCTGCTATGAGCGAGGAGA	337

16772285	1397880	LOC387895	GCTTTAGCTCATGGTTGGCATCTGA	338

16772285	12222	LOC387895	TAACTCAGGGTTTCCTAGCGAGAAG	339

16772285	1019962	LOC387895	GGGCCATGAAGGTGTTCCCGCCATT	340

16772285	419172	LOC387895	CATGAAGGTGTTCCCGCCATTGAGA	341

16772285	545238	LOC387895	CAGCTCTGGAGAGTCATTCCATTCC	342

16772285	1169029	LOC387895	TGCCACCATGACACGGAACAGCTTT	343

16772285	1235905	LOC387895	GAACTTTCAGGCTCTCCTAATGGCT	344

16772285	957489	LOC387895	GATACCTAGAAGGTTTGCCCCTCAG	345

16772285	755179	LOC387895	TGTATCCAGGCTCCAGGTGCATAGA	346

16772285	779644	LOC387895	TGAAGATTCCTGAAGGCCCTGGTCC	347

16772285	667095	LOC387895	CCCTGGTCCTAGGTCATAGTTGTTC	348

16772285	1219493	LOC387895	TTGAGTTACAGGGACCGAAGCAGCT	349

16772285	791436	LOC387895	TGGATTCAGATCTGGGCGATACCGC	350

16772285	359385	LOC387895	AACGTGGTTTTAGGATGTGAGTCTC	351

16772285	858521	LOC387895	CTATGGTTCAAATGTGGGATCTCAC	352

16772285	363506	LOC387895	GACGTGGTTTCATCTTGCAATTCGA	353

16772285	156152	LOC387895	AGGTCCTGCCCGCTAACAGAGAGAG	354

16772285	151154	LOC387895	TGGATGAAGCCCCTTAGTCCTCAAT	355

16772285	544867	LOC387895	GCAGTGCTTCAGTCAAGGTGATCAA	356

16772285	900280	LOC387895	CACCTGTGAAACTGTCCCTGTAAAC	357

16772285	1180877	LOC387895	CGCTTAGCATTCACCATGAGGGAAG	358

16772285	1096596	LOC387895	TCGATTAGAGAGTGTGCTGCGGCAA	359

16778559	465915	EPSTI1	CAACTCCTGGTTGCATGCTGGAAAA	360

16778559	202972	EPSTI1	AGTGAGGCACACCAAGCATAGACGC	361

16778559	1069341	EPSTI1	GAAAGACAAGCCTGTAGCACCCATA	362

16778559	1073179	EPSTI1	AACCTGAAAGCATCAAGTGACTCCC	363

16778559	388855	EPSTI1	TAATGTAGCATTTCCCTGGCAGTAG	364

16778559	66754	EPSTI1	GCATAAATGAGGACAAGGAGAAGCC	365

16778559	321472	EPSTI1	TAGGTGCCTCGAAAAAACTAATAGA	366

16778559	948101	EPSTI1	GGTGCCTCGAAAAAACTAATAGAGA	367

16778559	123919	EPSTI1	CAGATTGCTCGAGGCCACCTGGTTG	368

16778559	521358	EPSTI1	GGAGTCGGTCCAGAAAAGCATTATT	369

16778559	367695	EPSTI1	GGTGGATTTTGGCTCTTTCTTGCTC	370

16778559	1238287	EPSTI1	TGCCGTTTCAGTTCCAGTAATTCAC	371

16778559	667159	EPSTI1	CAGCTGTGATCCCTAGGCAGGATAG	372

16778559	1049850	EPSTI1	CTGTGATCCCTAGGCAGGATAGGAA	373

16778559	1313170	EPSTI1	CCATGTTGAGGATTGTGGGCCACAA	374

16778559	1041627	EPSTI1	GTTTGCTCAAGAACTCAGCGGTTTT	375

16778559	955415	EPSTI1	TTTGCTCAAGAACTCAGCGGTTTTG	376

16778559	1202698	EPSTI1	CCGTCTGGGCACCAGGTGAACCGGT	377

16778559	343646	EPSTI1	TAAGCCAGGCGAGAAATATCAAATC	378

16778559	1232576	EPSTI1	CAAGAGTCAGCACAGAGGGTTCGAA	379

16778559	102994	EPSTI1	TGCTACAGGTGGAGACCCTTGCTCT	380

16778559	135779	EPSTI1	GGTTTCAGGCACTCCAGACCACTGT	381

16778559	1399947	EPSTI1	TAGTCCCTGCATGGCTGTGATTGTC	382

16778559	1091105	EPSTI1	CAAAAACGAGTAAGATGTGGTCCCT	383

16778559	19416	EPSTI1	CATTTCTCCGGTTTATATTTGGTGC	384

16778559	753527	EPSTI1	TATTTGGTGCTATCAAGGTGTATGC	385

16778559	1055393	EPSTI1	TAAGAGGCTAGTTTATCTGCGAGTC	386

16778559	983023	EPSTI1	TCTTGCTGGGACGTAGGCTTGCTCC	387

16778559	168760	EPSTI1	TCTTGTTGACCCTTACCTGTTAGTG	388

16778559	756146	EPSTI1	GTGCACGACGCTCTCCCGCGAAGGG	389

16778559	202427	EPSTI1	GGAGTTCACCACTCTATTGCGGGTG	390

16778559	327005	EPSTI1	CGGCTGGGACGCTTAGCGAGTCTCA	391

16778559	1153908	EPSTI1	TAGCGAGTCTCAAGATGGGATTCCA	392

16791436	1325372	GZMH	TACACCAGAGATCCATTTATTACAG	393

16791436	218334	GZMH	TATTACAGTCCTGCAACCCCGACTG	394

16791436	61216	GZMH	CAGGCCCAGAGGAAGGTTAGTCTCA	395

16791436	944542	GZMH	GCCCAGAGGAAGGTTAGTCTCATGC	396

16791436	460195	GZMH	GAGGAAGGTTAGTCTCATGCCTGCT	397

16791436	627288	GZMH	GCAGGAAGTGTGAGACCTTGATGTA	398

16791436	417994	GZMH	TTTTGTTTCCATAGGAGAGAATACC	399

16791436	68633	GZMH	TTTCCATAGGAGAGAATACCTTGGG	400

16791436	20954	GZMH	GAAACCGGTCTGTGTCTTCTTTGGA	401

16791436	299361	GZMH	TGGAAGAGACGTTCACACTGGCAGT	402

16791436	1000239	GZMH	AGTGCTCATTGAGACATAACCCCAG	403

16791436	603476	GZMH	CAGAGCTGTTGGTGTTGACTCCTTC	404

16791436	601589	GZMH	GAGCTGTTGGTGTTGACTCCTTCCA	405

16797490	639258	IGHV3-20	CTGCATAACCTGTGCTACCACCATT	406

16797490	627535	IGHV3-20	TGCATAACCTGTGCTACCACCATTC	407

16797490	751562	IGHV3-20	TAACCTGTGCTACCACCATTCCAAT	408

16797490	1277561	IGHV3-20	CACCATTCCAATTAATACCAGAGAC	409

16797490	1277858	IGHV3-20	ACCATTCCAATTAATACCAGAGACC	410

16797490	408377	IGHV3-20	CCATTCCAATTAATACCAGAGACCC	411

16797490	1400985	IGHV3-20	GACCCAGCTCATGCCATAATCATCA	412

16797490	884431	IGHV3-20	CCAGCTCATGCCATAATCATCAAAG	413

16799289	1293117	C15orf54	GAAAGTTATATCTCTGTGTACATCC	414

16799289	303340	C15orf54	GAATCCAGCACGTGTACTCCTAAGT	415

16799289	1300540	C15orf54	TAATGAGAGAATCCAGCACGTGTAC	416

16799289	1056754	C15orf54	TGATTCTGGATAGTTGACTCATGAA	417

16799289	582631	C15orf54	CCACACCGCTTGAATAATAACTATG	418

16799289	858759	C15orf54	GCCATGGCATCAAATCTCCTTTTAA	419

16799289	1106899	C15orf54	CTAAGTCAGTGAGGTTTGCCATGGC	420

16799289	537954	C15orf54	GAAGAACAGTCTAAGTCAGTGAGGT	421

16799289	626193	C15orf54	GAAGCCATATGTGTTTCAGCCACTT	422

16799289	624527	C15orf54	TGAAGCCATATGTGTTTCAGCCACT	423

16799289	783180	C15orf54	TCTTGACACACTGAAGCCATATGTG	424

16799289	682580	C15orf54	TCAGGTCTTCTTGACACACTGAAGC	425

16799289	750014	C15orf54	GCCACCGTGCTTGCCAGTAATGAAT	426

16799289	845595	C15orf54	TTCAAGATCAAACTAGGCCATGGAG	427

16799289	1337167	C15orf54	CAAAGAGTAATGTCAATCCGCTGGA	428

16799289	1139060	C15orf54	CAAGAGTCAGCCAATATAGTGCACA	429

16799289	69435	C15orf54	CCAATACGAGGAGAGTGTCACTGAC	430

16799289	563212	C15orf54	TGAACCTCTTGGTGACCCGGAATGA	431

16799289	694060	C15orf54	TCCCAATGTCTAGCGTAGTGCCCAG	432

16799289	1199154	C15orf54	TATTCTGATTGCAACAGTAGGCAGC	433

16819539	536443	GPR56	CAGGCACCCAGTCTGAGCTTGTCTG	434

16819539	884741	GPR56	AGAGGCTTAACCTGCCAGCCCTGGT	435

16819539	982586	GPR56	GGCGGCTGGACCACCTTTCAGGATC	436

16819539	162145	GPR56	TGCTGTCCAGCCCTTGTTTGGGTAC	437

16819539	162573	GPR56	CTGCTGTCCAGCCCTTGTTTGGGTA	438

16819539	579213	GPR56	ACAGAGACTTTGAAGCTGGGCCACC	439

16819539	1183446	GPR56	GACGGAGTCACTCTTGGAAGTCACC	440

16819539	982848	GPR56	TTCCTCCGACGGAGTCACTCTTGGA	441

16819539	611067	GPR56	GCAGGAACAGTGTCGTCTGCAGCAG	442

16819539	943048	GPR56	CAGACTCAGCAGGAACAGTGTCGTC	443

16819539	1026664	GPR56	GAAGCGAAAGTCTTCCCTGTGGCCC	444

16819539	838761	GPR56	TGCAGAAGCGAAAGTCTTCCCTGTG	445

16819539	419729	GPR56	CAGCATGTCGGTTCCAGTAGAGGCA	446

16819539	1254623	GPR56	TTTGTCACTCAGCAAGAAGTCACGC	447

16819539	1382057	GPR56	CCACCGAGGCATTGTGAGCGGCCGT	448

16819539	136392	GPR56	TCCACCGAGGCATTGTGAGCGGCCG	449

16819539	158915	GPR56	TGGAGGTCCCTTTTGAGCTCGCACA	450

16819539	210893	GPR56	GCTGGAGGTCCCTTTTGAGCTCGCA	451

16819539	364720	GPR56	CAGAGGTCAGTTTCGACTCCAGGCT	452

16819539	516920	GPR56	GGTGTTCTGTACCACAATCCCCAAG	453

16819539	726048	GPR56	GGGTTTCTCTCCTGACGGTCTCACA	454

16819539	747815	GPR56	TCAGGTAGTGCTTGTGCACGGCGTC	455

16819539	312055	GPR56	CACCACGAGTCGGTAGAGGTTGTAC	456

16819539	997617	GPR56	TAGCCAGGGACATAGGTGCCAAAGA	457

16819539	1177325	GPR56	ATAGTTGTCCACATCCACCAGGGCC	458

16819539	1347949	GPR56	GGAGTCCTATGCACAGCCAAGATGA	459

16819539	1062511	GPR56	AAAAGGTAGAGGACGACAAGCTGGA	460

16819539	1111737	GPR56	GGCGCTGTCTGAGTTGCTCTTCAGA	461

16819539	205618	GPR56	GAATTAACCATGATGGGCGGCCGAG	462

16830214	31530	FBXO39	TGTTAGGCAGGGCTTCCAAAAATGA	463

16830214	133248	FBXO39	TGTGTGTTAGGCAGGGCTTCCAAAA	464

16830214	133301	FBXO39	CTGTGTGTTAGGCAGGGCTTCCAAA	465

16830214	626079	FBXO39	TACAGTGCAGCTGTGTGTTAGGCAG	466

16830214	1351048	FBXO39	GAACTGGGATGTACAGTGCAGCTGT	467

16830214	1143600	FBXO39	TTTCTGCAGACAAGAGCAGCCCTGG	468

16830214	765945	FBXO39	TGCATGTACCCTGGAAGGTCTCCCG	469

16830214	701297	FBXO39	GATGCTGTTCCTCCATACCAGGCGG	470

16830214	526507	FBXO39	TCAAGCAGCTCGTCGGAGATACAGT	471

16830214	567848	FBXO39	GACTCATGGTTGTTGTTGAATTCAC	472

16830214	259598	FBXO39	CAAGGAAAGCCCAGATTTTGAAGTA	473

16830214	450954	FBXO39	TTCTGACTCTTCAGGATCCGCTCCA	474

16830214	332602	FBXO39	TTGAATACACGCAGGGCACACTGCC	475

16830214	222187	FBXO39	GGTCTTGTCCTCTTCATTCGTCTCA	476

16830214	515051	FBXO39	TACTTCCTGTAAATTTCCTGCAGGG	477

16830214	757468	FBXO39	AATAGCTAAGCTCTGATTCGATCAG	478

16830214	495075	FBXO39	TACATCACAGAGTAAACGATGACAA	479

16830214	1132892	FBXO39	CGGCAGTGCCCAAGTGTAGTTCTAA	480

16830214	131382	FBXO39	TCAGGTCATGGGCAGTCTCAGCCTT	481

16830214	860380	FBXO39	TAGCGCTTTAAAGCCACCTGGAGCC	482

16844999	987467	DHX58	TAGGTCTGGACTAAGCTCTGGCCCT	483

16844999	344650	DHX58	TTCCCATTGCGGGAGCCTAAGCCAG	484

16844999	1090483	DHX58	TCCAGGGAGAGGTCCGACAAGTTCT	485

16844999	196639	DHX58	CACGCGGGACCACTTTTTGGCCTGG	486

16844999	599401	DHX58	CACATTGACATGGTGGGTGCCCTCC	487

16844999	242944	DHX58	GCTGCACGTGCTCCACTGGGAACTG	488

16844999	765471	DHX58	TACTCGGCCTGGTCCATTTTCTGCA	489

16844999	1291739	DHX58	CAAACGCGTATACACTCTGATCGGC	490

16844999	201230	DHX58	TCGTGGCCACCAGAAGGTTCAGGGT	491

16844999	810254	DHX58	CCAATCAGTAGCTGGGCCCGGATGT	492

16844999	1137231	DHX58	CCATGAGTTGCCAAGTGGGCCAGCT	493

16844999	360391	DHX58	GATCTGGGTTTTAGTGACGTGCTCC	494

16844999	1299515	DHX58	TGTGATAGAAATCCTGCAGCGCAGC	495

16844999	594494	DHX58	TGTACTGTTTGCAAGGCTGTTGGCT	496

16844999	1356086	DHX58	GGGTGACATGATGCACCACGTGTCC	497

16844999	805340	DHX58	CATCTGCAGAAGCTCTGCTGTGCAG	498

16844999	1181367	DHX58	AGGGTTGTCACGGTCCAGCGTCCAT	499

16844999	480340	DHX58	TCCCATTGGTAGGACCGAAGCTCCA	500

16844999	484684	DHX58	TCTAGTAGGTAGGTCTGCCCAGGGC	501

16844999	661479	DHX58	GCAGTCCCACTTAACTCAGCCTGGT	502

16844999	1124342	DHX58	GGAGCCAGCTGAGCCGACTTAGGAA	503

16844999	304493	DHX58	GCCAGCTGAGCCGACTTAGGAATCT	504

16844999	865566	DHX58	TCCGGTTAAGTACTGCTGCTGCGCC	505

16844999	1106892	DHX58	TGTGCTCAGCGCAGAGAGCAGAAAT	506

16844999	1265420	DHX58	TCAGCGCAGAGAGCAGAAATCAGAA	507

16870200	1323326	BST2	TCCAAGTTGATAGTCTGCATGCCGT	508

16870200	1392622	BST2	TGTACCATTGCATGGCTTCCACGTG	509

16870200	358859	BST2	CGTGAGTCGTTTACAAGGAGTTTGC	510

16870200	370046	BST2	GCATTACGTTTGCAACTGTGCTTGT	511

16870200	244386	BST2	GGCTTCGTCCATCTCAATCTTCAGT	512

16870200	560227	BST2	TCGTTAGTTGGGTCTGAAGCCGGCT	513

16870200	77722	BST2	CGTTAGTTGGGTCTGAAGCCGGCTC	514

16870200	527497	BST2	TAGTTGGGTCTGAAGCCGGCTCTGA	515

16870200	558474	BST2	TATTTTTTGGAGCTCAAAGACCCCA	516

16870200	286589	BST2	ACTCATTGTCCGGAGGGAGGCTCTG	517

16870200	1245167	BST2	CATGACCCGCTCAGAACTGATGAGA	518

16870200	499247	BST2	CAAGGGAATGTTCAAGCGAAAAGCC	519

16870200	682132	BST2	TAGTACTTCTTGTCCGCGATTCTCA	520

16870200	330209	BST2	GCGATTCTCACGCTTAAGACCTGGT	521

16870200	737897	BST2	CGATTCTCACGCTTAAGACCTGGTT	522

16870200	734012	BST2	GATTCTCACGCTTAAGACCTGGTTT	523

16870200	526625	BST2	TCTGCAGACGCGTCCTGAAGCTTAT	524

16870200	223401	BST2	TGCAGACGCGTCCTGAAGCTTATGG	525

16870200	223045	BST2	GCAGACGCGTCCTGAAGCTTATGGT	526

16870200	777670	BST2	GACGCGTCCTGAAGCTTATGGTTTA	527

16870200	884423	BST2	TGGTGAAGATAATCAAGGGCACCCC	528

16870200	1263417	BST2	TATCCCCAGCAGAAGCTTACAGCGC	529

16870200	1199398	BST2	TGGGCACTCTGCAATAGTCATACGA	530

16870200	426260	BST2	TGCTGGAATCTTCTACGGGCCACCC	531

16874828	79649	NKG7	GGGCAGATGTGGGACCAGACTTTCC	532

16874828	199223	NKG7	CAGATGTGGGACCAGACTTTCCCGA	533

16874828	1350139	NKG7	GAGGCTCCAGATGAGGCCTTTGGAA	534

16874828	893884	NKG7	TGGAATACAACGCTCAAAACTCATC	535

16874828	363812	NKG7	TCACAAGGTTTCATAGCCAGGACGG	536

16874828	271287	NKG7	GTTTCATAGCCAGGACGGGGACCGC	537

16874828	1211778	NKG7	TTTCATAGCCAGGACGGGGACCGCC	538

16874828	190114	NKG7	ACAGTGAGCACCCAGGCTCAGGGCA	539

16874828	1081558	NKG7	AGCAAGAGGATAGCTGAGACCCAGC	540

16874828	1079855	NKG7	GCAAGAGGATAGCTGAGACCCAGCC	541

16874828	811922	NKG7	CAAGAGGATAGCTGAGACCCAGCCC	542

16874828	187240	NKG7	AGGCTGGTCCCACCGCTCGCTGGTG	543

16874828	929847	NKG7	TCGCTGGTGTACACCGCCATGGCCA	544

16874828	1232999	NKG7	CAGGGCCCACAGAACAGCCATAATG	545

16874828	974917	NKG7	GCCATAATGCTGAAGGTCTGCGTCA	546

16874828	151824	NKG7	CTGATATGATGTCCCCATGCCCTGT	547

16874828	194244	NKG7	TATGATGTCCCCATGCCCTGTTGGC	548

16874828	886735	NKG7	CACAGCCTCAAACCAGAAATCGGTG	549

16874828	762848	NKG7	AAATCGGTGCTCAAAGCAATCAGGC	550

16874828	1246090	NKG7	GAGGCTGCTGATCAGACTCTTGAAT	551

16874828	1302484	NKG7	GACTCTTGAATCTCAGAGAGAAGGA	552

16874828	639151	NKG7	AAGGAGGCTGTGCACCCAGACTCCT	553

16874828	15055	NKG7	GACTCCTGGGTCCTTAGAGCCCAAG	554

16876764	252747	RSAD2	GAGCGCCGGCCGTTTATCGCGCACA	555

16876764	433855	RSAD2	GGGCCTCATTCGGTGTCAGCCCCGG	556

16876764	1237059	RSAD2	TAAGTGTTCAGTTAGGGTTAGCTCC	557

16876764	496709	RSAD2	GAGTCCTAGTAGCTGAACTTCCAGA	558

16876764	646348	RSAD2	CAGGACACACCTTCTTTGACTAACA	559

16876764	111072	RSAD2	TATAGGGATGGAAATCAGCAGTCTC	560

16876764	519804	RSAD2	AGAGCAGTCTCTGTATGCCAGGGAC	561

16876764	972885	RSAD2	GGTTGCCTGAACACACTCAAGAGCT	562

16876764	909053	RSAD2	TGTGTGGAAACAGAAGCCGCATTTG	563

16876764	710283	RSAD2	GAAGGTACTCTAGGAAAGACAGGAA	564

16876764	32738	RSAD2	AAATTCATCAGGGTGCACATCCAGA	565

16876764	183607	RSAD2	GGCTCTCCACCTGAAAAGTTGATCT	566

16876764	331047	RSAD2	GCTGGGCAGCCGCAACTCTACTTTG	567

16876764	244919	RSAD2	GATCAGGCTTCCATTGCTCACGATG	568

16876764	1208683	RSAD2	TAATGCCGTGCACAGCTTGAAAAGC	569

16876764	570811	RSAD2	GCCAAACTTGTTTACTGAGAGCCCT	570

16876764	1080752	RSAD2	TCACAGGAGATAGCGAGAATGTCCA	571

16876764	115300	RSAD2	TTGGCCACGGCCAATAAGGACATTG	572

16876764	54492	RSAD2	TTTCCAGCGGACAGGGTTTAGTGCT	573

16876764	753408	RSAD2	TTTGTGGCGCTCCAAGAATCTTTCA	574

16876764	1202471	RSAD2	TAGATTCAGGCACCAAGCAGGACAC	575

16876764	35096	RSAD2	CCAGAATAAGGTAGGAGTCTTTCAT	576

16876764	1281100	RSAD2	TTCATCCAGAATAAGGTAGGAGTCT	577

16876764	159626	RSAD2	CTTCCGTCCCTTTCTACAGTTCAGA	578

16876764	920230	RSAD2	GCTTCTTCTACACCAACATCCAGGA	579

16876764	648841	RSAD2	TTCAGATCAGCCTTACTCCATATGT	580

16876764	482437	RSAD2	TGACCACAGGTAATCAGATGCCACG	581

16876764	910546	RSAD2	GCATTCATGGAACAGCCACCGTGGG	582

16882332	986433	GNLY	TTCCAGCTGGACTCCCTTAGGCTGA	583

16882332	1246427	GNLY	TTCCTTCCAGCTGGACTCCCTTAGG	584

16882332	801372	GNLY	GCAGGGAGCCTGCAGCTTAATCTTT	585

16882332	497510	GNLY	CAGTGTGGCCAGTAGAGTTAGGACC	586

16882332	203465	GNLY	TGGCCTTCACCACGCAGATGCGGAG	587

16882332	330712	GNLY	GAGGAAACGCAGATCCACCGATGAG	588

16882332	421519	GNLY	ACTCTCCCTTCCAGAAGTGTTCTTG	589

16882332	421337	GNLY	CACTCTCCCTTCCAGAAGTGTTCTT	590

16882332	433702	GNLY	CACGTTCCTTCTAGAAAGCCAGGAG	591

16882332	845025	GNLY	CACTCTCAGCACAAACACGTGTTCT	592

16882332	937646	GNLY	AGGAGAGGGAAAGCCCGTTCTCCTG	593

16882332	493809	GNLY	CAGGTCGTAGTACTCAGGGCTCAGA	594

16882332	718254	GNLY	GATTTCTCCTCATCACGCAGGTGGG	595

16882332	504180	GNLY	CCAGCTCCTGTGTTTTGGTCAACAG	596

16882332	1243055	GNLY	GACTATCGTCAGACAGGTCCTGTAG	597

16882332	640930	GNLY	CCAGGATCACTGTGCAAGGTGCCCC	598

16882332	743659	GNLY	TATCCAGGGCTAAGTGCGAGCCTGC	599

16882332	103754	GNLY	CCTTCTGTGTGGAGAATGGTGCCCA	600

16882332	803691	GNLY	TGAAATTTCTGCAGACGTCGCGCCA	601

16882332	12671	GNLY	GGCCCTGGGTAACTCTAGACTGATA	602

16882332	264322	GNLY	CCAGTCGGCAGCCTGAGCAGGTTGT	603

16882332	1174988	GNLY	GCTTCTTCCACAGGACAAGGTGAGA	604

16889218	1393313	SPATS2L	CAAGTTACACATGGGCATCGTGGGC	605

16889218	898891	SPATS2L	GAAAATGAACTTTGCTCCCTCAGCA	606

16889218	302719	SPATS2L	CACAATCCGCACGTGTTGCAAGAGA	607

16889218	191246	SPATS2L	GAAGAATCCCAGTACAGCTTCCGCA	608

16889218	439558	SPATS2L	GGACTGGATTCCTTCACTGACACAA	609

16889218	798735	SPATS2L	AATCAAAGACTGCAACGGTGTGGCC	610

16889218	1199144	SPATS2L	GAATCCACAGCAATGTTCCTGAAAG	611

16889218	560507	SPATS2L	CACTGAGATGTTTGGCACTCCCTCC	612

16889218	155676	SPATS2L	TCTTTTCCCGAGTTTCCCATGAGGC	613

16889218	365969	SPATS2L	TCCCTTTTTGTGAAACTGCCCAGTG	614

16889218	703017	SPATS2L	GGTTTCCTCGTGCTCCAAATCAGGG	615

16889218	432615	SPATS2L	CAAATCGCTTTCTGACTTGCTTGTC	616

16889218	1288350	SPATS2L	TTCACATGAGTATTGAGTTCAGCCA	617

16889218	169890	SPATS2L	GATTCTAACCGCGATCCCTTGGAGA	618

16889218	323695	SPATS2L	TGCCAATCCTCGATCAGCACCATGG	619

16889218	102608	SPATS2L	CAAACTGTTGGAGCACCAGGACTAT	620

16889218	28661	SPATS2L	TTCTCACGAGGGATAAGGGCTGGTT	621

16889218	930149	SPATS2L	CTTGGGTTACAAGGCTGCTCAGCTG	622

16889218	1060912	SPATS2L	TATCTAGTTAGAGAAACGGTGCAGC	623

16889218	1364194	SPATS2L	CCATTTCTGCCATTAATGAAACTTC	624

16889218	864392	SPATS2L	CGGTTTTAAGTTGGCAGGTGTCAGT	625

16889218	775991	SPATS2L	TCTTCTCAGCACTGGGTTAGGTGCC	626

16889218	275751	SPATS2L	TAATTTCTGCCCTGAGTTCGGCCAG	627

16889218	150016	SPATS2L	GCAGGAACCCCATGATTACAGAAAT	628

16889218	286667	SPATS2L	CTTGTTGGCCGGCATGGTCTGGTGA	629

16889218	50480	SPATS2L	TCACAGCCGGGACTGAGAGAACTGC	630

16889218	830037	SPATS2L	TTTAGGAAAAGAACTGCGCAGGCCC	631

16894127	651726	CMPK2	CATTCCAGGCCTTGACTCGAGTGTG	632

16894127	1200096	CMPK2	TCATGACGAGTGCAACCAGATGTGG	633

16894127	1355847	CMPK2	CACTGGAACATGATGAGAGGGACCT	634

16894127	1060230	CMPK2	AATCTAGTTAGACGTGGCACCTGGC	635

16894127	1183138	CMPK2	TACGGTTCACTAAAACTATTCTGGA	636

16894127	874431	CMPK2	TTAGGCTTAATACCGTCTGCAGGAC	637

16894127	1376609	CMPK2	CAGGATTCTCCATCCGCTGGTAGGA	638

16894127	1072227	CMPK2	CACACGGGAAGCATCTAATAGGTAG	639

16894127	820683	CMPK2	AGATAACAATGCTGCAGCCCTGTGG	640

16894127	1067767	CMPK2	CAATCCTAAAGCCAGTGCCAGTGGT	641

16894127	1258626	CMPK2	CAGGTTTGAGCAGGTCCTCTGGCCA	642

16894127	1079429	CMPK2	GATTCTTTAGCTATTTCGGAGGCCA	643

16894127	1139518	CMPK2	CTCCACTGGCCAATGCAAGAGGGTG	644

16894127	648670	CMPK2	GAGGACAGCCTTAAGTGAATCTGCC	645

16894127	1141248	CMPK2	TCGATGGCAACAACCTGGAACTTTC	646

16894127	78630	CMPK2	TCTGTTTTGGGCACTGGTCGACCAG	647

16894127	861555	CMPK2	TTGCGCTCTTAACTGCTCCACAACG	648

16894127	154335	CMPK2	CAACGCTGTCCCGTAAGCTTGGAAA	649

16894127	1291225	CMPK2	GGAAAATATTCCCAAGATCCATGGG	650

16894127	81580	CMPK2	ACGGAACTGGGCAAGTCTGGCACCA	651

16894127	17735	CMPK2	GCTTGCCGGGTGTCAGGGTCATCCA	652

16894127	946306	CMPK2	TGCAGTCGGGAAGCTCCAGGACGAA	653

16894127	900188	CMPK2	GACTCTCCAACTGGGAAGTGTCGCC	654

16894127	1237108	CMPK2	GAAGTGTGTCAGGATAGCACCCTCT	655

16894127	871388	CMPK2	TGTTGCTGCCTAACAGTGTAACTGC	656

16895530	985145	OTOF	CATGAAGAGTGGACGCTGGGCTCCT	657

16895530	1071455	OTOF	AACCAGATGAAGCTCGTGTCGGGCC	658

16895530	1371858	OTOF	TCATCGTTCTCATTGCGGGCCAGGA	659

16895530	332052	OTOF	AAGTGGTCCGCATCCCAGATCTGCA	660

16895530	614928	OTOF	CTTCCGAGGTGAGATGTCCAGAGGC	661

16895530	623218	OTOF	CACATGCTCGTCTGTGGGCTTCCTC	662

16895530	269604	OTOF	GGTCCCGCCAGATATTGTAGCCATG	663

16895530	257075	OTOF	GAAGGAGGCCTCGATGTCAAAGGAC	664

16895530	588056	OTOF	GATGTCAGTCTTGCCTAGCCGGATG	665

16895530	930534	OTOF	GCACTTTGTACACGCAGAGGGAGCC	666

16895530	1191022	OTOF	TCAATGGAGGCAAAGTACTTGGACC	667

16895530	1177335	OTOF	GTTTGGACACACAATCAAGCTCAGC	668

16895530	95224	OTOF	TTTCTTGATGGGTACCTCTGGCTCC	669

16895530	1269120	OTOF	ACAGCACACGGCAGCGCCGGAGAAG	670

16895530	296332	OTOF	TCCACCACACGGATGTTCAAGGGCG	671

16895530	1329786	OTOF	TAATTGTGGATCAGGGACGACTGCA	672

16895530	252133	OTOF	GGTCCGGCCCATGAAGTCAGCTTTG	673

16895530	42286	OTOF	CATAGAGCTCCAGGTTGTCGAACAC	674

16895530	638771	OTOF	CCTGGTACATGTGCGCTCGGAGCTG	675

16895530	1099671	OTOF	TCCACGATGGAGAAGAGCAGGTCCT	676

16895530	432062	OTOF	TGCAGGAAGTTCTGGCACAGCCTCA	677

16895530	165284	OTOF	GATGAGTGGCCCTGGTCCTTGTCAG	678

16895530	11640	OTOF	GACGCTCAGGGTAGGACTTCTCCGT	679

16895530	700679	OTOF	CAAATGCCTCCTCCCTGTTGATCAG	680

16895530	758065	OTOF	TGATCTGGGAGCTCTCGCTAGGGCC	681

16895530	1277770	OTOF	GAAGTCATCAATTTCCCAGGTTCTG	682

16895530	735376	OTOF	TAGATGCAGGGCTTTCGCTCCAGGT	683

16895530	1380804	OTOF	GGCCTCGTCATCACTTGCGTTCTGA	684

16895530	1330081	OTOF	TCCGGTCGATCATTGAGGCCTCCAG	685

16895530	488573	OTOF	TGTGGAGCCGTACATGTTCACCCAG	686

16895530	1065596	OTOF	TTTTCACATAGAACCGGGCCCACTG	687

16895530	1163802	OTOF	CAGGATGGCCCACTTGTGATGGAAC	688

16895530	1019728	OTOF	CCATTTTGAAGGAGCCCACCAGGGT	689

16895530	1099054	OTOF	TGACATCCGGAGAGACATGGAAGTC	690

16895530	1392179	OTOF	ACAGGGTCCATGTTCAAGCCCACCA	691

16895530	875570	OTOF	GCTCCATCTTAATGTCTGGCTTAGA	692

16895530	96637	OTOF	AATGGCCAGATGGTCAAGGTCTTCC	693

16895530	245286	OTOF	TGGGAGCAGTCCATCCGTCTCTTGG	694

16895530	779420	OTOF	CGTCAGTGGCCTGATACCGGACCTC	695

16895530	1401005	OTOF	TTCTGCAGCACCATGCGGAAGGTCC	696

16895530	323755	OTOF	TCATTTCTGTCGATGCTGCTGGCCA	697

16895530	155031	OTOF	TCCAGGACCCGAGAGTAGAAGGATT	698

16895530	661383	OTOF	GAAAGTCACTTTGGCGATCCGGTCG	699

16895530	598590	OTOF	GCTAGCCGGTGGAGCACGGCTCACA	700

16896442	1400964	EIF2AK2	TATGGGATGCATCATGGAAGCCTCC	701

16896442	1001489	EIF2AK2	GAAACTGCAGACATTGAGGCCTGGA	702

16896442	866682	EIF2AK2	AAATTCTTAAGTCACATCAGGAGGG	703

16896442	18257	EIF2AK2	CCACCTTGGGTGATGCTAAATTGAA	704

16896442	875180	EIF2AK2	TGAATACATTAATGCCGTCCCTGGG	705

16896442	944370	EIF2AK2	CATATAGTTGGAAGGCCCACTGGGC	706

16896442	1226012	EIF2AK2	TCTTCCACACAGTCAAGGTCCTTAG	707

16896442	37256	EIF2AK2	CAGATGTGTTAGGTCGATCCTCAGG	708

16896442	1358759	EIF2AK2	TATATCTGAGATGATGCCATCCCGT	709

16896442	290468	EIF2AK2	GATGCCATCCCGTAGGTCTGTGAAA	710

16896442	151298	EIF2AK2	GAATTAGCCCCAAAGCGTAGAGGTC	711

16896442	952867	EIF2AK2	TACCGCCGAATAGCTGAATCCTCTG	712

16896442	519028	EIF2AK2	TCTGGGCTCATGTATCGCAAAGTTC	713

16896442	471910	EIF2AK2	TATCGCAAAGTTCCCTTACTCCTTG	714

16896442	1351893	EIF2AK2	TCCATTTGGATGAAAAGGCACTTAG	715

16896442	356414	EIF2AK2	GCCAATGCTTTTACTTCACGCTCCG	716

16896442	363777	EIF2AK2	GTAAGTCTTTCCGTCAATTCTGTGT	717

16896442	563634	EIF2AK2	GAAAACTTGGCCAAATCCACCTGAG	718

16896442	538747	EIF2AK2	TCAGGAAGGTCAAATCTGGGTGCCA	719

16896442	1372094	EIF2AK2	TGTAGCATGTGCACATAGTCAAAGA	720

16896442	760509	EIF2AK2	GAAACTCTGCTCAAATAAGGGTGTA	721

16896442	377741	EIF2AK2	GCCTTCCTTTGATTATTTCTGAGAC	722

16896442	583956	EIF2AK2	CCTTCCTTTGATTATTTCTGAGACC	723

16896442	506867	EIF2AK2	CGAAGAACTGTTTAAACTGTCACTG	724

16896442	1115243	EIF2AK2	TGATGTATCTGCTGAGAAGTCACCT	725

16896442	672138	EIF2AK2	TGTGCTGGTCACTAAAGAGTTGCTT	726

16896442	1033233	EIF2AK2	GAAGATATGCAAGTTTAGCGGCCAA	727

16896442	1051964	EIF2AK2	TCCTGTTTAGTAGAACCTGTACCAA	728

16896442	669429	EIF2AK2	GATAAGGCCTATGTAATTCCCCATG	729

16896442	965796	EIF2AK2	CCTTCTGAAGAATTCGTTGTTGTCA	730

16896442	878182	EIF2AK2	TCTCAACAGCTAATTTGGCTGCGGC	731

16896442	223252	EIF2AK2	CATGTGGAGGTCCTGAATTAGGCAG	732

16896442	180144	EIF2AK2	TGAAGAAACCTGCTGAAAGATCACC	733

16896442	1184747	EIF2AK2	CACGCAGATAATCACGGAAGTGTGG	734

16896442	946814	EIF2AK2	CTGAGTCAGATGGAAGAACTGCTAA	735

16896442	1146480	EIF2AK2	GGTCATTACAATTTACAAATCCAGG	736

16896442	112252	EIF2AK2	TATTGGGATGGACCTCGATGCCTCG	737

16896442	1164824	EIF2AK2	GAGCTGAATGCCACTGTGACCGCAA	738

16896442	529487	EIF2AK2	CAAGCCCTCGTCTGCTACGGGATTG	739

16896442	526633	EIF2AK2	AAGCCCTCGTCTGCTACGGGATTGG	740

16900144	1225703	IGKV6-21	TACTCTGATGACAGTAATACGTTGC	741

16900144	926107	IGKV6-21	TGACAGTAATACGTTGCAGCATCTT	742

16900144	922424	IGKV6-21	GACAGTAATACGTTGCAGCATCTTC	743

16900144	452143	IGKV6-21	CGTTGCAGCATCTTCAGCTTCCAGG	744

16900144	1114824	IGKV6-21	GACCCCTGAGAAGGACTGGGAAGCA	745

16900144	1017431	IGKV6-21	ccCCTGAGAAGGACTGGGAAGCATA	746

16900144	62322	IGKV6-21	CCCTGAGAAGGACTGGGAAGCATAC	747

16900144	988328	IGKV6-21	cCTGAGAAGGACTGGGAAGCATACT	748

16900144	947291	IGKV6-21	AGGACTGGGAAGCATACTTGATGAG	749

16900144	1138092	IGKV6-21	AGAAACCCAATGAGTTGTGATGGCA	750

16900144	1137101	IGKV6-21	GAAACCCAATGAGTTGTGATGGCAA	751

16900144	1340087	IGKV6-21	AAACCCAATGAGTTGTGATGGCAAC	752

16900144	1111225	IGKV6-21	AACCCAATGAGTTGTGATGGCAACA	753

16900144	477094	IGKV6-21	ACCCAATGAGTTGTGATGGCAACAT	754

16900152	148446	IGKV1-27	GATGGGACCCCTGATTGCAAAGTGG	755

16900152	162942	IGKV1-27	ATGGGACCCCTGATTGCAAAGTGGA	756

16900152	162623	IGKV1-27	TGGGACCCCTGATTGCAAAGTGGAT	757

16900152	164887	IGKV1-27	GGGACCCCTGATTGCAAAGTGGATG	758

16900152	784485	IGKV1-27	CTGTGTCCTGACTGAGAGAGACTTC	759

16900152	1113945	IGKV1-27	TGTCCTGACTGAGAGAGACTTCTGC	760

16900152	1114998	IGKV1-27	GTCCTGACTGAGAGAGACTTCTGCA	761

16900152	1105784	IGKV1-27	TCCTGACTGAGAGAGACTTCTGCAC	762

16916802	912473	SIGLEC1	TGAGACAAAACATGGCCTGCTGGTG	763

16916802	563029	SIGLEC1	AAGTGTGACTTGGAGCCCTGGCCTA	764

16916802	1376894	SIGLEC1	TGAAAAGCCATCTCCACCGAATTCT	765

16916802	48205	SIGLEC1	CAAGAGCGTGGGAACCTCATGGAGA	766

16916802	1060982	SIGLEC1	CAATCAGTTTAGAGTCGACAGGCAA	767

16916802	367419	SIGLEC1	GCTGGGCTTTTGTGCAGAGTGGCCT	768

16916802	1288882	SIGLEC1	GAACAGATGTATTCCCCTTGGTCGC	769

16916802	599449	SIGLEC1	CCATGCAAAGGTGGAGTTGCCCACA	770

16916802	633113	SIGLEC1	CGCCCGATGGTGCTGATTGAGCCCA	771

16916802	465278	SIGLEC1	CAACGACCGTTGTGGTACCAAGTAT	772

16916802	161456	SIGLEC1	TAGAAACCCTCATCCCTGGGCTGTG	773

16916802	45183	SIGLEC1	CACACAAGGCAGGTCAGGTTCACCA	774

16916802	949403	SIGLEC1	TTGAGCGTCGAAGTCAGCTGAGGCC	775

16916802	191165	SIGLEC1	TGATAGGCCCCAGCTTGTGTCAAAG	776

16916802	1269017	SIGLEC1	TAAAGGGCAGCATCAGTTCTGGCCA	777

16916802	221211	SIGLEC1	CAACACGGTCCTTGTGGAGCAGCTG	778

16916802	753668	SIGLEC1	GAAGCAGGGCTCCATTCAGGTACCA	779

16916802	120918	SIGLEC1	GAAGCGTGGGCTGTGATCACTGTCC	780

16916802	1055574	SIGLEC1	TATCAGCCCTAGTGGCCAAGTGCAG	781

16916802	1302626	SIGLEC1	TGGAGGTGAATCTCGCTCTGAGCCC	782

16916802	54799	SIGLEC1	TCTCGAAGCGGAAGTTGTAGGAACC	783

16920651	35350	ZBP1	CCATGATGGAAGGTAACTCCAGGCA	784

16920651	269290	ZBP1	TACTCCTGGCCATCAAAAGACCTGG	785

16920651	990513	ZBP1	TCAAACAAGACGCTAAGGAATGCAG	786

16920651	150951	ZBP1	TGTCCAAGCCCCACGTGAGGCTGTG	787

16920651	1041632	ZBP1	GTTTCCAAGAGTCATAGTTTCCAGC	788

16920651	199506	ZBP1	GATGGGCTGACCAATGTCTCGAGGA	789

16920651	1178579	ZBP1	CATAAGTGCAACACAGAGTGATTCC	790

16920651	695218	ZBP1	GATCACCAATCTACATGCCGTTAAG	791

16920651	526317	ZBP1	CGATGGTGGCGTCCTCGAGAAAGCA	792

16920651	947685	ZBP1	TTCAAACGAAGCTTCTGGGCCGGCA	793

16920651	639420	ZBP1	CTCGTGCTGTTGTGCTGTCTGGGAA	794

16920651	529782	ZBP1	GCTGCACCCGTCTCAGTATGGACTG	795

16920651	94594	ZBP1	GAATCACCTGGTGCCATTGAAGGGA	796

16920651	48122	ZBP1	CAGAGTACAGGGAAATCAGGAGAGC	797

16920651	250378	ZBP1	CTCAGGACGGCCGTAAAGGTGGACT	798

16920651	23034	ZBP1	AGAGGATCCGGTGGCTCCCCACCGA	799

16920651	599440	ZBP1	AGGATCCGGTGGCTCCCCACCGAGG	800

16920651	594347	ZBP1	TCGGAGTTTGCAATGGAAATCCAGC	801

16920651	2088	ZBP1	GGCGGTAAATCGTCCATGCTTTGGA	802

16920651	240696	ZBP1	TGCTCATCCATGTCCAGAAGGTGCC	803

16920651	1048231	ZBP1	AGTAGTCCTAGGGTTTGCATCTGCC	804

16920651	26938	ZBP1	TAGTCCTAGGGTTTGCATCTGCCCC	805

16920651	141723	ZBP1	CCGTTGTTGGCTGAACTGAGGGCCA	806

16920651	105139	ZBP1	GGGTCTCTGGAATTGTAGCTGCATG	807

16920651	167747	ZBP1	TGGGTGAACCCCAAAACAGTGCCTG	808

16920651	1123059	ZBP1	AAACCTGTGAGCTCCCATGTGGCAG	809

16920651	1081678	ZBP1	CATTCGGTAGAGGACTTGGTTGAGC	810

16920651	129049	ZBP1	TCACCAGCTGGGCAAGTTTCACCGG	811

16920651	619279	ZBP1	TAGGTACAGTGATAGGCTCCCCGTT	812

16920651	985701	ZBP1	TTAATGAGGACTAAGCAGGACCCCA	813

16920651	172883	ZBP1	CGGGAGCTACCGCTGGTCCTTGGAA	814

16920651	807420	ZBP1	GAGCTACCGCTGGTCCTTGGAAGGA	815

16920651	54699	ZBP1	TACAGCCCGGAAATAGATGCCTAGC	816

16920651	312070	ZBP1	CGGCCAGATTCGGTTTCAGGAGAAA	817

16926942	949377	USP18	TGGAAAGCGAAACTTACAGCGGCCT	818

16926942	474012	USP18	TCCGCTGCTGAGTTCCACGTCGGGA	819

16926942	1203367	USP18	ATGTGAGCCAGGCACGATGGAATCT	820

16926942	1344124	USP18	GAAGCGCTTATGTGAGCCAGGCACG	821

16926942	325687	USP18	TGCCTGGCCCGCGTTCAGGACAGCA	822

16926942	1127693	USP18	TCAGGAGCCCAAACGCCTTGCTCAT	823

16926942	275128	USP18	GACAGATTTGCCTCAGGAGCCCAAA	824

16926942	277161	USP18	TGACAGATTTGCCTCAGGAGCCCAA	825

16926942	77123	USP18	GACTCAGCCAGGATGGACTGACAGA	826

16927801	483233	IGLV3-21	TTGGACAGGTACAGGCCCCATTCCA	827

16927801	1264944	IGLV3-21	GAGCCCAATGCAGGGACGCTTCTCA	828

16927801	1332856	IGLV3-21	AAGAGCCCAATGCAGGGACGCTTCT	829

16927801	1332612	IGLV3-21	CAAGAGCCCAATGCAGGGACGCTTC	830

16927801	1135215	IGLV3-21	CCAAGAGCCCAATGCAGGGACGCTT	831

16927801	989181	IGLV3-21	TCATGTCCAAGACGGGTCCCCAAGA	832

16927801	1066279	IGLV3-21	TCGCTATCATCATAGACGACCAGCA	833

16927801	745539	IGLV3-21	GCCGGTCGCTATCATCATAGACGAC	834

16927801	325646	IGLV3-21	GGCCGGTCGCTATCATCATAGACGA	835

16927801	525458	IGLV3-21	GGGCCGGTCGCTATCATCATAGACG	836

16927801	525298	IGLV3-21	AGGGCCGGTCGCTATCATCATAGAC	837

16927801	21195	IGLV3-21	GAGGGCCGGTCGCTATCATCATAGA	838

16942367	32444	RN5S134	CTTCTGAGATCAGGGCGTGTTCAGG	839

16942367	1242589	RN5S134	GCTTCTGAGATCAGGGCGTGTTCAG	840

16942367	1242066	RN5S134	AGCTTCTGAGATCAGGGCGTGTTCA	841

16942367	1331207	RN5S134	TAGCTTCTGAGATCAGGGCGTGTTC	842

16949442	445288	RTP4	CAAACAGTTTCAGTTTCGGTGTTCG	843

16949442	317505	RTP4	AGGTTTGCTCGTTTCTCAGGAAGAG	844

16949442	813751	RTP4	CCCTCTGAAGCTGAGAGAGTAGCTT	845

16949442	1073090	RTP4	TCCCTCTGAAGCTGAGAGAGTAGCT	846

16949442	975179	RTP4	TTCCCTCTGAAGCTGAGAGAGTAGC	847

16949442	761503	RTP4	TGAAATGTCTGCTCCCAAGTCCAGA	848

16949442	803534	RTP4	TTGAAATGTCTGCTCCCAAGTCCAG	849

16949442	526222	RTP4	AACTTCAGCGTCCATGTGGCCCGGG	850

16949442	1019626	RTP4	CAGTCTAGCTGAAGGTTGCCATCCA	851

16949442	234190	RTP4	GTATTGCTTCCACCCTTGAGCCAGG	852

16949442	425776	RTP4	GGTATTGCTTCCACCCTTGAGCCAG	853

16949442	728295	RTP4	CAGCCAAATGCTCTCTGTTGGTATT	854

16949442	562698	RTP4	CAGAATCTGCACTTGGGCGGAAGCC	855

16949442	1292131	RTP4	TCAGGCATCTCATATTGGGACCAGG	856

16949442	967436	RTP4	GGTTGCTCAGAATCCTCATGGTGCT	857

16949442	1326098	RTP4	TGTGTCATGGGATCCTTCCAGGGAC	858

16949442	85616	RTP4	TCTTGGCTTGGTTTGCGAGGTACAC	859

16949442	722058	RTP4	GATCTGGGTCTCGACTGGGCCCTAA	860

16949442	861067	RTP4	CAGTTATATTAAAGTGGCAGCCAGT	861

16949442	142509	RTP4	TTCAGAGGATGGCTAGGAAACCAGT	862

16949442	562159	RTP4	AGTCATGCATATGTTGGGAGACACC	863

16949442	1306234	RTP4	GGTTCTTATCCACCCGGACAATATG	864

16949442	277783	RTP4	GAGCTTGTTGCCTCCCTGTTACAAA	865

16960186	1226928	PLSCR1	TATACAACCAGAGCTACAGGCCTTA	866

16960186	1112370	PLSCR1	TACAGGTATGAGTTTAGATAGTCTC	867

16960186	779067	PLSCR1	ACCACACTCCTGATTTTTGTTCCTG	868

16960186	632376	PLSCR1	CCTGGCTGCCAGTGCTTTCAAAAAA	869

16960186	489426	PLSCR1	GAACTGAGGTATGGACTAGTCCTTG	870

16960186	176872	PLSCR1	TCAGAATGAACCTAGAGAAAGCATC	871

16960186	1281228	PLSCR1	TCAAGATTAATAAGAACAGACTTAC	872

16960186	1368937	PLSCR1	AATTATGCACCATATGTAACCCTCA	873

16960186	900501	PLSCR1	TCATTAGATAACTGGAGGCTCCTGT	874

16960186	1260831	PLSCR1	CAATGACAGGGCAGAAATTCTTGCT	875

16960186	766351	PLSCR1	CAAAGTGCCCTGGTAATTGATCACA	876

16960186	1339350	PLSCR1	GGAGGTCAATGTGCCTTTATCTGCA	877

16960186	277460	PLSCR1	GGTCAATGTGCCTTTATCTGCATAA	878

16960186	870210	PLSCR1	TATTGAGACTAAAGAGCACTTCGCT	879

16960186	1140706	PLSCR1	TATCAGGCATACAACAAAGGCAGGA	880

16960186	813178	PLSCR1	TATACACTGGCTGATTTGGGACAGG	881

16960186	1164527	PLSCR1	GGGTAGCCACTATATCCTGGAGGTC	882

16960186	926530	PLSCR1	GAGGAGGATACCCAACTGGCAAGTT	883

16960186	501111	PLSCR1	GCAAGTTTGTTTCCGGGTGAGAAGC	884

16960186	552212	PLSCR1	TAACACACTGTCTACAAGGCCACAA	885

16960186	1142371	PLSCR1	TGAATCGGGATACTCTAAAACTACA	886

16960186	1354678	PLSCR1	GATACGGGATGAAACTGAGGTGACT	887

16960186	1020497	PLSCR1	CTTGTAACAAGGAGCCATTCCATAA	888

16960186	880842	PLSCR1	GCCATTCCATAAAAATCCTCTTGTG	889

16960186	887263	PLSCR1	TGGGAGTAACCTTTGCGCCAACACC	890

16965313	25440	LAP3	GGACTCAAGGGTGCGCCCGCATTCG	891

16965313	84369	LAP3	CTGGACCGCTGGGATCAAACCGCGG	892

16965313	299056	LAP3	ACGGCCAGACGTCGGACGACTACTC	893

16965313	598358	LAP3	TCATGTCTGCGGTGGAGAGACTCCG	894

16965313	801254	LAP3	AATTCTCTCCTGCACTTGTGAACTG	895

16965313	462247	LAP3	CATAAAAGGTTCGAGTCTTCCCTGC	896

16965313	881525	LAP3	TGATGCAGACCATAAAAGGTTCGAG	897

16965313	391166	LAP3	GAGGGTTTACCAAATGATCACGTTC	898

16965313	1248717	LAP3	TATGACTAGACAGCCCCAATACTTG	899

16965313	368163	LAP3	CAGCTGCCTTTTTGCCGAGGCCAAC	900

16965313	1037286	LAP3	TCATCAAAAAGAGTGGATCCTCAGG	901

16965313	1253755	LAP3	CAACCATATTCAGCAAGAGGAACTG	902

16965313	343486	LAP3	TATGACAAGAGCGAACAAATGGTAG	903

16965313	906451	LAP3	TGGGAAAACACAGCTCTAATATGAC	904

16965313	236708	LAP3	TGGAGTCAGTCCAAGACAACTCAAA	905

16965313	826563	LAP3	GAATCAGAAAACTGGAGTCAGTCCA	906

16965313	1301510	LAP3	AGGTCTTGAATCTGCCTGCACCCCG	907

16965313	1104325	LAP3	GTATTCATAGAGACCAAGCACCGCT	908

16965313	999025	LAP3	GCTTTGCCGACACAGCCATCTTCTT	909

16965313	382397	LAP3	TCCATAGAGCTTTGCCGACACAGCC	910

16965313	354740	LAP3	GATTCATTTTTTGTGATCTGACCCA	911

16965313	280572	LAP3	AATTGGCGTGCCAAGTTCTGCCCAG	912

16965313	1378646	LAP3	GGCTGTAACATCTCGAGTCTGTGAC	913

16965313	954990	LAP3	GATAGAAAGAACCTCAAACTCAGCT	914

16965313	53473	LAP3	GACACCTGGGAGCACCAATGCTGGA	915

16965313	1134024	LAP3	TGGAGATCCCAAGAGAGCGACGGAA	916

16965313	1157620	LAP3	CCTGTTCCTCAATCCAAGACTTGGG	917

16965313	596112	LAP3	GAGCATATAGTTGCAGCTCCTCCCA	918

16965313	1002740	LAP3	GCTTTGCAGCAGACACGATGGCTGA	919

16965313	1382944	LAP3	GCCGCTGGGCATATTTTCACAAAGA	920

16965313	208550	LAP3	GATGGTCTTCCCGTTTTTGGCTCTA	921

16965313	1234480	LAP3	TGTGCGTAACAGAGCGCATCAGCCA	922

16965313	1343385	LAP3	CGGCATTGAGGATGACCTTCGGGTT	923

16965313	419684	LAP3	GAGTTTGTTCCAGAGCCAGGATGAA	924

16965313	947699	LAP3	TAATGTTCGAAGAGAGGCATCCTCC	925

16965313	913976	LAP3	TGTTGTTAACATCAGCAAGCTGGCA	926

16965313	692930	LAP3	CGCCTGCTATGTCTAAATGTGCCCA	927

16965313	1365544	LAP3	CAGAGTGAAGACATTTTTGAGTATC	928

16965313	1389553	LAP3	GTTCCTAGCATCACAAATCTGAGTT	929

16968735	351119	HERC6	GACTGGGTGCGCGATGATTTCCTGA	930

16968735	150241	HERC6	AGTCGGCGCCCCAACAGAAGTACAT	931

16968735	645105	HERC6	GAAGACCCTTCCTTTGTGGCACACA	932

16968735	52065	HERC6	TAATGCCAGGGAGTGGTAGTGTCCA	933

16968735	949382	HERC6	AGCCAAACGAAGTCCCACAGAGAGA	934

16968735	983358	HERC6	CAAGTTGTGGACCTCTCTTCTCAGG	935

16968735	605187	HERC6	GACCAGTGGTGTGCACATATGCCAG	936

16968735	853644	HERC6	AAAGTCATAAATCCATGCTTAGAGT	937

16968735	1388903	HERC6	CAAAGTTGGCATATGTTCCAGCAAA	938

16968735	1338352	HERC6	TACATATTTATGGTCCGGCCCTGCC	939

16968735	1121181	HERC6	TCCCGGGAGCACGTGTGGAACTAGT	940

16968735	406283	HERC6	CTTATAATTTATCAGACAGAGCCAC	941

16968735	725945	HERC6	GAAGGTATCTCTTGCCATTTCTAAG	942

16968735	323767	HERC6	GCAGATCATCCTCGAGACACGTAGT	943

16968735	1330174	HERC6	TAAGCATCTGGATCAGCGGATTCAG	944

16968735	1306917	HERC6	GGTGGTTATCCCGAAAGAGCTGTCT	945

16968735	596414	HERC6	TGTGAATCAGCTTGCAATAATTTAA	946

16968735	861388	HERC6	GAGCATCTTTAACCAGGCGACTTCG	947

16968735	193573	HERC6	CATGCAGGAACCCATTTCAGGATAC	948

16968735	1254131	HERC6	GAGTCCACACAGCATTCCAAAGAGG	949

16968735	1267837	HERC6	AAAGCGTATGCAGAGCGCATCTCCA	950

16968735	1174541	HERC6	TTTGGTCCACAGGTATGGAGATCCC	951

16968735	471952	HERC6	GCTGTCATTAGTTCTTCAGGGTAGA	952

16968735	397479	HERC6	CATCCAAGGTTAGTTTGTGGAAAGC	953

16968735	631458	HERC6	CCAGAGATTCGTGCCCTATGCGGAT	954

16968735	1114466	HERC6	TGAGCATGGGTGAGACAAATCCTCT	955

16968765	342217	HERC5	TTGCGCTGCAGAGCGGGAACCAGCT	956

16968765	561150	HERC5	GAGCAGCAGAGTTGGCGCGTCACCT	957

16968765	1020981	HERC5	GAAGGCCAAGGTAAAATCCCATCAC	958

16968765	640599	HERC5	GAGAATCAGCATGTGCTCTGCTCCT	959

16968765	96289	HERC5	GCAAGAGAATGGTAATCTCCACATG	960

16968765	946359	HERC5	TCCAGCACCGAAAGTAAACAGCAGC	961

16968765	445459	HERC5	GATGATACTTTCACTGGAAGCGGCA	962

16968765	1107067	HERC5	TGTTACTTGAGGTCACCACTAAGCT	963

16968765	644093	HERC5	TTAACTCCTTTTCTGAGGTATGGCT	964

16968765	1096136	HERC5	CCTTCATTCAGAGTAGGAATTGTCC	965

16968765	1296716	HERC5	CATGTTAGTAATCCAGTCCTTTTGG	966

16968765	1199559	HERC5	TGGAGCACCTGCAAAAAGAAAACCT	967

16968765	505399	HERC5	CAGCACTAAGTGTTGTAGGGTCCCA	968

16968765	379912	HERC5	GCAGATTATCTTTGAGGCAGGTGGT	969

16968765	140349	HERC5	AATCCAACTGGCATATGACGGCTGT	970

16968765	783389	HERC5	GAAAGTGACTGAATATGACGCAGCA	971

16968765	299143	HERC5	TAGATCAAACGTGGGCCTCAAAGCG	972

16968765	1368318	HERC5	TGAACATCCCATATTCCGGCTGGAT	973

16968765	1307358	HERC5	TCAAAGTTATCACCTTCATCATCCA	974

16968765	623558	HERC5	TAAGTTTGTGTCGTTTCTGTCCCAG	975

16968765	938699	HERC5	TAGGAAGGAAAACTGAATTTAATCA	976

16968765	461360	HERC5	CAGTCACGGGTTCTAACCGGCCAGT	977

16974529	393930	FGFBP2	TAGCTGCTATTTACTGAACACTGGA	978

16974529	759568	FGFBP2	TCATAGAAGGCTCAGATCAACAAAG	979

16974529	554854	FGFBP2	TGTGTATGCTTGTCACTCTTGGGCC	980

16974529	419440	FGFBP2	TCAGCACCTGTTCCCTATCATATTG	981

16974529	114371	FGFBP2	GAATTTGGGCCGTTGCATCTGATTA	982

16974529	560939	FGFBP2	TGAGAACGTTGGATTGAAAGCGGCA	983

16974529	96300	FGFBP2	AAAAGAGATGGTTGTCTGTCAGGGA	984

16974529	775691	FGFBP2	TGAGTTTCACTGTGGCCTTGGGCCT	985

16974529	1028519	FGFBP2	GAGGCTGGAAGTCACCTGCTGCATA	986

16974529	734406	FGFBP2	TCCTGCAGGGCTTGATTCCAGTAAG	987

16974529	1068525	FGFBP2	TCAGCAGCGAAAGCCTGGCACATGC	988

16974529	1258608	FGFBP2	TGTGTTGCGGCAGTCGACACGAAGC	989

16974529	1264146	FGFBP2	GACGCATAGTGCAGGAATCTCTCCC	990

16974529	607141	FGFBP2	GAACACAAGTGGGACGAGTCACCCT	991

16974529	80353	FGFBP2	AACACAAGTGGGACGAGTCACCCTT	992

16974529	980143	FGFBP2	CACAAGTGGGACGAGTCACCCTTTA	993

16974529	19329	FGFBP2	TTAAAGGGTGCTGCACAAAAGACTC	994

16974529	633804	FGFBP2	TAAAGGGTGCTGCACAAAAGACTCT	995

16974529	1146980	FGFBP2	AGGGTGCTGCACAAAAGACTCTTTC	996

16974529	1145079	FGFBP2	GGGTGCTGCACAAAAGACTCTTTCT	997

16974529	843274	FGFBP2	GGTGCTGCACAAAAGACTCTTTCTC	998

16981219	828232	DDX60	CGTGACCTGAAAAACTACTATGGAA	999

16981219	734517	DDX60	TGTACCTGGCTTATAGTAACAGCTC	1000

16981219	1120817	DDX60	TGGAGCCTGAGAGCGATTGACACCG	1001

16981219	419033	DDX60	CATCATCAAAGTTCCCAGACAGACA	1002

16981219	532945	DDX60	GTGATACAAGTCCAGCAAACCCCAT	1003

16981219	881361	DDX60	AGTCACCACATAATAAGTAACTTAT	1004

16981219	465117	DDX60	CATGACTCTGGGTTGCTTGAAGGAC	1005

16981219	1168120	DDX60	GGCATGTTGACACCTAAAGCAAGTG	1006

16981219	719240	DDX60	CTTTGAAACTCATAGCACTGTGATG	1007

16981219	1267882	DDX60	GATCAGCATATGTGCAGTCCTGTGG	1008

16981219	500454	DDX60	CGAAGTTTGTTAGCCATGACATGGG	1009

16981219	1300959	DDX60	GGACTCAAATCTGCTTCAGGACTAA	1010

16981219	1191178	DDX60	TATCTGGAGGCAAATCCTCTGGGAG	1011

16981219	1175050	DDX60	TGCATTCCTGCCACAAAAGTCTAGA	1012

16981219	78125	DDX60	TAGTCTTTGGGAAAGCCGGCCTGAC	1013

16981219	509098	DDX60	TCGGTGAGATGTTCAGGATTACTTA	1014

16981219	848987	DDX60	AGAATTTCAAAGCAGGCAGGCACTG	1015

16981219	928515	DDX60	GCATCATGACGATACTCCCTGGTGA	1016

16981219	1378530	DDX60	TATCCACAACATCAAGGAGCTCTCG	1017

16981219	519692	DDX60	CTGGGCTGGATGTAAAGAACTTGCC	1018

16981219	1034849	DDX60	TGCACAGATCTAAGAACACGAGGGT	1019

16981219	1362300	DDX60	TTGGGCACCATTTCATTGGAGCTGT	1020

16981219	378069	DDX60	GACCAACTTTGATACGGTATTCCAG	1021

16981219	865966	DDX60	GCTCATCATTTAAGTCAGAAAGGTG	1022

16981219	201523	DDX60	TTTCCTGACCAGAGGAGGGCTCTCT	1023

16981219	735745	DDX60	TCTGCCCAGGCTTAAATGATATCTC	1024

16981219	829197	DDX60	TTCCTGTGAAAATGTTGTAAGAACA	1025

16981219	241267	DDX60	TGCCTGTGCCTCCAACCTGAACTGG	1026

16981219	1232487	DDX60	GAGTGAAACAGAGACCTAGCGCAGA	1027

16981219	1343892	DDX60	CAGTCTTTTATGCATCCGGCGGGAG	1028

16984783	1328787	GZMK	AAATGTGTTGATCCTGTGATGAAGG	1029

16984783	1355472	GZMK	GAAGCCCAGATGAAATGTGTTGATC	1030

16984783	384171	GZMK	GATTTAGATTTAAGAAGCCCAGATG	1031

16984783	184991	GZMK	CATATAAGCCCCAACTATTAGGAAA	1032

16984783	881796	GZMK	CACATGAGTCATATAAGCCCCAACT	1033

16984783	1295602	GZMK	ACACATGAGTCATATAAGCCCCAAC	1034

16984783	768535	GZMK	TAAATGGCCTGGAATGAGGTGACAC	1035

16984783	553147	GZMK	CAAACGTGATGTCCGCCATACTGGA	1036

16984783	621231	GZMK	GCACCCACTGTGGATCAATCAGAAC	1037

16984783	1338165	GZMK	AAAGCAGCAGAATGATTTCCAAATC	1038

16984783	239601	GZMK	CATTTGGTTCCAGATCTAAGAGAGG	1039

16984783	657893	GZMK	TAACAGTGACTTCTCGCAGGGTGTC	1040

16984783	230219	GZMK	TACAGGAATCCTTCTGGCCTTTGGC	1041

16984783	342630	GZMK	GAGACTATAGCGTGGAAGACACCTT	1042

16984783	734667	GZMK	GATTCCAGGCTTTGTGGCAACACCA	1043

16984783	1122679	GZMK	TAACCTGCGAGCATATTAGGAAAAA	1044

16984783	1367971	GZMK	GGACCCCATATGTGCTCTGCTTTAC	1045

16984783	1030703	GZMK	GACTTACAAGTGCAAAAATGGACCC	1046

16984783	1287598	GZMK	CAGTGACCTTATTGCCCTTTGGCGA	1047

16984783	1027161	GZMK	TGATCCAGCAGAAGTTACACCTAGT	1048

16984783	566215	GZMK	TAAACATTTGTTGCAAGGGCCTATC	1049

16997041	362379	LOC647859	AATTTGCTGTTTAACTGCTTGCAAT	1050

16997041	391494	LOC647859	TTTGCTGTTTAACTGCTTGCAATGA	1051

16997041	861511	LOC647859	TTGCTGTTTAACTGCTTGCAATGAT	1052

16997041	710794	LOC647859	TCATCACAGGACTCGCCACCAGTTG	1053

16997041	268508	LOC647859	CACAGGACTCGCCACCAGTTGTGTA	1054

16997041	257902	LOC647859	ACAGGACTCGCCACCAGTTGTGTAG	1055

16997041	1160561	LOC647859	CAGGACTCGCCACCAGTTGTGTAGT	1056

16997041	199082	LOC647859	GACTCGCCACCAGTTGTGTAGTCTG	1057

16997041	515607	LOC647859	CACCAGTTGTGTAGTCTGTCTCATA	1058

17025697	1377244	MIR3939	CCAGTGTGGACATCCTGTGGTCTGC	1059

17025697	232433	MIR3939	CAGTGTGGACATCCTGTGGTCTGCG	1060

17025697	231902	MIR3939	AGTGTGGACATCCTGTGGTCTGCGC	1061

17025697	771814	MIR3939	TGTGGACATCCTGTGGTCTGCGCGT	1062

17025697	771240	MIR3939	GTGGACATCCTGTGGTCTGCGCGTA	1063

17025697	622277	MIR3939	TGGACATCCTGTGGTCTGCGCGTAC	1064

17025697	622771	MIR3939	GGACATCCTGTGGTCTGCGCGTACA	1065

17025697	89321	MIR3939	GACATCCTGTGGTCTGCGCGTACAC	1066

17025697	530265	MIR3939	ACATCCTGTGGTCTGCGCGTACACA	1067

17025697	802563	MIR3939	CATCCTGTGGTCTGCGCGTACACAT	1068

17025697	489218	MIR3939	TGGTCTGCGCGTACACATGTGACAG	1069

17025697	489102	MIR3939	GGTCTGCGCGTACACATGTGACAGG	1070

17025697	931146	MIR3939	GTCTGCGCGTACACATGTGACAGGT	1071

17025697	1179503	MIR3939	TCTGCGCGTACACATGTGACAGGTA	1072

17025697	1221923	MIR3939	TACACATGTGACAGGTACGTGCACG	1073

17025697	43428	MIR3939	ACACATGTGACAGGTACGTGCACGC	1074

17025697	483528	MIR3939	CACATGTGACAGGTACGTGCACGCC	1075

17025697	482555	MIR3939	ACATGTGACAGGTACGTGCACGCCC	1076

17025697	917600	MIR3939	ATGTGACAGGTACGTGCACGCCCAC	1077

17056807	380060	TRGC2	CATTTGCATCCTTTGAATAATTGTA	1078

17056807	975041	TRGC2	GCATCCTTTGAATAATTGTATTTGG	1079

17056807	1282314	TRGC2	CATCCTTTGAATAATTGTATTTGGG	1080

17056807	881781	TRGC2	CCTTTGAATAATTGTATTTGGGATC	1081

17056807	1273803	TRGC2	CTTTGAATAATTGTATTTGGGATCC	1082

17056807	576608	TRGC2	TTGAATAATTGTATTTGGGATCCAC	1083

17056807	517357	TRGC2	TGAATAATTGTATTTGGGATCCACT	1084

17056807	516996	TRGC2	GAATAATTGTATTTGGGATCCACTG	1085

17056823	1032399	TARP	CTGTGACAACAAGTGTTGTTCCACT	1086

17056823	1028040	TARP	TGTGACAACAAGTGTTGTTCCACTG	1087

17056823	1029567	TARP	GTGACAACAAGTGTTGTTCCACTGC	1088

17056823	610118	TARP	TGACAACAAGTGTTGTTCCACTGCC	1089

17056823	609102	TARP	GACAACAAGTGTTGTTCCACTGCCA	1090

17056823	489622	TARP	ACAACAAGTGTTGTTCCACTGCCAA	1091

17056823	569123	TARP	CAACAAGTGTTGTTCCACTGCCAAA	1092

17056823	567714	TARP	AACAAGTGTTGTTCCACTGCCAAAG	1093

17056823	500979	TARP	ACAAGTGTTGTTCCACTGCCAAAGA	1094

17056823	419171	TARP	CAAGTGTTGTTCCACTGCCAAAGAG	1095

17056823	419065	TARP	AAGTGTTGTTCCACTGCCAAAGAGT	1096

17056823	236716	TARP	AGTGTTGTTCCACTGCCAAAGAGTT	1097

17056823	236294	TARP	GTGTTGTTCCACTGCCAAAGAGTTT	1098

17056823	1167136	TARP	TGTTGTTCCACTGCCAAAGAGTTTC	1099

17056853	1256547	TRGV2	TAGATTTCGCAGTATCAATCTCAAG	1100

17056853	218037	TRGV2	AAGTTGTTCCTTGTGCTTGCGTAAG	1101

17056853	207652	TRGV2	TAATACTTCCCTGGACTGACTCCTG	1102

17056853	1176615	TRGV2	TGATTCCAACACAACCTTGGAGTTG	1103

17056853	923772	TRGV2	GAGTCATAGTACTGAAGACGCTGTG	1104

17056853	465924	TRGV2	GATGTAGCCGTTACTTCCTTCAGCA	1105

17056853	1166024	TRGV2	TCAGGTTCCACTCAACAAGGAAGTG	1106

17056853	88884	TRGV2	GAGGAGGTGGTCTTCCTGAGACACA	1107

17056853	1114141	TRGV2	GTCTTCCTGAGACACAAGCAGAGGG	1108

17056853	1146518	TRGV2	TCCTGAGACACAAGCAGAGGGAAGT	1109

17059776	1114478	SAMD9L	GAATGCTGCTTGAGACTGTTCTGGC	1110

17059776	219409	SAMD9L	GGATGGCATTCCTTGACACTGAAAA	1111

17059776	162908	SAMD9L	TGAGGAAGCCCTCTAATCAGGCAGG	1112

17059776	477417	SAMD9L	CAGCCTGACCAGTTAGACGACGCAG	1113

17059776	750277	SAMD9L	AAAAGTGTGCTTGCCTGCTTGGACC	1114

17059776	237966	SAMD9L	GAGGATTTCCAGTGCAGTCAAGACA	1115

17059776	960024	SAMD9L	ATAACTGAAGAAGATCCACGGGCGG	1116

17059776	285994	SAMD9L	AATTGTCCCGGATCATGATTGTCAC	1117

17059776	1029533	SAMD9L	TTATCAAAAGTGCTGGACCCCATGG	1118

17059776	1263848	SAMD9L	TCTTCACTGAGCAGAATTTGCCCGT	1119

17059776	257665	SAMD9L	CTTTCCGTGCCTCCGGGAAAGGATG	1120

17059776	1300296	SAMD9L	GGATGCTCAGAATCCCAGCTGCAGC	1121

17059776	1331936	SAMD9L	GGCTGTTTGATCTGGATCCCTTAGA	1122

17059776	158061	SAMD9L	TAGTTCCCCTTTCTTGATAATTTGC	1123

17059776	1320021	SAMD9L	GCCGGAGGATATACTTGTTGAGAAC	1124

17059776	1121758	SAMD9L	TTCAATGTGGAGCAAATCCTATGGG	1125

17059776	263306	SAMD9L	TGGTCCAAGCCTTCCTCATCTCTTT	1126

17059776	219175	SAMD9L	GAATAGCTTCCTTGCCAGGTTCCCT	1127

17059776	1363664	SAMD9L	GAATGAGGCCATTTCTCACACAGCG	1128

17059776	36184	SAMD9L	CCTGGAGGAGGTCCCTTTTGACTCT	1129

17059776	803906	SAMD9L	ACAGACACAGTCTGCTCGGGTGAGA	1130

17059776	392669	SAMD9L	TCAGAAATTTAACCAGCCAGTCTCT	1131

17059776	861192	SAMD9L	AGAAATTTAACCAGCCAGTCTCTCT	1132

17059776	582339	SAMD9L	TCAGAAACTTGAAACAGGCCATTTG	1133

17059776	745105	SAMD9L	TCTTCTGATGGCTAGGAGACATGAA	1134

17059776	436825	SAMD9L	TGTGAAGTCTTCTGTTCTCCCAGTA	1135

17063828	1198758	TRBV7-3	CAGGCCTGACTGCAAAGAACCGATC	1136

17063828	1196695	TRBV7-3	GGCCTGACTGCAAAGAACCGATCGT	1137

17063828	846398	TRBV7-3	GCCTGACTGCAAAGAACCGATCGTT	1138

17063828	1034759	TRBV7-3	CCTGACTGCAAAGAACCGATCGTTG	1139

17063828	954914	TRBV7-3	TGACTGCAAAGAACCGATCGTTGGG	1140

17063828	953223	TRBV7-3	GACTGCAAAGAACCGATCGTTGGGC	1141

17063828	262571	TRBV7-3	CGTTGGGCAGCCCTGAGTCATCTGC	1142

17063828	289067	TRBV7-3	TGCCGCACCCGTGCCTTGGAAGTAA	1143

17063828	781503	TRBV7-3	TGGATCACACCTGAGCTCTACATAT	1144

17063828	1003051	TRBV7-3	CCTTCTCTGTGACCTTGTTACTGGG	1145

17063828	392847	TRBV7-3	GGGAGCTTTACCAGATCAGGGTCAC	1146

17077826	353745	MYBL1	TGCAGACTGTTTTTAGGGACCAAGG	1147

17077826	493109	MYBL1	TAGCCTAAGTAAATCAGCACATGGG	1148

17077826	582930	MYBL1	TATGAGAGCTCTTGAAGTACTACTG	1149

17077826	592621	MYBL1	CAGATATCTTCTTGCTTGTTCAGTC	1150

17077826	403686	MYBL1	TACATGGCTCTTAGAAAGCAGTGGC	1151

17077826	299284	MYBL1	TGCCAAAGACGTTTTCAAGGTATGC	1152

17077826	594132	MYBL1	GAATCAAGTTGCACCTATTGTCATG	1153

17077826	581438	MYBL1	CAGTCAACAGTTGAGTGCCTGATTC	1154

17077826	672624	MYBL1	TATCTAAGACTAGTGATTTTCTGAC	1155

17077826	955300	MYBL1	TCTTCCAAGAAAGCAAGTGGCTGGG	1156

17077826	1196733	MYBL1	TCTCCTGAGCAGCAAGCGCATTCTT	1157

17077826	915880	MYBL1	GGTGTGGTACCCAGTATAGATCTTC	1158

17077826	802542	MYBL1	TGAGAGCTTTCTGCCCACAAATAGG	1159

17077826	199499	MYBL1	TGTTCATTACCAGGACATGTGTTGA	1160

17077826	265123	MYBL1	TTTTAGCGCCATATTACCACCATCG	1161

17077826	631682	MYBL1	GCTGGTGGAGTGCTAAACTTGGCTA	1162

17077826	540956	MYBL1	GGTAACGTCACTCCATGCTACAGGA	1163

17077826	341469	MYBL1	GATAACACAGCGTTTGCCTCCACGG	1164

17077826	883760	MYBL1	TCTCAGCTGACATAAGAAGCATCTC	1165

17077826	1147322	MYBL1	TGTTCTATACAATTGCCTTCAGGTG	1166

17077826	1210684	MYBL1	GATCCATAGCTGCACAAGGTTTGTG	1167

17077826	1282838	MYBL1	CATCTTGTAAATAGCCCTCCTGTTC	1168

17077826	208296	MYBL1	AACGATTTCCCAACCGCTTATGTGC	1169

17077826	1313157	MYBL1	TACCTCAGGATTCAGATGATTATGC	1170

17077826	641198	MYBL1	CAAGGACCCTTTATCAATTCAGGAT	1171

17077826	973712	MYBL1	GATGCTGGCACTGAAAATCAGAGCG	1172

17077826	1079453	MYBL1	TGAAGATGACTAGCAATTAGAGTCC	1173

17077826	365913	MYBL1	CAGTCCTTTTTGTTGTGGTACTTCA	1174

17077826	783281	MYBL1	CATGATCGGCATACTGAAGGTCATC	1175

17077826	829815	MYBL1	CGTCATTCAGAAAAGAGTCGCCCGA	1176

17077826	426864	MYBL1	CAGTCAGTTTTCTCTGCGTAGCGGA	1177

17077826	797530	MYBL1	CAAGAAACCTGCCTCGAAGAAGTGG	1178

17077826	103496	MYBL1	TCAGAAATCTGGACGCGCATTACGG	1179

17077826	76412	MYBL1	CACTAGTTAGGATGCGCGGTCTTCA	1180

17077826	107207	MYBL1	CCCTGTCCTGGAGAATAACGCGTGA	1181

17082012	883210	LOC100133669	AAATCTATCATAACCTGGTAGCAGG	1182

17082012	1326974	LOC100133669	GGTAGCAGGATCCAAAAATTCAATC	1183

17082012	412155	LOC100133669	GCAGGTGCCATTACTGTGAGGCCAG	1184

17082012	1193825	LOC100133669	CAATGTTTTCAGCTACTAACCCAGC	1185

17082012	190256	LOC100133669	TACTAACCCAGCCATGTGTGACCAC	1186

17082012	1398121	LOC100133669	CCAGTGGCCCATGATGATCTAGTGA	1187

17082012	739001	LOC100133669	GAGAGGACGCTTCGGTCTCTGTACG	1188

17082012	817455	LOC100133669	GGTACCAGCTGCAGCCGACAGGTAA	1189

17082012	900622	LOC100133669	GACAGGTAACTGTTTCTTTCACTCT	1190

17082012	130228	LOC100133669	TAAATTGGGCAATGTCCTCTCCTCA	1191

17082012	56499	LOC100133669	TGGCTCCCGGAGGTTAGGAATCAAC	1192

17082012	1057734	LOC100133669	TACACTCTGATAGGTGGTGCCAGCC	1193

17082012	42916	LOC100133669	AAACACACAGGTACACTGGCGGGCA	1194

17082012	863461	LOC100133669	GGACCAGTAACGAGTCCCAGTGCGC	1195

17082012	533328	LOC100133669	AGTAACGAGTCCCAGTGCGCAGTGG	1196

17082012	83766	LOC100133669	AGTCCACTCTGGGTGTCCCGCAGTC	1197

17082012	330796	LOC100133669	GGTGTCCCGCAGTCCACTCCTGGTG	1198

17082012	523273	LOC100133669	AAGCCGGGTCCAGCTGTCACGGAAT	1199

17082012	809278	LOC100133669	CGGGTCCAGCTGTCACGGAATCCAA	1200

17082012	809659	LOC100133669	GGGTCCAGCTGTCACGGAATCCAAA	1201

17082012	1297731	LOC100133669	TGTCACGGAATCCAAAACCAAGCGG	1202

17082012	418226	LOC100133669	GAGCAAGCGTTCCTCTAACAGTGGG	1203

17082012	533163	LOC100133669	TCGGGCCAGTCGGTAAGAAGTTCCA	1204

17082012	1265181	LOC100133669	GACGCTATCTGCAGGTACCGGAATG	1205

17082012	738158	LOC100133669	CAGAACTGATGGCTTGCTCGGTGGC	1206

17082012	889666	LOC100133669	CCGAACACAACGAGGACTGTCCAGG	1207

17082012	308150	LOC100133669	CGAACACAACGAGGACTGTCCAGGT	1208

17082012	604235	LOC100133669	ACTGTCCAGGTGTCAGTGACGGTCA	1209

17082012	521094	LOC100133669	TCAGTGACGGTCACCCCGACCTGGT	1210

17093090	265563	DDX58	TCAACAGGGCCAAATGCGCAGAGGT	1211

17093090	625725	DDX58	TACGTCAGCTGTGTAACATGCCAAG	1212

17093090	316546	DDX58	AATACTGCTTCGTCCCATGTCTGAA	1213

17093090	1200656	DDX58	GAAGGAAGCACTTGCTACCTCTTGC	1214

17093090	661171	DDX58	CCAATATACACTTCTGTGCCGGGAG	1215

17093090	1217677	DDX58	TGCCACGTCCAGTCAATATGCCAGG	1216

17093090	999011	DDX58	CCTGCTGCTCGGACATTGCTGAAGA	1217

17093090	332322	DDX58	AAATTTGTCGCTAATCCGTGATTCC	1218

17093090	974265	DDX58	CAGTGGGCCTGAAGATCCTCCAAGT	1219

17093090	1325449	DDX58	CATACACTGGGATCTGATTCGCAAA	1220

17093090	1192298	DDX58	TTCATAGCAGGCAAAGCAAGCTCTA	1221

17093090	808620	DDX58	TAAATGGGCTGTACAAGTTTGTATC	1222

17093090	999859	DDX58	GAAGGTGGACATGAATTCTCACTAA	1223

17093090	1020355	DDX58	TCTGATCTGAGAAGGCATTCCACCA	1224

17093090	1341894	DDX58	GCCCAGGTGCATGCTTCTACTTTCA	1225

17093090	206898	DDX58	AAATGGCCACCATGCAGACTGCAAC	1226

17093090	132105	DDX58	GGTCTAGGGCATCCAAAAAGCCACG	1227

17093090	1077658	DDX58	TGTGCCTCACTAGCTTTAAAGCCGG	1228